



JC08 Rec'd PCT/PTO 26 JAN 2001


01-29-01

PCT

FORM PTO-990 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER <b>PF-0565 USN</b>
<b>TRANSMITTAL LETTER TO THE UNITED STATES. DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		U.S. APPLICATION NO. (If known, enter 37 CFR 1.53 TO BE ASSIGNED) <b>09/744794</b>
INTERNATIONAL APPLICATION NO. PCT/US99/17132	INTERNATIONAL FILING DATE 28 July 1999	PRIORITY DATE CLAIMED 28 July 1998
TITLE OF INVENTION <b>PHOSPHORYLATION EFFECTORS</b>		
APPLICANT(S) FOR DO/EO/US <b>INCYTE PHARMACEUTICALS, INC.; HILLMAN, Jennifer L.; LAI, Preeti; TANG, Y. Tom; CORLEY, Neil C.; GUEGLER, Karl J.; BAUGHN, Mariah R.; PATTERSON, Chandra; BANDMAN, Olga; AU-YOUNG, Janice; GORGONE, Gina A.; YUE, Henry; AZIMZAI, Valda; REDDY, Roopa; LU, Dyung Aina M.; SHIH, Leo :L.</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. <input checked="" type="checkbox"/> This is the <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371 (f)). 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau) b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
<b>Items 11 to 16 below concern document(s) or information included:</b>		
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.27 and 3.31 is included. 13. <input type="checkbox"/> A <b>FIRST</b> preliminary amendment. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information:  1) Transmittal Letter (2 pp, in duplicate) 2) Return Postcard 3) Express Mail Label No.: <b>EL 743 380 044 US</b>		



09744794 100501  
JC02 Rec'd PCT/PTO 26 JAN 2001

U.S. APPLICATION NO. (if applicable, see 37 CFR 1.53) <b>09/1744794</b>		INTERNATIONAL APPLICATION NO.: PCT/US99/17132	ATTORNEY'S DOCKET NUMBER PF-0565 USN
<p>17. <input type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....<b>\$1000.00</b> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..<b>\$860.00</b> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....<b>\$710.00</b> <input checked="" type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....<b>\$690.00</b> <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....<b>\$100.00</b></p>			
ENTER APPROPRIATE BASIC FEE AMOUNT =			\$690.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).			\$
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total Claims	20 =	0	X \$ 18.00
Independent Claims	2 =	0	X \$ 80.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00
TOTAL OF ABOVE CALCULATIONS =			\$690.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.			\$
SUBTOTAL =			\$690.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$
TOTAL NATIONAL FEE =			\$690.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by the appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$
TOTAL FEES ENCLOSED =			\$690.00
			Amount to be Refunded: \$
			Charged: \$
<p>a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>09-0108</u> in the amount of \$ <u>690.00</u> to cover the above fees. c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>09-0108</u>. A duplicate copy of this sheet is enclosed.</p> <p><b>NOTE:</b> Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p> <p>SEND ALL CORRESPONDENCE TO:</p> <p>INCYTE GENOMICS, INC. 3160 Porter Drive Palo Alto, CA 94304</p> <p> SIGNATURE</p> <p>NAME: Diana Hamlet-Cox</p> <p>REGISTRATION NUMBER: 33,302</p> <p>DATE: <u>26</u> January 2001</p>			

09744794  
09/744794  
Rec'd PCT/PTO 26 JAN 2001**PHOSPHORYLATION EFFECTORS****TECHNICAL FIELD**

5 This invention relates to nucleic acid and amino acid sequences of phosphorylation effectors and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, immune, and neuronal disorders.

Kinases and phosphatases are critical components of intracellular signal transduction mechanisms. Kinases catalyze the transfer of high energy phosphate groups from adenosine triphosphate (ATP) to various target proteins. Phosphatases, in contrast, remove phosphate groups from proteins. Reversible protein phosphorylation is the main strategy for regulating protein activity in eukaryotic cells. In general, proteins are activated by phosphorylation in response to extracellular signals such as hormones, neurotransmitters, and growth and differentiation factors.

15 Protein dephosphorylation occurs when down-regulation of a signaling pathway is required. The coordinate activities of kinases and phosphatases regulate key cellular processes such as proliferation, differentiation, and cell cycle progression. Kinases comprise the largest known enzyme superfamily and are widely varied in their substrate specificities. Kinases may be categorized based on the specific amino acid residues that are phosphorylated in their substrates:

20 protein tyrosine kinases (PTK) phosphorylate tyrosine residues, and protein serine/threonine kinases (STK) phosphorylate serine and/or threonine residues. Almost all kinases contain a conserved 250-300 amino acid catalytic domain. This domain can be further divided into 11 subdomains. N-terminal subdomains I-IV fold into a two-lobed structure which binds and orients the ATP donor molecule, and subdomain V spans the two lobes. C-terminal subdomains VIA-XI

25 bind the protein substrate and transfer the gamma phosphate from ATP to the hydroxyl group of a serine, threonine, or tyrosine residue. Each of the 11 subdomains contains specific catalytic residues or amino acid motifs characteristic of that subdomain. For example, subdomain I contains an 8-amino acid glycine-rich ATP binding consensus motif, subdomain II contains a critical lysine residue required for maximal catalytic activity, and subdomains VI and IX comprise

30 the highly conserved catalytic core. Kinases may also be categorized by additional amino acid sequences, generally between 5 and 100 residues, which either flank or occur within the kinase domain. These additional amino acid sequences regulate kinase activity and determine substrate specificity. (Reviewed in Hardie, G. and Hanks, S. (1995) The Protein Kinase Facts Books, Vol I:7-20 Academic Press, San Diego, CA.)

35 STKs include both protein kinase A (PKA) and calcium-dependent protein kinase C

(PKC), both of which transduce signals from plasma membrane receptors. The activities of PKA and PKC are directly regulated by second messenger signaling molecules such as cyclic AMP and diacylglycerol, respectively. A novel kinase identified by genetic analysis in the fission yeast Schizosaccharomyces pombe is encoded by the *cek1<sup>+</sup>* gene and is related to both PKA and PKC

5 (Samejima, I. and Yanagida, M. (1994) Mol. Cell. Biol. 14:6361-6371). *cek1<sup>+</sup>* encodes an unusually large kinase of 1309 amino acids. The kinase domain spans residues 585 to 987, and 112 additional amino acids are present in this domain between subdomains VII and VIII. Overexpression of *cek1<sup>+</sup>* suppresses mutations in *cut8<sup>+</sup>*, a gene required for chromosome segregation during mitosis. Therefore, *cek1<sup>+</sup>* may encode a unique member of the PKA/PKC

10 protein family with a role in mitotic signaling and cell cycle progression.

PTKs may be classified as either transmembrane or nontransmembrane proteins. Transmembrane tyrosine kinases function as receptors for most growth factors. Binding of growth factor to the receptor activates the transfer of a phosphate group from ATP to selected tyrosine side chains of the receptor itself and other specific second messenger proteins. Growth factors

15 (GF) that associate with receptor PTKs include epidermal GF, platelet-derived GF, fibroblast GF, hepatocyte GF, insulin and insulin-like GFs, nerve GF, vascular endothelial GF, and macrophage colony stimulating factor. Nontransmembrane PTKs form signaling complexes with the cytosolic domains of plasma membrane receptors. Receptors that signal through nontransmembrane PTKs include cytokine, hormone, and antigen-specific lymphocytic receptors. Many PTKs were first

20 identified as oncogene products in cancer cells in which PTK activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs. Furthermore, cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity (Charbonneau, H. and Tonks, N. K. (1992) Annu. Rev. Cell Biol. 8:463-93). Regulation of PTK activity may therefore be an important strategy in controlling some

25 types of cancer.

Some kinases utilize carbohydrates as their substrates and are important for glucose metabolism. For example, glycolysis employs four distinct kinases to effect the conversion of glucose to pyruvate, a key metabolite in the production of ATP. One of these enzymes is phosphofructokinase (PFK) which catalyzes the transfer of phosphate from ATP to fructose 6-

30 phosphate. PFK is an allosteric enzyme and a key regulator of glycolysis. In certain genetic muscle disorders, such as muscle phosphofructokinase deficiency type VII, phosphofructokinase activity is absent in muscle and deficient in red blood cells. As a result, afflicted individuals suffer from mild hemolytic anemia and muscle pain (Isselbacher, K.J. et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, New York, NY, p. 2102).

35 Kinase-mediated phosphorylation is antagonized by the activity of phosphatases, which



remove phosphate groups by hydrolysis. Phosphatases are classified into one of three evolutionarily distinct families: the protein serine/threonine phosphatases (PPs), the protein tyrosine phosphatases, and the acid/alkaline phosphatases. PPs may be further categorized into four distinct groups: PP-I, PP-IIA, PP-IIB, and PP-IIC. (Cohen, P. (1989) *Annu. Rev. Biochem.* 58:453-508). PP-I, in particular, dephosphorylates many of the proteins phosphorylated by PKA and is therefore an important regulator of signal transduction pathways. Kinase-activated proteins which bind to and inhibit PP-I have been identified. These inhibitors potentiate the activity of kinases such as PKA by allowing protein substrates to remain in their phosphorylated, activated state. A novel inhibitor of PP-1 has been purified from porcine aorta (Eto, M. et al. (1995) *J. Biochem.* 118:1104-1107; Eto, M. et al. (1997) *FEBS Lett.* 410:356-360). This inhibitor, called CPI17, is 147 amino acids in length and is activated by PKC. CPI17 expression is restricted to smooth muscle tissues such as aorta and bladder, suggesting that CPI17 functions in PKC-mediated signal transduction pathways in these tissues, possibly through a calcium-dependent mechanism.

15           The discovery of new phosphorylation effectors and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, immune, and neuronal disorders.

#### SUMMARY OF THE INVENTION

20

The invention features substantially purified polypeptides, phosphorylation effectors, referred to collectively as "PHSP" and individually as "PHSP-1 to PHSP-31". In one aspect, the invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof.

25           The invention further provides a substantially purified variant having at least 90% amino acid identity to at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:1-31, and fragments thereof. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof. The invention also includes an

30           isolated and purified polynucleotide variant having at least 80% polynucleotide sequence identity to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof.

          Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising

35           an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments

thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof.

The invention also provides a method for detecting a polynucleotide in a sample  
5 containing nucleic acids, the method comprising the steps of (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide in the sample. In one aspect, the method further comprises amplifying the polynucleotide prior to hybridization.

10 The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:32-62, and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least 80% polynucleotide sequence identity to the polynucleotide sequence selected from the group consisting of SEQ ID NO:32-62, and fragments thereof. The invention also provides an  
15 isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:32-62, and fragments thereof.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the  
20 group consisting of SEQ ID NO:1-31, and fragments thereof. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide under conditions suitable for the expression of the polypeptide; and  
25 (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide selected  
30 from the group consisting of SEQ ID NO:1-31, and fragments thereof. The invention also provides a purified agonist and a purified antagonist to the polypeptide.

The invention also provides a method for treating or preventing a disorder associated with decreased expression or activity of PHSP, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a  
35 substantially purified polypeptide having the amino acid sequence selected from the group

consisting of SEQ ID NO:1-31, and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a disorder associated with increased expression or activity of PHSP, the method comprising administering to a subject in  
5 need of such treatment an effective amount of an antagonist of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof.

### BRIEF DESCRIPTION OF THE TABLES

Table 1 shows nucleotide and polypeptide sequence identification numbers (SEQ ID NO),  
10 clone identification numbers (clone ID), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding PHSP.

Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods and algorithms used for identification of PHSP.

Table 3 shows the tissue-specific expression patterns of each nucleic acid sequence as  
15 determined by northern analysis, diseases, disorders, or conditions associated with these tissues, and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding PHSP were isolated.

Table 5 shows the tools, programs, and algorithms used to analyze PHSP, along with  
20 applicable descriptions, references, and threshold parameters.

### DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods  
25 described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for  
30 example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention  
35 belongs. Although any machines, materials, and methods similar or equivalent to those described

herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be  
5 construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

### DEFINITIONS

"PHSP" refers to the amino acid sequences of substantially purified PHSP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine,  
10 and preferably the human species, from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which, when bound to PHSP, increases or prolongs the duration of the effect of PHSP. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of PHSP.

15 An "allelic variant" is an alternative form of the gene encoding PHSP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or  
20 substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding PHSP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polynucleotide the same as PHSP or a polypeptide with at least one functional characteristic of PHSP. Included within this  
25 definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding PHSP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding PHSP. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change  
30 and result in a functionally equivalent PHSP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of PHSP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, positively charged amino acids may include lysine and arginine, and amino acids with  
35 uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine,

and valine; glycine and alanine; asparagine and glutamine; serine and threonine; and phenylalanine and tyrosine.

The terms "amino acid" or "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, "fragments," "immunogenic fragments," or "antigenic fragments" refer to fragments of PHSP which are preferably at least 5 to about 15 amino acids in length, most preferably at least 14 amino acids, and which retain some biological activity or immunological activity of PHSP. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which, when bound to PHSP, decreases the amount or the duration of the effect of the biological or immunological activity of PHSP. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of PHSP.

The term "antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind PHSP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (given regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition containing a nucleic acid sequence which is complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell,

the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" can refer to the antisense strand, and the designation "positive" can refer to the sense strand.

The term "biologically active," refers to a protein having structural, regulatory, or  
5 biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic PHSP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" or "complementarity" refer to the natural binding of  
10 polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of  
15 complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" or a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given  
20 polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding PHSP or fragments of PHSP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl),  
25 detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using the XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping  
30 sequences of more than one Incyte Clone using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

The term "correlates with expression of a polynucleotide" indicates that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding PHSP, by  
35 northern analysis is indicative of the presence of nucleic acids encoding PHSP in a sample, and

thereby correlates with expression of the transcript from the polynucleotide encoding PHSP.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a  
5 polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide  
10 from which it was derived.

The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of  
15 hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced  
20 stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not  
25 hybridize to the second non-complementary target sequence.

The phrases "percent identity" and "% identity" refer to the percentage of sequence similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, e.g., by using the MEGALIGN program (DNASTAR, Madison WI) which creates alignments between two or more sequences according to methods  
30 selected by the user, e.g., the clustal method. (See, e.g., Higgins, D.G. and P.M. Sharp (1988) Gene 73:237-244.) The clustal algorithm groups sequences into clusters by examining the distances between all pairs. The clusters are aligned pairwise and then in groups. The percentage similarity between two amino acid sequences, e.g., sequence A and sequence B, is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the  
35 number of gap residues in sequence B, into the sum of the residue matches between sequence A

and sequence B, times one hundred. Gaps of low or of no similarity between the two amino acid sequences are not included in determining percentage similarity. Percent identity between nucleic acid sequences can also be counted or calculated by other methods known in the art, e.g., the Jotun Hein method. (See, e.g., Hein, J. (1990) Methods Enzymol. 183:626-645.) Identity between  
5 sequences can also be determined by other methods known in the art, e.g., by varying hybridization conditions.

“Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

10 The term “humanized antibody” refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

“Hybridization” refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

15 The term “hybridization complex” refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g.,  $C_0t$  or  $R_0t$  analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate  
20 substrate to which cells or their nucleic acids have been fixed).

The words “insertion” or “addition” refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, to the sequence found in the naturally occurring molecule.

25 “Immune response” can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

The term “microarray” refers to an arrangement of distinct polynucleotides on a substrate.

The terms “element” or “array element” in a microarray context, refer to hybridizable  
30 polynucleotides arranged on the surface of a substrate.

The term “modulate” refers to a change in the activity of PHSP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of PHSP.

The phrases “nucleic acid” or “nucleic acid sequence,” as used herein, refer to a  
35 nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to



DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material. In this context, "fragments" refers to those nucleic acid sequences which, comprise a region of unique polynucleotide sequence that specifically identifies  
5 SEQ ID NO:32-62, for example, as distinct from any other sequence in the same genome. For example, a fragment of SEQ ID NO:32-62 is useful in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:32-62 from related polynucleotide sequences. A fragment of SEQ ID NO:32-62 is at least about 15-20 nucleotides in length. The precise length of the fragment of SEQ ID NO:32-62 and the region of SEQ ID  
10 NO:32-62 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment. In some cases, a fragment, when translated, would produce polypeptides retaining some functional characteristic, e.g., antigenicity, or structural domain characteristic, e.g., ATP-binding site, of the full-length polypeptide

The terms "operably associated" or "operably linked" refer to functionally related nucleic  
15 acid sequences. A promoter is operably associated or operably linked with a coding sequence if the promoter controls the translation of the encoded polypeptide. While operably associated or operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain genetic elements, e.g., repressor genes, are not contiguously linked to the sequence encoding the polypeptide but still bind to operator sequences that control expression of the polypeptide.

20 The term "oligonucleotide" refers to a nucleic acid sequence of at least about 6 nucleotides to 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in PCR amplification or in a hybridization assay or microarray. "Oligonucleotide" is substantially equivalent to the terms "amplimer," "primer," "oligomer," and "probe," as these terms are commonly defined in the art.

25 "Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

30 The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding PHSP, or fragments thereof, or PHSP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" or "specifically binding" refer to that interaction between a  
35 protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon

the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds  
5 to the antibody.

The term "stringent conditions" refers to conditions which permit hybridization between polynucleotides and the claimed polynucleotides. Stringent conditions can be defined by salt concentration, the concentration of organic solvent, e.g., formamide, temperature, and other conditions well known in the art. In particular, stringency can be increased by reducing the  
10 concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with  
15 which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers,  
20 microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

"Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of  
25 foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host  
30 chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of PHSP polypeptides refers to an amino acid sequence that is altered by one or more amino acid residues. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with  
35 isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of

glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR).

5       The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to PHSP. This definition may also include, for example, "allelic" (as defined above), "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The  
10       corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide  
15       polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

#### THE INVENTION

      The invention is based on the discovery of new human phosphorylation effectors (PHSP),  
20       the polynucleotides encoding PHSP, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, immune, and neuronal disorders.

      Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding PHSP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte  
25       clones in which nucleic acids encoding each PHSP were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. The clones in column 5 were used to assemble the consensus nucleotide sequence of each PHSP and are useful as fragments in hybridization technologies.

30       The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO and column 2 shows the number of amino acid residues in each polypeptide. Columns 3 and 4 show potential phosphorylation sites and potential glycosylation sites, respectively. Column 5 shows the amino acid residues comprising signature sequences and motifs. Column 6 shows homologous sequences as identified by BLAST analysis,  
35       while column 7 shows analytical methods used to identify each polypeptide through sequence

homology and protein motifs.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding PHSP. The first column of Table 3 lists the SEQ ID NOs. Column 2 lists tissue categories which express PHSP as a fraction of total tissue  
5 categories expressing PHSP. Column 3 lists diseases, disorders, or conditions associated with those tissues expressing PHSP. Column 4 lists the vectors used to subclone the cDNA library.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding PHSP were isolated. Column 1 references the SEQ ID NO, column 2 shows the cDNA libraries from which these clones were isolated, and column 3  
10 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

The following fragments of the nucleotide sequences encoding PHSP are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:32-62 and to distinguish between SEQ ID NO:32-62 and related polynucleotide sequences. The useful  
15 fragments include, the fragment of SEQ ID NO:32 from about nucleotide 81 to about nucleotide 110; the fragment of SEQ ID NO:33 from about nucleotide 323 to about nucleotide 352; the fragment of SEQ ID NO:34 from about nucleotide 83 to about nucleotide 112; the fragment of SEQ ID NO:35 from about nucleotide 524 to about nucleotide 553; the fragment of SEQ ID NO:36 from about nucleotide 275 to about nucleotide 346; the fragment of SEQ ID NO:37 from  
20 about nucleotide 1328 to about nucleotide 1396; the fragment of SEQ ID NO:38 from about nucleotide 245 to about nucleotide 304; the fragment of SEQ ID NO:39 from about nucleotide 1253 to about nucleotide 1312; the fragment of SEQ ID NO:41 from about nucleotide 117 to about nucleotide 170; the fragments of SEQ ID NO:42 from about nucleotide 109 to about nucleotide 153, and from about nucleotide 325 to about nucleotide 369; the fragments of SEQ ID NO:43 from  
25 about nucleotide 380 to about nucleotide 424, and from about nucleotide 1190 to about nucleotide 1234; the fragment of SEQ ID NO:44 from about nucleotide 1 to about nucleotide 46; the fragment of SEQ ID NO:45 from about nucleotide 533 to about nucleotide 577; the fragments of SEQ ID NO:46 from about nucleotide 109 to about nucleotide 153, and from about nucleotide 379 to about nucleotide 423; the fragment of SEQ ID NO:47 from about nucleotide 1730 to about  
30 nucleotide 1774; the fragment of SEQ ID NO:48 from about nucleotide 433 to about nucleotide 477; the fragment of SEQ ID NO:49 from about nucleotide 1117 to about nucleotide 1155; the fragment of SEQ ID NO:50 from about nucleotide 166 to about nucleotide 213; the fragment of SEQ ID NO:51 from about nucleotide 60 to about nucleotide 95; the fragment of SEQ ID NO:52 from about nucleotide 326 to about nucleotide 370; the fragment of SEQ ID NO:53 from about  
35 nucleotide 25 to about nucleotide 66; the fragment of SEQ ID NO:54 from about nucleotide 55 to

about nucleotide 102; the fragment of SEQ ID NO:55 from about nucleotide 138 to about nucleotide 167; the fragment of SEQ ID NO:56 from about nucleotide 29 to about nucleotide 58; the fragment of SEQ ID NO:57 from about nucleotide 455 to about nucleotide 484; the fragment of SEQ ID NO:58 from about nucleotide 226 to about nucleotide 255; the fragment of SEQ ID NO:59 from about nucleotide 557 to about nucleotide 598; the fragment of SEQ ID NO:60 from about nucleotide 284 to about nucleotide 325; the fragment of SEQ ID NO:61 from about nucleotide 1043 to about nucleotide 1090; and the fragment of SEQ ID NO:62 from about nucleotide 84 to about nucleotide 132. The polypeptides encoded by the fragments of SEQ ID NO:32-62 are useful, for example, as immunogenic peptides.

10 The invention also encompasses PHSP variants. A preferred PHSP variant is one which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% amino acid sequence identity to the PHSP amino acid sequence, and which contains at least one functional or structural characteristic of PHSP.

The invention also encompasses polynucleotides which encode PHSP. In a particular  
15 embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:32-62, which encodes PHSP.

The invention also encompasses a variant of a polynucleotide sequence encoding PHSP. In particular, such a variant polynucleotide sequence will have at least about 80%, more preferably at least about 85%, and most preferably at least about 95% polynucleotide sequence identity to the  
20 polynucleotide sequence encoding PHSP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:32-62 which has at least about 80%, more preferably at least about 85%, and most preferably at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:32-62. Any one of the polynucleotide variants described above can encode  
25 an amino acid sequence which contains at least one functional or structural characteristic of PHSP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding PHSP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could  
30 be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring PHSP, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode PHSP and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring PHSP under appropriately  
35 selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding

PHSP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide  
5 sequence encoding PHSP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode PHSP and PHSP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the  
10 synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding PHSP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID  
15 NO:32-62 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and most preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low  
20 stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and most preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, more preferably of at least about 37°C, and most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the  
25 concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35%  
30 formamide, and 100 µg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42°C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50 % formamide, and 200 µg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

The washing steps which follow hybridization can also vary in stringency. Wash stringency  
35 conditions can be defined by salt concentration and by temperature. As above, wash stringency can

be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include temperature of at least  
5 about 25°C, more preferably of at least about 42°C, and most preferably of at least about 68°C. In a preferred embodiment, wash steps will occur at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a most preferred embodiment, wash steps will occur at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will  
10 be readily apparent to those skilled in the art.

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations  
15 of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 (Hamilton, Reno NV), Peltier thermal cycler 200 (PTC200; MJ Research, Watertown MA) and the ABI CATALYST 800 (Perkin-Elmer). Sequencing is then carried out using the ABI 373 or 377 DNA sequencing systems (Perkin-Elmer), or the MEGABACE  
20 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

25 The nucleic acid sequences encoding PHSP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.)  
30 Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et  
35 al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions

and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) *Nucleic Acids Res.* 19:3055-306). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode PHSP may be cloned in recombinant DNA molecules that direct expression of PHSP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express PHSP.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter PHSP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction



sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

In another embodiment, sequences encoding PHSP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, and Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232.)  
5 Alternatively, PHSP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of PHSP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other  
10 proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New  
15 York NY.)

In order to express a biologically active PHSP, the nucleotide sequences encoding PHSP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and  
20 inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding PHSP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding PHSP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding PHSP and its initiation codon and upstream regulatory sequences are inserted into  
25 the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion  
30 of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding PHSP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and  
35 in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory

Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding PHSP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding PHSP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding PHSP can be achieved using a multifunctional *E. coli* vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or pSPORT1 plasmid (Life Technologies). Ligation of sequences encoding PHSP into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for *in vitro* transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509.) When large quantities of PHSP are needed, e.g. for the production of antibodies, vectors which direct high level expression of PHSP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of PHSP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH, may be used in the yeast *Saccharomyces cerevisiae* or *Pichia pastoris*. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, *supra*; Grant et al. (1987) *Methods Enzymol.* 153:516-54; and Scorer, C. A. et al. (1994) *Bio/Technology* 12:181-184.)

Plant systems may also be used for expression of PHSP. Transcription of sequences encoding PHSP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY,

pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding PHSP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses PHSP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of PHSP in cell lines is preferred. For example, sequences encoding PHSP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* or *apr* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides, neomycin and G-418; and *als* or *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech),  $\beta$  glucuronidase and its substrate  $\beta$ -glucuronide, or luciferase and its substrate luciferin may

be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) *Methods Mol. Biol.* 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding PHSP is inserted within a marker gene sequence, transformed cells containing sequences encoding PHSP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding PHSP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding PHSP and that express PHSP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of PHSP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on PHSP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul MN, Sect. IV; Coligan, J. E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding PHSP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding PHSP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for

ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding PHSP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein  
5 produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode PHSP may be designed to contain signal sequences which direct secretion of PHSP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the  
10 inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational  
15 activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC, Bethesda MD) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding PHSP may be ligated to a heterologous sequence resulting in translation of a  
20 fusion protein in any of the aforementioned host systems. For example, a chimeric PHSP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of PHSP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST),  
25 maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies  
30 that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the PHSP encoding sequence and the heterologous protein sequence, so that PHSP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch 10). A variety of commercially available kits may also be used to facilitate expression and purification of  
35 fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled PHSP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract systems (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, preferably <sup>35</sup>S-methionine.

Fragments of PHSP may be produced not only by recombinant production, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, supra, pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Various fragments of PHSP may be synthesized separately and then combined to produce the full length molecule.

### THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of PHSP and protein phosphatases. In addition, the expression of PHSP is closely associated with reproductive tissue, nervous tissue, gastrointestinal tissue, cell proliferation, cancer, inflammation, and immune response. Therefore, PHSP appears to play a role in cell proliferative, immune, and neuronal disorders. In the treatment of disorders associated with increased PHSP expression or activity, it is desirable to decrease the expression or activity of PHSP. In the treatment of disorders associated with decreased PHSP expression or activity, it is desirable to increase the expression or activity of PHSP.

Therefore, in one embodiment, PHSP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PHSP. Examples of such disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an immune disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis,

WO 00/06728

PCT/US99/17132

hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner  
5 syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and a neuronal disorder, such as akathisia, Alzheimer's disease, amnesia, amyotrophic lateral sclerosis, bipolar disorder, catatonia, dementia, depression, diabetic neuropathy, Down's syndrome, tardive dyskinesia, dystonias, epilepsy, Huntington's disease, peripheral neuropathy, multiple sclerosis, neurofibromatosis, Parkinson's  
10 disease, paranoid psychoses, postherpetic neuralgia, schizophrenia, and Tourette's disorder.

In another embodiment, a vector capable of expressing PHSP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PHSP including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified  
15 PHSP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PHSP including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of PHSP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity  
20 of PHSP including, but not limited to, those listed above.

In a further embodiment, an antagonist of PHSP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PHSP. Examples of such disorders include, but are not limited to, those described above. In one aspect, an antibody which specifically binds PHSP may be used directly as an antagonist or indirectly as a targeting or delivery  
25 mechanism for bringing a pharmaceutical agent to cells or tissue which express PHSP.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding PHSP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PHSP including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary  
30 sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic  
35 efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of PHSP may be produced using methods which are generally known in the art. In particular, purified PHSP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind PHSP. Antibodies to PHSP may also be generated using methods that are well known in the art. Such antibodies may include, but are not  
5 limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with PHSP or with any fragment or oligopeptide thereof  
10 which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

15 It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to PHSP have an amino acid sequence consisting of at least about 5 amino acids, and, more preferably, of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of PHSP amino acids may be  
20 fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to PHSP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma  
25 technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate  
30 antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce PHSP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be  
35 generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton



D.R. (1991) Proc. Natl. Acad. Sci. 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837; 5 Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for PHSP may also be generated. For example, such fragments include, but are not limited to, F(ab')<sub>2</sub> fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and 10 easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such 15 immunoassays typically involve the measurement of complex formation between PHSP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering PHSP epitopes is preferred, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay 20 techniques may be used to assess the affinity of antibodies for PHSP. Affinity is expressed as an association constant,  $K_a$ , which is defined as the molar concentration of PHSP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The  $K_a$  determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple PHSP epitopes, represents the average affinity, or avidity, of the antibodies for 25 PHSP. The  $K_a$  determined for a preparation of monoclonal antibodies, which are monospecific for a particular PHSP epitope, represents a true measure of affinity. High-affinity antibody preparations with  $K_a$  ranging from about  $10^9$  to  $10^{12}$  L/mole are preferred for use in immunoassays in which the PHSP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with  $K_a$  ranging from about  $10^6$  to  $10^7$  L/mole are preferred for use in immunopurification and similar 30 procedures which ultimately require dissociation of PHSP, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington, DC; Liddell, J. E. and Cryer, A. (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to 35 determine the quality and suitability of such preparations for certain downstream applications. For

example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is preferred for use in procedures requiring precipitation of PHSP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra,  
5 and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding PHSP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding PHSP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary  
10 to polynucleotides encoding PHSP. Thus, complementary molecules or fragments may be used to modulate PHSP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding PHSP.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or  
15 from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding PHSP. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

Genes encoding PHSP can be turned off by transforming a cell or tissue with expression  
20 vectors which express high levels of a polynucleotide, or fragment thereof, encoding PHSP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the  
25 vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding PHSP. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, are preferred. Similarly,  
30 inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A  
35 complementary sequence or antisense molecule may also be designed to block translation of mRNA

by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding PHSP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding PHSP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such

therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of PHSP, antibodies to PHSP, and mimetics, agonists, antagonists, or inhibitors of PHSP. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.

Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol.

5 Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in

10 aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil,

15 or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be

20 permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many

25 acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

30 After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of PHSP, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The

35 determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for  
5 administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example PHSP or fragments thereof, antibodies of PHSP, and agonists, antagonists or inhibitors of PHSP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by  
10 calculating the  $ED_{50}$  (the dose therapeutically effective in 50% of the population) or  $LD_{50}$  (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the  $LD_{50}/ED_{50}$  ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such  
15 compositions is preferably within a range of circulating concentrations that includes the  $ED_{50}$  with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the  
20 active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular  
25 formulation.

Normal dosage amounts may vary from about 0.1  $\mu\text{g}$  to 100,000  $\mu\text{g}$ , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their  
30 inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

#### DIAGNOSTICS

In another embodiment, antibodies which specifically bind PHSP may be used for the diagnosis of disorders characterized by expression of PHSP, or in assays to monitor patients being  
35 treated with PHSP or agonists, antagonists, or inhibitors of PHSP. Antibodies useful for diagnostic

purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for PHSP include methods which utilize the antibody and a label to detect PHSP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter  
5 molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring PHSP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of PHSP expression. Normal or standard values for PHSP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to PHSP under conditions suitable  
10 for complex formation. The amount of standard complex formation may be quantitated by various methods, preferably by photometric means. Quantities of PHSP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding PHSP may be used for  
15 diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of PHSP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of PHSP, and to monitor regulation of PHSP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding PHSP or closely related molecules may be used to identify nucleic acid sequences which encode PHSP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification (maximal, high,  
25 intermediate, or low), will determine whether the probe identifies only naturally occurring sequences encoding PHSP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably have at least 50% sequence identity to any of the PHSP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:32-  
30 62 or from genomic sequences including promoters, enhancers, and introns of the PHSP gene.

Means for producing specific hybridization probes for DNAs encoding PHSP include the cloning of polynucleotide sequences encoding PHSP or PHSP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA  
35 polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a

variety of reporter groups, for example, by radionuclides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding PHSP may be used for the diagnosis of disorders associated with expression of PHSP. Examples of such disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an immune disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and a neuronal disorder, such as akathisia, Alzheimer's disease, amnesia, amyotrophic lateral sclerosis, bipolar disorder, catatonia, dementia, depression, diabetic neuropathy, Down's syndrome, tardive dyskinesia, dystonias, epilepsy, Huntington's disease, peripheral neuropathy, multiple sclerosis, neurofibromatosis, Parkinson's disease, paranoid psychoses, postherpetic neuralgia, schizophrenia, and Tourette's disorder. The polynucleotide sequences encoding PHSP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered PHSP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding PHSP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding PHSP may be labeled by standard methods and added to a fluid or tissue sample



from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding PHSP in the sample  
5 indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of PHSP, a normal or standard profile for expression is established. This may be accomplished by combining  
10 body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding PHSP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples  
15 from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from  
20 successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance  
25 of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding PHSP may involve the use of PCR. These oligomers may be chemically synthesized, generated  
30 enzymatically, or produced *in vitro*. Oligomers will preferably contain a fragment of a polynucleotide encoding PHSP, or a fragment of a polynucleotide complementary to the polynucleotide encoding PHSP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantitation of closely related DNA or RNA sequences.

35 Methods which may also be used to quantify the expression of PHSP include radiolabeling

or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) *Proc. Natl. Acad. Sci.* 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) *Proc. Natl. Acad. Sci.* 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding PHSP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) *Nat Genet.* 15:345-355; Price, C.M. (1993) *Blood Rev.* 7:127-134; and Trask, B.J. (1991) *Trends Genet.* 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) site. Correlation between the location of the gene encoding PHSP on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known.

New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that  
5 area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, PHSP, its catalytic or immunogenic fragments, or  
10 oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between PHSP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds  
15 having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with PHSP, or fragments thereof, and washed. Bound PHSP is then detected by methods well known in the art. Purified PHSP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively,  
20 non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding PHSP specifically compete with a test compound for binding PHSP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PHSP.

25 In additional embodiments, the nucleotide sequences which encode PHSP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding  
30 description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. 09/173,482, 09/123,494, 09/152,814, 09/229,005, 60/106,889, 60/109,093,  
35 and 60/113,796, are hereby expressly incorporated by reference.

## EXAMPLES

### I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A<sup>+</sup>) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6). Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), pSPORT1 plasmid (Life Technologies), or pINCY (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells including XL1-BLUE, XL1-BLUERF, or SOLR from Stratagene or DH5 $\alpha$ , DH10B, or ELECTROMAX DH10B from Life Technologies.

### II. Isolation of cDNA Clones

Plasmids were recovered from host cells by in vivo excision, using the UNIZAP vector system (Stratagene) or cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid kit from QIAGEN.

Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a Fluoroskan II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

### III. Sequencing and Analysis

cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Perkin-Elmer) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing systems (Perkin-Elmer) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST,

dynamic programing, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases, such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS to acquire annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Str. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:32-62. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

#### IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, *supra*, ch. 7; Ausubel, 1995, *supra*, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ database (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding PHSP occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic,

developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation/trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories.

5 Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

#### V. Extension of PHSP Encoding Polynucleotides

The full length nucleic acid sequences of SEQ ID NO:32-62 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this

10 fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in

15 hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction

20 mix contained DNA template, 200 nmol of each primer, reaction buffer containing  $Mg^{2+}$ ,  $(NH_4)_2SO_4$ , and  $\beta$ -mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the

25 alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100  $\mu$ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE

30 and 0.5  $\mu$ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5  $\mu$ l to 10  $\mu$ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending

35 the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulphoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

In like manner, the nucleotide sequences of SEQ ID NO:32-62 are used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

#### VI. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:32-62 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250  $\mu$ Ci of [ $\gamma$ -<sup>32</sup>P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10<sup>7</sup> counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon



membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are compared.

5 **VII. Microarrays**

A chemical coupling procedure and an ink jet device can be used to synthesize array elements on the surface of a substrate. (See, e.g., Baldeschweiler, supra.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand  
10 or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

15 Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an  
20 appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

25 **VIII. Complementary Polynucleotides**

Sequences complementary to the PHSP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring PHSP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are  
30 designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of PHSP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the PHSP-encoding transcript.

**IX. Expression of PHSP**

35 Expression and purification of PHSP is achieved using bacterial or virus-based expression

systems. For expression of PHSP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express PHSP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of PHSP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding PHSP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, PHSP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from PHSP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch 10 and 16). Purified PHSP obtained by these methods can be used directly in the following activity assay.

#### **X. Demonstration of PHSP Activity**

PHSP protein kinase is measured by the phosphorylation of a substrate in the presence of gamma-labeled  $^{32}\text{P}$ -ATP. PHSP is incubated with an appropriate substrate and  $^{32}\text{P}$ -ATP in a buffered solution.  $^{32}\text{P}$ -labeled product is separated from free  $^{32}\text{P}$ -ATP by gel electrophoresis or chromatographic procedures, and the incorporated  $^{32}\text{P}$  is quantified by phosphorimage analysis or using a scintillation counter. The amount of  $^{32}\text{P}$  detected is proportional to the activity of PHSP in this assay. The specific amino acid residue phosphorylated by PHSP may be determined by

phosphoamino acid analysis of the labeled, hydrolyzed protein.

PHSP phosphatase activity is measured by the removal of phosphate from a [ $^{32}\text{P}$ ]-labelled substrate. PHSP is incubated with an appropriate [ $^{32}\text{P}$ ]-labelled substrate in a buffered solution. Reaction products are separated by gel electrophoresis or chromatographic procedures, and the level of  $^{32}\text{P}$  associated with the substrate molecule is quantified by phospho-image analysis or scintillation counting. The difference in  $^{32}\text{P}$  associated with untreated substrate versus PHSP-treated substrate is a measure of phosphatase activity and is proportional to PHSP activity.

#### **XI. Functional Assays**

PHSP function is assessed by expressing the sequences encoding PHSP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10  $\mu\text{g}$  of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2  $\mu\text{g}$  of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate properties, for example, their apoptotic state. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of PHSP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding PHSP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art.

Expression of mRNA encoding PHSP and other genes of interest can be analyzed by northern analysis or microarray techniques.

## **XII. Production of PHSP Specific Antibodies**

PHSP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g.,  
5 Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the PHSP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for  
10 selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase  
15 immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

## **XIII. Purification of Naturally Occurring PHSP Using Specific Antibodies**

20 Naturally occurring or recombinant PHSP is substantially purified by immunoaffinity chromatography using antibodies specific for PHSP. An immunoaffinity column is constructed by covalently coupling anti-PHSP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

25 Media containing PHSP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PHSP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/PHSP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and PHSP is collected.

## **XIV. Identification of Molecules Which Interact with PHSP**

PHSP, or biologically active fragments thereof, are labeled with <sup>125</sup>I Bolton-Hunter reagent. (See, e.g., Bolton et al. (1973) *Biochem. J.* 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled PHSP, washed, and any wells with labeled PHSP complex are assayed. Data obtained using different concentrations of PHSP are used to  
35 calculate values for the number, affinity, and association of PHSP with the candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific  
5 embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

TABLE I

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	32	132240	BMARNOT02	132240H1 and 132240R1 (BMARNOT02), 3254142H1 (OVRTUT01), 1453821X14F1 and 1453821F6 (PENITUT01)
2	33	2180116	SININOT01	2180116H1 and 2180116T6 (SININOT01), 3046645H1 (HEAANOT01), 1918183H1 (PROSNOT06), and 1482405F1 (CORPNOT02)
3	34	2197671	SPLNFET02	2197671H1 (SPLNFET02), 666366X22R1 (SCORNOT01), 693783X14 (SYNORAT03), 824265X33F1 (PROSNOT06), 039482R1 and 039482F1 (HUVENOB01), 1453984T6 (PENITUT01), 1663987H1 (BRSTNOT09), and 125901R1 (LUNGNOT01)
4	35	2594943	OVRTUT02	2594943H1 (OVRTUT02), 3617557H1 (EPIPNOT01), 2269005R6 (UTRSNOT02), 1307764F6 (COLNFET02), 1377794F6 (LUNGNOT10), and 1286608H1 (BRAINOT11)
5	36	1513871	PANCTUT01	754239R6 (BRAITUT02), 1513871H1 (PANCTUT01), 2414420F6 (HNT3AZT01), 3291775F6 (BONRFET01), 3821451F6 (BONSTUT01)
6	37	156108	THP1PLB02	156108F1 and 156108H1 (THP1PLB02), 336346R6 (EOSIHET02), 1319528F1 (BLADNOT04), 2375549F6 (ISLTNOT01), SBFA04563F1, SBFA04977F1
7	38	2883243	UTRSTUT05	1342082F6 (COLNTUT03), 1933387T6 (COLNNOT16), 2766460F6 (BRSTNOT12), 2883243H1 (UTRSTUT05), 3524262H1 (ESOGTUN01), 3766487F6 (BRSTNOT24)

TABLE 1 cont.

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
8	39	3173355	UTRSTUT04	1300803F6 and 1300803T6 (BRSTNOT07), 2477542F6 (SMCANOT01), 2477542T6 (SMCANOT01), 2875968H1 (THYRNOT10), 3173355F6 and 3173355H1 (UTRSTUT04), 3290825H1 (BONRFET01), 5192561H1 (OVARIT06)
9	40	5116906	SMCBUNT01	267517F1 (HNT2NOT01), 263823R1 (HNT2AGT01), 5116906H1 (SMCBUNT01)
10	41	940589	ADRENOT03	029801R6 (SPLNFET01), 940589H1 (ADRENOT03), 1737403T6 (COLNNOT22), 1805477F6 and 1805477T6 (SINTNOT13), 2447613H1 (THP1NOT03), 3408563H1 (PROSTUS08), 3519506H1 (LUNGNOT03), 3637343T6 (LUNGNOT30)
11	42	304421	TESTNOT04	304421H1, 304421X318B2, and 304421X323B2 (TESTNOT04), 2639579F6 (BONTNOT01), 2951859H1 (KIDNFET01)
12	43	1213802	BRSTTUT01	894574R1 (BRSTNOT05), 1213802H1 (BRSTTUT01), 1233414F1 and 1234238H1 (LUNGFET03), 1255782F2 and 1255782T1 (MENITUT03), 1455429F1 (COLNFET02), 1576102T1 (LNODNOT03), 2189267F6 (PROSNOT26), 2748179F6 (LUNGNOT11), 2831667H1 (TLYMNOT03), 3031229H1 (TLYMNOT05), 3054893H1 (LNODNOT08), 3797030F6 (SPLNNOT12), 3880154H1 (SPLNNOT11), 4852525H1 (TESTNOT10), 5514137H1 (BRADDI01), 5518378H1 (LIVRDIR01)
13	44	1378134	LUNGNOT10	1378134H1 and 1378134X11 (LUNGNOT10), 2205185F6 (SPLNFET02), 4959694H1 (TLYMNOT05), SAMA00107F1, SAMA00160F1, SAMA00020F1

TABLE 1 cont.

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
14	45	1490070	UCMCL5T01	432218H1 (BRAVUNT02), 1490070H1 (UCMCL5T01), 1535394F1 (SPLNNOT04), 1616509F6 and 1616509T6 (BRAITUT12), 2490845H1 (EOSITXT01), 2723789F6 (LUNGUT10), SAOA00263F1
15	46	1997814	BRSTTUT03	855350R1 (NGANNOT01), 875417R1 (LUNGAST01), 895096R1 (BRSTNOT05), 1271348F1 (TESTTUT02), 1331289F6 (PANCNOT07), 1359243F1 (LUNGNOT12), 1540824T1 (SINTTUT01), 1839828H1 (EOSITXT01), 1997814H1 (BRSTTUT03), 2170638F6 (ENDCNOT03), 3751363F6 (UTRSNOT18)
16	47	2299715	BRSTNOT05	637354R6 and 637354T6 (NEUTGMT01), 1852144F6 (LUNGFET03), 2172576F6 (ENDCNOT03), 2232449F6 (PROSNOT16), 2299715H1 (BRSTNOT05), 2509737X325D2 (CONUTUT01), 2606210F6 (LUNGUT07), 2692024F6 (LUNGNOT23), 2805893F6 (BLADTUT08), 2986160H1 (CARGDIT01), 3085382H1 (HEAONOT03), 3136101F6 and 3136587H1 (SMCCNOT01), 4249977H1 (BRADDIR01)
17	48	209854	SPLNNOT02	209854H1 and 209854T6 (SPLNNOT02), 3152165R6 and 3152165T6 (ADRENON04)
18	49	1384286	BRAITUT08	676123R6 and 676123T6 (CRBLNOT01), 989218X11 and 989218X12 (LVENNOT03), 1384286H1 (BRAITUT08), 3099868H1 (PROSBPT03), 4693167H1 (BRAENOT02)
19	50	1512656	PANCUT01	322847X5 (EOSIHET02), 1253795T6 (LUNGFET03), 1512656H1 (PANCUT01), 1561686X303D1 (SPLNNOT04), 2212305H1 (SINTFET03), 2697679H1 (UTRSNOT12), 3205172H1 (PENCNOT03), 5313318H1 (KIDETXS02)



TABLE 1 cont.

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
20	51	2098635	BRAITUT02	1268848T1, 1268848X301F1, and 2157157H1 (BRAINOT09), 2098635H1 and 2098635R6 (BRAITUT02), 2198819F6, 2198819X301D4, 2198819X303D1, 2198819X309B2, and 2198819X309D4 (SPLNFET02), 2784975H2 (BRSTNOT13), 3320340H1 (PROSBPT03)
21	52	2446646	THP1NOT03	000297R6 and 000297X61 (U937NOT01), 2446646H1 (THP1NOT03), 2557274F6 (THYMNOT03)
22	53	2764911	BRSTNOT12	678618T6 and 678618X14 (UTRSNOT02), 2304126R6 (BRSTNOT05), 2764911H1 (BRSTNOT12), 2834475F6 (TLYMNOT03), 2915803F6 (THYMFET03), 3035012F6 (TLYMNOT05), SAFC00027F1, SAFC00254F1, SAFC02376F1, SAFC01609F1
23	54	3013946	MUSCNOT07	673753H1 (CRBLNOT01), 989218X11 and 989218X14 (LVENNOT03), 2821720F6 (ADRETUT06), 3013946F6, 3013946H1, and 3013946T6 (MUSCNOT07), 4693167H1 (BRAENOT02)
24	55	067967	HUVESB01	067967X92, 067966R1, and 067967H1 (HUVESB01), SAIA02074F1, SAIA03254F1, SAIA03603F1, and SAIA02259F1
25	56	346275	THYMNOT02	346275H1 (THYMNOT02), 609792X12 (COLNNOT01), SAGA03543F1, SAGA02528F1, and SAGA00285F1
26	57	283746	CARDNOT01	283746H1 and 283746X10 (CARDNOT01), 4903108H1 (TLYMNOT08), 557918X15 (MPHGLPT02), and 2379045F6 (ISLTNOT01)
27	58	2696537	UTRSNOT12	2696537H1 (UTRSNOT12), 3173337F6 (UTRSTUT04), 082658X100 (HUVESB01), and 603219T6 (BRSTTUT01)

TABLE 1 cont.

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
28	59	551178	BEPINOT01	551178H1 (BEPINOT01), 861522R1 (BRAITUT03), 965838R1 (BRSTNOT05), 1574007F1 and 1574007T1 (LNODNOT03), 1830083T6 and 1831194T6 (THP1AZT01), 3098496H1 (CERVNOT03), 3293481H1 (TLYJINT01)
29	60	619292	PGANNOT01	613165F1 (COLNTUT02), 619292H1 and 619292X13 (PGANNOT01)
30	61	2054049	BEPINOT01	1736355F6 (COLNNOT22), 2054049H1 (BEPINOT01), 2379092T6 (ISLTNOT01), 3127284T3 (LUNGUT12), 3136377F6 (SMCCNOT01), SBMA00545F1, SBMA00827F1, SBMA02930F1, SBMA02853F1
31	62	2843910	DRGLNOT01	036294X71 (HUVENOB01), 066017X102, 068399R1, and 068399X3 (HUVESTB01), 1527276H1 (UCMCL5T01), 1846570T6 (COLNNOT09), 2843910H1 (DRGLNOT01)

TABLE 2

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
1	300	S3 S15 S19 S20 S24 T98 S125 S231 T238 S257 S282 S12 S41 S70 T120 T143 S146 T242	N85 N88 N96	Protein kinase motifs: G161-F256 catalytic tk domain IX: V180-E202	Protein kinase	BLAST PFAM PRINTS
2	147	S85 T38 S90		Calcium-binding repeat motifs: G28-L115	PKC- potentiated inhibitory protein of Pp1 (CPII7)	BLAST PRINTS BLOCKS
3	431	T178 S282 T25 S34 S75 S106 S194 S198 T208 T264 S299 S303 S304 S308 T328 S345 S388 T46 S137 S260	N44 N242	PTK signatures: A18-Y283 ATP-binding site: I30-K53, E127-G164 Y196-H219 PK catalytic subdomains: M99-E112, Y134-L152 G181-I191, Y243- A265	Ste20-like protein kinase	BLOCKS PRINTS PROFILES SCAN BLAST
4	218	S108 S68 S90 T133 T170 S172 T34 T123 T207		Phosphofructokinase domains: I47, V177-Q195 L148-Y164		PRINTS

TABLE 2 cont.

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
5	474	S14 S89 S98 S132 S472 T22 S26 S62 S66 T204 T320 T345 T359 S427 S443 S94 S128 T211 T336 S443 Y155		Protein kinase family signature: Y144-F425	serine /threonine protein kinase	MOTIFS PFAM BLOCKS PRINTS ProfileScan BLAST
6	540	S102 S183 S267 T296 T301 S442 S34 S58 S180 S207 S224 T360 S374 S401 S428 S478 T484 Y23	N100 N391 N457 N537	Protein kinase family signature: L18-L287	serine /threonine protein kinase	MOTIFS PFAM BLOCKS PRINTS PROFILESAN BLAST
7	454	S57 S69 S130 T203 T212 S338 S420 S91 T101 T220 S271 S295 T315 S359 S381 Y197	N55 N140 N218 N403 N437 N441	SH2 domain: W63-Y138, W354-Y428 PI 3 kinase P85 regulator: K153-G176, A216- N257, R287-N332	phosphatidyl- inositol 3- kinase	PFAM BLOCKS PRINTS BLAST
8	502	S246 T498 T21 S65 S76 T193 T203 S275 S312 S355 T484 S106 T222 S323 T498 Y347	N302 N414	Signal peptide: M1-T21 SH2 domain: V70-E80 ER targeting signal: K499-L502	tyrosine kinase	SigPept BLOCKS MOTIFS BLAST

TABLE 2 (cont.)

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
9	281	T66 T140 T141 T182 S210	N117 N139	Signal peptide: M1-I76	calcium /calmodulin- dependent protein kinase	PFAM BLAST
10	510	T297 S323 S358 S51 T312 S323 T325 S329 T377 T390 T483 S24 S152 T201 S210 S247 T292 T406 T407	N185 N349 N381 N405	Protein kinase family signature: R52-V261	Serine /threonine protein kinase	PFAM BLOCKS PRINTS MOTIFS BLAST
11	248	S5 S20 S36 T210 T245	N208	Tyrosine specific phosphatase active site: F166-A220 Dual specificity phosphatase: H95-R240	Tyrosine phosphatase or Dual specificity phosphatase	BLAST, MOTIFS BLOCKS, PRINTS PROFILES SCAN PFAM

TABLE 2 cont.

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
12	810	S62 S290 T429 S758 T17 T104 S108 T216 S279 T316 S330 T360 S386 T405 S425 S465 T473 S497 T547 T561 T715 S733 S738 S768 S196 S222 S229 S267 T281 T321 T347 S370 T400 T512 S534 T609 S617 S663 S751 T754 T762 Y67	N33		Protein kinase	BLAST, MOTIFS
13	549	S6 T502 T21 T116 S125 S320 T417 S46 S87 T240 S390 S397 S405 S430 S497	N238	ATP/GTP-binding site (p-loop): G58-T65 Protein kinase signature: I176-K199 I292-L304 Y347-L370 F456-L483	Dual specificity tyrosine /serine protein kinase	BLAST, MOTIFS BLOCKS, PRINTS PFAM
14	416	S312 T20 T97 S104 S183 T185 T211 T274 S381 S411 S72 S79 S140 S318 Y53		SH3 domain: A366-D384 N402-E414	PEST phosphatase interacting protein	BLAST, MOTIFS BLOCKS, PRINTS PFAM

TABLE 2 cont.

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
15	425	T34 S233 S234 S25 S107 T144 T198 T250 S251 S258 S282 S300 S324 S345 T390 T51 T133 S365 S383 Y71	N23 N176 N362		SH3 binding protein	BLAST, MOTIFS
16	1135	S77 T187 S259 S554 S815 S9 S17 T59 S112 T124 T222 S264 T319 S324 S326 S550 T572 S625 S681 S682 T688 T689 S706 S720 T931 S958 S978 S999 S255 T309 T351 T543 S550 S624 S632 S726 T811 S898 S1012 S1113 Y321 Y323 Y467	N33 N570 N718 N1067	Protein kinase signature: V31-K54 V149-L161 W129-V182 Tyrosine kinase catalytic site: G190-I200 S214-M236 NIK1-like kinase domain: Y836-R1115	NIK kinase	BLAST, MOTIFS PROFILES SCAN BLOCKS, PRINTS PFAM
17	228	T163 S60 T78 T68 S88 S147	N19 N100 N114		Interferon- induced PK regulator (P52rIPK)	BLAST

TABLE 2 cont.

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
18	503	S51 T262 T36 S79 T94 S109 T361 T362 T403 S472 T47 S334 S343 Y17	N313 N333 N360	Protein kinase signature: I20-K43 V132-L144 V195-E217 Protein kinase domain: Y14-V272	calcium /calmodulin- dependent protein kinase II, beta 3 isoform	BLAST, BLOCKS, PRINTS, MOTIFS, PFAM, PROFILERSCAN
19	433	S12 S77 S124 S131 S255 S290 T327 S365 S402 T70 Y88			Choline kinase isolog 384D8_3	BLAST, MOTIFS
20	527	S417 S154 S199 T367 S453 T120 S178 S413 T447 S473	N470	Protein kinase signature: I144-K167 I260-V172 ATP-binding site: Q247-G284 Y318-F341 Protein kinase domain: I138-L427	MAP-related protein kinase	BLAST, BLOCKS MOTIFS, PFAM, PROFILERSCAN



TABLE 2 cont.

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
21	322	S19 S122 T198 T200 T236 S251 T260 S264 T301 S14 S52 T181 T225	N196 N249	Protein kinase signature: L163-I175 ATP-binding site: M150-V187 I224-H247 Protein kinase domain: S32-E316	Protein tyrosine kinase	BLAST, BLOCKS, PRINTS, MOTIFS, PFAM, PROFILES CAN
22	802	S70 T87 S750 T14 T98 S144 T150 S230 S263 T353 T465 T470 S517 S633 T751 S758 T27 T74 T100 T207 S268 S368 S458	N36 N655	Protein kinase signature: L55-K81, L432-K455 ATP-binding site: E160-G197, H232-F255 PTK catalytic domain: H534-F552, C603-H625 Protein kinase domains: F49-F318, L427-L687 Protein kinase C domain: Q319-I382	Ribosomal S6 protein kinase	BLAST, BLOCKS, PRINTS, MOTIFS, PFAM, PROFILES CAN
23	641	S51 T262 S398 S436 S479 T36 S79 T94 S109 T375 T376 T541 S610 T47 S315 S333 S342 S393 S422 S431 S465 S474 S508 Y17	N313 N332 N374	Protein kinase signature: I20-K43 V132-L144 ATP-binding site: Q119-A156 Y191-F214 Protein kinase domain: Y14-V272	Ca2+ /calmodulin dependent protein kinase	BLAST, BLOCKS, PRINTS, MOTIFS, PFAM, PROFILES CAN

TABLE 2 cont.

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
24	588	S106 T155 S359 T388 T456 T531 T4, S58 S108 T126 S132 T279 S350 S436 S469 S508 S537 Y32	N63 N130 N574	Protein kinase catalytic domain: Y209-S445, F495-I522 ATP-binding site: I215-K238 STK core catalytic motif: I331-L343	Protein kinase Dyrk2	MOTIFS PFAM BLOCKS PRINTS BLAST
25	389	S31 T301 S56 S96 S134 T149 S186 S201 S283 S358 S375 Y148 Y165	N257 N343 N364	Protein kinase catalytic domain: E73-I311 STK core catalytic motif: I172-Y184 PTK core domain: D152-D208	CaM-like protein kinase	BLAST PFAM MOTIFS BLOCKS PRINTS PROFILES CAN
26	343	S68 S81 S137 S184 T219 S276 S297 T29 T125 Y86 Y211	N332	EF hand calcium-binding signature: D176-L188	protein phosphatase 2A (PR72)	BLAST MOTIFS BLOCKS
27	184	S36 T105 S40 S70 T117 Y50	N62	Tyrosine phosphatase active site domain: L63-V118	MAP kinase phosphatase (X17C)	BLAST PROFILES CAN BLOCKS PRINTS MOTIFS

TABLE 2 cont.

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
28	367	S10 S21 S44 S103 T116 T267 T309 S191 S213 S218 S256 T305 S352 Y159 Y344	N16 N17		protein phosphatase 2A, A-subunit	BLAST
29	118	S34 S84	N43	Signal peptide: M1-A27 PDZ domain: H8-S73	tyrosine phosphatase	SPScan PFAM BLAST
30	356	S9 S94 T209 T220 S259 S337 S5 S26 S75 S121 T154 S282 S332 S339 Y15 Y84	N333	tyrosine-specific protein phosphatase active site: I108-K164	tyrosine phosphatase (myotubularin)	PROFILES SCAN MOTIFS BLOCKS PRINTS BLAST
31	453	S38 S73 S119 S131 S193 S200 T236 S293 S341 T379 T124 S173 T214 S252 T256 S282 S302 S313 S391 S397	N43 N67 N357	protein phosphatase 2A p55 subunit: P10-K451	protein phosphatase 2A p55 regulatory subunit, alpha isoform	PFAM MOTIFS BLOCKS PRINTS BLAST

TABLE 3

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
32	Hematopoietic/Immune (0.333) Reproductive (0.333)	Cell proliferation (0.500) Inflammation (0.333)	PBLUESCRIPT
33	Nervous (0.216) Reproductive (0.235) Cardiovascular (0.118)	Cell proliferation (0.530) Inflammation (0.352)	pINCY
34	Reproductive (0.293) Gastrointestinal (0.192)	Cell proliferation (0.641) Inflammation (0.335)	pINCY
35	Reproductive (0.284) Nervous (0.210) Cardiovascular (0.1213)	Cell proliferation (0.729) Inflammation (0.272)	pINCY
36	Nervous (0.529) Developmental (0.118) Gastrointestinal (0.118)	Cell proliferation (0.588) Neurological (0.118) Inflammation (0.118)	pINCY
37	Hematopoietic/Immune (0.268) Reproductive (0.244) Nervous (0.122)	Inflammation (0.488) Cell Proliferative (0.415)	PBLUESCRIPT
38	Reproductive (0.400) Hematopoietic/Immune (0.160) Nervous (0.160)	Cell proliferation (0.600) Inflammation (0.320)	pINCY
39	Cardiovascular (0.312) Reproductive (0.312) Developmental (0.188)	Cell proliferation (0.938) Inflammation (0.125)	pINCY
40	Nervous (0.400) Gastrointestinal (0.267) Developmental (0.133)	Cell proliferation (0.733) Neurological (0.133) Inflammation (0.133)	pINCY
41	Gastrointestinal (0.267) Nervous (0.233) Reproductive (0.167)	Inflammation (0.533) Cell proliferation (0.534)	pSPORT1

Table 3 cont.

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
42	Musculoskeletal (0.500) Developmental (0.167) Gastrointestinal (0.167)	Cancer (0.834) Inflammation (0.167)	PBLUESCRIPT
43	Reproductive (0.240) Nervous (0.151) Gastrointestinal (0.135)	Cell proliferation (0.536) Inflammation (0.417)	pSPORT1
44	Hematopoietic/Immune (0.278) Nervous (0.222) Dermatologic (0.111)	Cell proliferation (0.444) Inflammation (0.389)	pINCY
45	Hematopoietic/Immune (0.500) Gastrointestinal (0.125) Nervous (0.125)	Inflammation (0.500) Cell proliferative (0.500)	PBLUESCRIPT
46	Nervous (0.220) Reproductive (0.213) Hematopoietic/Immune (0.140)	Cell proliferation (0.573) Inflammation (0.380)	pSPORT1
47	Hematopoietic/Immune (0.190) Gastrointestinal (0.165) Nervous (0.139)	Cell proliferation (0.582) Inflammation (0.354)	pSPORT1

Table 3 cont.

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
48	Nervous (0.333) Reproductive (0.333) Hematopoietic/Immune (0.111)	Cancer (0.444) Inflammation (0.222) Neurological (0.111)	PBLUESCRIPT
49	Nervous (0.724) Cardiovascular (0.103)	Inflammation (0.276) Cancer (0.241) Neurological (0.172)	pINCY
50	Reproductive (0.235) Hematopoietic/Immune (0.188) Gastrointestinal (0.129)	Cancer (0.447) Inflammation (0.282) Fetal (0.153)	pINCY
51	Nervous (0.368) Developmental (0.158) Gastrointestinal (0.105)	Cancer (0.368) Fetal (0.211) Inflammation (0.105)	pSPORT1
52	Cardiovascular (0.312) Hematopoietic/Immune (0.312) Reproductive (0.158)	Fetal (0.688) Cancer (0.421) Inflammation (0.125)	pINCY
53	Reproductive (0.412) Nervous (0.235) Developmental (0.118)	Cancer (0.471) Fetal (0.235) Inflammation (0.235)	pINCY
54	Nervous (0.714) Cardiovascular (0.107)	Cancer (0.250) Inflammation (0.250) Neurological (0.179)	pINCY

Table 3 cont.

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	PBLUESCRIPT
55	Reproductive (0.533) Nervous (0.133)	Cell proliferation (0.601) Inflammation (0.270)	PBLUESCRIPT
56	Hematopoietic/Immune (0.278) Nervous (0.222) Reproductive (0.154)	Cell proliferation (0.388) Inflammation (0.333) Neurological (0.111)	PBLUESCRIPT
57	Hematopoietic/Immune (0.211) Cardiovascular (0.193) Nervous (0.175)	Cell proliferation (0.474) Inflammation (0.491)	PBLUESCRIPT
58	Reproductive (0.286) Cardiovascular (0.229) Musculoskeletal (0.143)	Cell proliferation (0.715) Inflammation (0.200)	pINCY
59	Reproductive (0.253) Gastrointestinal (0.211) Nervous (0.147)	Cancer and Cell proliferation (0.684) Inflammation and Immune Response (0.242)	pSPORT1
60	Nervous (0.667) Reproductive (0.333)	Cancer (1.000)	pSPORT1
61	Reproductive (0.357) Cardiovascular (0.179) Nervous (0.125)	Cancer and Cell proliferation (0.642) Inflammation and Immune Response (0.232)	pSPORT1
62	Nervous (0.228) Reproductive (0.175) Cardiovascular (0.158) Hematopoietic/Immune (0.158)	Cancer (0.368) Inflammation and Immune Response (0.263) Fetal (0.211)	pINCY

TABLE 4

Polynucleotide SEQ ID NO:	Library	Library Comment
32	BMARNOT02	Library was constructed using RNA isolated from the bone marrow of 24 male and female Caucasian donors, 16 to 70 years old.
33	SININOT01	Library was constructed using RNA isolated from ileum tissue removed from the small intestine of a 4-year-old Caucasian female, who died from a closed head injury. Patient history included jaundice as a baby. Previous surgeries included a double hernia repair
34	SPLNFET02	Library was constructed using RNA isolated from spleen tissue removed from a Caucasian male fetus, who died at 23 weeks' gestation from premature birth. Family history included diabetes.
35	OVARTUT02	Library was constructed using RNA isolated from ovarian tumor tissue removed from a 51-year-old Caucasian female during an exploratory laparotomy, total abdominal hysterectomy, salpingo-oophorectomy, and an incidental appendectomy. Pathology indicated mucinous cystadenoma presenting as a multiloculated neoplasm involving the entire left ovary. The right ovary contained a follicular cyst and a hemorrhagic corpus luteum. The uterus showed proliferative endometrium and a single intramural leiomyoma. The peritoneal biopsy indicated benign glandular inclusions consistent with endosalpingiosis. The patient presented with abnormal weight gain and ascites. Patient history included depressive disorder, joint pain, allergies, alcohol use, and a normal delivery. Family history included atherosclerotic coronary artery disease, benign hypertension, breast cancer and uterine cancer.



TABLE 4 cont.

Polynucleotide SEQ ID NO:	Library	Library Comment
36	PANCTUT01	Library was constructed using RNA isolated from pancreatic tumor tissue removed from a 65-year-old Caucasian female during radical subtotal pancreatectomy. Pathology indicated an invasive grade 2 adenocarcinoma. Patient history included type II diabetes, osteoarthritis, cardiovascular disease, and benign neoplasm in the large bowel. Previous surgeries included a total splenectomy, cholecystectomy, and abdominal hysterectomy. Family history included cardiovascular disease, type II diabetes, and stomach cancer.
37	SMCBUNT01	Library was constructed using RNA isolated from bronchial smooth muscle cell tissue removed from a 21-year-old Caucasian male.
38	UTRSTUT05	Library was constructed using RNA isolated from uterine tumor tissue removed from a 41-year-old Caucasian female during a vaginal hysterectomy with dilation and curettage. Pathology indicated uterine leiomyoma. The endometrium was secretory and contained fragments of endometrial polyps. Benign endo- and ectocervical mucosa were identified in the endocervix. Patient history included a ventral hernia and a benign ovarian neoplasm.
39	UTRSTUT04	Library was constructed using RNA isolated from uterine tumor tissue removed from a 34-year-old Caucasian female during a hysteroscopy and an exploratory laparotomy with dilation and curettage. Pathology indicated an endometrial polyp, subserosal leiomyoma, and fragments of leiomyoma. Family history included hyperlipidemia, depressive disorder, benign hypertension, cerebrovascular disease, arteriosclerotic cardiovascular disease, and type II diabetes.

TABLE 4 cont.

Polynucleotide SEQ ID NO:	Library	Library Comment
40	SMCBUNT01	library was constructed using RNA isolated from bronchial smooth muscle cell tissue removed from a 21-year-old Caucasian male.
41	ADRENOT03	library was constructed using RNA isolated from the adrenal tissue of a 17-year-old Caucasian male, who died from cerebral anoxia.
42	TESTNOT04	library was constructed using RNA isolated from testicular tissue removed from a 37-year-old Caucasian male who died from liver disease. Patient history included cirrhosis, jaundice, and liver failure.
43	BRSTTUT01	library was constructed using RNA isolated from breast tumor tissue removed from a 55-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated invasive grade 4 mammary adenocarcinoma of mixed lobular and ductal type, extensively involving the left breast. The tumor was identified in the deep dermis near the lactiferous ducts with extracapsular extension. Seven mid and low and five high axillary lymph nodes were positive for tumor. Proliferative fibrocystic changes were characterized by apocrine metaplasia, sclerosing adenosis, cyst formation, and ductal hyperplasia without atypia. Patient history included atrial tachycardia, blood in the stool, and a benign breast neoplasm. Family history included benign hypertension, atherosclerotic coronary artery disease, cerebrovascular disease, and depressive disorder.
44	LUNGNOT10	library was constructed using RNA isolated from the lung tissue of a Caucasian male fetus who died at 23 weeks' gestation.
45	UCMCL5T01	library was constructed using RNA isolated from mononuclear cells obtained from the umbilical cord blood of 12 individuals. The cells were cultured for 12 days with IL-5 before RNA was isolated from the pooled lysates.

TABLE 4 cont.

Polynucleotide SEQ ID NO:	Library	Library Comment
46	BRSTTUT03	library was constructed using RNA isolated from breast tumor tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated multicentric invasive grade 4 lobular carcinoma. The mass was identified in the upper outer quadrant, and three separate nodules were found in the lower outer quadrant of the left breast. Patient history included skin cancer, rheumatic heart disease, osteoarthritis, and tuberculosis. Family history included cerebrovascular disease, coronary artery aneurysm, breast cancer, prostate cancer, atherosclerotic coronary artery disease, and type I diabetes.
47	BRSTNOT05	library was constructed using RNA isolated from breast tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated multicentric invasive grade 4 lobular carcinoma. Patient history included skin cancer, rheumatic heart disease, osteoarthritis, and tuberculosis. Family history included cerebrovascular and cardiovascular disease, breast and prostate cancer, and type I diabetes.

TABLE 4 cont.

Polynucleotide SEQ ID NO:	Library	Library Comment
48	SPLNNOT02	The library was constructed using RNA isolated from the spleen tissue of a 29-year-old Caucasian male, who died from head trauma. Serologies were positive for cytomegalovirus (CMV). Patient history included alcohol, marijuana, and tobacco use.
49	BRAITUT08	The library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe of a 47-year-old Caucasian male during excision of cerebral meningeal tissue. Pathology indicated grade 4 fibrillary astrocytoma with focal tumoral radionecrosis. Patient history included cerebrovascular disease, deficiency anemia, hyperlipidemia, epilepsy, and tobacco use. Family history included cerebrovascular disease and a malignant prostate neoplasm.
50	PANCTUT01	The library was constructed using RNA isolated from pancreatic tumor tissue removed from a 65-year-old Caucasian female during radical subtotal pancreatectomy. Pathology indicated an invasive grade 2 adenocarcinoma. Patient history included type II diabetes, osteoarthritis, cardiovascular disease, benign neoplasm in the large bowel, and a cataract. Previous surgeries included a total splenectomy, cholecystectomy, and abdominal hysterectomy. Family history included cardiovascular disease, type II diabetes, and stomach cancer.
51	BRAITUT02	The library was constructed using RNA isolated from brain tumor tissue removed from the frontal lobe of a 58-year-old Caucasian male during excision of a cerebral meningeal lesion. Pathology indicated a grade 2 metastatic hypernephroma. Patient history included a grade 2 renal cell carcinoma, insomnia, and chronic airway obstruction. Family history included a malignant neoplasm of the kidney.

TABLE 4 cont.

Polynucleotide SEQ ID NO:	Library	Library Comment
52	THP1NOT03	The library was constructed using RNA isolated from untreated THP-1 cells. THP-1 (ATCC TIB 202) is a human promonocyte line derived from the peripheral blood of a 1-year-old Caucasian male with acute monocytic leukemia (ref: Int. J. Cancer (1980) 26:171).
53	BRSTNOT12	The library was constructed using RNA isolated from diseased breast tissue removed from a 32-year-old Caucasian female during a bilateral reduction mammoplasty. Pathology indicated nonproliferative fibrocystic disease. Family history included cardiovascular disease.
54	MUSCNOT07	The library was constructed using RNA isolated from muscle tissue removed from the forearm of a 38-year-old Caucasian female during a soft tissue excision. Pathology for the associated tumor tissue indicated intramuscular hemangioma. Family history included breast cancer, benign hypertension, cerebrovascular disease, colon cancer, and type II diabetes.
55	HUVESTB01	Library was constructed using RNA isolated from shear-stressed HUV-EC-C (ATCC CRL 1730) cells. HUV-EC-C is an endothelial cell line derived from the vein of a normal human umbilical cord (ref:PNAS 81:6413).
56	THYMNOT02	Library was constructed using polyA RNA isolated from thymus tissue removed from a 3-year-old Caucasian male, who died from drowning.
57	CARDNOT01	Library was constructed using RNA isolated from the cardiac muscle of a 65-year-old Caucasian male, who died from a self-inflicted gunshot wound.

TABLE 4 cont.

Polynucleotide SEQ ID NO:	Library	Library Comment
58	UTRSNOT12	Library was constructed using RNA isolated from uterine myometrial tissue removed from a 41-year-old Caucasian female during a vaginal hysterectomy with a dilatation and curettage. The endometrium was secretory and contained fragments of endometrial polyps. Benign endo- and ectocervical mucosa were identified in the endocervix. Pathology for the associated tumor tissue indicated uterine leiomyoma. The patient presented with an unspecified menstrual disorder. Patient history included ventral hernia, normal delivery, a benign ovarian neoplasm, and tobacco abuse. Previous surgeries included a bilateral destruction of fallopian tubes, removal of a solitary ovary, and an exploratory laparotomy.
59	BEPINOT01	Library was constructed using RNA isolated from a bronchial epithelium primary cell line derived from a 54-year-old Caucasian male.
60	PGANNOT01	Library was constructed using RNA isolated from paraganglionic tumor tissue removed from the intra-abdominal region of a 46-year-old Caucasian male during exploratory laparotomy. Pathology indicated a benign paraganglioma and association with a grade 2 renal cell carcinoma, clear cell type.
61	BEPINOT01	Library was constructed using RNA isolated from a bronchial epithelium primary cell line derived from a 54-year-old Caucasian male.
62	DRGLNOT01	Library was constructed using RNA isolated from dorsal root ganglion tissue removed from the low thoracic/high lumbar region of a 32-year-old Caucasian male who died from acute pulmonary edema and bronchopneumonia, bilateral pleural and pericardial effusions, and malignant lymphoma (natural killer cell type). Patient history included probable cytomegalovirus infection, hepatic congestion and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, and Bell's palsy.

Table 5

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) <i>J. Mol. Biol.</i> 215:403-410; Altschul, S.F. et al. (1997) <i>Nucleic Acids Res.</i> 25: 3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) <i>Proc. Natl. Acad. Sci.</i> 85:2444-2448; Pearson, W.R. (1990) <i>Methods Enzymol.</i> 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) <i>Adv. Appl. Math.</i> 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLOCKS IMPROVED Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff, <i>Nucl. Acid Res.</i> , 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) <i>Methods Enzymol.</i> 266:88-105; and Attwood, T.K. et al. (1997) <i>J. Chem. Inf. Comput. Sci.</i> 37: 417-424.	Score=1000 or greater, Ratio of Score/Strength = 0.75 or larger; and, if applicable, Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) <i>J. Mol. Biol.</i> , 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) <i>Nucleic Acids Res.</i> 26:320-322.	Score=10-50 bits for PFAM hits, depending on individual protein families

Table 5 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221.	Normalized quality score $\geq$ GCG-specified "HIGH" value for that particular Prosite motif. Generally, score = 1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score = 120 or greater; Match length = 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439.	Score = 3.5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch et al. <u>supra</u> ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	



What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof.
- 5 2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.
3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
4. An isolated and purified polynucleotide variant having at least 80% polynucleotide sequence identity to the polynucleotide of claim 3.
- 10 5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.
7. A method for detecting a polynucleotide, the method comprising the steps of:
  - 15 (a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and
  - (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.
8. The method of claim 7 further comprising amplifying the polynucleotide prior to  
20 hybridization.
9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:32-62 and fragments thereof.
10. An isolated and purified polynucleotide variant having at least 80% polynucleotide sequence identity to the polynucleotide of claim 9.
- 25 11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.
12. An expression vector comprising at least a fragment of the polynucleotide of claim 3.
13. A host cell comprising the expression vector of claim 12.
- 30 14. A method for producing a polypeptide, the method comprising the steps of:
  - a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and
  - b) recovering the polypeptide from the host cell culture.
15. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction  
35 with a suitable pharmaceutical carrier.
16. A purified antibody which specifically binds to the polypeptide of claim 1.

- 76-

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

09744794 100501



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 15/12, C07K 14/47, C12N 9/12, 5/10, C07K 16/18, A61K 38/17</b>		A3	(11) International Publication Number: <b>WO 00/06728</b>
			(43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: <b>PCT/US99/17132</b>		(72) Inventors; and	
(22) International Filing Date: 28 July 1999 (28.07.99)		(75) Inventors/Applicants (for US only): <b>HILLMAN, Jennifer, L.</b> [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US); <b>LAL, Preeti</b> [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US); <b>PANG, Y., Tom</b> [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US); <b>CORLEY, Neil, C.</b> [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US); <b>GUEGLER, Karl, J.</b> [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US); <b>BAUGHN, Mariah, R.</b> [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US); <b>PATTERSON, Chandra</b> [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US); <b>BANDMAN, Olga</b> [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US); <b>AU-YOUNG, Janice</b> [US/US]; 1419 Kains Avenue, Berkeley, CA 94709 (US); <b>GORGONE, Gina, A.</b> [US/US]; 1253 Pinecrest Drive, Boulder Creek, CA 95006 (US); <b>YUE, Henry</b> [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US); <b>AZIMZAI, Yalda</b> [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US); <b>REDDY, Roopa</b> [IN/US]; 1233 W. McKinley Drive, Sunnyvale, CA 94086 (US); <b>LU, Dyung, Aina, M.</b> [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US); <b>SHIH, Leo, L.</b> [US/US]; Apt. B, 1081 Tanland Drive, Palo Alto, CA 94303 (US).	
(30) Priority Data:			
09/123,494	28 July 1998 (28.07.98)	US	
Not furnished	28 July 1998 (28.07.98)	US	
09/152,814	14 September 1998 (14.09.98)	US	
Not furnished	14 September 1998 (14.09.98)	US	
09/173,482	14 October 1998 (14.10.98)	US	
Not furnished	14 October 1998 (14.10.98)	US	
60/106,889	3 November 1998 (03.11.98)	US	
60/109,093	19 November 1998 (19.11.98)	US	
60/113,796	22 December 1998 (22.12.98)	US	
09/229,005	12 January 1999 (12.01.99)	US	
Not furnished	12 January 1999 (12.01.99)	US	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications			
US	Not furnished (CIP)		
Filed on	28 July 1998 (28.07.98)		
US	09/123,494 (CIP)		
Filed on	28 July 1998 (28.07.98)		
US	09/152,814 (CIP)		
Filed on	14 September 1998 (14.09.98)		
US	Not furnished (CIP)		
Filed on	14 September 1998 (14.09.98)		
US	09/173,482 (CIP)		
Filed on	14 October 1998 (14.10.98)		
US	Not furnished (CIP)		
Filed on	14 October 1998 (14.10.98)		
US	60/106,889 (CIP)		
Filed on	3 November 1998 (03.11.98)		
US	60/109,093 (CIP)		
Filed on	19 November 1998 (19.11.98)		
US	60/113,796 (CIP)		
Filed on	22 December 1998 (22.12.98)		
US	09/229,005 (CIP)		
Filed on	12 January 1999 (12.01.99)		
US	Not furnished (CIP)		
Filed on	12 January 1999 (12.01.99)		
(71) Applicant (for all designated States except US): <b>INCYTE PHARMACEUTICALS, INC.</b> [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).		(74) Agents: <b>BILLINGS, Lucy, J. et al.</b> ; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).	
		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
		Published With international search report.	
		(88) Date of publication of the international search report: 4 May 2000 (04.05.00)	
(54) Title: <b>PHOSPHORYLATION EFFECTORS</b>			
(57) Abstract			
The invention provides human phosphorylation effectors (PHSP) and polynucleotides which identify and encode PHSP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of PHSP.			



09744794, 100501

Docket No.: PF-0565 USN

**DECLARATION AND POWER OF ATTORNEY FOR  
UNITED STATES PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,  
and

I believe that I am the original, first and sole inventor (if only one name is listed below)  
or an original, first and joint inventor (if more than one name is listed below) of the subject  
matter which is claimed and for which a United States patent is sought on the invention entitled

**PHOSPHORYLATION EFFECTORS**

the specification of which:

   / is attached hereto.

   / was filed on \_\_\_\_\_ as application Serial No. \_\_\_\_\_ and if this box  
contains an X    /, was amended on \_\_\_\_\_.

  X   / was filed as Patent Cooperation Treaty international application No. PCT/US99/17132  
on July 28, 1999, if this box contains an X    /, was amended on under Patent Cooperation Treaty  
Article 19 on \_\_\_\_\_ 2001, and if this box contains an X    /, was amended on \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above-identified  
specification, including the claims, as amended by any amendment referred to above.

I acknowledge my duty to disclose information which is material to the examination of  
this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under Title 35, United States Code, §119 or §365(a)-(b) of any  
foreign application(s) for patent or inventor's certificate indicated below and of any Patent  
Cooperation Treaty international applications(s) designating at least one country other than the  
United States indicated below and have also identified below any foreign application(s) for  
patent or inventor's certificate and Patent Cooperation Treaty international application(s)  
designating at least one country other than the United States for the same subject matter and  
having a filing date before that of the application for said subject matter the priority of which is  
claimed:

Docket No.: PF-0565 USN

Country	Number	Filing Date	Priority Claimed
_____	_____	_____	// Yes // No
_____	_____	_____	// Yes // No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

Application Serial No.	Filed	Status (Pending, Abandoned, Patented)
60/155,213	June 9, 1999	Expired
60/155,196	July 14, 1999	Expired
60/155,239	July 15, 1999	Expired
60/106,889	Nov. 3, 1998	Expired
60/109,093	Nov. 19, 1998	Expired
60/113,796	Dec. 22, 1998	Expired

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application Serial No.	Filed	Status (Pending, Abandoned, Patented)
_____	_____	_____

I hereby appoint the following:

Lucy J. Billings	Reg. No. 36,749
Michael C. Cerrone	Reg. No. <u>39,132</u>
Diana Hamlet-Cox	Reg. No. <u>33,302</u>
Richard C. Ekstrom	Reg. No. <u>37,027</u>
Barrie D. Greene	Reg. No. <u>46,740</u>
Matthew R. Kaser	Reg. No. <u>44,817</u>
Lynn E. Murry	Reg. No. <u>42,918</u>
Shirley A. Recipon	Reg. No. <u>47,016</u>
Susan K. Sather	Reg. No. <u>44,316</u>
Michelle M. Stempien	Reg. No. <u>41,327</u>
David G. Streeter	Reg. No. <u>43,168</u>
Stephen Todd	Reg. No. <u>47,139</u>
Christopher Turner	Reg. No. <u>45,167</u>
P. Ben Wang	Reg. No. <u>41,420</u>

14

Docket No.: PF-0565 USN

respectively and individually, as my patent attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

**LEGAL DEPARTMENT**  
**INCYTE GENOMICS, INC.**  
**3160 PORTER DRIVE, PALO ALTO, CA 94304**

TEL: 650-855-0555

FAX: 650-849-8886 or 650-845-4166

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

**Sole Inventor or  
First Joint Inventor:**

10

Full name:

JENNIFER L. HILLMAN

Signature:

*Jennifer L. Hillman*

Date:

February 16, 2001

Citizenship

United States

Residence:

Mountain View, California CA

P.O. Address:

230 Monroe Drive, #17  
Mountain View, California 94040

**Second Joint Inventor:**

20

Full name:

PREETI LAL

Signature:

*Preeti Lal*

Date:

FEBRUARY, 16, 2001

Citizenship

India

Residence:

Santa Clara, California CA

P.O. Address:

2382 Lass Drive  
Santa Clara, California 95054

Docket No.: PF-0565 USN

## Third Joint Inventor:

3<sup>rd</sup>

Full name:

Y. TOM TANG

Signature:

Y. Tom Tang

Date:

February 27, 2001

Citizenship

People's Republic of China <sup>USA</sup>

Residence:

San Jose, California <sup>CA</sup>

P.O. Address:

4230 Ranwick Court  
San Jose, California 95118

U.S. 2/27/2001

## Fourth Joint Inventor:

4<sup>th</sup>

Full name:

NEIL C. CORLEY

Signature:

Neil C. Corley

Date:

MARCH 5, 2001

Citizenship

United States

Residence:

Castro Valley, California <sup>CA</sup>

P.O. Address:

20426 Crow Creek Road  
Castro Valley, California 94552

## Fifth Joint Inventor:

5<sup>th</sup>

Full name:

KARL J. GUEGLER

Signature:

K. J. Gugler

Date:

02/02, 2001

Citizenship

Switzerland

Residence:

Menlo Park, California <sup>CA</sup>

P.O. Address:

1048 Oakland Avenue  
Menlo Park, California 94025

Docket No.: PF-0565 USN

## Sixth Joint Inventor:

6-d

Full name:

MARIAH R. BAUGHN

Signature:

M.R. Baughn

Date:

February 12, 2001

Citizenship

United States

Residence:

San Leandro, California CA

P.O. Address:

14244 Santiago Road  
San Leandro, California 94577

## Seventh Joint Inventor:

7-d

Full name:

CHANDRA PATTERSON

Signature:

Chandra Patterson

Date:

February 7, 2001

Citizenship

United States

Residence:

Menlo Park, California CA

P.O. Address:

490 Sherwood Way, #1  
Menlo Park, California 94025

## Eighth Joint Inventor:

8-d

Full name:

OLGA BANDMAN

Signature:

Olga Bandman

Date:

16 February, 2001

Citizenship

United States

Residence:

Mountain View, California CA

P.O. Address:

366 Anna Avenue  
Mountain View, California 94043



Docket No.: PF-0565 USN

## Ninth Joint Inventor:

G.W.

Full name:

JANICE AU-YOUNG

Signature:

Janice Au-Young

Date:

February 2, 2001

Citizenship

United States

Residence:

Brisbane, California

CA

P.O. Address:

233 Golden Eagle Lane  
Brisbane, California 94005

## Tenth Joint Inventor:

10-0

Full name:

GINA A. GORGONE

Signature:

Gina A. Gorgone

Date:

Feb 5, 2001

Citizenship

United States

Residence:

Boulder Creek, California

CA

P.O. Address:

1253 Pinecrest Drive  
Boulder Creek, California 95006

## Eleventh Joint Inventor:

11-0

Full name:

HENRY YUE

Signature:

Henry Yue

Date:

March 07, 2001

Citizenship

United States

Residence:

Sunnyvale, California

CA

P.O. Address:

826 Lois Avenue  
Sunnyvale, California 94087

Docket No.: PF-0565 USN

## Twelfth Joint Inventor:

12-a

Full name:

YALDA AZIMZAI

Signature:

Yalda Azimzai

Date:

February 20, 2001

Citizenship

United States

Residence:

Castro Valley, California CA

P.O. Address:

5518 Boulder Canyon Drive  
Castro Valley, California 94552

## Thirteenth Joint Inventor:

13-a

Full name:

ROOPA REDDY

Signature:

Roopa Reddy

Date:

February 27<sup>th</sup>, 2001

Citizenship

India

Residence:

Sunnyvale, California CA

P.O. Address:

1233 W. McKinley Avenue  
#3  
Sunnyvale, California 94086

## Fourteenth Joint Inventor:

14-a

Full name:

DYUNG AINA M. LU

Signature:

Dyung Aina M. Lu

Date:

March 22, 2001

Citizenship

United States

Residence:

San Jose, California CA

P.O. Address:

233 Coy Drive  
San Jose, California 95123


Docket No.: PF-0565 USN

## Fifteenth Joint Inventor:

Full name:

LEO L. SHIH

Signature:



Date:

March 12, 2001

Citizenship

United States

Residence:

East Palo Alto  
Palo Alto, California

P.O. Address:

1081 Tanland DriveApt. BPalo Alto, California 94303908 O'Connor St.East Palo Alto, CA 94303J.S.  
3/12/2001

Rec'd PCT/PTO 21 NOV 2002

09/744794 100509  
09/744794

<110> INYCTE PHARMACEUTICALS, INC.; HILLMAN, Jennifer L.  
 LAL, Preeti; TANG, Y. Tom  
 CORLEY, Neil C.; GUEGLER, Karl J.  
 BAUGHN, Mariah R.; PATTERSON, Chandra  
 BANDMAN, Olga; AU-YOUNG, Janice  
 GORGONE, Gina A.; YUE, Henry  
 AZIMZAI, Valda; REDDY, Roopa  
 LU, Dyung Aina M.; SHIH, Leo L.

<120> PHOSPHORYLATION EFFECTORS

<130> PF-0565 USN

<140> US 09/744,794

<141> 2001-01-26

<150> US 99/17132

<151> 1999-07-28

<150> US 60/155,233

<151> 1999-01-12

<150> US 60/113,796

<151> 1998-12-22

<150> US 60/109,093

<151> 1998-11-19

<150> US 60/106,889

<151> 1998-11-03

<160> 61

<170> PERL Program

<210> 1

<211> 300

<212> PRT

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 132240

<400> 1

Met	Glu	Ser	Pro	Leu	Glu	Ser	Gln	Pro	Leu	Asp	Ser	Asp	Arg	Ser
1				5					10					15
Ile	Lys	Glu	Ser	Ser	Phe	Glu	Glu	Ser	Asn	Ile	Glu	Asp	Pro	Leu
				20					25					30
Ile	Val	Thr	Pro	Asp	Cys	Gln	Glu	Lys	Thr	Ser	Pro	Lys	Gly	Val
				35					40					45
Glu	Asn	Pro	Ala	Val	Gln	Glu	Ser	Asn	Gln	Lys	Met	Leu	Gly	Pro
				50					55					60
Pro	Leu	Glu	Val	Leu	Lys	Thr	Leu	Ala	Ser	Lys	Arg	Asn	Ala	Val
				65					70					75
Ala	Phe	Arg	Ser	Phe	Asn	Ser	His	Ile	Asn	Ala	Ser	Asn	Asn	Ser
				80					85					90
Glu	Pro	Ser	Arg	Met	Asn	Met	Thr	Ser	Leu	Asp	Ala	Met	Asp	Ile
				95					100					105
Ser	Cys	Ala	Tyr	Ser	Gly	Ser	Tyr	Pro	Met	Ala	Ile	Thr	Pro	Thr
				110					115					120
Gln	Lys	Arg	Arg	Ser	Cys	Met	Pro	His	Gln	Thr	Pro	Asn	Gln	Ile
				125					130					135
Lys	Ser	Gly	Thr	Pro	Tyr	Arg	Thr	Pro	Lys	Ser	Val	Arg	Arg	Gly
				140					145					150
Val	Ala	Pro	Val	Asp	Asp	Gly	Arg	Ile	Leu	Gly	Thr	Pro	Asp	Tyr
				155					160					165
Leu	Ala	Pro	Glu	Leu	Leu	Leu	Gly	Arg	Ala	His	Gly	Pro	Ala	Val

PF-0565 USN

	170		175		180
Asp Trp Trp Ala	Leu Gly Val Cys Leu	Phe Glu Phe Leu Thr	Gly		
	185		190		195
Ile Pro Pro Phe	Asn Asp Glu Thr Pro	Gln Gln Val Phe Gln	Asn		
	200		205		210
Ile Leu Lys Arg	Asp Ile Pro Trp Pro	Glu Gly Glu Glu Lys	Leu		
	215		220		225
Ser Asp Asn Ala	Gln Ser Ala Val Glu	Ile Leu Leu Thr Ile	Asp		
	230		235		240
Asp Thr Lys Arg	Ala Gly Met Lys Glu	Leu Lys Arg His Pro	Leu		
	245		250		255
Phe Ser Asp Val	Asp Trp Glu Asn Leu	Gln His Gln Thr Met	Pro		
	260		265		270
Phe Ile Pro Gln	Pro Asp Asp Glu Thr	Asp Thr Ser Tyr Phe	Glu		
	275		280		285
Ala Arg Asn Thr	Ala Gln His Leu Thr	Val Ser Gly Phe Ser	Leu		
	290		295		300

<210> 2  
 <211> 147  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2180116

<400> 2  
 Met Ala Ala Gln Arg Leu Gly Lys Arg Val Leu Ser Lys Leu Gln  
 1 5 10 15  
 Ser Pro Ser Arg Ala Arg Gly Pro Gly Gly Ser Pro Gly Gly Met  
 20 25 30  
 Gln Lys Arg His Ala Arg Val Thr Val Lys Tyr Asp Arg Arg Glu  
 35 40 45  
 Leu Gln Arg Arg Leu Asp Val Glu Lys Trp Ile Asp Gly Arg Leu  
 50 55 60  
 Glu Glu Leu Tyr Arg Gly Met Glu Ala Asp Met Pro Asp Glu Ile  
 65 70 75  
 Asn Ile Asp Glu Leu Leu Glu Leu Glu Ser Glu Glu Glu Arg Ser  
 80 85 90  
 Arg Lys Ile Gln Gly Leu Leu Lys Ser Cys Gly Lys Pro Val Glu  
 95 100 105  
 Asp Phe Ile Gln Glu Leu Leu Ala Lys Leu Gln Gly Leu His Arg  
 110 115 120  
 Gln Pro Gly Leu Arg Gln Pro Ser Pro Ser His Asp Gly Ser Leu  
 125 130 135  
 Ser Pro Leu Gln Asp Arg Ala Arg Thr Ala His Pro  
 140 145

<210> 3  
 <211> 431  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2197671

<400> 3  
 Met Ala His Ser Pro Val Gln Ser Gly Leu Pro Gly Met Gln Asn  
 1 5 10 15  
 Leu Lys Ala Asp Pro Glu Glu Leu Phe Thr Lys Leu Glu Lys Ile  
 20 25 30  
 Gly Lys Gly Ser Phe Gly Glu Val Phe Lys Gly Ile Asp Asn Arg  
 35 40 45  
 Thr Gln Lys Val Val Ala Ile Lys Ile Ile Asp Leu Glu Glu Ala

PF-0565 USN

	50		55		60
Glu Asp Glu Ile Glu Asp Ile Gln Gln Glu Ile Thr Val Leu Ser					
	65		70		75
Gln Cys Asp Ser Pro Tyr Val Thr Lys Tyr Tyr Gly Ser Tyr Leu					
	80		85		90
Lys Asp Thr Lys Leu Trp Ile Ile Met Glu Tyr Leu Gly Gly Gly					
	95		100		105
Ser Ala Leu Asp Leu Leu Glu Pro Gly Arg Leu Asp Glu Thr Gln					
	110		115		120
Ile Ala Thr Ile Leu Arg Glu Ile Leu Lys Gly Leu Asp Tyr Leu					
	125		130		135
His Ser Glu Lys Lys Ile His Arg Asp Ile Lys Ala Ala Asn Val					
	140		145		150
Leu Leu Ser Glu His Gly Glu Val Lys Leu Ala Asp Phe Gly Val					
	155		160		165
Ala Gly Gln Leu Thr Asp Thr Gln Ile Lys Arg Asn Thr Phe Val					
	170		175		180
Gly Thr Pro Phe Trp Met Ala Pro Glu Val Ile Lys Gln Ser Ala					
	185		190		195
Tyr Asp Ser Lys Ala Asp Ile Trp Ser Leu Gly Ile Thr Ala Ile					
	200		205		210
Glu Leu Ala Arg Gly Glu Pro Pro His Ser Glu Leu His Pro Met					
	215		220		225
Lys Val Leu Phe Leu Ile Pro Lys Asn Asn Pro Pro Thr Leu Glu					
	230		235		240
Gly Asn Tyr Ser Lys Pro Leu Lys Glu Phe Val Glu Ala Cys Leu					
	245		250		255
Asn Lys Glu Pro Ser Phe Arg Pro Thr Ala Lys Glu Leu Leu Lys					
	260		265		270
His Lys Phe Ile Leu Arg Asn Ala Lys Lys Thr Ser Tyr Leu Thr					
	275		280		285
Glu Leu Ile Asp Arg Tyr Lys Arg Trp Lys Ala Glu Gln Ser His					
	290		295		300
Asp Asp Ser Ser Ser Glu Asp Ser Asp Ala Glu Thr Asp Gly Gln					
	305		310		315
Ala Ser Gly Gly Ser Asp Ser Gly Asp Trp Ile Phe Thr Ile Arg					
	320		325		330
Glu Lys Asp Pro Lys Asn Leu Glu Asn Gly Ala Leu Gln Pro Ser					
	335		340		345
Asp Leu Asp Arg Asn Lys Met Lys Asp Ile Pro Lys Arg Pro Phe					
	350		355		360
Ser Gln Cys Leu Ser Thr Ile Ile Ser Pro Leu Phe Ala Glu Leu					
	365		370		375
Lys Glu Lys Ser Gln Ala Cys Gly Gly Asn Leu Gly Ser Ile Glu					
	380		385		390
Glu Leu Arg Gly Ala Ile Tyr Leu Ala Glu Glu Ala Cys Pro Gly					
	395		400		405
Ile Ser Asp Thr Met Val Ala Gln Leu Val Gln Arg Leu Gln Arg					
	410		415		420
Tyr Ser Leu Ser Gly Gly Gly Thr Ser Ser His					
	425		430		

<210> 4  
 <211> 218  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2594943

<400> 4  
 Met Asn Cys Arg Ser Glu Val Leu Glu Val Ser Val Glu Gly Arg  
 1 5 10 15  
 Gln Val Glu Glu Ala Met Leu Ala Val Leu His Thr Val Leu Leu  
 20 25 30  
 His Arg Ser Thr Gly Lys Phe His Tyr Lys Lys Glu Gly Thr Tyr

PF-0565 USN

	35		40		45
Ser Ile Gly Thr Val Gly Thr Gln Asp Val Asp Cys Asp Phe Ile					
	50		55		60
Asp Phe Thr Tyr Val Arg Val Ser Ser Glu Glu Leu Asp Arg Ala					
	65		70		75
Leu Arg Lys Val Val Gly Glu Phe Lys Asp Ala Leu Arg Asn Ser					
	80		85		90
Gly Gly Asp Gly Leu Gly Gln Met Ser Leu Glu Phe Tyr Gln Lys					
	95		100		105
Lys Lys Ser Arg Trp Pro Phe Ser Asp Glu Cys Ile Pro Trp Glu					
	110		115		120
Val Trp Thr Val Lys Val His Val Val Ala Leu Ala Thr Glu Gln					
	125		130		135
Glu Arg Gln Ile Cys Arg Glu Lys Val Gly Glu Lys Leu Cys Glu					
	140		145		150
Lys Ile Ile Asn Ile Val Glu Val Met Asn Arg His Glu Tyr Leu					
	155		160		165
Pro Lys Met Pro Thr Gln Ser Glu Val Asp Asn Val Phe Asp Thr					
	170		175		180
Gly Leu Arg Asp Val Gln Pro Tyr Leu Tyr Lys Ile Ser Phe Gln					
	185		190		195
Ile Thr Asp Ala Leu Gly Thr Ser Val Thr Thr Met Arg Arg					
	200		205		210
Leu Ile Lys Asp Thr Leu Ala Leu					
	215				

&lt;210&gt; 5

&lt;211&gt; 474

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1513871

&lt;400&gt; 5

Met Ile Met Asn Lys Met Lys Asn Phe Lys Arg Arg Phe Ser Leu					
1	5		10		15
Ser Val Pro Arg Thr Glu Thr Ile Glu Glu Ser Leu Ala Glu Phe					
	20		25		30
Thr Glu Gln Phe Asn Gln Leu His Asn Arg Arg Asn Glu Asn Leu					
	35		40		45
Gln Leu Gly Pro Leu Gly Arg Asp Pro Pro Gln Glu Cys Ser Thr					
	50		55		60
Phe Ser Pro Thr Asp Ser Gly Glu Glu Pro Gly Gln Leu Ser Pro					
	65		70		75
Gly Val Gln Phe Gln Arg Arg Gln Asn Gln Arg Arg Phe Ser Met					
	80		85		90
Glu Asp Val Ser Lys Arg Leu Ser Leu Pro Met Asp Ile Arg Leu					
	95		100		105
Pro Gln Glu Phe Leu Gln Lys Leu Gln Met Glu Ser Pro Asp Leu					
	110		115		120
Pro Lys Pro Leu Ser Arg Met Ser Arg Arg Ala Ser Leu Ser Asp					
	125		130		135
Ile Gly Phe Gly Lys Leu Glu Thr Tyr Val Lys Leu Asp Lys Leu					
	140		145		150
Gly Glu Gly Thr Tyr Ala Thr Val Phe Lys Gly Arg Ser Lys Leu					
	155		160		165
Thr Glu Asn Leu Val Ala Leu Lys Glu Ile Arg Leu Glu His Glu					
	170		175		180
Glu Gly Ala Pro Cys Thr Ala Ile Arg Glu Val Ser Leu Leu Lys					
	185		190		195
Asn Leu Lys His Ala Asn Ile Val Thr Leu His Asp Leu Ile His					
	200		205		210
Thr Asp Arg Ser Leu Thr Leu Val Phe Glu Tyr Leu Asp Ser Asp					
	215		220		225
Leu Lys Gln Tyr Leu Asp His Cys Gly Asn Leu Met Ser Met His					

PF-0565 USN

Asn Val Lys Ile	230	Phe Met Phe Gln Leu	235	Leu Arg Gly Leu Ala Tyr	240
	245		250		255
Cys His His Arg	260	Lys Ile Leu His Arg	265	Asp Leu Lys Pro Gln Asn	270
	275		280		285
Leu Leu Ile Asn	290	Glu Arg Gly Glu Leu	295	Lys Leu Ala Asp Phe Gly	300
	305		310		315
Val Val Thr Leu	320	Trp Tyr Arg Pro Pro	325	Asp Val Leu Leu Gly Ser	330
	335		340		345
Thr Glu Tyr Ser	350	Thr Pro Ile Asp Met	355	Trp Gly Val Gly Cys Ile	360
	365		370		375
His Tyr Glu Met	380	Ala Thr Gly Arg Pro	385	Leu Phe Pro Gly Ser Thr	390
	395		400		405
Val Lys Glu Glu	410	Leu His Leu Ile Phe	415	Arg Leu Leu Gly Thr Pro	420
	425		430		435
Thr Glu Glu Thr	440	Trp Pro Gly Val Thr	445	Ala Phe Ser Glu Phe Arg	450
	455		460		465
Thr Tyr Ser Phe	470	Pro Cys Tyr Leu Pro		Gln Pro Leu Ile Asn His	
Ala Pro Arg Leu		Asp Thr Asp Gly Ile		His Leu Leu Ser Ser Leu	
Leu Leu Tyr Glu		Ser Lys Ser Arg Met		Ser Ala Glu Ala Ala Leu	
Ser His Ser Tyr		Phe Arg Ser Leu Gly		Glu Arg Val His Gln Leu	
Glu Asp Thr Ala		Ser Ile Phe Ser Leu		Lys Glu Ile Gln Leu Gln	
Lys Asp Pro Gly		Tyr Arg Gly Leu Ala		Phe Gln Gln Pro Gly Arg	
Gly Lys Asn Arg		Arg Gln Ser Ile Phe			

&lt;210&gt; 6

&lt;211&gt; 540

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 156108

&lt;400&gt; 6

Met Asn Gly Glu Ala	1	Ile Cys Ser Ala Leu	10	Pro Thr Ile Pro Tyr	15
	5		10		15
His Lys Leu Ala Asp	20	Leu Arg Tyr Leu Ser	25	Arg Gly Ala Ser Gly	30
	25		25		30
Thr Val Ser Ser Ala	35	Arg His Ala Asp Trp	40	Arg Val Gln Val Ala	45
	40		40		45
Val Lys His Leu His	50	Ile His Thr Pro Leu	55	Leu Asp Ser Glu Arg	60
	55		55		60
Lys Asp Val Leu Arg	65	Glu Ala Glu Ile Leu	70	His Lys Ala Arg Phe	75
	70		70		75
Ser Tyr Ile Leu Pro	80	Ile Leu Gly Ile Cys	85	Asn Glu Pro Glu Phe	90
	85		85		90
Leu Gly Ile Val Thr	95	Glu Tyr Met Pro Asn	100	Gly Ser Leu Asn Glu	105
	100		100		105
Leu Leu His Arg Lys	110	Thr Glu Tyr Pro Asp	115	Val Ala Trp Pro Leu	120
	115		115		120
Arg Phe Arg Ile Leu	125	His Glu Ile Ala Leu	130	Gly Val Asn Tyr Leu	135
	130		130		135
His Asn Met Thr Pro	140	Pro Leu Leu His His	145	Asp Leu Lys Thr Gln	150
	145		145		150
Asn Ile Leu Leu Asp	155	Asn Glu Phe His Val	160	Lys Ile Ala Asp Phe	165
	160		160		165
Gly Leu Ser Lys Trp		Arg Met Met Ser Leu		Ser Gln Ser Arg Ser	



PF-0565 USN

	170	175	180
Ser Lys Ser Ala	Pro Glu Gly Gly Thr	Ile Ile Tyr Met Pro	Pro
	185	190	195
Glu Asn Tyr Glu	Pro Gly Gln Lys Ser	Arg Ala Ser Ile Lys	His
	200	205	210
Asp Ile Tyr Ser	Tyr Ala Val Ile Thr	Trp Glu Val Leu Ser	Arg
	215	220	225
Lys Gln Pro Phe	Glu Asp Val Thr Asn	Pro Leu Gln Ile Met	Tyr
	230	235	240
Ser Val Ser Gln	Gly His Arg Pro Val	Ile Asn Glu Glu Ser	Leu
	245	250	255
Pro Tyr Asp Ile	Pro His Arg Ala Arg	Met Ile Ser Leu Ile	Glu
	260	265	270
Ser Gly Trp Ala	Gln Asn Pro Asp Glu	Arg Pro Ser Phe Leu	Lys
	275	280	285
Cys Leu Ile Glu	Leu Glu Pro Val Leu	Arg Thr Phe Glu Glu	Ile
	290	295	300
Thr Phe Leu Glu	Ala Val Ile Gln Leu	Lys Lys Thr Lys Leu	Gln
	305	310	315
Ser Val Ser Ser	Ala Ile His Leu Cys	Asp Lys Lys Lys Met	Glu
	320	325	330
Leu Ser Leu Asn	Ile Pro Val Asn His	Gly Pro Gln Glu Glu	Ser
	335	340	345
Cys Gly Ser Ser	Gln Leu His Glu Asn	Ser Gly Ser Pro Glu	Thr
	350	355	360
Ser Arg Ser Leu	Pro Ala Pro Gln Asp	Asn Asp Phe Leu Ser	Arg
	365	370	375
Lys Ala Gln Asp	Cys Tyr Phe Met Lys	Leu His His Cys Pro	Gly
	380	385	390
Asn His Ser Trp	Asp Ser Thr Ile Ser	Gly Ser Gln Arg Ala	Ala
	395	400	405
Phe Cys Asp His	Lys Thr Thr Pro Cys	Ser Ser Ala Ile Ile	Asn
	410	415	420
Pro Leu Ser Thr	Ala Gly Asn Ser Glu	Arg Leu Gln Pro Gly	Ile
	425	430	435
Ala Gln Gln Trp	Ile Gln Ser Lys Arg	Glu Asp Ile Val Asn	Gln
	440	445	450
Met Thr Glu Ala	Cys Leu Asn Gln Ser	Leu Asp Ala Leu Leu	Ser
	455	460	465
Arg Asp Leu Ile	Met Lys Glu Asp Tyr	Glu Leu Val Ser Thr	Lys
	470	475	480
Pro Thr Arg Thr	Ser Lys Val Arg Gln	Leu Leu Asp Thr Thr	Asp
	485	490	495
Ile Gln Gly Glu	Glu Phe Ala Lys Val	Ile Val Gln Lys Leu	Lys
	500	505	510
Asp Asn Lys Gln	Met Gly Leu Gln Pro	Tyr Pro Glu Ile Leu	Val
	515	520	525
Val Ser Arg Ser	Pro Ser Leu Asn Leu	Leu Gln Asn Lys Ser	Met
	530	535	540

<210> 7  
 <211> 454  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2883243

<400> 7  
 Met Tyr Asn Thr Val Trp Asn Met Glu Asp Leu Asp Leu Glu Tyr  
 1 5 10 15  
 Ala Lys Thr Asp Ile Asn Cys Gly Thr Asp Leu Met Phe Tyr Ile  
 20 25 30  
 Glu Met Asp Pro Pro Ala Leu Pro Pro Lys Pro Pro Thr  
 35 40 45

PF-0565 USN

```

Thr Val Ala Asn Asn Gly Met Asn Asn Asn Met Ser Leu Gln Asp
50 55 60
Ala Glu Trp Tyr Trp Gly Asp Ile Ser Arg Glu Glu Val Asn Glu
65 70 75
Lys Leu Arg Asp Thr Ala Asp Gly Thr Phe Leu Val Arg Asp Ala
80 85 90
Ser Thr Lys Met His Gly Asp Tyr Thr Leu Thr Leu Arg Lys Gly
95 100 105
Gly Asn Asn Lys Leu Ile Lys Ile Phe His Arg Asp Gly Lys Tyr
110 115 120
Gly Phe Ser Asp Pro Leu Thr Phe Ser Ser Val Val Glu Leu Ile
125 130 135
Asn His Tyr Arg Asn Glu Ser Leu Ala Glu Tyr Asn Pro Lys Leu
140 145 150
Asp Val Lys Leu Leu Tyr Pro Val Ser Lys Tyr Gln Gln Asp Gln
155 160 165
Val Val Lys Glu Asp Asn Ile Glu Ala Val Gly Lys Lys Leu His
170 175 180
Glu Tyr Asn Thr Gln Phe Gln Glu Lys Ser Arg Glu Tyr Asp Arg
185 190 195
Leu Tyr Glu Glu Tyr Thr Arg Thr Ser Gln Glu Ile Gln Met Lys
200 205 210
Arg Thr Ala Ile Glu Ala Phe Asn Glu Thr Ile Lys Ile Phe Glu
215 220 225
Glu Gln Cys Gln Thr Gln Glu Arg Tyr Ser Lys Glu Tyr Ile Glu
230 235 240
Lys Phe Lys Arg Glu Gly Asn Glu Lys Glu Ile Gln Arg Ile Met
245 250 255
His Asn Tyr Asp Lys Leu Lys Ser Arg Ile Ser Glu Ile Ile Asp
260 265 270
Ser Arg Arg Arg Leu Glu Glu Asp Leu Lys Lys Gln Ala Ala Glu
275 280 285
Tyr Arg Glu Ile Asp Lys Arg Met Asn Ser Ile Lys Pro Asp Leu
290 295 300
Ile Gln Leu Arg Lys Thr Arg Asp Gln Tyr Leu Met Trp Leu Thr
305 310 315
Gln Lys Gly Val Arg Gln Lys Lys Leu Asn Glu Trp Leu Gly Asn
320 325 330
Glu Asn Thr Glu Asp Gln Tyr Ser Leu Val Glu Asp Asp Glu Asp
335 340 345
Leu Pro His His Asp Glu Lys Thr Trp Asn Val Gly Ser Ser Asn
350 355 360
Arg Asn Lys Ala Glu Asn Leu Leu Arg Gly Lys Arg Asp Gly Thr
365 370 375
Phe Leu Val Arg Glu Ser Ser Lys Gln Gly Cys Tyr Ala Cys Ser
380 385 390
Val Val Val Asp Gly Glu Val Lys His Cys Val Ile Asn Lys Thr
395 400 405
Ala Thr Gly Tyr Gly Phe Ala Glu Pro Tyr Asn Leu Tyr Ser Ser
410 415 420
Leu Lys Glu Leu Val Leu His Tyr Gln His Thr Ser Leu Val Gln
425 430 435
His Asn Asp Ser Leu Asn Val Thr Leu Ala Tyr Pro Val Tyr Ala
440 445 450
Gln Gln Arg Arg

```

&lt;210&gt; 8

&lt;211&gt; 502

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3173355

&lt;400&gt; 8

PF-0565 USN

Met	Phe	Gly	Thr	Leu	Leu	Leu	Tyr	Cys	Phe	Phe	Leu	Ala	Thr	Val
1				5					10					15
Pro	Ala	Leu	Ala	Glu	Thr	Gly	Gly	Glu	Arg	Gln	Leu	Ser	Pro	Glu
				20					25					30
Lys	Ser	Glu	Ile	Trp	Gly	Pro	Gly	Leu	Lys	Ala	Asp	Val	Val	Leu
				35					40					45
Pro	Ala	Arg	Tyr	Phe	Tyr	Ile	Gln	Ala	Val	Asp	Thr	Ser	Gly	Asn
				50					55					60
Lys	Phe	Thr	Ser	Ser	Pro	Gly	Glu	Lys	Val	Phe	Gln	Val	Lys	Val
				65					70					75
Ser	Ala	Pro	Glu	Glu	Gln	Phe	Thr	Arg	Val	Gly	Val	Gln	Val	Leu
				80					85					90
Asp	Arg	Lys	Asp	Gly	Ser	Phe	Ile	Val	Arg	Tyr	Arg	Met	Tyr	Ala
				95					100					105
Ser	Tyr	Lys	Asn	Leu	Lys	Val	Glu	Ile	Lys	Phe	Gln	Gly	Gln	His
				110					115					120
Val	Ala	Lys	Ser	Pro	Tyr	Ile	Leu	Lys	Gly	Pro	Val	Tyr	His	Glu
				125					130					135
Asn	Cys	Asp	Cys	Pro	Leu	Gln	Asp	Ser	Ala	Ala	Trp	Leu	Arg	Glu
				140					145					150
Met	Asn	Cys	Pro	Glu	Thr	Ile	Ala	Gln	Ile	Gln	Arg	Asp	Leu	Ala
				155					160					165
His	Phe	Pro	Ala	Val	Asp	Pro	Glu	Lys	Ile	Ala	Val	Glu	Ile	Pro
				170					175					180
Lys	Arg	Phe	Gly	Gln	Arg	Gln	Ser	Leu	Cys	His	Tyr	Thr	Leu	Lys
				185					190					195
Asp	Asn	Lys	Val	Tyr	Ile	Lys	Thr	His	Gly	Glu	His	Val	Gly	Phe
				200					205					210
Arg	Ile	Phe	Met	Asp	Ala	Ile	Leu	Leu	Ser	Leu	Thr	Arg	Lys	Val
				215					220					225
Lys	Met	Pro	Asp	Val	Glu	Leu	Phe	Val	Asn	Leu	Gly	Asp	Trp	Pro
				230					235					240
Leu	Glu	Lys	Lys	Lys	Ser	Asn	Ser	Asn	Ile	His	Pro	Ile	Phe	Ser
				245					250					255
Trp	Cys	Gly	Ser	Thr	Asp	Ser	Lys	Asp	Ile	Val	Met	Pro	Thr	Tyr
				260					265					270
Asp	Leu	Thr	Asp	Ser	Val	Leu	Glu	Thr	Met	Gly	Arg	Val	Ser	Leu
				275					280					285
Asp	Met	Met	Ser	Val	Gln	Ala	Asn	Thr	Gly	Pro	Pro	Trp	Glu	Ser
				290					295					300
Lys	Asn	Ser	Thr	Ala	Val	Trp	Arg	Gly	Arg	Asp	Ser	Arg	Lys	Glu
				305					310					315
Arg	Leu	Glu	Leu	Val	Lys	Leu	Ser	Arg	Lys	His	Pro	Glu	Leu	Ile
				320					325					330
Asp	Ala	Ala	Phe	Thr	Asn	Phe	Phe	Phe	Phe	Lys	His	Asp	Glu	Asn
				335					340					345
Leu	Tyr	Gly	Pro	Ile	Val	Lys	His	Ile	Ser	Phe	Phe	Asp	Phe	Phe
				350					355					360
Lys	His	Lys	Tyr	Gln	Ile	Asn	Ile	Asp	Gly	Thr	Val	Ala	Ala	Tyr
				365					370					375
Arg	Leu	Pro	Tyr	Leu	Leu	Val	Gly	Asp	Ser	Val	Val	Leu	Lys	Gln
				380					385					390
Asp	Ser	Ile	Tyr	Tyr	Glu	His	Phe	Tyr	Asn	Glu	Leu	Gln	Pro	Trp
				395					400					405
Lys	His	Tyr	Ile	Pro	Val	Lys	Ser	Asn	Leu	Ser	Asp	Leu	Leu	Glu
				410					415					420
Lys	Leu	Lys	Trp	Ala	Lys	Asp	His	Asp	Glu	Glu	Ala	Lys	Lys	Ile
				425					430					435
Ala	Lys	Ala	Gly	Gln	Glu	Phe	Ala	Arg	Asn	Asn	Leu	Met	Gly	Asp
				440					445					450
Asp	Ile	Phe	Cys	Tyr	Tyr	Phe	Lys	Leu	Phe	Gln	Glu	Tyr	Ala	Asn
				455					460					465
Leu	Gln	Val	Ser	Glu	Pro	Gln	Ile	Arg	Glu	Gly	Met	Lys	Arg	Val
				470					475					480
Glu	Pro	Gln	Thr	Glu	Asp	Asp	Leu	Phe	Pro	Cys	Thr	Cys	His	Arg
				485					490					495
Lys	Lys	Thr	Lys	Asp	Glu	Leu								

```
<210> 9
<211> 282
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5116906
```

```
<210> 10
<211> 510
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 940589
```

9

PF-0565 USN

Ser	Asn	Thr	Gln	Asn	Ser	Arg	Lys	Glu	Ala	Val	Leu	Leu	Ala	Lys
				50					55					60
Met	Lys	His	Pro	Asn	Ile	Val	Ala	Phe	Lys	Glu	Ser	Phe	Glu	Ala
				65					70					75
Glu	Gly	His	Leu	Tyr	Ile	Val	Met	Glu	Tyr	Cys	Asp	Gly	Gly	Asp
				80					85					90
Leu	Met	Gln	Lys	Ile	Lys	Gln	Gln	Lys	Gly	Lys	Leu	Phe	Pro	Glu
				95					100					105
Asp	Met	Ile	Leu	Asn	Trp	Phe	Thr	Gln	Met	Cys	Leu	Gly	Val	Asn
				110					115					120
His	Ile	His	Lys	Lys	Arg	Val	Leu	His	Arg	Asp	Ile	Lys	Ser	Lys
				125					130					135
Asn	Ile	Phe	Leu	Thr	Gln	Asn	Gly	Lys	Val	Lys	Leu	Gly	Asp	Phe
				140					145					150
Gly	Ser	Ala	Arg	Leu	Leu	Ser	Asn	Pro	Met	Ala	Phe	Ala	Cys	Thr
				155					160					165
Tyr	Val	Gly	Thr	Pro	Tyr	Tyr	Val	Pro	Pro	Glu	Ile	Trp	Glu	Asn
				170					175					180
Leu	Pro	Tyr	Asn	Asn	Lys	Ser	Asp	Ile	Trp	Ser	Leu	Gly	Cys	Ile
				185					190					195
Leu	Tyr	Glu	Leu	Cys	Thr	Leu	Lys	His	Pro	Phe	Gln	Ala	Asn	Ser
				200					205					210
Trp	Lys	Asn	Leu	Ile	Leu	Lys	Val	Cys	Gln	Gly	Cys	Ile	Ser	Pro
				215					220					225
Leu	Pro	Ser	His	Tyr	Ser	Tyr	Glu	Leu	Gln	Phe	Leu	Val	Lys	Gln
				230					235					240
Met	Phe	Lys	Arg	Asn	Pro	Ser	His	Arg	Pro	Ser	Ala	Thr	Thr	Leu
				245					250					255
Leu	Ser	Arg	Gly	Ile	Val	Ala	Arg	Leu	Val	Gln	Lys	Cys	Leu	Pro
				260					265					270
Pro	Glu	Ile	Ile	Met	Glu	Tyr	Gly	Glu	Glu	Val	Leu	Glu	Glu	Ile
				275					280					285
Lys	Asn	Ser	Lys	His	Asn	Thr	Pro	Arg	Lys	Lys	Thr	Asn	Pro	Ser
				290					295					300
Arg	Ile	Arg	Ile	Ala	Leu	Gly	Asn	Glu	Ala	Ser	Thr	Val	Gln	Glu
				305					310					315
Glu	Glu	Gln	Asp	Arg	Lys	Gly	Ser	His	Thr	Asp	Leu	Glu	Ser	Ile
				320					325					330
Asn	Glu	Asn	Leu	Val	Glu	Ser	Ala	Leu	Arg	Arg	Val	Asn	Arg	Glu
				335					340					345
Glu	Lys	Gly	Asn	Lys	Ser	Val	His	Leu	Arg	Lys	Ala	Ser	Ser	Pro
				350					355					360
Asn	Leu	His	Arg	Arg	Gln	Trp	Glu	Lys	Asn	Val	Pro	Asn	Thr	Ala
				365					370					375
Leu	Thr	Ala	Leu	Glu	Asn	Ala	Ser	Ile	Leu	Thr	Ser	Ser	Leu	Thr
				380					385					390
Ala	Glu	Asp	Asp	Arg	Gly	Gly	Ser	Val	Ile	Lys	Tyr	Ser	Lys	Asn
				395					400					405
Thr	Thr	Arg	Lys	Gln	Trp	Leu	Lys	Glu	Thr	Pro	Asp	Thr	Leu	Leu
				410					415					420
Asn	Ile	Leu	Lys	Asn	Ala	Asp	Leu	Ser	Leu	Ala	Phe	Gln	Thr	Tyr
				425					430					435
Thr	Ile	Tyr	Arg	Pro	Gly	Ser	Glu	Gly	Phe	Leu	Lys	Gly	Pro	Leu
				440					445					450
Ser	Glu	Glu	Thr	Glu	Ala	Ser	Asp	Ser	Val	Asp	Gly	Gly	His	Asp
				455					460					465
Ser	Val	Ile	Leu	Asp	Pro	Glu	Arg	Leu	Glu	Pro	Gly	Leu	Asp	Glu
				470					475					480
Glu	Asp	Thr	Asp	Phe	Glu	Glu	Glu	Asp	Asn	Pro	Asp	Trp	Val	
				485					490					495
Ser	Glu	Leu	Lys	Lys	Arg	Ala	Gly	Trp	Gln	Gly	Leu	Cys	Asp	Arg
				500					505					510

<210> 11  
 <211> 248  
 <212> PRT

PF-0565 USN

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 304421

&lt;400&gt; 11

Met	Ala	Glu	Thr	Ser	Leu	Pro	Glu	Leu	Gly	Gly	Glu	Asp	Lys	Ala
1				5					10					15
Thr	Pro	Cys	Pro	Ser	Ile	Leu	Glu	Leu	Glu	Glu	Leu	Leu	Arg	Ala
				20					25					30
Gly	Lys	Ser	Ser	Cys	Ser	Arg	Val	Asp	Glu	Val	Trp	Pro	Asn	Leu
				35					40					45
Phe	Ile	Gly	Asp	Ala	Met	Asp	Ser	Leu	Gln	Lys	Gln	Asp	Leu	Arg
				50					55					60
Arg	Pro	Lys	Ile	His	Gly	Ala	Val	Gln	Ala	Ser	Pro	Tyr	Gln	Pro
				65					70					75
Pro	Thr	Leu	Ala	Ser	Leu	Gln	Arg	Leu	Leu	Trp	Val	Arg	Gln	Ala
				80					85					90
Ala	Thr	Leu	Asn	His	Ile	Asp	Glu	Val	Trp	Pro	Ser	Leu	Phe	Leu
				95					100					105
Gly	Asp	Ala	Tyr	Ala	Ala	Arg	Asp	Lys	Ser	Lys	Leu	Ile	Gln	Leu
				110					115					120
Gly	Ile	Thr	His	Val	Val	Asn	Ala	Ala	Ala	Gly	Lys	Phe	Gln	Val
				125					130					135
Asp	Thr	Gly	Ala	Lys	Phe	Tyr	Arg	Gly	Met	Ser	Leu	Glu	Tyr	Tyr
				140					145					150
Gly	Ile	Glu	Ala	Asp	Asp	Asn	Pro	Phe	Phe	Asp	Leu	Ser	Val	Tyr
				155					160					165
Phe	Leu	Pro	Val	Ala	Arg	Tyr	Ile	Arg	Ala	Ala	Leu	Ser	Val	Pro
				170					175					180
Gln	Gly	Arg	Val	Leu	Val	His	Cys	Ala	Met	Gly	Val	Ser	Arg	Ser
				185					190					195
Ala	Thr	Leu	Val	Leu	Ala	Phe	Leu	Met	Ile	Tyr	Glu	Asn	Met	Thr
				200					205					210
Leu	Val	Glu	Ala	Ile	Gln	Thr	Val	Gln	Ala	His	Arg	Asn	Ile	Cys
				215					220					225
Pro	Asn	Ser	Gly	Phe	Leu	Arg	Gln	Leu	Gln	Val	Leu	Asp	Asn	Arg
				230					235					240
Leu	Gly	Arg	Glu	Thr	Gly	Arg	Phe							
				245										

&lt;210&gt; 12

&lt;211&gt; 810

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1213802

&lt;400&gt; 12

Met	Pro	Asn	Gln	Gly	Glu	Asp	Cys	Tyr	Phe	Phe	Phe	Tyr	Ser	Thr
1				5					10					15
Cys	Thr	Lys	Gly	Asp	Ser	Cys	Pro	Phe	Arg	His	Cys	Glu	Ala	Ala
				20					25					30
Ile	Gly	Asn	Glu	Thr	Val	Cys	Thr	Leu	Trp	Gln	Glu	Gly	Arg	Cys
				35					40					45
Phe	Arg	Gln	Val	Cys	Arg	Phe	Arg	His	Met	Glu	Ile	Asp	Lys	Lys
				50					55					60
Arg	Ser	Glu	Ile	Pro	Cys	Tyr	Trp	Glu	Asn	Gln	Pro	Thr	Gly	Cys
				65					70					75
Gln	Lys	Leu	Asn	Cys	Ala	Phe	His	His	Asn	Arg	Gly	Arg	Tyr	Val
				80					85					90
Asp	Gly	Leu	Phe	Leu	Pro	Pro	Ser	Lys	Thr	Val	Leu	Pro	Thr	Val
				95					100					105
Pro	Glu	Ser	Pro	Glu	Glu	Glu	Val	Lys	Ala	Ser	Gln	Leu	Ser	Val

PF-0565 USN

	110		115		120
Gln Gln Asn Lys	Leu Ser Val Gln Ser	Asn Pro Ser Pro Gln Leu			
	125		130		135
Arg Ser Val Met	Lys Val Glu Ser Ser	Glu Asn Val Pro Ser Pro			
	140		145		150
Thr His Pro Pro	Val Val Ile Asn Ala	Ala Asp Asp Asp Glu Asp			
	155		160		165
Asp Asp Asp Gln	Phe Ser Glu Glu Gly	Asp Glu Thr Lys Thr Pro			
	170		175		180
Thr Leu Gln Pro	Thr Pro Glu Val His	Asn Gly Leu Arg Val Thr			
	185		190		195
Ser Val Arg Lys	Pro Ala Val Asn Ile	Lys Gln Gly Glu Cys Leu			
	200		205		210
Asn Phe Gly Ile	Lys Thr Leu Glu Glu	Ile Lys Ser Lys Lys Met			
	215		220		225
Lys Glu Lys Ser	Lys Lys Gln Gly Glu	Gly Ser Ser Gly Val Ser			
	230		235		240
Ser Leu Leu Leu	His Pro Glu Pro Val	Pro Gly Pro Glu Lys Glu			
	245		250		255
Asn Val Arg Thr	Val Val Arg Thr Val	Thr Leu Ser Thr Lys Gln			
	260		265		270
Gly Glu Glu Pro	Leu Val Arg Leu Ser	Leu Thr Glu Arg Leu Gly			
	275		280		285
Lys Arg Lys Phe	Ser Ala Gly Gly Asp	Ser Asp Pro Pro Leu Lys			
	290		295		300
Arg Ser Leu Ala	Gln Arg Leu Gly Lys	Lys Val Glu Ala Pro Glu			
	305		310		315
Thr Asn Ile Asp	Lys Thr Pro Lys Lys	Ala Gln Val Ser Lys Ser			
	320		325		330
Leu Lys Glu Arg	Leu Gly Met Ser Ala	Asp Pro Asp Asn Glu Asp			
	335		340		345
Ala Thr Asp Lys	Val Asn Lys Val Gly	Glu Ile His Val Lys Thr			
	350		355		360
Leu Glu Glu Ile	Leu Leu Glu Arg Ala	Ser Gln Lys Arg Gly Glu			
	365		370		375
Leu Gln Thr Lys	Leu Lys Thr Glu Gly	Pro Ser Lys Thr Asp Asp			
	380		385		390
Ser Thr Ser Gly	Ala Arg Ser Ser Ser	Thr Ile Arg Ile Lys Thr			
	395		400		405
Phe Ser Glu Val	Leu Ala Glu Lys Lys	His Arg Gln Gln Glu Ala			
	410		415		420
Glu Arg Gln Lys	Ser Lys Lys Asp Thr	Thr Cys Ile Lys Leu Lys			
	425		430		435
Ile Asp Ser Glu	Ile Lys Lys Thr Val	Val Leu Pro Pro Ile Val			
	440		445		450
Ala Ser Arg Gly	Gln Ser Glu Glu Pro	Ala Gly Lys Thr Lys Ser			
	455		460		465
Met Gln Glu Val	His Ile Lys Thr Leu	Glu Glu Ile Lys Leu Glu			
	470		475		480
Lys Ala Leu Arg	Val Gln Gln Ser Ser	Glu Ser Ser Thr Ser Ser			
	485		490		495
Pro Ser Gln His	Glu Ala Thr Pro Gly	Ala Arg Arg Leu Leu Arg			
	500		505		510
Ile Thr Lys Arg	Thr Gly Met Lys Glu	Glu Lys Asn Leu Gln Glu			
	515		520		525
Gly Asn Glu Val	Asp Ser Gln Ser Ser	Ile Arg Thr Glu Ala Lys			
	530		535		540
Glu Ala Ser Gly	Glu Thr Thr Gly Val	Asp Ile Thr Lys Ile Gln			
	545		550		555
Val Lys Arg Cys	Glu Thr Met Arg Glu	Lys His Met Gln Lys Gln			
	560		565		570
Gln Glu Arg Glu	Lys Ser Val Leu Thr	Pro Leu Arg Gly Asp Val			
	575		580		585
Ala Ser Cys Asn	Thr Gln Val Ala Glu	Lys Pro Val Leu Thr Ala			
	590		595		600
Val Pro Gly Ile	Thr Arg His Leu Thr	Lys Arg Leu Pro Thr Lys			
	605		610		615

PF-0565 USN

Ser	Ser	Gln	Lys	Val	Glu	Val	Glu	Thr	Ser	Gly	Ile	Gly	Asp	Ser	
				620					625					630	
Leu	Leu	Asn	Val	Lys	Cys	Ala	Ala	Gln	Thr	Leu	Glu	Lys	Arg	Gly	
				635					640					645	
Lys	Ala	Lys	Pro	Lys	Val	Asn	Val	Lys	Pro	Ser	Val	Val	Lys	Val	
				650					655					660	
Val	Ser	Ser	Pro	Lys	Leu	Ala	Pro	Lys	Arg	Lys	Ala	Val	Glu	Met	
				665					670					675	
His	Ala	Ala	Val	Ile	Ala	Ala	Val	Lys	Pro	Leu	Ser	Ser	Ser	Ser	
				680					685					690	
Val	Leu	Gln	Glu	Pro	Pro	Ala	Lys	Lys	Ala	Ala	Val	Ala	Val	Val	
				695					700					705	
Pro	Leu	Val	Ser	Glu	Asp	Lys	Ser	Val	Thr	Val	Pro	Glu	Ala	Glu	
				710					715					720	
Asn	Pro	Arg	Asp	Ser	Leu	Val	Leu	Pro	Pro	Thr	Gln	Ser	Ser	Ser	
				725					730					735	
Asp	Ser	Ser	Pro	Pro	Glu	Val	Ser	Gly	Pro	Ser	Ser	Ser	Gln	Met	
				740					745					750	
Ser	Met	Lys	Thr	Arg	Arg	Leu	Ser	Ser	Ala	Ser	Thr	Gly	Lys	Pro	
				755					760					765	
Pro	Leu	Ser	Val	Glu	Asp	Asp	Phe	Glu	Lys	Leu	Ile	Trp	Glu	Ile	
				770					775					780	
Ser	Gly	Gly	Lys	Leu	Glu	Ala	Glu	Ile	Asp	Leu	Asp	Pro	Gly	Lys	
				785					790					795	
Asp	Glu	Asp	Asp	Leu	Leu	Leu	Glu	Leu	Ser	Glu	Met	Ile	Asp	Ser	
				800					805					310	

&lt;210&gt; 13

&lt;211&gt; 549

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1378134

&lt;400&gt; 13

Met	Arg	Arg	Arg	Ala	Ser	Asn	Ala	Ala	Ala	Ala	Ala	His	Thr	Ile	
1				5					10					15	
Gly	Gly	Ser	Lys	His	Thr	Met	Asn	Asp	His	Leu	His	Val	Gly	Ser	
				20					25					30	
His	Ala	His	Gly	Gln	Ile	Gln	Val	Arg	Gln	Leu	Phe	Glu	Asp	Asn	
				35					40					45	
Ser	Asn	Lys	Arg	Thr	Val	Leu	Thr	Thr	Gln	Pro	Asn	Gly	Leu	Thr	
				50					55					60	
Thr	Val	Gly	Lys	Thr	Gly	Leu	Pro	Val	Val	Pro	Glu	Arg	Gln	Leu	
				65					70					75	
Asp	Ser	Ile	His	Arg	Arg	Gln	Gly	Ser	Ser	Thr	Ser	Leu	Lys	Ser	
				80					85					90	
Met	Glu	Gly	Met	Gly	Lys	Val	Lys	Ala	Thr	Pro	Met	Thr	Pro	Glu	
				95					100					105	
Gln	Ala	Met	Lys	Gln	Tyr	Met	Gln	Lys	Leu	Thr	Ala	Phe	Glu	His	
				110					115					120	
His	Glu	Ile	Phe	Ser	Tyr	Pro	Glu	Ile	Tyr	Phe	Leu	Gly	Leu	Asn	
				125					130					135	
Ala	Lys	Lys	Arg	Gln	Gly	Met	Thr	Gly	Gly	Pro	Asn	Asn	Gly	Gly	
				140					145					150	
Tyr	Asp	Asp	Asp	Gln	Gly	Ser	Tyr	Val	Gln	Val	Pro	His	Asp	His	
				155					160					165	
Val	Ala	Tyr	Arg	Tyr	Glu	Val	Leu	Lys	Val	Ile	Gly	Lys	Gly	Ser	
				170					175					180	
Phe	Gly	Gln	Val	Val	Lys	Ala	Tyr	Asp	His	Lys	Val	His	Gln	His	
				185					190					195	
Val	Ala	Leu	Lys	Met	Val	Arg	Asn	Glu	Lys	Arg	Phe	His	Arg	Gln	
				200					205					210	
Ala	Ala	Glu	Glu	Ile	Arg	Ile	Leu	Glu	His	Leu	Arg	Lys	Gln	Asp	



PF-0565 USN

	215		220		225
Lys Asp Asn Thr	Met Asn Val Ile His	Met Leu Glu Asn Phe	Thr		
	230		235		240
Phe Arg Asn His	Ile Cys Met Thr Phe	Glu Leu Leu Ser Met	Asn		
	245		250		255
Leu Tyr Glu Leu	Ile Lys Lys Asn Lys	Phe Gln Gly Phe Ser	Leu		
	260		265		270
Pro Leu Val Arg	Lys Phe Ala His Ser	Ile Leu Gln Cys Leu	Asp		
	275		280		285
Ala Leu His Lys	Asn Arg Ile Ile His	Cys Asp Leu Lys Pro	Glu		
	290		295		300
Asn Ile Leu Leu	Lys Gln Gln Gly Arg	Ser Gly Ile Lys Val	Ile		
	305		310		315
Asp Phe Gly Ser	Ser Cys Tyr Glu His	Gln Arg Val Tyr Thr	Tyr		
	320		325		330
Ile Gln Ser Arg	Phe Tyr Arg Ala Pro	Glu Val Ile Leu Gly	Ala		
	335		340		345
Arg Tyr Gly Met	Pro Ile Asp Met Trp	Ser Leu Gly Cys Ile	Leu		
	350		355		360
Ala Glu Leu Leu	Thr Gly Tyr Pro Leu	Leu Pro Gly Glu Asp	Glu		
	365		370		375
Gly Asp Gln Leu	Ala Cys Met Ile Glu	Leu Leu Gly Met Pro	Ser		
	380		385		390
Gln Lys Leu Leu	Asp Ala Ser Lys Arg	Ala Lys Asn Phe Val	Ser		
	395		400		405
Ser Lys Gly Tyr	Pro Arg Tyr Cys Thr	Val Thr Thr Leu Ser	Asp		
	410		415		420
Gly Ser Val Val	Leu Asn Gly Gly Arg	Ser Arg Arg Gly Lys	Leu		
	425		430		435
Arg Gly Pro Pro	Glu Ser Arg Glu Trp	Gly Asn Ala Leu Lys	Gly		
	440		445		450
Cys Asp Asp Pro	Leu Phe Leu Asp Phe	Leu Lys Gln Cys Leu	Glu		
	455		460		465
Trp Asp Pro Ala	Val Arg Met Thr Pro	Gly Gln Ala Leu Arg	His		
	470		475		480
Pro Trp Leu Arg	Arg Arg Leu Pro Lys	Pro Pro Thr Gly Glu	Lys		
	485		490		495
Thr Ser Val Lys	Arg Ile Thr Glu Ser	Thr Gly Ala Ile Thr	Ser		
	500		505		510
Ile Ser Lys Leu	Pro Pro Pro Ser Ser	Ser Ala Ser Lys Leu	Arg		
	515		520		525
Thr Asn Leu Ala	Gln Met Thr Asp Ala	Asn Gly Asn Ile Gln	Gln		
	530		535		540
Arg Thr Val Leu	Pro Lys Leu Val Ser				
	545				

&lt;210&gt; 14

&lt;211&gt; 416

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1490070

&lt;400&gt; 14

Met Met Pro Gln Leu	Gln Phe Lys Asp	Ala Phe Trp Cys Arg	Asp
1	5	10	15
Phe Thr Ala His Thr	Gly Tyr Glu Val	Leu Leu Gln Arg Leu	Leu
	20	25	30
Asp Gly Arg Lys Met	Cys Lys Asp Met	Val Glu Leu Leu Trp	Gln
	35	40	45
Arg Ala Gln Ala Glu	Glu Arg Tyr Gly	Lys Glu Leu Val Gln	Ile
	50	55	60
Ala Arg Lys Ala Gly	Gly Gln Thr Glu	Ile Asn Ser Leu Arg	Ala
	65	70	75
Ser Phe Asp Ser Leu	Lys Gln Gln Met	Glu Asn Val Gly Ser	Ser

PF-0565 USN

	80		85		90
His Ile Gln Leu	Ala Leu Thr Leu Arg	Glu Glu Leu Arg Ser	Leu		
	95		100		105
Glu Glu Phe Arg	Glu Arg Gln Lys Glu	Gln Arg Lys Lys Tyr	Glu		
	110		115		120
Ala Val Met Asp	Arg Val Gln Lys Ser	Lys Leu Ser Leu Tyr	Lys		
	125		130		135
Lys Ala Met Glu	Ser Lys Lys Thr Tyr	Glu Gln Lys Cys Arg	Asp		
	140		145		150
Ala Asp Asp Ala	Glu Gln Ala Phe Glu	Arg Ile Ser Ala Asn	Gly		
	155		160		165
His Gln Lys Gln	Val Glu Lys Ser Gln	Asn Lys Ala Arg Gln	Cys		
	170		175		180
Lys Asp Ser Ala	Thr Glu Ala Glu Arg	Val Tyr Arg Gln Ser	Ile		
	185		190		195
Ala Gln Leu Glu	Lys Val Arg Ala Glu	Trp Glu Gln Glu His	Arg		
	200		205		210
Thr Thr Cys Glu	Ala Phe Gln Leu Gln	Glu Phe Asp Arg Leu	Thr		
	215		220		225
Ile Leu Arg Asn	Ala Leu Trp Val His	Ser Asn Gln Leu Ser	Met		
	230		235		240
Gln Cys Val Lys	Asp Asp Glu Leu Tyr	Glu Glu Val Arg Leu	Thr		
	245		250		255
Leu Glu Gly Cys	Ser Ile Asp Ala Asp	Ile Asp Ser Phe Ile	Gln		
	260		265		270
Ala Lys Ser Thr	Gly Thr Glu Pro Pro	Ala Pro Val Pro Tyr	Gln		
	275		280		285
Asn Tyr Tyr Asp	Arg Glu Val Thr Pro	Leu Thr Ser Ser Pro	Gly		
	290		295		300
Ile Gln Pro Ser	Cys Gly Met Ile Lys	Arg Phe Ser Gly Leu	Leu		
	305		310		315
His Gly Ser Pro	Lys Thr Thr Ser Leu	Ala Ala Ser Ala Ala	Ser		
	320		325		330
Thr Glu Thr Leu	Thr Pro Thr Pro Glu	Arg Asn Glu Gly Val	Tyr		
	335		340		345
Thr Ala Ile Ala	Val Gln Glu Ile Gln	Gly Asn Pro Ala Ser	Pro		
	350		355		360
Ala Gln Glu Tyr	Arg Ala Leu Tyr Asp	Tyr Thr Ala Gln Asn	Pro		
	365		370		375
Asp Glu Leu Asp	Leu Ser Ala Gly Asp	Ile Leu Glu Val Ile	Leu		
	380		385		390
Glu Gly Glu Asp	Gly Trp Trp Thr Val	Glu Arg Asn Gly Gln	Arg		
	395		400		405
Gly Phe Val Pro	Gly Ser Tyr Leu Glu	Lys Leu			
	410		415		

&lt;210&gt; 15

&lt;211&gt; 425

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1997814

&lt;400&gt; 15

Met Glu Gln Gly	Leu Glu Glu Glu Glu	Glu Val Asp Pro Arg	Ile
1	5	10	15
Gln Gly Glu Leu	Glu Lys Leu Asn Gln	Ser Thr Asp Asp Ile	Asn
	20	25	30
Arg Arg Glu Thr	Glu Leu Glu Asp Ala	Arg Gln Lys Phe Arg	Ser
	35	40	45
Val Leu Val Glu	Ala Thr Val Lys Leu	Asp Glu Leu Val Lys	Lys
	50	55	60
Ile Gly Lys Ala	Val Glu Asp Ser Lys	Pro Tyr Trp Glu Ala	Arg
	65	70	75
Arg Val Ala Arg	Gln Ala Gln Leu Glu	Ala Gln Lys Ala Thr	Gln

PF-0565 USN

	80		85		90
Asp Phe Gln Arg Ala Thr Glu Val Leu Arg Ala Ala Lys Glu Thr					
	95		100		105
Ile Ser Leu Ala Glu Gln Arg Leu Leu Glu Asp Asp Lys Arg Gln					
	110		115		120
Phe Asp Ser Ala Trp Gln Glu Met Leu Asn His Ala Thr Gln Arg					
	125		130		135
Val Met Glu Ala Glu Gln Thr Lys Thr Arg Ser Glu Leu Val His					
	140		145		150
Lys Glu Thr Ala Ala Arg Tyr Asn Ala Ala Met Gly Arg Met Arg					
	155		160		165
Gln Leu Glu Lys Lys Leu Lys Arg Ala Ile Asn Lys Ser Lys Pro					
	170		175		180
Tyr Phe Glu Leu Lys Ala Lys Tyr Tyr Val Gln Leu Glu Gln Leu					
	185		190		195
Lys Lys Thr Val Asp Asp Leu Gln Ala Lys Leu Thr Leu Ala Lys					
	200		205		210
Gly Glu Tyr Lys Met Ala Leu Lys Asn Leu Glu Met Ile Ser Asp					
	215		220		225
Glu Ile His Glu Arg Arg Arg Ser Ser Ala Met Gly Pro Arg Gly					
	230		235		240
Cys Gly Val Gly Ala Glu Gly Ser Ser Thr Ser Val Glu Asp Leu					
	245		250		255
Pro Gly Ser Lys Pro Glu Pro Asp Ala Ile Ser Val Ala Ser Glu					
	260		265		270
Ala Phe Glu Asp Asp Ser Cys Ser Asn Phe Val Ser Glu Asp Asp					
	275		280		285
Ser Glu Thr Gln Ser Val Ser Ser Phe Ser Ser Gly Pro Thr Ser					
	290		295		300
Pro Ser Glu Met Pro Asp Gln Phe Pro Ala Val Val Arg Pro Gly					
	305		310		315
Ser Leu Asp Leu Pro Ser Pro Val Ser Leu Ser Glu Phe Gly Met					
	320		325		330
Met Phe Pro Val Leu Gly Pro Arg Ser Glu Cys Ser Gly Ala Ser					
	335		340		345
Ser Pro Glu Cys Glu Val Glu Arg Gly Asp Arg Ala Glu Gly Ala					
	350		355		360
Glu Asn Lys Thr Ser Asp Lys Ala Asn Asn Asn Arg Gly Leu Ser					
	365		370		375
Ser Ser Ser Gly Ser Gly Gly Ser Ser Lys Ser Gln Ser Ser Thr					
	380		385		390
Ser Pro Glu Gly Gln Ala Leu Glu Asn Arg Met Lys Gln Leu Ser					
	395		400		405
Leu Gln Cys Ser Lys Gly Arg Asp Gly Ile Ile Ala Asp Ile Lys					
	410		415		420
Met Val Gln Ile Gly					
	425				

&lt;210&gt; 16

&lt;211&gt; 1135

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2299715

&lt;400&gt; 16

Met Ala Asn Asp Ser Pro Ala Lys Ser Leu Val Asp Ile Asp Leu					
1	5		10		15
Ser Ser Leu Arg Asp Pro Ala Gly Ile Phe Glu Leu Val Glu Val					
	20		25		30
Val Gly Asn Gly Thr Tyr Gly Gln Val Tyr Lys Gly Arg His Val					
	35		40		45
Lys Thr Gly Gln Leu Ala Ala Ile Lys Val Met Asp Val Thr Glu					
	50		55		60
Asp Glu Glu Glu Glu Ile Lys Leu Glu Ile Asn Met Leu Lys Lys					

PF-0565 USN

	65	70	75
Tyr Ser His His Arg	Asn Ile Ala Thr	Tyr Tyr Gly Ala Phe	Ile
	80	85	90
Lys Lys Ser Pro Pro	Gly His Asp Asp	Gln Leu Trp Leu Val	Met
	95	100	105
Glu Phe Cys Gly Ala	Gly Ser Ile Thr	Asp Leu Val Lys Asn	Thr
	110	115	120
Lys Gly Asn Thr Leu	Lys Glu Asp Trp	Ile Ala Tyr Ile Ser	Arg
	125	130	135
Glu Ile Leu Arg Gly	Leu Ala His Leu	His Ile His His Val	Ile
	140	145	150
His Arg Asp Ile Lys	Gly Gln Asn Val	Leu Leu Thr Glu Asn	Ala
	155	160	165
Gly Val Lys Leu Val	Asp Phe Gly Val	Ser Ala Gln Leu Asp	Arg
	170	175	180
Thr Val Gly Arg Arg	Asn Thr Phe Ile	Gly Thr Pro Tyr Trp	Met
	185	190	195
Ala Pro Glu Val Ile	Ala Cys Asp Glu	Asn Pro Asp Ala Thr	Tyr
	200	205	210
Asp Tyr Arg Ser Asp	Leu Trp Ser Cys	Gly Ile Thr Ala Ile	Glu
	215	220	225
Met Ala Glu Gly Ala	Pro Pro Leu Cys	Asp Met His Pro Met	Arg
	230	235	240
Ala Leu Phe Leu Ile	Pro Arg Asn Pro	Pro Pro Arg Leu Lys	Ser
	245	250	255
Lys Lys Trp Ser Lys	Lys Phe Phe Ser	Phe Ile Glu Gly Cys	Leu
	260	265	270
Val Lys Asn Tyr Met	Gln Arg Pro Ser	Thr Glu Gln Leu Leu	Lys
	275	280	285
His Pro Phe Ile Arg	Asp Gln Pro Asn	Glu Arg Gln Val Arg	Ile
	290	295	300
Gln Leu Lys Asp His	Ile Asp Arg Thr	Arg Lys Lys Arg Gly	Glu
	305	310	315
Lys Asp Glu Thr Glu	Tyr Glu Tyr Ser	Gly Ser Glu Glu Glu	Glu
	320	325	330
Glu Glu Val Pro Glu	Gln Glu Gly Glu	Pro Ser Ser Ile Val	Asn
	335	340	345
Val Pro Gly Glu Ser	Thr Leu Arg Arg	Asp Phe Leu Arg Leu	Gln
	350	355	360
Gln Glu Asn Lys Glu	Arg Ser Glu Ala	Leu Arg Arg Gln Gln	Leu
	365	370	375
Leu Gln Glu Gln Gln	Leu Arg Glu Gln	Glu Glu Tyr Lys Arg	Gln
	380	385	390
Leu Leu Ala Glu Arg	Gln Lys Arg Ile	Glu Gln Gln Lys Glu	Gln
	395	400	405
Arg Arg Arg Leu Glu	Glu Gln Gln Arg	Arg Glu Arg Glu Ala	Arg
	410	415	420
Arg Gln Gln Glu Arg	Glu Gln Arg Arg	Arg Glu Gln Glu Glu	Lys
	425	430	435
Arg Arg Leu Glu Glu	Leu Glu Arg Arg	Arg Lys Glu Glu Glu	Glu
	440	445	450
Arg Arg Arg Ala Glu	Glu Glu Glu Lys	Arg Val Glu Arg Glu	Gln
	455	460	465
Glu Tyr Ile Arg Arg	Gln Leu Glu Glu	Glu Gln Arg His Leu	Glu
	470	475	480
Val Leu Gln Gln Gln	Leu Leu Gln Glu	Gln Ala Met Leu Leu	His
	485	490	495
Asp His Arg Arg Pro	His Pro Gln His	Ser Gln Gln Pro Pro	Pro
	500	505	510
Pro Gln Gln Glu Arg	Ser Lys Pro Ser	Phe His Ala Pro Glu	Pro
	515	520	525
Lys Ala His Tyr Glu	Pro Ala Asp Arg	Ala Arg Glu Val Pro	Val
	530	535	540
Arg Thr Thr Ser Arg	Ser Pro Val Leu	Ser Arg Arg Asp Ser	Pro
	545	550	555
Leu Gln Gly Ser Gly	Gln Gln Asn Ser	Gln Ala Gly Gln Arg	Asn
	560	565	570

PF-0565 USN

Ser Thr Ser Ile	Glu Pro Arg Leu Leu Trp	Glu Arg Val Glu Lys	
575	580	585	
Leu Val Pro Arg	Pro Gly Ser Gly Ser Ser	Ser Gly Ser Ser Asn	
590	595	600	
Ser Gly Ser Gln	Pro Gly Ser His Pro Gly	Ser Gln Ser Gly Ser	
605	610	615	
Gly Glu Arg Phe	Arg Val Arg Ser Ser Ser	Lys Ser Glu Gly Ser	
620	625	630	
Pro Ser Gln Arg	Leu Glu Asn Ala Val Lys	Lys Pro Glu Asp Lys	
635	640	645	
Lys Glu Val Phe	Arg Pro Leu Lys Pro Ala	Asp Leu Thr Ala Leu	
650	655	660	
Ala Lys Glu Leu	Arg Ala Val Glu Asp Val	Arg Pro Pro His Lys	
665	670	675	
Val Thr Asp Tyr	Ser Ser Ser Ser Glu Glu	Ser Gly Thr Thr Asp	
680	685	690	
Glu Glu Asp Asp	Asp Val Glu Gln Glu Gly	Ala Asp Glu Ser Thr	
695	700	705	
Ser Gly Pro Glu	Asp Thr Arg Ala Ala Ser	Ser Ser Leu Asn Leu Ser	
710	715	720	
Asn Gly Glu Thr	Glu Ser Val Lys Thr Met	Ile Val His Asp Asp	
725	730	735	
Val Glu Ser Glu	Pro Ala Met Thr Pro Ser	Lys Glu Gly Thr Leu	
740	745	750	
Ile Val Arg Gln	Thr Gln Ser Ala Ser Ser	Thr Leu Gln Lys His	
755	760	765	
Lys Ser Ser Ser	Ser Phe Thr Pro Phe Ile	Asp Pro Arg Leu Leu	
770	775	780	
Gln Ile Ser Pro	Ser Ser Gly Thr Thr Val	Thr Ser Val Val Gly	
785	790	795	
Phe Ser Cys Asp	Gly Met Arg Pro Glu Ala	Ile Arg Gln Asp Pro	
800	805	810	
Thr Arg Lys Gly	Ser Val Val Asn Val Asn	Pro Thr Asn Thr Arg	
815	820	825	
Pro Gln Ser Asp	Thr Pro Glu Ile Arg Lys	Tyr Lys Lys Arg Phe	
830	835	840	
Asn Ser Glu Ile	Leu Cys Ala Ala Leu Trp	Gly Val Asn Leu Leu	
845	850	855	
Val Gly Thr Glu	Ser Gly Leu Met Leu Leu	Asp Arg Ser Gly Gln	
860	865	870	
Gly Lys Val Tyr	Pro Leu Ile Asn Arg Arg	Arg Phe Gln Gln Met	
875	880	885	
Asp Val Leu Glu	Gly Leu Asn Val Leu Val	Thr Ile Ser Gly Lys	
890	895	900	
Lys Asp Lys Leu	Arg Val Tyr Tyr Leu Ser	Trp Leu Arg Asn Lys	
905	910	915	
Ile Leu His Asn	Asp Pro Glu Val Glu Lys	Lys Gln Gly Trp Thr	
920	925	930	
Thr Val Gly Asp	Leu Glu Gly Cys Val His	Tyr Lys Val Val Lys	
935	940	945	
Tyr Glu Arg Ile	Lys Phe Leu Val Ile Ala	Leu Lys Ser Ser Val	
950	955	960	
Glu Val Tyr Ala	Trp Ala Pro Lys Pro Tyr	His Lys Phe Met Ala	
965	970	975	
Phe Lys Ser Phe	Gly Glu Leu Val His Gly	Ser Cys Ala Gly Phe	
980	985	990	
His Ala Val Asp	Val Asp Ser Gly Ser Val	Tyr Asp Ile Tyr Leu	
995	1000	1005	
Pro Thr His Ile	Gln Cys Ser Ile Lys Pro	His Ala Ile Ile Ile	
1010	1015	1020	
Leu Pro Asn Thr	Asp Gly Met Glu Leu Leu	Val Cys Tyr Glu Asp	
1025	1030	1035	
Glu Gly Val Tyr	Val Asn Thr Tyr Gly Arg	Ile Thr Lys Asp Val	
1040	1045	1050	
Val Leu Gln Trp	Gly Glu Met Pro Thr Ser	Val Ala Tyr Ile Arg	
1055	1060	1065	
Ser Asn Gln Thr	Met Gly Trp Gly Glu Lys	Ala Ile Glu Ile Arg	

PF-0565 USN

				1070					1075					1080
Ser	Val	Glu	Thr	Gly	His	Leu	Asp	Gly	Val	Phe	Met	His	Lys	Arg
				1085					1090					1095
Ala	Gln	Arg	Leu	Lys	Phe	Leu	Cys	Glu	Arg	Asn	Asp	Lys	Val	Phe
				1100					1105					1110
Phe	Ala	Ser	Val	Arg	Ser	Gly	Gly	Ser	Ser	Gln	Val	Tyr	Phe	Met
				1115					1120					1125
Thr	Leu	Gly	Arg	Thr	Ser	Leu	Leu	Ser	Trp					
				1130					1135					

```
<210> 17
<211> 228
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> misc_feature  
<223> Incyte ID No: 209854
```

[illegible]

```
<210> 18
<211> 503
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> misc_feature
<223> Incyte ID No: 1384286
```

<400>	18														
Met	Ala	Thr	Thr	Val	Thr	Cys	Thr	Arg	Phe	Thr	Asp	Glu	Tyr	Gln	
1				5					10					15	
Leu	Tyr	Glu	Asp	Ile	Gly	Lys	Gly	Ala	Phe	Ser	Val	Val	Arg	Arg	
				20					25					30	

PF-0565 USN

Cys	Val	Lys	Leu	Cys	Thr	Gly	His	Glu	Tyr	Ala	Ala	Lys	Ile	Ile
				35					40					45
Asn	Thr	Lys	Lys	Leu	Ser	Ala	Arg	Asp	His	Gln	Lys	Leu	Glu	Arg
				50					55					60
Glu	Ala	Arg	Ile	Cys	Arg	Leu	Leu	Lys	His	Ser	Asn	Ile	Val	Arg
				65					70					75
Leu	His	Asp	Ser	Ile	Ser	Glu	Glu	Gly	Phe	His	Tyr	Leu	Val	Phe
				80					85					90
Asp	Leu	Val	Thr	Gly	Gly	Glu	Leu	Phe	Glu	Asp	Ile	Val	Ala	Arg
				95					100					105
Glu	Tyr	Tyr	Ser	Glu	Ala	Asp	Ala	Ser	His	Cys	Ile	Gln	Gln	Ile
				110					115					120
Leu	Glu	Ala	Val	Leu	His	Cys	His	Gln	Met	Gly	Val	Val	His	Arg
				125					130					135
Asp	Leu	Lys	Pro	Glu	Asn	Leu	Leu	Leu	Ala	Ser	Lys	Cys	Lys	Gly
				140					145					150
Ala	Ala	Val	Lys	Leu	Ala	Asp	Phe	Gly	Leu	Ala	Ile	Glu	Val	Gln
				155					160					165
Gly	Asp	Gln	Gln	Ala	Trp	Phe	Gly	Phe	Ala	Gly	Thr	Pro	Gly	Tyr
				170					175					180
Leu	Ser	Pro	Glu	Val	Leu	Arg	Lys	Glu	Ala	Tyr	Gly	Lys	Pro	Val
				185					190					195
Asp	Ile	Trp	Ala	Cys	Gly	Val	Ile	Leu	Tyr	Ile	Leu	Leu	Val	Gly
				200					205					210
Tyr	Pro	Pro	Phe	Trp	Asp	Glu	Asp	Gln	His	Lys	Leu	Tyr	Gln	Gln
				215					220					225
Ile	Lys	Ala	Gly	Ala	Tyr	Asp	Phe	Pro	Ser	Pro	Glu	Trp	Asp	Thr
				230					235					240
Val	Thr	Pro	Glu	Ala	Lys	Asn	Leu	Ile	Asn	Gln	Met	Leu	Thr	Ile
				245					250					255
Asn	Pro	Ala	Lys	Arg	Ile	Thr	Ala	His	Glu	Ala	Leu	Lys	His	Pro
				260					265					270
Trp	Val	Cys	Gln	Arg	Ser	Thr	Val	Ala	Ser	Met	Met	His	Arg	Gln
				275					280					285
Glu	Thr	Val	Glu	Cys	Leu	Lys	Lys	Phe	Asn	Ala	Arg	Arg	Lys	Leu
				290					295					300
Lys	Gly	Ala	Ile	Leu	Thr	Thr	Met	Leu	Ala	Thr	Arg	Asn	Phe	Ser
				305					310					315
Ala	Ala	Lys	Ser	Leu	Leu	Asn	Lys	Lys	Ala	Asp	Gly	Val	Lys	Pro
				320					325					330
His	Thr	Asn	Ser	Thr	Lys	Asn	Ser	Ala	Ala	Ala	Thr	Ser	Pro	Lys
				335					340					345
Gly	Thr	Leu	Pro	Pro	Ala	Ala	Leu	Glu	Ser	Ser	Asp	Ser	Ala	Asn
				350					355					360
Thr	Thr	Ile	Glu	Asp	Glu	Asp	Ala	Lys	Ala	Arg	Lys	Gln	Glu	Ile
				365					370					375
Ile	Lys	Thr	Thr	Glu	Gln	Leu	Ile	Glu	Ala	Val	Asn	Asn	Gly	Asp
				380					385					390
Phe	Glu	Ala	Tyr	Ala	Lys	Ile	Cys	Asp	Pro	Gly	Leu	Thr	Ser	Phe
				395					400					405
Glu	Pro	Glu	Ala	Leu	Gly	Asn	Leu	Val	Glu	Gly	Met	Asp	Phe	His
				410					415					420
Arg	Phe	Tyr	Phe	Glu	Asn	Leu	Leu	Ala	Lys	Asn	Ser	Lys	Pro	Ile
				425					430					435
His	Thr	Thr	Ile	Leu	Asn	Pro	His	Val	His	Val	Ile	Gly	Glu	Asp
				440					445					450
Ala	Ala	Cys	Ile	Ala	Tyr	Ile	Arg	Leu	Thr	Gln	Tyr	Ile	Asp	Gly
				455					460					465
Gln	Gly	Arg	Pro	Arg	Thr	Ser	Gln	Ser	Glu	Glu	Thr	Arg	Val	Trp
				470					475					480
His	Arg	Arg	Asp	Gly	Lys	Trp	Gln	Asn	Val	His	Phe	His	Cys	Ser
				485					490					495
Gly	Ala	Pro	Val	Ala	Pro	Leu	Gln							
				500										

&lt;210&gt; 19

&lt;211&gt; 433

PF-0565 USN

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1512656

&lt;400&gt; 19

Met	Thr	Gly	Glu	Ala	Gln	Ala	Gly	Arg	Lys	Arg	Ser	Arg	Ala	Arg	1	5	10	15
Pro	Glu	Gly	Thr	Glu	Pro	Val	Arg	Arg	Glu	Arg	Thr	Gln	Pro	Gly	20	25	30	35
Leu	Gly	Pro	Gly	Arg	Ala	Arg	Ala	Met	Ala	Ala	Glu	Ala	Thr	Ala	40	45	50	55
Val	Ala	Gly	Ser	Gly	Ala	Val	Gly	Gly	Cys	Leu	Ala	Lys	Asp	Gly	60	65	70	75
Leu	Gln	Gln	Ser	Lys	Cys	Pro	Asp	Thr	Thr	Pro	Lys	Arg	Arg	Arg	80	85	90	95
Ala	Ser	Ser	Leu	Ser	Arg	Asp	Ala	Glu	Arg	Arg	Ala	Tyr	Gln	Trp	100	105	110	115
Cys	Arg	Glu	Tyr	Leu	Gly	Gly	Ala	Trp	Arg	Arg	Val	Gln	Pro	Glu	120	125	130	135
Glu	Leu	Arg	Val	Tyr	Pro	Val	Ser	Gly	Gly	Leu	Ser	Asn	Leu	Leu	140	145	150	155
Phe	Arg	Cys	Ser	Leu	Pro	Asp	His	Leu	Pro	Ser	Val	Gly	Glu	Glu	160	165	170	175
Pro	Arg	Glu	Val	Leu	Leu	Arg	Leu	Tyr	Gly	Ala	Ile	Leu	Gln	Gly	180	185	190	195
Val	Asp	Ser	Leu	Val	Leu	Glu	Ser	Val	Met	Phe	Ala	Ile	Leu	Ala	200	205	210	215
Glu	Arg	Ser	Leu	Gly	Pro	Gln	Leu	Tyr	Gly	Val	Phe	Pro	Glu	Gly	220	225	230	235
Arg	Leu	Glu	Gln	Tyr	Ile	Pro	Ser	Arg	Pro	Leu	Lys	Thr	Gln	Glu	240	245	250	255
Leu	Arg	Glu	Pro	Val	Leu	Ser	Ala	Ala	Ile	Ala	Thr	Lys	Met	Ala	260	265	270	275
Gln	Phe	His	Gly	Met	Glu	Met	Pro	Phe	Thr	Lys	Glu	Pro	His	Trp	280	285	290	295
Leu	Phe	Gly	Thr	Met	Glu	Arg	Tyr	Leu	Lys	Gln	Ile	Gln	Asp	Leu	300	305	310	315
Pro	Pro	Thr	Gly	Leu	Pro	Glu	Met	Asn	Leu	Leu	Glu	Met	Tyr	Ser	320	325	330	335
Leu	Lys	Asp	Glu	Met	Gly	Asn	Leu	Arg	Lys	Leu	Leu	Glu	Ser	Thr	340	345	350	355
Pro	Ser	Pro	Val	Val	Phe	Cys	His	Asn	Asp	Ile	Gln	Glu	Gly	Asn	360	365	370	375
Ile	Leu	Leu	Leu	Ser	Glu	Pro	Glu	Asn	Ala	Asp	Ser	Leu	Met	Leu	380	385	390	395
Val	Asp	Phe	Glu	Tyr	Ser	Ser	Tyr	Asn	Tyr	Arg	Gly	Phe	Asp	Ile	400	405	410	415
Gly	Asn	His	Phe	Cys	Glu	Trp	Val	Tyr	Asp	Tyr	Thr	His	Glu	Glu	420	425	430	435
Trp	Pro	Phe	Tyr	Lys	Ala	Arg	Pro	Thr	Asp	Tyr	Pro	Thr	Gln	Glu	440	445	450	455
Gln	Gln	Leu	His	Phe	Ile	Arg	His	Tyr	Leu	Ala	Glu	Ala	Lys	Lys	460	465	470	475
Gly	Glu	Thr	Leu	Ser	Gln	Glu	Glu	Gln	Arg	Lys	Leu	Glu	Glu	Asp	480	485	490	495
Leu	Leu	Val	Glu	Val	Ser	Arg	Tyr	Ala	Leu	Ala	Ser	His	Phe	Phe	500	505	510	515
Trp	Gly	Leu	Trp	Ser	Ile	Leu	Gln	Ala	Ser	Met	Ser	Thr	Ile	Glu	520	525	530	535
Phe	Gly	Tyr	Leu	Asp	Tyr	Ala	Gln	Ser	Arg	Phe	Gln	Phe	Tyr	Phe	540	545	550	555
Gln	Gln	Lys	Gly	Gln	Leu	Thr	Ser	Val	His	Ser	Ser	Ser			560	565	570	575



PF-0565 USN

&lt;210&gt; 20

&lt;211&gt; 527

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2098635

&lt;400&gt; 20

Met	Ser	Leu	Cys	Gly	Ala	Arg	Ala	Asn	Ala	Lys	Met	Met	Ala	Ala
1				5					10					15
Tyr	Asn	Gly	Gly	Thr	Ser	Ala	Ala	Ala	Ala	Gly	His	His	His	His
				20					25					30
His	His	His	His	Leu	Pro	His	Leu	Pro	Pro	Pro	His	Leu	Leu	His
				35					40					45
His	His	His	Pro	Gln	His	His	Leu	His	Pro	Gly	Ser	Ala	Ala	Ala
				50					55					60
Val	His	Pro	Val	Gln	Gln	His	Thr	Ser	Ser	Ala	Ala	Ala	Ala	Ala
				65					70					75
Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Met	Leu	Asn	Pro	Gly	Gln	Gln
				80					85					90
Gln	Pro	Tyr	Phe	Pro	Ser	Pro	Ala	Pro	Gly	Gln	Ala	Pro	Gly	Pro
				95					100					105
Ala	Ala	Ala	Ala	Pro	Ala	Gln	Val	Gln	Ala	Ala	Ala	Ala	Ala	Thr
				110					115					120
Val	Lys	Ala	His	His	His	Gln	His	Ser	His	His	Pro	Gln	Gln	Gln
				125					130					135
Leu	Asp	Ile	Glu	Pro	Asp	Arg	Pro	Ile	Gly	Tyr	Gly	Ala	Phe	Gly
				140					145					150
Val	Val	Trp	Ser	Val	Thr	Asp	Pro	Arg	Asp	Gly	Lys	Arg	Val	Ala
				155					160					165
Leu	Lys	Lys	Met	Pro	Asn	Val	Phe	Gln	Asn	Leu	Val	Ser	Cys	Lys
				170					175					180
Arg	Val	Phe	Arg	Glu	Leu	Lys	Met	Leu	Cys	Phe	Phe	Lys	His	Asp
				185					190					195
Asn	Val	Leu	Ser	Ala	Leu	Asp	Ile	Leu	Gln	Pro	Pro	His	Ile	Asp
				200					205					210
Tyr	Phe	Glu	Glu	Ile	Tyr	Val	Val	Thr	Glu	Leu	Met	Gln	Ser	Asp
				215					220					225
Leu	His	Lys	Ile	Ile	Val	Ser	Pro	Gln	Pro	Leu	Ser	Ser	Asp	His
				230					235					240
Val	Lys	Val	Phe	Leu	Tyr	Gln	Ile	Leu	Arg	Gly	Leu	Lys	Tyr	Leu
				245					250					255
His	Ser	Ala	Gly	Ile	Leu	His	Arg	Asp	Ile	Lys	Pro	Gly	Asn	Leu
				260					265					270
Leu	Val	Asn	Ser	Asn	Cys	Val	Leu	Lys	Ile	Cys	Asp	Phe	Gly	Leu
				275					280					285
Ala	Arg	Val	Glu	Glu	Leu	Asp	Glu	Ser	Arg	His	Met	Thr	Gln	Glu
				290					295					300
Val	Val	Thr	Gln	Tyr	Tyr	Arg	Ala	Pro	Glu	Ile	Leu	Met	Gly	Ser
				305					310					315
Arg	His	Tyr	Ser	Asn	Ala	Ile	Asp	Ile	Trp	Ser	Val	Gly	Cys	Ile
				320					325					330
Phe	Ala	Glu	Leu	Leu	Gly	Arg	Arg	Ile	Leu	Phe	Gln	Ala	Gln	Ser
				335					340					345
Pro	Ile	Gln	Gln	Leu	Asp	Leu	Ile	Thr	Asp	Leu	Leu	Gly	Thr	Pro
				350					355					360
Ser	Leu	Glu	Ala	Met	Arg	Thr	Ala	Cys	Glu	Gly	Ala	Lys	Ala	His
				365					370					375
Ile	Leu	Arg	Gly	Pro	His	Lys	Gln	Pro	Ser	Leu	Pro	Val	Leu	Tyr
				380					385					390
Thr	Leu	Ser	Ser	Gln	Ala	Thr	His	Glu	Ala	Val	His	Leu	Leu	Cys
				395					400					405
Arg	Met	Leu	Val	Phe	Asp	Pro	Ser	Lys	Arg	Ile	Ser	Ala	Lys	Asp
				410					415					420
Ala	Leu	Ala	His	Pro	Tyr	Leu	Asp	Glu	Gly	Arg	Leu	Arg	Tyr	His

PF-0565 USN

	425		430		435
Thr Cys Met Cys	Lys Cys Cys Phe Ser	Thr Ser Thr Gly Arg Val			
	440		445		450
Tyr Thr Ser Asp	Phe Glu Pro Val Thr	Asn Pro Lys Phe Asp Asp			
	455		460		465
Thr Phe Glu Lys	Asn Leu Ser Ser Val	Arg Gln Val Lys Glu Ile			
	470		475		480
Ile His Gln Phe	Ile Leu Glu Gln Gln	Lys Gly Asn Arg Val Pro			
	485		490		495
Leu Cys Ile Asn	Pro Gln Ser Ala Ala	Phe Lys Ser Phe Ile Ser			
	500		505		510
Ser Thr Val Ala	Gln Pro Ser Glu Met	Pro Pro Ser Pro Leu Val			
	515		520		525
Trp Glu					

&lt;210&gt; 21

&lt;211&gt; 322

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2446646

&lt;400&gt; 21

Met Glu Gly Ile Ser	Asn Phe Lys Thr Pro	Ser Lys Leu Ser Glu
1 5	10	15
Lys Lys Lys Ser Val	Leu Cys Ser Thr Pro	Thr Ile Asn Ile Pro
20	25	30
Ala Ser Pro Phe Met	Gln Lys Leu Gly Phe	Gly Thr Gly Val Asn
35	40	45
Val Tyr Leu Met Lys	Arg Ser Pro Arg Gly	Leu Ser His Ser Pro
50	55	60
Trp Ala Val Lys Lys	Ile Asn Pro Ile Cys	Asn Asp His Tyr Arg
65	70	75
Ser Val Tyr Gln Lys	Arg Leu Met Asp Glu	Ala Lys Ile Leu Lys
80	85	90
Ser Leu His His Pro	Asn Ile Val Gly Tyr	Arg Ala Phe Thr Glu
95	100	105
Ala Asn Asp Gly Ser	Leu Cys Leu Ala Met	Glu Tyr Gly Gly Glu
110	115	120
Lys Ser Leu Asn Asp	Leu Ile Glu Glu Arg	Tyr Lys Ala Ser Gln
125	130	135
Asp Pro Phe Pro Ala	Ala Ile Ile Leu Lys	Val Ala Leu Asn Met
140	145	150
Ala Arg Gly Leu Lys	Tyr Leu His Gln Glu	Lys Lys Leu Leu His
155	160	165
Gly Asp Ile Lys Ser	Ser Asn Val Val Ile	Lys Gly Asp Phe Glu
170	175	180
Thr Ile Lys Ile Cys	Asp Val Gly Val Ser	Leu Pro Leu Asp Glu
185	190	195
Asn Met Thr Val Thr	Asp Pro Glu Ala Cys	Tyr Ile Gly Thr Glu
200	205	210
Pro Trp Lys Pro Lys	Glu Ala Val Glu Glu	Asn Gly Val Ile Thr
215	220	225
Asp Lys Ala Asp Ile	Phe Ala Phe Gly Leu	Thr Leu Trp Glu Met
230	235	240
Met Thr Leu Ser Ile	Pro His Ile Asn Leu	Ser Asn Asp Asp Asp
245	250	255
Asp Glu Asp Lys Thr	Phe Asp Glu Ser Asp	Phe Asp Asp Glu Ala
260	265	270
Tyr Tyr Ala Ala Leu	Gly Thr Arg Pro Pro	Ile Asn Met Glu Glu
275	280	285
Leu Asp Glu Ser Tyr	Gln Lys Val Ile Glu	Leu Phe Ser Val Cys
290	295	300
Thr Asn Glu Asp Pro	Lys Asp Arg Pro Ser	Ala Ala His Ile Val

PF-0565 USN

305 310 315  
 Glu Ala Leu Glu Thr Asp Val  
 320

<210> 22  
 <211> 802  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2764911

<400> 22  
 Met Glu Glu Glu Gly Gly Ser Ser Gly Gly Ala Ala Gly Thr Ser  
 1 5 10 15  
 Ala Asp Gly Gly Asp Gly Gly Glu Gln Leu Thr Val Lys His  
 20 25 30  
 Glu Leu Arg Thr Ala Asn Leu Thr Gly His Ala Glu Lys Val Gly  
 35 40 45  
 Ile Glu Asn Phe Glu Leu Leu Lys Val Leu Gly Thr Gly Ala Tyr  
 50 55 60  
 Gly Lys Val Phe Leu Val Arg Lys Ile Ser Gly His Asp Thr Gly  
 65 70 75  
 Lys Leu Tyr Ala Met Lys Val Leu Lys Lys Ala Thr Ile Val Gln  
 80 85 90  
 Lys Ala Lys Thr Thr Glu His Thr Arg Thr Glu Arg Gln Val Leu  
 95 100 105  
 Glu His Ile Arg Gln Ser Pro Phe Leu Val Thr Leu His Tyr Ala  
 110 115 120  
 Phe Gln Thr Glu Thr Lys Leu His Leu Ile Leu Asp Tyr Ile Asn  
 125 130 135  
 Gly Gly Glu Leu Phe Thr His Leu Ser Gln Arg Glu Arg Phe Thr  
 140 145 150  
 Glu His Glu Val Gln Ile Tyr Val Gly Glu Ile Val Leu Ala Leu  
 155 160 165  
 Glu His Leu His Lys Leu Gly Ile Ile Tyr Arg Asp Ile Lys Leu  
 170 175 180  
 Glu Asn Ile Leu Leu Asp Ser Asn Gly His Val Val Leu Thr Asp  
 185 190 195  
 Phe Gly Leu Ser Lys Glu Phe Val Ala Asp Glu Thr Glu Arg Ala  
 200 205 210  
 Tyr Ser Phe Cys Gly Thr Ile Glu Tyr Met Ala Pro Asp Ile Val  
 215 220 225  
 Arg Gly Gly Asp Ser Gly His Asp Lys Ala Val Asp Trp Trp Ser  
 230 235 240  
 Leu Gly Val Leu Met Tyr Glu Leu Leu Thr Gly Ala Ser Pro Phe  
 245 250 255  
 Thr Val Asp Gly Glu Lys Asn Ser Gln Ala Glu Ile Ser Arg Arg  
 260 265 270  
 Ile Leu Lys Ser Glu Pro Pro Tyr Pro Gln Glu Met Ser Ala Leu  
 275 280 285  
 Ala Lys Asp Leu Ile Gln Arg Leu Leu Met Lys Asp Pro Lys Lys  
 290 295 300  
 Arg Leu Gly Cys Gly Pro Arg Asp Ala Asp Glu Ile Lys Glu His  
 305 310 315  
 Leu Phe Phe Gln Lys Ile Asn Trp Asp Asp Leu Ala Ala Lys Lys  
 320 325 330  
 Val Pro Ala Pro Phe Lys Pro Val Ile Arg Asp Glu Leu Asp Val  
 335 340 345  
 Ser Asn Phe Ala Glu Glu Phe Thr Glu Met Asp Pro Thr Tyr Ser  
 350 355 360  
 Pro Ala Ala Leu Pro Gln Ser Ser Glu Lys Leu Phe Gln Gly Tyr  
 365 370 375  
 Ser Phe Val Ala Pro Ser Ile Leu Phe Lys Arg Asn Ala Ala Val  
 380 385 390  
 Ile Asp Pro Leu Gln Phe His Met Gly Val Glu Arg Pro Gly Val

PF-0565 USN

				395					400				405	
Thr	Asn	Val	Ala	Arg	Ser	Ala	Met	Met	Lys	Asp	Ser	Pro	Phe	Tyr
				410					415					420
Gln	His	Tyr	Asp	Leu	Asp	Leu	Lys	Asp	Lys	Pro	Leu	Gly	Glu	Gly
				425					430					435
Ser	Phe	Ser	Ile	Cys	Arg	Lys	Cys	Val	His	Lys	Lys	Ser	Asn	Gln
				440					445					450
Ala	Phe	Ala	Val	Lys	Ile	Ile	Ser	Lys	Arg	Met	Glu	Ala	Asn	Thr
				455					460					465
Gln	Lys	Glu	Ile	Thr	Ala	Leu	Glu	Leu	Cys	Glu	Gly	His	Pro	Asn
				470					475					480
Ile	Val	Lys	Leu	His	Glu	Val	Phe	His	Asp	Gln	Leu	His	Thr	Phe
				485					490					495
Leu	Val	Met	Glu	Leu	Leu	Asn	Gly	Gly	Glu	Leu	Phe	Glu	Arg	Ile
				500					505					510
Lys	Lys	Lys	Lys	His	Phe	Ser	Glu	Thr	Glu	Ala	Ser	Tyr	Ile	Met
				515					520					525
Arg	Lys	Leu	Val	Ser	Ala	Val	Ser	His	Met	His	Asp	Val	Gly	Val
				530					535					540
Val	His	Arg	Asp	Leu	Lys	Pro	Glu	Asn	Leu	Leu	Phe	Thr	Asp	Glu
				545					550					555
Asn	Asp	Asn	Leu	Glu	Ile	Lys	Ile	Ile	Asp	Phe	Gly	Phe	Ala	Arg
				560					565					570
Leu	Lys	Pro	Pro	Asp	Asn	Gln	Pro	Leu	Lys	Thr	Pro	Cys	Phe	Thr
				575					580					585
Leu	His	Tyr	Ala	Ala	Pro	Glu	Leu	Leu	Asn	Gln	Asn	Gly	Tyr	Asp
				590					595					600
Glu	Ser	Cys	Asp	Leu	Trp	Ser	Leu	Gly	Val	Ile	Leu	Tyr	Thr	Met
				605					610					615
Leu	Ser	Gly	Gln	Val	Pro	Phe	Gln	Ser	His	Asp	Arg	Ser	Leu	Thr
				620					625					630
Cys	Thr	Ser	Ala	Val	Glu	Ile	Met	Lys	Lys	Ile	Lys	Lys	Gly	Asp
				635					640					645
Phe	Ser	Phe	Glu	Gly	Glu	Ala	Trp	Lys	Asn	Val	Ser	Gln	Glu	Ala
				650					655					660
Lys	Asp	Leu	Ile	Gln	Gly	Leu	Leu	Thr	Val	Asp	Pro	Asn	Lys	Arg
				665					670					675
Leu	Lys	Met	Ser	Gly	Leu	Arg	Tyr	Asn	Glu	Trp	Leu	Gln	Asp	Gly
				680					685					690
Ser	Gln	Leu	Ser	Ser	Asn	Pro	Leu	Met	Thr	Pro	Asp	Ile	Leu	Gly
				695					700					705
Ser	Ser	Gly	Ala	Ala	Val	His	Thr	Cys	Val	Lys	Ala	Thr	Phe	His
				710					715					720
Ala	Phe	Asn	Lys	Tyr	Lys	Arg	Glu	Gly	Phe	Cys	Leu	Gln	Asn	Val
				725					730					735
Asp	Lys	Ala	Pro	Leu	Ala	Lys	Arg	Arg	Lys	Met	Lys	Lys	Thr	Ser
				740					745					750
Thr	Ser	Thr	Glu	Thr	Arg	Ser	Ser	Ser	Ser	Glu	Ser	Ser	His	Ser
				755					760					765
Ser	Ser	Ser	His	Ser	His	Gly	Lys	Thr	Thr	Pro	Thr	Lys	Thr	Leu
				770					775					780
Gln	Pro	Ser	Asn	Pro	Ala	Asp	Ser	Asn	Asn	Pro	Glu	Thr	Leu	Phe
				785					790					795
Gln	Phe	Ser	Asp	Ser	Val	Ala								
				800										

&lt;210&gt; 23

&lt;211&gt; 641

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3013946

&lt;400&gt; 23

Met Ala Thr Thr Val Thr Cys Thr Arg Phe Thr Asp Glu Tyr Gln

PF-0565 USN

1	5	10	15
Leu Tyr Glu Asp Ile	Gly Lys Gly Ala Phe	Ser Val Val Arg Arg	
	20	25	30
Cys Val Lys Leu Cys	Thr Gly His Glu Tyr	Ala Ala Lys Ile Ile	
	35	40	45
Asn Thr Lys Lys Leu	Ser Ala Arg Asp His	Gln Lys Leu Glu Arg	
	50	55	60
Glu Ala Arg Ile Cys	Arg Leu Leu Lys His	Ser Asn Ile Val Arg	
	65	70	75
Leu His Asp Ser Ile	Ser Glu Glu Gly Phe	His Tyr Leu Val Phe	
	80	85	90
Asp Leu Val Thr Gly	Gly Glu Leu Phe Glu	Asp Ile Val Ala Arg	
	95	100	105
Glu Tyr Tyr Ser Glu	Ala Asp Ala Ser His	Cys Ile Gln Gln Ile	
	110	115	120
Leu Glu Ala Val Leu	His Cys His Gln Met	Gly Val Val His Arg	
	125	130	135
Asp Leu Lys Pro Glu	Asn Leu Leu Leu Ala	Ser Lys Cys Lys Gly	
	140	145	150
Ala Ala Val Lys Leu	Ala Asp Phe Gly Leu	Ala Ile Glu Val Gln	
	155	160	165
Gly Asp Gln Gln Ala	Trp Phe Gly Phe Ala	Gly Thr Pro Gly Tyr	
	170	175	180
Leu Ser Pro Glu Val	Leu Arg Lys Glu Ala	Tyr Gly Lys Pro Val	
	185	190	195
Asp Ile Trp Ala Cys	Gly Val Ile Leu Tyr	Ile Leu Leu Val Gly	
	200	205	210
Tyr Pro Pro Phe Trp	Asp Glu Asp Gln His	Lys Leu Tyr Gln Gln	
	215	220	225
Ile Lys Ala Gly Ala	Tyr Asp Phe Pro Ser	Pro Glu Trp Asp Thr	
	230	235	240
Val Thr Pro Glu Ala	Lys Asn Leu Ile Asn	Gln Met Leu Thr Ile	
	245	250	255
Asn Pro Ala Lys Arg	Ile Thr Ala His Glu	Ala Leu Lys His Pro	
	260	265	270
Trp Val Cys Gln Arg	Ser Thr Val Ala Ser	Met Met His Arg Gln	
	275	280	285
Glu Thr Val Glu Cys	Leu Lys Lys Phe Asn	Ala Arg Arg Lys Leu	
	290	295	300
Lys Gly Ala Ile Leu	Thr Thr Met Leu Ala	Thr Arg Asn Phe Ser	
	305	310	315
Ala Lys Ser Leu Leu	Asn Lys Lys Ala Asp	Gly Val Lys Pro Gln	
	320	325	330
Thr Asn Ser Thr Lys	Asn Ser Ala Ala Ala	Thr Ser Pro Lys Gly	
	335	340	345
Thr Leu Pro Pro Ala	Ala Leu Glu Pro Gln	Thr Thr Val Ile His	
	350	355	360
Asn Pro Val Asp Gly	Ile Lys Glu Ser Ser	Asp Ser Ala Asn Thr	
	365	370	375
Thr Ile Glu Asp Glu	Asp Ala Lys Ala Pro	Arg Val Pro Asp Ile	
	380	385	390
Leu Ser Ser Val Arg	Arg Gly Ser Gly Ala	Pro Glu Ala Glu Gly	
	395	400	405
Pro Leu Pro Cys Pro	Ser Pro Ala Pro Phe	Gly Pro Leu Pro Ala	
	410	415	420
Pro Ser Pro Arg Ile	Ser Asp Ile Leu Asn	Ser Val Arg Arg Gly	
	425	430	435
Ser Gly Thr Pro Glu	Ala Glu Gly Pro Leu	Ser Ala Gly Pro Pro	
	440	445	450
Pro Cys Leu Ser Pro	Ala Leu Leu Gly Pro	Leu Ser Ser Pro Ser	
	455	460	465
Pro Arg Ile Ser Asp	Ile Leu Asn Ser Val	Arg Arg Gly Ser Gly	
	470	475	480
Thr Pro Glu Ala Lys	Gly Pro Ser Pro Val	Gly Pro Pro Pro Cys	
	485	490	495
Pro Ser Pro Thr Ile	Pro Gly Pro Leu Pro	Thr Pro Ser Arg Lys	
	500	505	510



PF-0565 USN

Met	Ala	Phe	Glu	Leu	Leu	Ser	Ile	Asp	Leu	Tyr	Glu	Leu	Ile	Lys
				290					295					300
Lys	Asn	Lys	Phe	Gln	Gly	Phe	Ser	Val	Gln	Leu	Val	Arg	Lys	Phe
				305					310					315
Ala	Gln	Ser	Ile	Leu	Gln	Ser	Leu	Asp	Ala	Leu	His	Lys	Asn	Lys
				320					325					330
Ile	Ile	His	Cys	Asp	Leu	Lys	Pro	Glu	Asn	Ile	Leu	Leu	Lys	His
				335					340					345
His	Gly	Arg	Ser	Ser	Thr	Lys	Val	Ile	Asp	Phe	Gly	Ser	Ser	Cys
				350					355					360
Phe	Glu	Tyr	Gln	Lys	Leu	Tyr	Thr	Tyr	Ile	Gln	Ser	Arg	Phe	Tyr
				365					370					375
Arg	Ala	Pro	Glu	Ile	Ile	Leu	Gly	Ser	Arg	Tyr	Ser	Thr	Pro	Ile
				380					385					390
Asp	Ile	Trp	Ser	Phe	Gly	Cys	Ile	Leu	Ala	Glu	Leu	Leu	Thr	Gly
				395					400					405
Gln	Pro	Leu	Phe	Pro	Gly	Glu	Asp	Glu	Gly	Asp	Gln	Leu	Ala	Cys
				410					415					420
Met	Met	Glu	Leu	Leu	Gly	Met	Pro	Pro	Pro	Lys	Leu	Leu	Glu	Gln
				425					430					435
Ser	Lys	Arg	Ala	Lys	Tyr	Phe	Ile	Asn	Ser	Lys	Gly	Ile	Pro	Arg
				440					445					450
Tyr	Cys	Ser	Val	Thr	Thr	Gln	Ala	Asp	Gly	Arg	Val	Val	Leu	Val
				455					460					465
Gly	Gly	Arg	Ser	Arg	Arg	Gly	Lys	Lys	Arg	Gly	Pro	Pro	Gly	Ser
				470					475					480
Lys	Asp	Trp	Gly	Thr	Ala	Leu	Lys	Gly	Cys	Asp	Asp	Tyr	Leu	Phe
				485					490					495
Ile	Glu	Phe	Leu	Lys	Arg	Cys	Leu	His	Trp	Asp	Pro	Ser	Ala	Arg
				500					505					510
Leu	Thr	Pro	Ala	Gln	Ala	Leu	Arg	His	Pro	Trp	Ile	Ser	Lys	Ser
				515					520					525
Val	Pro	Arg	Pro	Leu	Thr	Thr	Ile	Asp	Lys	Val	Ser	Gly	Lys	Arg
				530					535					540
Val	Val	Asn	Pro	Ala	Ser	Ala	Phe	Gln	Gly	Leu	Gly	Ser	Lys	Leu
				545					550					555
Pro	Pro	Val	Val	Gly	Ile	Ala	Asn	Lys	Leu	Lys	Ala	Asn	Leu	Met
				560					565					570
Ser	Glu	Thr	Asn	Gly	Ser	Ile	Pro	Leu	Cys	Ser	Val	Leu	Pro	Lys
				575					580					585
Leu	Ile	Ser												

&lt;210&gt; 25

&lt;211&gt; 389

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 346275

&lt;400&gt; 25

Met	Ser	Asp	Val	Cys	Ser	Ser	Gln	Arg	Ala	Glu	His	Glu	His	Leu
1				5					10					15
Pro	Gly	Leu	Val	Pro	Pro	Pro	Ser	Gly	Met	Gly	Val	Arg	Lys	Gly
				20					25					30
Ser	Ser	Pro	Leu	Lys	Ser	His	Pro	Cys	Arg	Glu	Lys	Ser	Val	Ser
				35					40					45
Asn	Arg	Arg	Ser	Gly	Lys	Thr	Ile	Val	Arg	Ser	Ala	Val	Glu	Glu
				50					55					60
Val	Arg	Thr	Ala	Gly	Leu	Phe	Arg	Ser	Gly	Phe	Ser	Glu	Glu	Lys
				65					70					75
Ala	Thr	Gly	Lys	Leu	Phe	Ala	Val	Lys	Cys	Ile	Pro	Lys	Lys	Ala
				80					85					90
Leu	Lys	Gly	Lys	Glu	Ser	Ser	Ile	Glu	Asn	Glu	Ile	Ala	Val	Leu
				95					100					105





PF-0565 USN

Cys	Ser	Phe	Leu	Asp	Asp	Leu	Leu	Glu	Leu	Arg	Asp	Glu	Glu	Leu
				140					145					150
Ser	Lys	Glu	Ser	Gln	Glu	Thr	Asn	Trp	Phe	Ser	Ala	Pro	Ser	Ala
				155					160					165
Leu	Arg	Val	Tyr	Gly	Gln	Tyr	Leu	Asn	Leu	Asp	Lys	Asp	His	Asn
				170					175					180
Gly	Met	Leu	Ser	Lys	Glu	Glu	Leu	Ser	Arg	Tyr	Gly	Thr	Ala	Thr
				185					190					195
Met	Thr	Asn	Val	Phe	Leu	Asp	Arg	Val	Phe	Gln	Glu	Cys	Leu	Thr
				200					205					210
Tyr	Asp	Gly	Glu	Met	Asp	Tyr	Lys	Thr	Tyr	Leu	Asp	Phe	Val	Leu
				215					220					225
Ala	Leu	Glu	Asn	Arg	Lys	Glu	Pro	Ala	Ala	Leu	Gln	Tyr	Ile	Phe
				230					235					240
Lys	Leu	Leu	Asp	Ile	Glu	Asn	Lys	Gly	Tyr	Leu	Asn	Val	Phe	Ser
				245					250					255
Leu	Asn	Tyr	Phe	Phe	Arg	Ala	Ile	Gln	Glu	Leu	Met	Lys	Ile	His
				260					265					270
Gly	Gln	Asp	Pro	Val	Ser	Phe	Gln	Asp	Val	Lys	Asp	Glu	Ile	Phe
				275					280					285
Asp	Met	Val	Lys	Pro	Lys	Asp	Pro	Leu	Lys	Ile	Ser	Leu	Gln	Asp
				290					295					300
Leu	Ile	Asn	Ser	Asn	Gln	Gly	Asp	Thr	Val	Thr	Thr	Ile	Leu	Ile
				305					310					315
Asp	Leu	Asn	Gly	Phe	Trp	Thr	Tyr	Glu	Asn	Arg	Glu	Ala	Leu	Val
				320					325					330
Ala	Asn	Asp	Ser	Glu	Asn	Ser	Ala	Asp	Leu	Asp	Asp	Thr		
				335					340					

&lt;210&gt; 27

&lt;211&gt; 134

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2696537

&lt;400&gt; 27

Met	Gly	Asn	Gly	Met	Asn	Lys	Ile	Leu	Pro	Gly	Leu	Tyr	Ile	Gly
1				5					10					15
Asn	Phe	Lys	Asp	Ala	Arg	Asp	Ala	Glu	Gln	Leu	Ser	Lys	Asn	Lys
				20					25					30
Val	Thr	His	Ile	Leu	Ser	Val	His	Asp	Ser	Ala	Arg	Pro	Met	Leu
				35					40					45
Glu	Gly	Val	Lys	Tyr	Leu	Cys	Ile	Pro	Ala	Ala	Asp	Ser	Pro	Ser
				50					55					60
Gln	Asn	Leu	Thr	Arg	His	Phe	Lys	Glu	Ser	Ile	Lys	Phe	Ile	His
				65					70					75
Glu	Cys	Arg	Leu	Arg	Gly	Glu	Ser	Cys	Leu	Val	His	Cys	Leu	Ala
				80					85					90
Gly	Val	Ser	Arg	Ser	Val	Thr	Leu	Val	Ile	Ala	Tyr	Ile	Met	Thr
				95					100					105
Val	Thr	Asp	Phe	Gly	Trp	Glu	Asp	Ala	Leu	His	Thr	Val	Arg	Ala
				110					115					120
Gly	Arg	Ser	Cys	Ala	Asn	Pro	Asn	Val	Gly	Phe	Gln	Arg	Gln	Leu
				125					130					135
Gln	Glu	Phe	Glu	Lys	His	Glu	Val	His	Gln	Tyr	Arg	Gln	Trp	Leu
				140					145					150
Lys	Glu	Glu	Tyr	Gly	Glu	Ser	Pro	Leu	Gln	Asp	Ala	Glu	Glu	Ala
				155					160					165
Lys	Asn	Ile	Leu	Ala	Ala	Pro	Gly	Ile	Leu	Lys	Phe	Trp	Ala	Phe
				170					175					180
Leu	Arg	Arg	Leu											

&lt;210&gt; 28



PF-0565 USN

	230		235		240
Arg Gly Lys Glu	Asn Leu Pro Lys Arg	Thr Val Ser Leu Trp	Ser		
	245		250		255
Tyr Ile Asn Ser	Gln Leu Glu Asp Phe	Thr Asn Pro Leu Tyr	Gly		
	260		265		270
Ser Tyr Ser Asn	His Val Leu Tyr Pro	Val Ala Ser Met Arg	His		
	275		280		285
Leu Glu Leu Trp	Val Gly Tyr Tyr Ile	Arg Trp Asn Pro Arg	Met		
	290		295		300
Lys Pro Gln Glu	Pro Ile His Asn Arg	Tyr Lys Glu Leu Leu	Ala		
	305		310		315
Lys Arg Ala Glu	Leu Gln Lys Lys Val	Glu Glu Leu Gln Arg	Glu		
	320		325		330
Ile Ser Asn Arg	Ser Thr Ser Ser Ser	Glu Arg Ala Ser Ser	Pro		
	335		340		345
Ala Gln Cys Val	Thr Pro Val Gln Thr	Val Val			
	350		355		

&lt;210&gt; 30

&lt;211&gt; 453

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2843910

&lt;400&gt; 30

Met Ala Gly Ala Gly	Gly Phe Gly Cys Pro	Ala Gly Gly Asn Asp	
1	5	10	15
Phe Gln Trp Cys Phe	Ser Gln Val Lys Gly	Ala Ile Asp Glu Asp	
	20	25	30
Val Ala Glu Ala Asp	Ile Ile Ser Thr Val	Glu Phe Asn Tyr Ser	
	35	40	45
Gly Asp Leu Leu Ala	Thr Gly Asp Lys Gly	Gly Arg Val Val Ile	
	50	55	60
Phe Gln Arg Glu Gln	Glu Asn Lys Ser Arg	Pro His Ser Arg Gly	
	65	70	75
Glu Tyr Asn Val Tyr	Ser Thr Phe Gln Ser	His Glu Pro Glu Phe	
	80	85	90
Asp Tyr Leu Lys Ser	Leu Glu Ile Glu Glu	Lys Ile Asn Lys Ile	
	95	100	105
Arg Trp Leu Pro Gln	Asn Ala Ala His	Phe Leu Leu Ser Thr	
	110	115	120
Asn Asp Lys Thr Ile	Lys Leu Trp Lys Ile	Ser Glu Arg Asp Lys	
	125	130	135
Arg Ala Glu Gly Tyr	Asn Leu Lys Asp Glu	Asp Gly Arg Leu Arg	
	140	145	150
Asp Pro Phe Arg Ile	Thr Ala Leu Arg Val	Pro Ile Leu Lys Pro	
	155	160	165
Met Asp Leu Met Val	Glu Ala Ser Pro Arg	Arg Ile Phe Ala Asn	
	170	175	180
Ala His Thr Tyr His	Ile Asn Ser Ile Ser	Val Asn Ser Asp His	
	185	190	195
Glu Thr Tyr Leu Ser	Ala Asp Asp Leu Arg	Ile Asn Leu Trp His	
	200	205	210
Leu Glu Ile Thr Asp	Arg Ser Phe Asn Ile	Val Asp Ile Lys Pro	
	215	220	225
Ala Asn Met Glu Glu	Leu Thr Glu Val Ile	Thr Ala Ala Glu Phe	
	230	235	240
His Pro His Gln Cys	Asn Val Phe Val Tyr	Ser Ser Ser Lys Gly	
	245	250	255
Thr Ile Arg Leu Cys	Asp Met Arg Ser Ser	Ala Leu Cys Asp Arg	
	260	265	270
His Ser Lys Phe Phe	Glu Glu Pro Glu Asp	Pro Ser Ser Arg Ser	
	275	280	285
Phe Phe Ser Glu Ile	Ile Ser Ser Ile Ser	Asp Val Lys Phe Ser	

PF-0565 USN

	290		295		300
His Ser Gly Arg Tyr Met Met Thr Arg Asp Tyr Leu Ser Val Lys					
	305		310		315
Val Trp Asp Leu Asn Met Glu Ser Arg Pro Val Glu Thr His Gln					
	320		325		330
Val His Glu Tyr Leu Arg Ser Lys Leu Cys Ser Leu Tyr Glu Asn					
	335		340		345
Asp Cys Ile Phe Asp Lys Phe Glu Cys Cys Trp Asn Gly Ser Asp					
	350		355		360
Ser Ala Ile Met Thr Gly Ser Tyr Asn Asn Phe Phe Arg Met Phe					
	365		370		375
Asp Arg Asp Thr Arg Arg Asp Val Thr Leu Glu Ala Ser Arg Glu					
	380		385		390
Ser Ser Lys Pro Arg Ala Ser Leu Lys Pro Arg Lys Val Cys Thr					
	395		400		405
Gly Gly Lys Arg Arg Lys Asp Glu Ile Ser Val Asp Ser Leu Asp					
	410		415		420
Phe Asn Lys Lys Ile Leu His Thr Ala Trp His Pro Val Asp Asn					
	425		430		435
Val Ile Ala Val Ala Ala Thr Asn Asn Leu Tyr Ile Phe Gln Asp					
	440		445		450
Lys Ile Asn					

<210> 31  
 <211> 1221  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 132240

<400> 31.  
 cttttcctgg aatttctata atggaaagtc cattagaaag tcagccctta gattcagata 60  
 gaagcatcaa agaatcctct tttgaagaat caaatattga agatccactt attgtaacac 120  
 cagattgccca agaaaagacc tcacccaaaag gtgtcgagaa ccctgctgta caagagagta 180  
 accaaaaaat gttaggtcct cctttggagg tgctgaaaac gttagcctct aaaagaaatg 240  
 ctgttgcttt tcgaagtttt aacagtcata ttaatgcata caataactca gaaccatcca 300  
 gaatgaacat gacttcttta gatgcaatgg atatttcgtg tgcttacagt gggtcatatc 360  
 ccatggctat aaccctact caaaaaagaa gatcctgtat gccacatcag accccaaatc 420  
 agatcaagtc gggaaactcca taccgaactc cgaagagtgt gagaagaggg gtggcccccg 480  
 ttgatgatgg gcgaattcta ggaaccccg actaccttgc acctgagctg ttactaggca 540  
 gggcccatgg tcctgcggta gactgggtgg cacttggagt ttgcttggtt gaatttctaa 600  
 caggaattcc ccttttcaat gatgaaacac cacaacaagt attccagaat attctgaaaa 660  
 gagatatccc ttggccagaa ggtgaagaaa agttatctga taatgctcaa agtgcagtag 720  
 aaatactttt aaccattgat gatacaaaaga gagctggaat gaaagagcta aaacgtcatc 780  
 ctctcttcag tgatgtggac tgggaaaatc tgcagcatca gactatgcct ttcattcccc 840  
 agccagatga tgaacagat acctcctatt ttgaagccag gaatactgct cagcacctga 900  
 ctgtatctgg atttagtctg tagcacaaaa attttccttt tagtctagcc ttgtgttata 960  
 gaatgaactt gcataattat atactcctta atactagatt gatctaaggg ggaaagatca 1020  
 ttatttaacc tagttcaatg tgcttttaat gtacgttaca gctttcacag agttaaaagg 1080  
 ctgaaaggaa tatagtcagt aatttatctt aacctcaaaa ctgtatataa atcttcaaag 1140  
 cttttttcat ttatttattt tgtttattgc actttatgaa aactgaagca tcaataaaat 1200  
 tagaggacac taaaaaaaaa a 1221

<210> 32  
 <211> 542  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2180116

<400> 32  
 tggccaggct ggggtccagca gcgcgatggc agctcagcgg ctgggcaagc gcgtgctgag 60

PF-0565 USN

```

caagctgcag tctccatcgc gggcccgcg gccagggggc agtcccgggg ggatgcagaa 120
gcgccacgcg cgcgtcaccg tcaagtatga ccggcgggag ctgcagcggc ggctggacgt 180
ggagaagtgg atcgacgggc gcctggagga gctgtaccgc ggcatggagg cagacatgcc 240
cgatgagatc aacattgatg aattgttggg gttagagagt gaagaggaga gaagccggaa 300
aatccaggga ctctgaagt catgtgggaa acctgtcgag gacttcatcc aggagctgct 360
ggcaaagctt caaggcctcc acaggcagcc cgccctccgc cagccaagcc cctcccacga 420
cggcagcctc agccccctcc aggaccgggc cgggactgct caccctgac cctcttgcac 480
tctccctgcc ccccggacgc cgcccagctt gcttgtgtat aagttgtatt taatggattc 540
tt

```

&lt;210&gt; 33

&lt;211&gt; 2778

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2197671

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (1) ... (2778)

&lt;223&gt; a, t, c, g, or other

&lt;400&gt; 33

```

cgcggatcgt cgcgggcccg ccgtcccgtc ccaggaagtg gccgtcctga ggcgccatggc 50
tactccccg gtgcagtcgg gcctgcccg catgcagaac cttaaaggcag acccagaaga 120
gctttttaca aaactagaga aaattgggaa gggctccttt ggagaggtgt tcaaaggcat 180
tgacaatcgg actcagaaag tggttgccat naagatcatt gatctggaag aagctgaaga 240
tgagatagag gacattcaac aagaaatcac agtgctgagt cagtgtgaca gtccatattgt 300
aaccaaatat tatggatcct atctgaagga tacaaaatta tggataataa tggaatatct 360
tgggtggagc tccgcactag atctattaga acctggccga ttagatgaaa ccagatcgc 420
tactatatta agagaaatac tgaaaggact cgattatctc cattccggaga agaaaatcca 480
cagagacatt aaagcggcca acgtcctgct gtctgagcat ggcgaggtga agctggcgga 540
ctttggcgtg gctggccagc tgacagacac ccagatcaaa aggaacacct tcgtgggcac 600
cccattctgg atggcacccg aggtcatcaa acagtcggcc tatgactcga aggcagacat 560
ctggtccctg ggcataacag ctattgaact tgcaagaggg gaaccacctc attccgagct 720
gcaccccatg aaagttttat tctcattcc aaagaacaac ccaccgacgt tggaaaggaaa 780
ctacagttaa cccctcaagg agtttgtgga ggcctgtttg aataaggagc cgagctttag 840
acccactgct aaggagtatt tgaagcacia gtttatacta cgcaatgcaa agaaaacttc 900
ctacttgacc gagctcatcg acaggtacaa gagatggaag gccgagcaga gccatgacga 960
ctcgagctcc gaggattccg acgcggaaac agatggccaa gcctcggggg gcagtgatcc 1020
tggggactgg atcttcacaa tccgagaaaa agatcccaag aatctcgaga atggagctct 1080
tcagccatcg gacttggaca gaaataagat gaaagacat ccaaagaggc ctttctctca 1140
gtgtttatct acaattattt ctctctgtgt tgcagagttg aaggagaaga gccaggcgtg 1200
cggagggaac ttgggggtcca ttgaagagct gcgagggggc atctacctag cggaggaggc 1260
gtgccctggc atctccgaca ccatggtggc ccagctcgtg cagcggctcc agagatactc 1320
tctaagtggg ggaggaaact catcccactg aaattccttt ggcatttggg gttttgtttt 1380
tctttttttt cttcttcac tctctcctt tttaaaagtc aacgagagcc ttcgctgact 1440
ccaccgaaga ggtgcgccac tgggagccac ccagtgcca ggcgcccgtc cagggacaca 1500
cacagtcttc actgtgctgc agccagatga agtctctcag atgggtgggg agggtcagct 1560
ccttcacgcg atcattttat tttattttat tacttttgtt tttaatttta accatagtgc 1620
acatattcca ggaaagtgtc tttaaaaaca aaaacaaacc ctgaaatgta tatttgggat 1680
tatgataagg caactaaaga catgaaacct caggtatcct gctttaagtt gataactccc 1740
tctgggagct ggagaatcgc tctggtggat ggggtgtacag atttgtatat aatgtcattt 1800
ttacggaaac ctttccggcg tgcataagga atcactgtgt acaaaactggc caagtgtctc 1860
tgtagataac gtcagtggag taaatatccg acaggccata acttgagctc attgccttgc 1920
ctttattaca tgtacatttt gaattctgtg accagtgatt tgggttttat tttgtatttg 1980
cagggtttgt cattaataat taatgcccct ctcttacaga acactcctat ttgtacctca 2040
acaaatgcaa attttcccg tttgcccac gccccttttg gtacacctag aggttgattt 2100
cctttttcat cgatggtact atttcttagt gttttaaatt ggaacatatc ttgctcatg 2160
aagctttaaa ttataatttt cagtttctcc ccatgaagcg ctctcgtctg acatttgttt 2220
ggaatcgtgc cactgctggg ctgcgccaga tgtaccgtcc tttccaatac gattttctgt 2280
tgcaccttgt agtggattct gcataatcat tttcccacct aaaaatgtct gaatgcttac 2340
acaaataaat ttctataac gcttatttgc cactactcct gaaatgtgac tcttcagagg 2400
acagggtacc tgtgtgtat gtgtggccgt gcgtgtgtac tcgtggctgt gtgtgtgtga 2460
tgagacactt tgggaagactc caggggagaag ttcccagggc tggagctgcc gagtgcccg 2520

```

PF-0565 USN

```

gtcagcgcgc tgggctgctt ggcgaatngc tcaccngat gatgcattgg aggttgctga 2580
cctgtgcgat tgctgtagcg gttgccaggg accttaaggg gttattttgc ttccctggga 2640
ggggncctat gtttctaggg aagcagccat gtgtctaatt ttctgggttt gctgtgggga 2700
cctgattggg ggagggggaa anctttgggg ttcttgagat gggagggttc gtgccancaa 2760
tnttncctgg taaaaaag                                     2778

```

```

<210> 34
<211> 1424
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2594943

```

```

<400> 34
ggctcagcct ccgacccagg tggctctggag cctgcgcggga gagggtgggc atctgagagg 60
ctggctcgtg actgtggttg ggggaggtgg gagctgtttt aaccgtgtgc cccctctcct 120
gtgccggcgt gggcatcccc cggggcagtg gaacgcgggc gtcctccag ctcccgagtc 180
cagccagcct gggcgcgggg cggcgcccc gagacacccg aggagtcctg tctccctgg 240
ttacgtggac tgtggagctg gtctcttggt gctcagcgcg gtgcggagggt tgaagcgta 300
ctgcggagggt cgcaccaggg cgtgaggagg aggaggaagg gcatgagccg agcttgagga 360
atccgtgctc caaactctac actcaagggt ggcccttggg tagggtgaag atccccgtc 420
tttatcctag ttccacacct tgggtgtgggt tactgggtgc aggatgaact gtcgctcgga 480
ggtgctggag gtgtcgggtg aggggcggca ggtggaggag gccatgctgg ctgtgctgca 540
cacggtgctt ctgcaccgca gcacaggcaa gttccactac aagaaggagg gcacctactc 600
cattggcacc gtgggcaccc aggatgttga ctgtgacttc atcgacttca cttatgtgcg 660
tgtctcttct gaggaactgg atcgtgccct gcgcaagggt gttggggagt tcaaggatgc 720
actgcgcaac tctggtggcg atgggctggg gcagatgtcc ttggagttct accagaagaa 780
gaagtctcgc tggccattct cagacgagtg catcccatgg gaagtgtgga cggctcaagg 840
gcatgtggtg gccctggcca cggagcagga gcggcagatc tgccgggaga aggtgggtga 900
gaaactctgc gagaagatca tcaacatcgt ggagggtgat aatcggcatt agtacttgcc 960
caagatgccc acacagtcgg aggtggataa cgtgtttgac acaggcttgc gggacgtgca 1020
gccctacctg tacaagatct ccttcagat cactgatgcc ctgggcaact cagtcaccac 1080
caccatgcgc aggtcatca aagacacct tgcctctga gcgtcgctgg atctctggga 1140
gtcctctgat ggctcccaga ccttggtttt tgggaattgc acttttgggc ctttgggctc 1200
tggaacctgc tctgggtcat tggtgagact tgggaagggg agcccccgct ggcttcttgg 1260
ttttgtggtt gccagcctca ggtcatcctt ttaatctttg ctgatgggtc agtccctgct 1320
ctactgtctc tccatagccc tgggtggggt ccccttcttt ctccactgta cagaagagcc 1380
accactggga tggggaataa agttgagaac atgaaaaaaa aaaa                                     1424

```

```

<210> 35
<211> 1839
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1513871

```

```

<400> 35
ctcctcctc ggccagctca ggttgcaagt tctctgggga actgctcacc tttccggagc 60
aggggaagct gccccgtgcc cgggagggag cgggcgcacc gcggccccc ggacacgcgc 120
tgaccgggct gcccagtcct tcatgatcat gaacaagatg aagaacttta agcgccgttt 180
ctccctgtca gtgccccgca ctgagaccat tgaagaatcc ttggctgaat tcacggagca 240
attcaaccag ctccacaacc ggcggaatga gaacttgag ctcggtcctc ttggcagaga 300
ccccccgcag gagtgcagca ccttctcccc aacagacagc ggggaggagc cggggcagct 360
ctccccctgg gtgcagttcc agcggcgcca gaaccagcgc cgcttctcca tggaggacgt 420
cagcaagagg ctctctctgc ccattggatat ccgcctgccc caggaattcc tacagaagct 480
acagatggag atccccagatc tgccccagcc atgtcccgc gggcctcct 540
gtcagacatt ggctttggga aactggaaac atacgtgaaa ctggacaaac tgggagaggg 600
cacctatgcc acagtcttca aaggcgcgag caaactgacg gagaaccttg tggccctgaa 660
agagatccgg ctggagcacg aggagggagc gccctgcact gccatccgag aggtgtctct 720
gctgaagaac ctgaagcacg ccaatattgt gaccctgcat gacctcatcc acacagatcg 780
gtccctcacc ctggtgtttg agtacctgga cagtgacctg aagcagatc tggaccactg 840
tgggaacctc atgagcatgc acaacgtcaa gattttcatg ttccagctgc tccggggcct 900
cgctactgtt caccaccgca agatcctgca ccgggacctg aagccccaga acctgctcat 960

```

PF-0565 USN

```

caacgagagg ggggagctga agctggccga ctttggactg gccagggcca agtcagtgcc 1020
cacaaagact tactccaatg aggtggtgac cctgtggtac agggcccccg atgtgctgct 1080
gggatccaca gactactcca cccccattga tatgtggggc gtgggctgca tccactacga 1140
gatggccaca gggaggcccc tcttcccggt cccacagtc aaggaggagc tgcacctcat 1200
ctttcgctc ctcgggaccc ccacagaaga gacgtggccc ggcgtgaccg ctttctctga 1260
gttcgcgacc tacagcttcc cctgctacct cccgcagccg ctcacaaacc acgcgccag 1320
gttgatacg gatggcatcc acctcctgag cagcctgctc ctgtatgaat ccaagagtcg 1380
catgtcagca gaggtgccc tgagtcactc ctacttccgg tctctgggag agcgtgtgca 1440
ccagcttgaa gacactgcct ccattctctc cctgaaggag atccagctcc agaaggacc 1500
aggctaccga ggcttggcct tccagcagcc aggacgaggg aagaacaggc ggcagagcat 1560
cttctgagcc acgcccacct tgctgtggcc aagggacaag agatcacatg gagcacaat 1620
tcgggtagga tggagcctgt gtggccctcg gaggactgaa gaacgagggc tgacagcagc 1680
ctggaagacc gcttggcagg gctttggcca agtgtttttc tttgtggttt cgatctgctg 1740
ccagtagttt cagtggatcc aacgtgcttt aggagtggg tgggaaagtc ttgctagagg 1800
gtttaggggg aggtttctac cgttgactcg gtttagggc 1839

```

&lt;210&gt; 36

&lt;211&gt; 2024

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 156108

&lt;400&gt; 36

```

gtcagctctg gttcggagaa gcagcggctg gctggggcca tccggggaat gggcgccctc 60
gtgacctagt gttgcggggc aaaaagggtc ttgcggccct cgctcgtgca gggcgctatc 120
tgggcgcctg agcgcggcgt gggagccttg ggagccgccc cagcaggggg cacacccgga 180
accggcctga gcgccccgga ccatgaacgg ggaggccatc tgcagcgccc tgcaccacct 240
ccctaccac aaactcgccg acctgcgcta cctgagccgc ggcgcctctg gcaactgtgtc 300
gtccgcccgc cagcgagact ggcgcgctca ggtggccgtg aagcacctgc acatccacac 360
tccgctgctc gacagtgaag gaaaggatgt cttaaagaga gctgaaattt tacacaaagc 420
tagatttagt tacattcttc caattttggg aatttgcaat gaggctgaat ttttgggaat 480
agttactgaa tacatgcca atggatcatt aatgaactc ctacatagga aaactgaata 540
tcctgatgtt gcttggccat tgagatttct catcctgcat gaaattgccc ttggtgtaaa 600
ttacctgcac aatatgactc ctcttttact tcatcatgac ttgaagactc agaatatctt 660
attggacaat gaatttcatg ttaagattgc agattttggt ttatcaaagt ggcgcctgat 720
gtccctctca cagtcacgaa gtaccaaate tgcaccagaa ggagggacaa ttatctatat 780
gccacctgaa aactatgaac ctggacaaaa atcaagggcc agtatcaagc acgatataata 840
tagctatgca gttatcacat gggaagtgtt atccagaaaa cagccttttg aagatgtcac 900
caatcctttg cagataatgt atagtgtgtc acaaggacat cgacctgtta ttaatgaaga 960
aagtttgcca tatgatatac ctaccgagc acgtatgac tctctaatag aaagtggatg 1020
ggcacaaaa ccagatgaaa gacctcttt cttaaaatgt ttaatagaac ttgaaccagt 1080
tttgagaaca tttgaagaga taacttttct tgaagctgtt attcagctaa agaaaaacaa 1140
gttacagagt gtttcaagt ccattcacct atgtgacaag aagaaaatgg aattatctct 1200
gaacatacct gtaaatacat gtccacaaga ggaatcatgt ggatcctctc agctccatga 1260
aaatagtgtt tctcctgaaa ctccaaggct cctgccagct cctcaagaca atgatttttt 1320
atctagaaaa gctcaagact gttattttat gaagctgcat cactgtcctg gaaatcacag 1380
ttgggatagc accatttctg gatctcaaag ggctgcattc tgtgatcaca agaccactcc 1440
atgctcttca gcaataataa atccactctc aactgcagga aactcagaac gtctgcagcc 1500
tggtatagcc cagcagtgga tccagagcaa aagggaagac attgtgaacc aaatgacaga 1560
agcctgcctt aaccagtgc tagatgccct tctgtccagg gacttgatca tgaaagagga 1620
ctatgaactt gttagtacca agcctacaag gacctcaaaa gtcagacaat tactagacac 1680
tactgacatc caaggagaag aatttgccaa agttatagta caaaaattga aagataacaa 1740
acaaatgggt ctccagcctt acccggaat acttggtgtt tctagatcac catcttttaa 1800
tttacttcaa aataaaagca tgtaagtgc tgtttttcaa gaagaaatgt gtttcataaa 1860
aggatattta tatctctgtt gctttgactt tttttatata aaatccgtga gtattaaagc 1920
tttattgaag gttcttttggg taaatattag tctccctcca tgacactgca gtattttttt 1980
taattaatac aagtaaaaaag tttgaatttt gtcacataaa aaaa 2024

```

&lt;210&gt; 37

&lt;211&gt; 1861

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

PF-0565 USN

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2883243

&lt;400&gt; 37

```

gcttcttagt gaggttggca ttatgttaag gctggtatgg aagacaactg atgaagcagg 60
agtggctctgg tgacattttt ctgacttgat tggctggggc gtgtgatgta ataggtttca 120
gtgcagcccc ttataggttt taaaatgaat tccaagacac cattacaaag aaagccggac 180
tcttttctta taactgagct cagccaagga aactcttgca caaatgtaca atactgtttg 240
gaatatggaa gacctggatt tagaatatgc caagacagat ataaattgtg gcacagactt 300
gatgttttat atagaaatgg acccaccagc actgcctcct aaaccaccaa aacctactac 360
tgtagccaac aacgggtatga ataacaatat gtccttacaa gatgctgaat ggtactgggg 420
agatatctcg agggagaag tgaatgaaaa acttcgagat acagcagacg ggaccttttt 480
ggtagcagat gcgtctacta aaatgcatgg tgattatact cttacactaa ggaaaggggg 540
aaataacaaa ttaatcaaaa tatttcacgc agatgggaaa tatggcttct ctgacctatt 600
aaccttcagt tctgtggttg aattaataaa ccactaccgg aatgaatctc tagctcagta 660
taatcccaaa ttggatgtga aattacttta tccagtatcc aaataccaac aggatcaagt 720
tgtcaaaaga gataatattg aagctgtagg gaaaaaatta catgaatata acactcagt 780
tcaagaaaaa agtcgagaat atgatagatt atatgaagaa tatacccgca catcccagga 840
aatccaaatg aaaaggacag ctattgaagc atttaatgaa accataaaaa tatttgaaga 900
acagtgccag acccaagagc ggtacagcaa agaatacata gaaaagttaa aacgtgaagg 960
caatgagaaa gaaatacaaa ggattatgca taattatgat aagttgaagt ctcgaaatcag 1020
tgaaattatt gacagtagaa gaagattgga agaagacttg aagaagcagg cagctgagta 1080
tcgagaaatt gacaaacgta tgaacagcat taaaccagac cttatccagc tgagaaagac 1140
gagagaccaa tacttgatgt ggttgactca aaaaggtgtt cggcaaaaga agttgaacga 1200
gtggttgggc aatgaaaaca ctgaagacca atattcactg gtggaagatg atgaagattt 1260
gccccatcat gatgagaaga catggaatgt tgggaagcagc aaccgaaaca aagctgaaaa 1320
cctgttgcca gggaagcag atggcacttt tcttgtccgg gagagcagta aacagggctg 1380
ctatgcctgc tctgtagtgg tggacggcga agtaaacgat tgtgtcataa acaaaacagc 1440
aactggctat ggccttgccg agccctataa cttgtacagc tctctgaaag aactgggtgt 1500
acattaccaaa cacacctccc ttgtgcagca caacgactcc ctcaatgtca cactagccta 1560
cccagtatat gcacagcaga ggcgatgaag cgcttaactc ttgactcctc tctgaagtt 1620
cagccacctt gaggcctctg gaaagcaaa ggtcctctc cagtctgac tgtgaattga 1680
gctgcagaaa cgaagccaac tttttttgga tgggactagt gctttcttcc acaaaaaga 1740
agtaygggaa gacatgcagc ctaaggctgt atgatgacca caggttccca agctggagt 1800
cttateccct ctttttcttt ttttttttgg ttttaatttaa agccacaacc acatacaaga 1860

```

&lt;210&gt; 38

&lt;211&gt; 2045

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3173355

&lt;400&gt; 38

```

cttggctgga acctgagacg gattecgtcc caaatgatgc tccagtggca ggagcaactc 60
aagttcatca ttgtcctgag agagaggagc agcgcgggtc tcggccggga cagcagaacg 120
ccaggggacc ctacacctgg cgcgcggggg cacgggcttt gattgtcctg gggtcgcyga 180
gacccgcgcg cctgccttgc acgcggggcg gcaacctttg cagtgcgctt ggetgctgcg 240
atcggccggc gggtccttgc cgaaggctcg gctgcttctg tccacctctt acacttcttc 300
atztatcggt ggatcatttc gagagtccgt cttgtaaatg tttggcactt tgctacttta 360
ttgcttcttt ctggcgacag ttccagcact cgccgagacc ggcggagaaa ggcagctgag 420
ccgggagaag agcgaatat ggggacccgg gctaaaaagca gacgtcgtcc ttccgcgccg 480
ctatttctat attcaggcag tggatacatc agggataaaa ttcacatctt ctccaggcga 540
aaaggtcttc caggtgaaag tctcagcacc agaggagcaa ttcactagag ttggagtcca 600
ggtttttagac cgaaaagatg ggtccttcat agtaagatac agaatgtatg caagctacaa 660
aaatctgaag gtggaaatta aattccaagg gcaacatgtg gccaaatccc catatatttt 720
aaaagggccg gtttaccatg agaactgtga cgtcctctg caagatagtg cagcctggct 780
acgggagatg aactgccttg aaaccattgc tcagattcag agagatctgg cacatttccc 840
tgctgtggat ccagaaaaga ttgcagtaga aatcccaaaa agatttggac agaggcagag 900
cctatgtcac tacaccttaa aggataacaa ggtttatatc aagactcatg gtgaacatgt 960
aggtttttaga attttcatgg atgccatact actttctttg actagaaagg tgaagatgcc 1020
aagatgtggag ctctttgtta atttgggaga ctggcctttg gaaaaaaaga aatccaattc 1080
aacatccat ccgacttttt cctgggtgtg tccacagat tccaaggata tcgtgatgcc 1140
tacgtacgat ttgactgatt ctgttctgga aaccatgggc cgggtaagtc tggatatgat 1200

```



PF-0565 USN

```

gtccgtgcaa gctaacacgg gtcctccctg ggaaagcaaa aattccactg ccgtctggag 1260
agggcgagac agccgcaaag agagactcga gctggttaaa ctcahtagaa aacaccaga 1320
actcatagac gctgctttca ccaacttttt cttcttttaa cacgatgaaa acctgtatgg 1380
tcccattgtg aaacatattt ctttttttga tttcttcaag cataagtatc aaataaatat 1440
cgatggcact gtagcagctt atcgccctgc atatttgcta gttggtgaca gtgtgtgtgt 1500
gaagcaggat tccatctact atgaacattt ttacaatgag ctgcagccct ggaaacacta 1560
cattccagtt aagagcaacc tgagcgatct gctagaaaaa cttaaattggg cgaaagatca 1620
cgatgaagag gccaaaaaga tagcaaaagc aggacaagaa tttgcaagaa ataattctcat 1680
gggcgatgac atattctgtt attatttcaa acttttccag gaatatgcc aattacaagt 1740
gagtgaagccc caaatccgag agggcatgaa aagggtagaa ccacagactg aggacgacct 1800
cttcccttgt acttgccata ggaaaaagac caaagatgaa ctctgatatg caaaataact 1860
tctattagaa taatgggtgt ctgaagactc ttcttaacta aaaagaagaa tttttttaag 1920
tattaattcc atggacaata taaaatctgt gtgattgttt gcagtatgaa gacacatttc 1980
tacttatgca gtattctcat gactgtactt taaagtacat ttttagaatt ttataataaa 2040
accac 2045

```

```

<210> 39
<211> 1260
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 5116906

```

```

<400> 39
cgatattttt ctttcttagt ttcccatttc atattgtttt gtcaaataca ctgtgactca 60
ttaacatctc ttttccttag gttttgtcgg cacacctgga tatctttctc cagaagtttt 120
acgtaaagat ccttatggaa agccagtgga tatgtgggca tgtggtgtca ttctctatat 180
tctactttgt ggggtatccac ccttctggga tgaagaccaa cacagactct atcagcagat 240
caaggctgga gcttatgatt ttccatcacc agaattgggac acgggtgactc ctgaagccaa 300
agacctcatc aataaaatgc ttactatcaa ccttgccaaa cgcatacagc cctcagaggc 360
actgaagcac ccatggatct gtcaacgttc tactgttgct tccatgatgc acagacagga 420
gactgtagac tgcttgaaga aatttaattgc tagaagaaaa ctaaagggtg ccattcttgac 480
aactatgctg gctacaagga atttctcagc agccaagagt ttgttgaaga aaccagatgg 540
agtaaaggag tcaactgaga gttcaaatat aacaattgag gatgaagatg tgaaagcacg 600
aaagcaagag attatcaaag tcaactgaaca actgatcgaa gctatcaaca atggggactt 660
tgaagcctac acaaaaatct gtgaccagg ccttactgct ttggaacctg aagcttttggg 720
taatttagtg gaagggatgg attttcaccg attctacttt gaaaatgctt tgtccaaaag 780
caataaacca atccacacta ttattctaaa cctcatgta catctggtag gggatgatgc 840
cgctgcata gcatatatta ggctcacaca gtacatggat ggcagtggaa tgccaaagac 900
aatgcagtca gaagagactc gtgtgtggca ccgccgggat ggaaagtggc agaattgtca 960
ttttcatcgc tcgggggtcac caacagtacc catcaactaa atttcaacag tggcacttct 1020
gcattctctg ttctcaaggc acctggatgg tgacctggg ccgtcctctc ctctcttca 1080
tgcatgtttc tgagtgcatt aagttgtgaa ggctctacat gtaatgcata tgtgatgcat 1140
catcttatca tatattcctt cctatacatt gtttacactt caactacggg gatgttccac 1200
acaaacttaa attactgttg gcaaaaacaat aggggggagat tagacaaaaa aaaaaaaaaa 1260

```

```

<210> 40
<211> 2059
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 940589

```

```

<400> 40
aaaccataga aacgctaatt aaagcagaca tcaaaatctg gatccttaca ggggacaagc 60
aagaaactgc cattaacatc ggacactcct gcaaaactgt gaagaagaac atgggaatga 120
ttgttataaa tgaaggctct cttgattctt tctctaatac acagaattct aggaaggagg 180
ctgtttcttt agccaaaatg aaacacccta atattgttgc cttcaaagaa tcatttgaag 240
ctgaaggaca cttgtatatt gtgatggaat actgtgatgg aggggatcta atgcaaaaaga 300
ttaaacagca gaaaggaaaag ttatttcctg aagacatgat acttaattgg ttaccctaaa 360
tgtgccttgg agtaaatacac attcacaaga aacgtgtgct acacagagat atcaagtcca 420
agaatatctt cctcactcag aatggaaaag tgaaattggg agactttgga tctgcccgtc 480
ttctctccaa tccgatggca tttgcttgta cctatgtggg aactccttat tatgtgcctc 540

```

PF-0565 USN

```

cagaaatttg ggaaaacctg ccttataaca ataaaagtga catctggtcc ttgggttgca 600
tcctgtatga actctgtacc ctttaagcatc catttcaggc aaatagttgg aaaaatctta 660
tcctcaaagt atgtcaaggg tgcatacgtc cactgccgtc tcattactcc tatgaacttc 720
agttcctagt caagcagatg tttaaaagga atccctcaca tcgcccctcg gctacaacgc 780
ttctctctcg aggcatcgta gctcggtctt tccagaagtg cttaccccc gagatcatca 840
tggaatatgg tgaggaagta ttagaagaaa taaaaaattc gaagcataac acaccaagaa 900
aaaaaacaaa cccagcaga atcaggatag ctttgggaaa tgaagcaagc acagtgaag 960
aggaagaaca agatagaaag ggtagccata ctgatttgga aagcattaat gaaaatttag 1020
ttgaaagtgc attgagaaga gtaaacagag aagaaaaagg taataagtca gtccatctga 1080
ggaaagccag ttcaccaa atccatagac gacagtggga gaaaaatgta cccaatacag 1140
ctcttacagc tttggaaaat gcataccatac tcacctccag ttaacagca gaggacgata 1200
gaggtgggtc tgtaataaag tacagcaaaa atactactcg taagcagtgg ctcaaagaga 1260
ccccggacac tttgttgaac atccttaaga atgctgatct cagcttggtt tttcaaacat 1320
acacaatata tagaccaggt tcagaagggt tcttgaaagg cccctgtct gaagaaacag 1380
aagcatcgga cagtgttgat ggaggtcagc attctgtcat tttggatcca gagcgacttg 1440
agcctgggct agatgaggag gacacggact ttgaggagga agatgacaac cccgactggg 1500
tgtcagagct gaagaagcga gctggatggc aaggcctgtg cgacagataa tgcctgagga 1560
aatgttccct agtcacgtcg aggagagcct tcactcagga gttcatgctg agatgatcat 1620
gagttcatgc gacgtatatt ttcttttggg aacagaatga agcagaggaa actcttaata 1680
cttaaaatcg ttcttgatta gtatcgtgag tttgaaaagt ctagaactcc tgaagtttt 1740
tgaactcaag ggagaaggta tagtggaatg agtgtgagca tcgggctttg cagtcccata 1800
gaacagaaat gggatgctag cgtgccacta cctacttgtg aaaatgaaga taataatgcc tacctcagag 1860
acctcttcaa gcccaattt cctcaacctat tatagcagcc cgtatgatat tattcacatt atgatatgtg 1920
ggatgctgac cacagacctt tatagcagcc cgtatgatat tattcacatt atgatatgtg 1980
tttattatta tgtgactctt tttacatttc ctaaagggtt gagaattaaa tatatttaat 2040
tatgaaaaaa aaaaaaaa 2059

```

<210> 41  
<211> 1023  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 304421

```

<400> 41
gaggcagagg ggtgggaggg ctggcccctg gctgagacct ctctcccaga gctgggggga 60
gaggacaaag ccacgccttg cccagcctc ctggagctgg aggagctcct gcgggcaggg 120
aagtcttctt gcagccgtgt ggacgaagtt tggcccaacc ttttcatagg agatgcgatg 180
gactcactgc agaagcagga cctccggagg cccaagatcc atggggcagt ccaggcatct 240
ccctaccagc cgccacatt ggcttcgctg cagcgttgc tgtgggtccg tcaggctgcc 300
acactgaacc atatcgatga ggtctggccc agcctcttcc tgggagatgc gtacgcagcc 360
cgggacaaga gcaagctgat ccagctggga atcaccacg ttgtgaatgc cgtgcaggc 420
aagttccagg tggacacagg tgccaaattc taccgtggaa tgtccctgga gtactatggc 480
atcgaggcgg atgacaaccc cttcttcgac ctcaagtgtc actttctgcc tgttgctcga 540
tacatccgag ctgccctcag tgttcccaa ggccgcgtgc tggtagactg tgccatgggg 600
gtaagccgct ctgccacact tgtcctggcc ttcctcatga tctatgagaa catgacgtc 660
gtagaggcca tccagacggg gcaggcccac cgcaatatct gccctaactc aggttcttc 720
cggcagctcc aggttctgga caaccgactg gggcgggaga cggggcggtt ctgatctggc 780
aggcagccag gatccctgac ccttgcccca accccaccag cctggccctg ggaacagcag 840
gctctgctgt ttctagtgc cctgagatgt aaacagcaag tgggggctga ggcagaggca 900
gggatagctg ggtggtgacc tcttagcggg tggatttccc tgaccaatt cagagattct 960
ttatgcaaaa gtgagttcag tccatctcta taataaaata ttcacgtca taaaaaaaa 1020
aaa 1023

```

<210> 42  
<211> 4416  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1213802

```

<400> 42
gaaatttttt tctgcctcat tattattaat tcatggattg agtgttggtt cgacctacag 60

```

PF-0565 USN

gcgtaataga	ttggaactca	gtgaagacac	agatgttcct	gttcagagca	accagcta	120
gattacagtt	taaagacaat	ttctgtgac	aagttgtcat	ttggaagatt	aaacccattt	180
cacgaggact	tggagcctgg	tccttgcttt	gaggaaagcag	tggcttgctt	caagaagcca	240
cttctgatct	aagaatctac	ccagcatgcc	taatcaagga	gaagactgct	atTTTTTTTT	300
ctattccaca	tgtaccaaag	gcgacagctg	cccatccctg	cactgtgaag	ctgcaatagg	360
aaatgaaact	gtttgcacat	tatggcaaga	agggcgctgt	tttcgacagg	tgtgcagggt	420
tcggcacatg	gagattgata	aaaaacgcag	tgaatttctt	tgttattggg	aaaatcagcc	480
aacaggatgt	caaaaattaa	actgcgcttt	ccatcacaa	agaggacgat	atgttgatgg	540
ccttttctta	cctccgagca	aaactgtggt	gcccactgtg	cctgagtcac	cagaagagga	600
agtgaaggct	agccaacttt	cagttcagca	gaacaaattg	tctgtccagt	ccaatccttc	660
ccctcagctg	cggagcggtt	tgaagtaga	aagttccgaa	aatgttctta	gccccacgca	720
tcaccacagtt	gtaattaatg	ctgcagatga	tgaatgaag	gatgatgatc	agttttctga	780
ggaaggtgat	gaaacccaaa	cacctaccct	gcaaccaact	cctgaagttc	acaatggatt	840
acgagtga	tctgtccgga	aaactgcagt	caatataaag	caaggtgaat	gtttgaattt	900
tggataaaaa	actcttgagg	aaattaagtc	aaagaaaatg	aaggaaaaat	ctaagaagca	960
aggtgagggg	tcttcaggag	tttccagctt	tttactccac	cctgagcccg	ttccagggtc	1020
tgaaaaaaga	aatgtcagga	ctgtggtgag	gacagtaact	ctctccacca	aacaaggaga	1080
agaacccttg	gttagattga	gtcttactga	gagactyggg	aaacgaaaa	tttcagcagg	1140
cgggtgacagt	gacccctcat	taaagcgtag	cctggcacag	aggctaggga	agaaagttga	1200
agctccagaa	actaacattg	acaaaacacc	aaagaaagct	caagtttcca	agtctcttaa	1260
ggagcgatta	ggcatgtcag	ctgatccaga	taatgaggat	gcaacagata	aagttaataa	1320
agttggtgag	atccattgtg	agacattaga	agaaattctt	cttgaaagag	ccagtcagaa	1380
acgtggagaa	tgtcaacta	aactcaagac	agaaggacct	tcaaaaactg	atgattctac	1440
ttcaggagca	agaagctcct	ccactatccg	tatcaaaacc	ttctctgagg	tcctggctga	1500
aaaaaaacat	cggcagcagg	aagcagagag	acaaaaaagc	aaaaaggata	caacttgcac	1560
caagctaaag	attgatagtg	aaattaaaaa	aacagtagtt	ttgccaccca	ttgttgccag	1620
cagaggacaa	tcagaggagc	ctgcaggtaa	aacaaagtct	atgcaggagg	tgcaatcaa	1680
gacgctggaa	gaaattaaac	tggagaaggc	actgaggggt	cagcagagct	ctgagcagag	1740
caccagctcc	cctgtccaac	acgagggcac	tcagggggca	aggcggtgc	tgcaatcac	1800
caaaagaaca	gggatgaaag	aagagaagaa	ccttcaggga	ggaaatgaag	ttgattctca	1860
gagcagtatt	agaacagaag	ctaaagaggc	ttcagggtgag	accacaggag	ttgacatcac	1920
taaaattcaa	gtcaagagat	gtgagaccat	gagagagaag	cacatgcaga	aacagcagga	1980
gagggaaaaa	tcagtcttga	cacctcttgc	gggagatgta	gcctcttgca	ataccgaagt	2040
ggcagagaaa	ccagtgctca	ctgctgtgcc	uggaatcaca	cggcacctga	ccaagcggct	2100
ccccacaaag	tcacccagga	aggtggagggt	agaaacctca	gggattggag	actcattatt	2160
gaatgtgaaa	tgtgcagcac	agaccttgga	aaaaaggggt	aaagctaaac	ccaaagtga	2220
cgtgaagcca	tctgtgggtt	aagttgtgtc	atcccccaaa	ttggccccaa	aacgtaaggc	2280
agtggagatg	ccagctgtctg	tcattgcccgc	tgtgaagcca	ctcagctcca	gcagtgctcc	2340
acaggaaccc	ccagccaaaa	aggcagctgt	ggctgtgtgc	ccgcttgtct	ctgaggacaa	2400
atcagtcact	gtgcctgaag	cagaaaatcc	tagagacagt	cttgtgtctc	ctccaacca	2460
gtcctcttca	gattctctac	ccccggagggt	gtctggccct	tcctcatccc	aatgagcat	2520
gaaaactcgc	cgactcagct	ctgcctcaac	aggaaagccc	ccactctctg	tggaggatga	2580
ttttgagaaa	ctaataaggg	agatttccagg	aggcaaatg	gaagctgaga	ttgacctgga	2640
tctggggaaa	gataagatg	accttctgct	tgagctatca	gaaatgattg	atagctgaag	2700
gtggtagtga	ggacacttta	aaaaaaaaaat	cgccaaaaaa	ctggacttag	tttcatctat	2760
tgtaacattt	acctgagatg	atcatttctt	tagtctagaa	tttgcccaaa	atcagaagta	2820
tacctctgaa	ttatctgtat	gtgtcctgga	ttccttgggg	tcagattttt	aaagttactt	2880
tataaccatt	ttgtccattt	gatgccattg	tttatcatct	tttgagaaaa	aagttctgtc	2940
atacccttct	ctccacaaaa	aagagactga	gaggagagac	aagtgaagg	gtgcaagcga	3000
acttagtgac	tccttgagggt	gtttgtcagt	tttgggtttt	ttcttctttg	ttgtattctt	3060
tatgtattgt	cttgatgtac	ttaatattac	ctgagtttga	aatggatgaa	gacagctgct	3120
accattaaag	accaaatttt	atgctaccac	taaacaaaaa	taccactca	gtctgtgtta	3180
aattgtatgt	ctttttaaag	gtattttaaag	attcaactaa	gctttaaaga	gggctgagca	3240
gctcaggaag	cctgtaattg	gggcataact	ctttggacct	gatcttgatg	ctctgctgct	3300
tctgttagcc	tctgaagagc	aatatctaat	ttattattac	tgtaatTTTT	taaaaggcct	3360
taaagtgcct	caggggtccc	ctgaaactaa	ttttctattt	ctgggattcc	ctggattcat	3420
tatatgagat	ggtgacatga	ttagaggaat	tcttttttag	tatgaaaaat	gtcccttttc	3480
ttcttcagta	cttgccctct	tgtgtgcatt	gaattaacac	agggacaaaa	tttggttaat	3540
tttttatttc	taattctccc	aacaaacccc	agttgccag	tatttggttg	gtggccttta	3600
accacctgag	ggaaaaaatg	agcttattca	agctgccaat	atztatctat	gggctgtagc	3660
agtacactga	attgtactgt	gccagggata	ttgagatgct	ctgggggtgt	attgtatacc	3720
tgccagtttt	cttcatttct	gaattgagtt	ttcttttctt	gatgttggtt	tccttcatat	3780
cacctcaagg	tttagatttg	tgaaggaata	agcatgatgg	aaataatagt	cttgaaagga	3840
gatatgttgt	atataatcag	gaggaagagg	aaggaaggag	ttaccatttt	tgatattttg	3900
ctgtaggtgg	ccagttttgt	ttctcatagg	gaactctgac	ccacctgtca	tgttggtctc	3960
taaggaaactg	ctgttgtaag	cggtctcatca	agagttgaac	ttcacgtagc	cttgttggtg	4020
atatggaaaa	ggaagaaagc	cacaggactg	cccatcagct	cttgggaaga	ttgggatgat	4080

PF-0565 USN

```

tctgcacaag caaaaatgac tgaagtttat gtatagacac acctctacca atccatcttc 4140
agctgactga atgttgatg atagcccttc tccaaagcag aggtagaatg ttcagggttc 4200
accatggatt ttctacttat ttcgtttttg gaatcagctt acagattcca ggtccctttt 4260
gtatatatct tttattcttt tgcgttttta aaaaataatt ttgtttcata tttaaagcac 4320
ttgtattagt caatgtttcg tgttccgcat tatttgaacc atttgccctt acagaaagag 4380
aaatacttgt ttgtgtttta aataaaactg atgtag 4416

```

```

<210> 43
<211> 2068
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1378134

```

```

<400> 43
gcagtccatc agtccgctga tgcgtcgccg ggccagcaac gctgcccgcg cagcccacac 60
gattggcggc agtaagcaca caatgaatga tcacctgcat gtcggcagcc acgctcacgg 120
acagatccag gttcgacagt tgtttgagga taacagtaac aagcggacag tgctcacgac 180
acaaccaaatt gggcttacaa cagtgggcaa aacgggcttg ccagtgggtg cagagcggca 240
gctggacagc attcatagac ggcaggggag ctccacctct cttaaagtcca tggaaggcat 300
ggggaagggtg aaagccaccc ccattgacac tgaacaagca atgaagcaat acatgcaaaa 360
actcacagcc ttccaacacc atgagatttt cagctaccct gaaatatatt tcttgggtct 420
aatgctaag aagcgccagg gcatgacagg tgggcccac aatgggtggct atgatgatga 480
ccagggatca tatgtgcagg tgcctcacga tcacgtggct tacaggatat aggtcctcaa 540
ggtcattggg aaggggagct ttgggcaggt ggtcaaggcc tacgatcaca aagtccacca 600
gcacgtggcc cttaaagatg tgcggaatga gaagcgcttc caccggcaag cagcggagga 660
gatccgaatc ctggaacacc tgcggaagca ggacaaggat aacacaatga atgtcatcca 720
tatgtcggag aatttcacct tccgcaacca catctgcatg acgtttgagc tgctgagcat 780
gaacctctat gagctcatca agaagaataa attccagggc ttcagtctgc ctttgggtcg 840
caagtttgcc cactcgattc tgcagtgttt ggatgctttg caaaaaaca gaataattca 900
ctgtgacctt aagcccagga acattttgtt aaagcagcag ggtagaagcg gtattaaagt 960
aattgatttt ggctccagtt gttacgagca tcagcgtgtc tacacgtaca tccagtcgag 1020
ttttaccggg gctccagaag tgatccttgg ggccagggtat ggcattgcca ttgatattgt 1080
gagcctgggc tgcatttttag cagagctcct gacgggttac cccctcttgc ctgggggaaga 1140
tgaaggggac cagctggcct gtatgattga actgttgggc atgccctcac agaaactgct 1200
ggatgcacct aaacgagcca aaaattttgt gagctccaag ggttatcccc gttactgcac 1260
tgtcacgact ctctcagatg gctctgtggt cctaaacgga ggccgttccc ggagggggaa 1320
actgaggggc ccaccggaga gcagagagtg ggggaacgcg ctgaaggggt gtgatgatcc 1380
ccttttcctt gactctttaa aacagtgttt agagtgggat cctgcagtgc gcatgacccc 1440
aggccaggct ttggcgacc cctggctgag gaggcgggtt ccaaagcctc ccaccgggga 1500
gaaaacgtca gtgaaaagga taactgagag caccggtgct atcacatcta tatccaagtt 1560
acctccacct tctagctcag cttccaaact gaggactaat ttggcgaga tgacagatgc 1620
caatgggaat attcagcaga ggacagtgtt gccaaaactt gttagctgag ctcacgtccc 1680
ctgatgctgg taacctgaaa gatacgacat tgctgagcct tactgggttg aaaaggagta 1740
gtcagacctt gtttttattt gctcaataac tctactcatt tgtatctttt cagcacttaa 1800
ttttaatgta agaaagtgtt tcattttgtt tttataaaat acatgaggac aatgctttta 1860
gtttttatata tttcagaaac tttttgtgtt ctaaaagtac aatgagcctt actgtattta 1920
gtgtggcaga ataataacat cagtggcagg ccactgatta cttcatgact gccacgcatt 1980
tacagattgg tgtcaaagac attcactatg tttttatggt tcatgttata tctctcccag 2040
ggtagacagc ccttaaggcc ctccctttt 2068

```

```

<210> 44
<211> 1850
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1490070

```

```

<400> 44
gggtgcctg cctgcctgcc tgcctgcctg gcccgcccgc agctccagcc tgccctcttc 60
actggccact gcctcccacc cagggtctgg atccctgctc cctgccctgg gtcccagact 120
gtgtccctca tcaccgcagg tcggtgaggg gctgggctgg acaccagggc ccgccctccc 180
atcactgagc tccactcctt cctcattttg ctgctgattc tagccccaaa caaaacaggt 240

```

PF-0565 USN

```

tgagcttttt cctccccca gaagctctc tctggctcgt ggctgccttc tgagtgttgc 300
agacggcgcc ggccgggaag gggggcctgg gccagccctg ccaggactgg gacgctgctg 360
ctggcgccctg gccctccatc agggcagcct gtggcaggag agtgagcttt gcccgggcag 420
acgcctgagg atgatcccc agctgcagtt caaagatgcc ttttgggtgca gggacttcac 480
agccacacag ggctacgagg tgctgctgca gcggcttctg gatggcagga agatgtgcaa 540
agacatgggtg gagctactgt ggcagagggc ccaggcggag gagcggtagc ggaaggagct 600
gggtgcagatc gcacgggaagg cagggtggcca gacggagatc aactccctga gggcctcctt 660
tgactccttg aagcagcaaa tggagaatgt gggcagctca cacatccagc tggccctgac 720
cctgcgtgag gagctgcgga gtctcgagga gtttcgtgag aggcagaagg agcagaggaa 780
gaagtatgag gccgtcatgg accgggtcca gaagagcaag ctgtcgctct acaagaaggc 840
catggagtcc aagaagacat acgagcagaa gtgccgggac gcggacgacg cggagcaggc 900
cttcgagcgc attagcgcca acggccacca gaagcagggt gagaagagtc agaacaagc 960
caggcagtcg aaggactcgg ccaccgaggg agagcgggta tacaggcaga gcattgcgca 1020
gctggagaag gtccgggctg agtgggagca ggagcaccgg accacctgtg aggcctttca 1080
gctgcaagag tttgaccggc tgaccattct ccgcaacgcc ctgtgggtgc acagcaacca 1140
gctctccatg cagtgtgtca aggatgatga gctctacgag gaagtgcggc tgacgctgga 1200
aggctgcagc atagacgccg acatcgacag ttcatccag gccaaagaca cgggcacaga 1260
gcccccgct ccggtgccct accagaacta ttacgatcgg gaggtcaccc cgctgaccag 1320
cagccctygc atacagccgt cctgcggcat gataaagagg ttctctggac tgctgcacgg 1380
aagtcccaag accacttcgt tggcagcttc tgctgcgtcc acagagaccc tgacccccac 1440
ccccgagcgg aatgaggggtg tctacacayc catcgcagtg caggagatac agggaaaccc 1500
ggcctcacca gcccaggagt accgggcgct ctacgattat acagcgaga accagatga 1560
gctggagctg tcccgggag acatcctgga ggtgatcctg gaaggggagg atggctgggt 1620
gactgtggag aggaacgggc agcgtggctt cgtccctggg tctacctgg agaagctttg 1680
aggaagggcc aggagccct tcggacctgc cctgccagtg gagccagcag tgccccacg 1740
actgtcccca ccttgctagg gcccagaacc aagcgtcccc cagccccgag agggagcctg 1800
tcgtctccca ggaataaaag gagtgcgttc tgttctcaaa aaaaaaaaaa 1850

```

```

<210> 45
<211> 2534
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1997814

```

```

<400> 45
gaagagggga tggagcaggg gctggaggag gaagaagagg tggatccccg gatccagggg 50
gaactggaga agttaaataca gtccacggat gatatacaaa gacgggagac tgaacttgag 120
gatgctcgtc agaagttccg ctctgttctg gttgaagcaa cggtgaaact ggatgaactg 180
gtgaagaaaa ttggcaaaagc tgtggaagac tccaagccct actgggaggc acggaggggtg 240
gcgaggcagg ctcagctgga agctcagaaa gccacgcagg acttccagag ggccacagag 300
gtgtccgtg ccgccaagga gaccatctcc ctggccgagc agcggctgct ggaggatgac 360
aagcggcagt tcgactccgc ctggcaggag atgctgaatc acgccactca gagggtcatg 420
gaggcggagc agaccaagac caggagcgag ctggtgcata aggagacggc agccaggtag 480
aatgccgcca tgggccgcat gcgacagctg gagaagaaac tcaagagagc catcaacaag 540
tccaagcctt attttgaact caaggcaaa tactatgtgc agctcgagca actgaaaaag 600
actgtggatg acctgcaggc caaactgacc ctggcaaaaag gcgagtacaa gatggccctg 660
aagaacctgg agatgatctc agatgagatc caccagcggc ggcgtccag tgccatgggg 720
cctcggggat gcggtgttgg tgctgagggc agcagcacat ctgtggagga tctgccaggg 780
agcaaacctg agcctgatgc catttctgtg gcctcggagg cctttgaaga tgacagctgt 840
agcaactttg tgtctgaaga tgactcggaa acccagtcgg tgtccagctt tagttcagga 900
ccaacaagcc cgtctgagat gcctgaccag ttccttgagg ttgtgaggcc tggcagcctg 960
gatctgcccc gccctgtgtc cctgtcagag tttgggatga tgttcccagt gttgggcccct 1020
cgaagtgaat gcagcggggc ctcctccctt gaatgtgaag tagaacgagg agacagggca 1080
gaaggggcag agaataaaac aagtgacaaa gccacaaca accggggcct cagcagtagc 1140
agtggcagtg gtggcagcag taagagccaa agcagcacct cccctgaggg ccaggccttg 1200
gagaaccgga tgaagcagct ctccctacag tgctcaaagg gaagagatgg aattattgtg 1260
gacataaaaa tgggtgcagat tggctgattc atcctgggct ctggccgatg tgcatatcaa 1320
catttataca tggaaactgga gaacattgtg caaataatca tttaatatat gccaaatctt 1380
acacgtctac tctaaactgc tctaatgaag tttcagtgac cttgagggct aaagattgtt 1440
cttctgggta agagctcttg ggctgggttt tcagagcaga gttcttgttg tgggtagact 1500
gtgactaggt tcacagcctt tgtggaacat tccgtataac ggcattgttg aagcaataac 1560
tagttcttat gaaagaacca gagctgggaa gatggctggg aagccaggcc aaagtggggg 1620
caacagcttg cttctcttcc cctcagtttg atgggaaaat ggagatgtcc 1680
tctccacttt atccccagat atctaaatga aaaagaaaga aaaccacac acaagcaaa 1740

```

PF-0565 USN

```

aactcaagta ttaagagcac atatttttga cccagtggag gcttaaaaaa aaaaaaatcc 1800
aagaacacaa ttcattttca ccacctctgg tggtcagagg gggcttttaa aaaagcgtgt 1860
atgctgggat acccattaaa accattttct agaaggctac catgagctgc actttttggg 1920
gtgggaaagg tgaatgccag tggggatgcy gggggatgag ggtaggaggg acttatagaa 1980
ggggatttgt ggctgtgggg gagaagggtc tacagcataa gccttacct gccagccaag 2040
gggatttatt ctaagagaag tgcattgtga gaatgggtgc cactgttatt agattgacaa 2100
gatgttaatt tctctgtagg ttgtaacttt aaaaataaat gaaattattt aagggttatg 2160
ctgcactagt attccttaga ggaaacagtt ctttaaagtt aggaaaggga gtaggcaggc 2220
atgtgttggc aaaggctggt aatagtagtt aagtgttaag actgcttttc tttaacgttt 2280
tcattggtaat gcatttttag agcactgtat ttttgccttg ttaagaaaat ttagcatttc 2340
taaaagaaaa aagcaaccct ctttcaaact gttaattctg tcacagcctg tatatttttag 2400
tcattgttaa atctcttcat acaatagtga cttctttttt gactgataca gtatcttaat 2460
tacaaggtta ttttgtactt gtcttaatac actaagtgtg ataaaaacgg cttgagaaaa 2520
gttaaaaaaa aaaa 2534

```

&lt;210&gt; 46

&lt;211&gt; 3786

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2299715

&lt;400&gt; 46

```

ccgtcctcga ggcgaggaga gtaccggggc ggcccggctg ccgcgcgagg agcgcggctc 60
gcgccctggg ctgcggctga gatacacaga gcgacagaga catttattgt tatttgtttt 120
ctggtggcaa aaagggaaaa tggcgaacga ctcctctgca aaaagtctgg tggacatcga 180
cctctcctcc ctgcgggcat ctgctgggat ttttgagctg gtggaagtgg ttggaaatgg 240
ccctatgga caagtctata agggctcgaca tgttaaaacg ggtcagttgg cagccatcaa 300
agttatggat gtcactgagg atgaagagga agaaatcaaa ctggagataa atatgctaaa 360
gaaactactc catcacagaa acattgcaac atattatggt gctttcatca aaaagagccc 420
ccaggacat catgaccaac tctggcttgt tatggagtrc tgtggggctg ggctcattac 480
agaccttgtg aagaacacca aagggaacac actcaaagaa gactggatcg cttacatctc 540
cagagaaatc ctgaggggac tggcacatct tcacattcat catgtgattc accgggatat 600
caagggccag aatgtgttgc tgactgagaa tgcaggggtg aaacttgttg actttgggtg 660
gagtgtctag ctggacagga ctgtggggcg gagaaatacg ttcattaggca ctccctactg 720
gatggctcct gaggtcatcg cctgtgatga gaacctagat gccacctatg attacagaag 780
tgatcttttg tcttgtggca ttacagccat tgagatggca gaaggtgctc cccctctctg 840
tgacatgcat ccaatgagag cactgtttct cattcccaga aacctctctc cccygcgtga 900
gtcaaaaaaa tggctgaaga agtttttttag ttttatagaa ggggtgcctg tgaagaatta 960
catgcagcgg cctctctacag agcagctttt gaaacatcct tttataaggg atcagccaaa 1020
tgaaaggcaa gttagaatcc agcttaagga tcatatagat cgtaccagga agaagagagg 1080
cgagaaagat gaaactgagt atgagtacag tgggagttag gaagaagagg aggaagtgcc 1140
tgaacaggaa ggagagccaa gttccattgt gaacgtgcct ggtgagtcta ctcttcgccg 1200
agatttcctg agactgcagc aggagaacaa ggaacgttcc gaggtctctc ggagacaaca 1260
gttactacag gagcaacagc tccgggagca ggaagaatat aaaaggcaac tgcctggcaga 1320
gagacagaag cggattgagc agcagaaaga acagaggcga cggctagaag agcaacaaaag 1380
gagagagcgg gaagctagaa ggcagcagga acgtgaacag cgaaggagag aacaagaaga 1440
aaagaggcgt ctagaggagt tggagagaag gcgcaaagaa gaagaggaga ggagacgggc 1500
agaagaagaa aagaggagag ttgaaagaga acaggagtat atcaggcgac agctagaaga 1560
ggagcagcgg cacttggaag tcttccagca gcagctgctc caggagcagg ccatgttact 1620
gcatgaccat aggaggccgc acccgcagca ctcgcagcag ccgccaccac cgcagcagga 1680
aaggagcaag ccaagcttcc atgctcccga gccc aaagcc cactacgagc ctgctgaccg 1740
agcgcgagag gttcctgtga gaacaacatc tgcgtccctt gttctgtccc gtcgagattc 1800
cccactgcag ggcagtgggc agcagaatag ccaggcagga cagagaaact ccaccagtat 1860
tgagcccagg cttctgtggg agagagtggg gaagctggtg cccagacctg gcagtggcag 1920
ctcctcaggg tccagcaact caggatcccc gcccggtctc caccctgggt ctgagagtgg 1980
ctccggggaa cgcttcagag tgagatcatt atccaagtct gaaggctctc catctcagcg 2040
cctggaaaaa accgtgaaa taaaaggaa gttttcagac cctcaagcc 2100
tgctgatctg accgcaactg ccaaagagct tcgagcagtg gaagatgtac ggccacctca 2160
caaagtaacg gactactcct catccagtga ggagtcgggg acgacggatg aggaggacga 2220
cgatgtggag caggaagggg ctgacgagtc cacctcagga ccagaggaca ccagagcagc 2280
gtcatctctg aatttgagca atgggtgaaac ggaatctgtg aaaaccatga ttgtccatga 2340
tgatgtagaa agtgagccgg ccatgacccc ggcaactctaa tgcctcgcca 2400
gactcagtc cactccagaa acacaaatct tctcctcctt ttacaccttt 2460
tatagacccc agattactac agattttctc atctagcgga acaacagtga catctgtggt 2520

```

PF-0565 USN

```

gggattttcc tgtgatggga tgagaccaga agccataagg caagatccta cccggaaagg 2580
ctcagtgggc aatgtgaatc ctaccaacac taggccacag agtgacaccc cggagattcg 2640
taaatacaag aagaggttta actctgagat tctgtgtgct gccttatggg gaggtaattt 2700
gctagtgggt acagagagtg gcctgatgct gctggacaga agtggccaag ggaaggtcta 2760
tcctcttata aaccgaagac gatttcaaca aatggacgta cttgagggct tgaatgtctt 2820
ggtgacaata tctggcaaaa aggataagtt acgtgtctac tatttgcctt ggtaagaaa 2880
taaaatactt cacaatgac cagaagttga gaagaagcag ggatggacaa ccgtagggga 2940
tttggaaagg tgtgtacatt ataaagttgt aaaatatgaa agaatacaat ttctggtgat 3000
tgctttgaag agttctgttg aagtctatgc gtgggcacca aagccatata acaaatttat 3060
ggcctttaag tcatttggag aattggtaca tggatcctgt gctggattcc atgctgttga 3120
tgtggattca ggatcagttc atgacattta tctaccaaca catatccagt gtagcatcaa 3180
accccatgca atcatcatcc tccccaatat agatggaatg gagcttcttg tgtgctatga 3240
agatgagggg gtttatgtaa acacatatgg aaggatcacc aaggatgtag ttctacagt 3300
gggagagatg cctacatcag tagcatatat tcatccaat cagacaatgg gctggggaga 3360
gaaggccata gagatccgat ctgtggaaac tggctacttg gatggtgtgt tcatgcacaa 3420
aagggctcaa agactaaaat tcttgtgtga acgcaatgac aaggtgttct ttgcctctgt 3480
tcggtctggg ggcagcagtc aggtttatct catgacctta ggcaggactt ctctctctag 3540
ctggtagaag cagtgtgac cagggtattc tggcctccag agtcttcaag atcctgagaa 3600
cttggaaatt cttgtaactg gagctcggag ctgcaccgag ggcaaccagg acagctgtgt 3660
gtgcagacct catgtgttgg gtctctctcc ctctctctct tctctcttat ataccagttt 3720
atccccatcc tttttttttt tcttactcca aaataaatca aggtctgaat gcagctggtg 3780
ctgtta 3786

```

<210> 47  
 <211> 1182  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 209854

```

<400> 47
gttggtgaag tcaagcgaag ggcactagag ctccaggagg gctagtcttg tgggtcttag 60
tcggccatat taataaagag aaaggggaagg ctgaccgtcc ttgcctcccg cccccacata 120
cacacccctt ctccccactc cgctctcacg actaagctct cagcatgaag gcacgcctgc 180
ctcgattgtc cagcctctgc cagaagaaag cttagcagcc agcgcctcag tagagacct 240
agggcgctga atgagtggga aagggaaatg ccgaccaatt gcgctgcggc gggctgtgcc 300
actacctaca acaagcacat taacatcagc ttccacaggt ttcttttga tctaaaaga 360
agaaaagaat gggttcgctt ggtaggcgc aaaaattttg tgccaggaaa acacactttt 420
ctttgttcaa agcactttga agcctcctgt tttgacctaa caggacaaac tgcagactt 480
aaaatggatg ctgttccaac catttttgat tttgtacct atataaagtc tatgaaactc 540
aagtcaagga atcttttgaa gaaaaacaac agttgttctc cagctggacc atctaattta 600
aaatcaaaaca ttagtagtca gcaagtacta cttgaacaca gctatgcct taggaatcct 660
atggaggcaa aaaagaggat cattaaactg gaaaaagaaa tagcaagctt aagaagaaaa 720
atgaaaactt gctacaaaaa ggaacgcaga gcaactcgaa gatggatcaa agccacgtgt 780
ttggtaaaga atttagaagc aaatagtgtt ttacctaaag gtacatcaga acacatgtta 840
ccaactgcct taagcagttc tcttttgaa gattttaaga tcttgaaca agatcaaca 900
gataaaacac tgctaagttc aaatctaaaa cagaccaaga gtaccttcac ttaaatatag 960
cttgacacaga gcttgatgcc tctcttcat tcttttcaga agtaaagata attatggcac 1020
ttatgccaaa attcattatt taataaagtt ttacttgaag taacattact gaatttgtga 1080
agacttgatt acaaaagaat aaaaaacttc atatggaaat tttatttgaa aatgagtgg 1140
agtgccttac attagaatta cggactttca aaactatgat aa 1182

```

<210> 48  
 <211> 1676  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 1384286

```

<400> 48
tcgccgagcc cgtccgcccgc cgccatggcc accacggtga cctgcacccg cttcacccgac 60
gagtaccagc tctacgagga tattggcaag ggggctttct ctgtggtccg acgctgtgtc 120
aagctctgca ccggccatga gtatgcagcc aagatcatca acaccaagaa gctgtcagcc 180

```



PF-0565 USN

```

agagatcacc agaagctgga gagagaggct cggatctgcc gccttctgaa gcattccaac 240
atcgtgcgtc tccacgacag catctccgag gagggcttcc actacctggt cttegatctg 300
gtcactgggtg gggagctctt tgaagacatt gtggcgagag agtactacag cgaggctgat 360
gccagtcact gtatccagca gatactggag gccgttctcc attgtcacca aatgggggtc 420
gtccacagag acctcaagcc ggagaacctg cttctggcca gcaagtcaa aggggctgca 480
gtgaagctgg cagacttcgg cctagctatc gaggtgcagg gggaccagca ggcattggtt 540
ggtttcgctg gcacaccagg ctacctgtcc cctgagggtcc ttcgcaaaga ggcgtacggc 600
aagcccgtgg acatctgggc atgtggggtg atcctgtaca tcctgctcgt gggctacca 660
cccttctggg acgaggacca gcacaagctg taccagcaga tcaaggctgg tgccatgac 720
ttcccgtccc ctgagtggga caccgtcact cctgaagcca aaaacctcat caaccagatg 780
ctgaccatca acctgccc aaacatcaca gcccatgagg ccctgaagca cccgtgggtc 840
tgccaacgct ccacggtagc atccatgatg cacagacagg agactgtgga gtgtctgaaa 900
aagttcaatg ccaggagaaa gctcaaggga gccatcctca ccaccatgct ggccacacgg 960
aattttctcag cagccaagag tttactcaac aagaaagcag atggagtcaa gccccatacg 1020
aatagcacca aaaacagtgc agccgccacc agcccaaaag ggacgcttcc tcctgccgcc 1080
ctggagtctt ctgacagtgc caataccacc atagaggatg aagacgctaa agcccgggaag 1140
caggagatca ttaagaccac ggagcagctc atcgaggccg tcaacaacgg tgactttgag 1200
gcctacgca aaactctgtga cccagggctg acctcgtttg agcctgaagc actgggcaac 1260
ctgggttgaag ggatggactt ccacagattc tacttcgaga acctgctggc caagaacagc 1320
aagccgateg acacgaccat cctgaaccca cacgtgcacg tcattggaga ggatgccgcc 1380
tgcategctt acatccggct caccgagtag attgacgggc agggccggcc ccgcaccagc 1440
cagctctgagg agaccccgct gtggcaccgc cgcgacggca agtggcagaa cgtgcacttc 1500
acagagtggg tgtttggagg cgcactgccc tcgggcacac ggctgctctg tcgcatgttt 1560
gtgtctgctt cgttccctcc cctgggtgct gtgtctgcag aaaaacaage ccgact 1676

```

&lt;210&gt; 49

&lt;211&gt; 1597

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1512656

&lt;400&gt; 49

```

tcggccttcg gaaagacccc cgggcccggg cacygagaga gccgagcgcc gcagccgtga 50
gccgaataga gccggagaga cccgagtatg accggagaag cccaggccgg ccggaagagg 120
agccgagcgc ggcgggaagg aaccgagccc gtccgaaggg agcggacgca gccctggcctg 180
gggcccggtc gagcccgcgc catggcggcc gaggcgacag ctgtggccgg aagcggggct 240
gttggcggct gcctggccaa agacggcttg cagcagtcta agtggccgga cactacccca 300
aaacggcggc gcgcctcgtc gctgtcgcgt gacgcgagc gccgagccta ccaatgggtgc 360
cgggagtact tgggcccggc ctgggcgcga gtgcagcccg aggagctgag ggtttaccce 420
gtgagcggag gcctcagcaa cctgctcttc cgtctctcgc tcccggacca cctgcccagc 480
gttggcagg agccccggga ggtgcttctg cggctgtacg gagccatctt gcagggcgctg 540
gactccctgg tgctagaaag cgtgatgttc gccatacttg cggagcggtc gctggggccc 600
cagctgtacg gactcttccc agagggccgg ctggaacagt acatcccaag tcggccattg 660
aaaactcaag agcttcgaga gccagtgttg tcagcagcca ttgccacgaa gatggcgcaa 720
tttcatggca tggagatgcc tttcaccaag ggaacccact ggctgtttgg gaccatggag 780
cggtagcctaa aacagatcca ggacctgccc ccaactggcc tccttgagat gaacctgctg 840
gagatgtaca gcctgaagga tgagatgggc aaacctcagga agttactaga gtctacccca 900
tcgccagtcg tcttctgcca caatgacatc caggaaggga acatcttgct gctctcagag 960
ccagaaaatg ctgacagcct catgctgggtg gacttcgagt acagcagtta taactatagg 1020
ggctttgaca ttgggaacca tttttgtgag tgggtttatg attatactca cgaggaatgg 1080
cctttctaca aagcaaggcc cacagactac ccaactcaag aacagcagtt gcattttatt 1140
cgtattacc tggcagaggc aaagaaaggt gagaccctct cccaagagga gcagagaaaa 1200
ctggaagaag atttgcctgg agaagtcagt cgggtatgctc tggcatccca tttcttctgg 1260
ggctctgtgg ccactcctcca ggcattccatg tccaccatag aatttggtta cttggactat 1320
gccagctctc ggttccagtt ctacttccag cagaaggggc agctgaccag tgtccactcc 1380
tcatectgac tccacctccc cactccttgg atttctctg gagcctccag ggcaggacct 1440
tggaggagg aacaacgagc agaagccctt ggcagctggg ctgagccccc aagtgaact 1500
gaggttcagg agaccggcct gttcctgagt ttgagtaggt ccccatggct ggcaggccag 1560
agccccgtgc tgtgtatgta acacaataaa caagctg 1597

```

&lt;210&gt; 50

&lt;211&gt; 2145

&lt;212&gt; DNA



PF-0565 USN

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2098635

&lt;400&gt; 50

```

cccacgcgtc cggacagctt gacccagttt gctttccaat caaagggcat ttattttgaa 60
tgtctctttg tggcgcaaga gccaacgcaa aaatgatggc ggcttacaat ggcggtacat 120
ctgcagcagc agcagggtcac caccaccacc atcaccacca ccttccacac ctcctctctc 180
ctcacctgct tcaccaccac caccctcaac accatcttca tccggggctcg gctgcccgtg 240
tacaccctgt acagcagcac acctcttcgg cagctgcggc agccgcagca gcggctgcag 300
ctgcagccat gttaaaccct gggcaacaac agccatattt cccatcaccc gcaccggggc 360
aggctcctgg accagctgca gcagccccag ctccaggtaca ggctgcccga gctgctacag 420
ttaaggcgca ccatcatcag cactcgcctc atccacagca gcagctggat attgagccgg 480
atagacctat tggatatgga gcctttgggtg ttgtctgggtc agtaacagat ccaagagatg 540
gaaagagagt agcgtcaaaa aagatgcccc acgtcttcca gaatctgggtc tcttgcaaaa 600
gggtcttccg ggaattgaag atgttggtgt tttttaagca tgataatgta ctctctgccc 660
ttgacatact ccaacctcca cacattgact attttgaaga aatatatgtt gtcacagaat 720
tgatgcagag tgacctacat aaaattatcg tctctctcca accactcagc tcagatcatg 780
tcaaagtttt tctttatcag attttgccgag gtttgaaata tctccattca gctggcattt 840
tacatcgaga cattaagcca gggaaatctc ttgtgaacag caactgtgtt ctaaagattt 900
gtgatttttg attggccaga gtggaagagt tagatgaatc ccgtcatatg actcaggaag 960
ttgttactca gtattatcgg gctccagaaa tcttgatggg cagccgtcat tacagcaatg 1020
ctattgacat ctgggtctgt ggatgtatct ttgcagaact actaggacga agaattattg 1080
ttcaggcaca ggtcccatc cagcagttgg atttgatcac ggatctgttg ggcacaccat 1140
cactggaagc aatgaggaca gcttggtgaag gcgctaaggg acatatactc aggggtcctc 1200
ataaacagcc atctcttctt gtactctata cctgtcttag ccaggctaca catgaagctg 1260
ttcatctcct ttgcaggatg ttgggtcttg atccatccaa aagaatatcc gctaaggatg 1320
ccttagcccc cccctaccta gatgaagggc gactacgata tcacacatgt atgtgtaaat 1380
gttgcttttc cacctccact ggaagagttt ataccagtga ctttgagcct gtcaccaatc 1440
ccaaatttga tgacacttcc gagaagaacc tcagttctgt ccgacaggtt aaagaaatta 1500
ttcatcagtt catttttgaa cagcagaaag gaaacagagt gcctctctgc atcaaccctc 1560
agctcgtgcg ttttaagagc tttattagtt ccactgttgc tcagccatct gagatgcccc 1620
catctcctct ggtgtgggag tgatggtgga agataatgta ctactgaaga tgtaatgtag 1680
ctttccactg gagtctggga tttgcaattc tggagggttaa tcatgcttgt actgtaattt 1740
tactaatgaa gtttttaatt aacaaccact acttgatgta tatgaataat atttagaaat 1800
gttactagac ttttaattct gttaaagtgtg tgtgctttta gaagaaaaat attttacca 1860
gagttgcaca tgttttatga atttagtgca gctgttatgg ctcaacctcag aacaaaagag 1920
aattgaacca aatttgggag tttgggggtt tatgttttgt ttttcttttc taaaatgaag 1980
tgagattggt cacacacaca cacacacaca cacacacaca cacaaacaca aaggacagtc 2040
atacattttg atatttgagc cattcctaaa gatttgggggt tttctaaaaa taaagaatct 2100
aggaaccttg cctgcgacca atcatggagc cacgtgagct gatcg 2145

```

&lt;210&gt; 51

&lt;211&gt; 1454

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2446646

&lt;400&gt; 51

```

gggttcgaat tgcaacggca gctgcccggc gtatgtgttg gtgctagagg cagctgcagg 60
gtctcgctgg gggccgctcg ggaccaattt tgaagaggta cttggccacg acttattttc 120
acctccgacc tttccttcca ggccgtgaga ctctggactg agagtggctt tcacaatgga 180
agggatcagt aatttcaaga caccaagcaa attatcagaa aaaaagaaat ctgtattatg 240
ttcaactcca actataaata tcccggcctc tccgtttatg cagaagcttg gctttgggtac 300
tggggtaaat gtgtacctaa tgaaaagatc tccaagaggt ttgtctcatt ctccttgggc 360
tgtaaaaaag attaatccta tatgtaatga tcattatcga agtgtgtatc aaaagagact 420
aatggatgaa gctaagattt tgaaaagcct tcatcatcca aacattgttg gttatcgtgc 480
ttttactgaa gccaatgatg gcagtctgtg tcttgctatg gaatatggag gtgaaaagtc 540
tctaaatgac ttaatagaag aacgatataa agccagccaa gatecttttc cagcagccat 600
aatttttaaaa gttgcttttg atatggcaag aggggttaaag tatctgcacc aagaaaagaa 660
actgcttcat ggagacataa agtcttcaaa tgttgtaatt aaaggcgatt ttgaaacaat 720
taaaatctgt gatgtaggag tctctctacc actggatgaa aatatgactg tgactgacct 780

```

PF-0565 USN

tgaggcttgt	tacattggca	cagagccatg	gaaacccaaa	gaagctgtgg	aggagaatgg	840
tggtattact	gacaaggcag	acatatattgc	ctttggcctt	actttgtggg	aaatgatgac	900
tttatcgatt	ccacacatta	atctttcaaa	tgatgatgat	gatgaagata	aaacttttga	960
tgaagtgat	tttgatgatg	aagcatacta	tgcagcgttg	ggaactaggc	cacctattaa	1020
tatggaagaa	ctggatgaat	cataccagaa	agtaattgaa	ctcttctctg	tatgactaa	1080
tgaagacct	aaagatcgtc	cttctgctgc	acacattgtt	gaagctctgg	aaacagatgt	1140
ctagtgatca	tctcagctga	agtgtggcct	gcgtaaataa	ctgtttattc	caaaatattt	1200
acatagttac	tatcagtagt	tattagactc	taaaattggc	atatttgagg	accatagttt	1260
cttgtaaca	tatggataac	tatttcta	atgaaatatg	cttatattgg	ctataagcac	1320
ttggaattgt	actgggtttt	ctgtaaagtt	ttagaaacta	gctacataag	tactttgata	1380
ctgctcatgc	tgacttaaaa	cactagcagt	aaaacgctgt	aaactgtaac	attaaattga	1440
atgaccatta	cttt					1454

<210> 52  
 <211> 3225  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2764911

<400> 52

tgaggcaggg	ggcggtttgg	ttgcgcggta	ctagcgggtgc	ccgcccgaatg	gggaggaggc	60
gaggagcgag	ccgtgcggcc	agagcgggaa	agagactcgt	ctttgcgtcc	gagttctgga	120
gcccgcgcac	cccgaactcct	ggggccgcgg	cagcggctgc	gaggggacgg	gcgtccgctg	180
tctcctgggt	tccccctgta	gcgaccgcgg	ggatcggaaa	aaaaggagaa	gatggaggag	240
gaggytgga	gcagcggcgg	cgccgcgggg	accagcgcgg	acggcggcga	cggaggagag	300
cagctccctca	ctgtcaagca	cgagctgcgg	actgctaatt	tgacaggaca	tgctgagaag	360
gtgggaatag	aaaattttga	gctcctgaag	gtcctaggaa	ctggagctta	tggaaaagta	420
ttctagttc	gtaaaataag	tggccatgat	actggaaagc	tgtatgccat	gaaagttttg	480
aaaaaggraa	caatcgttca	aaaggccaaa	accacagagc	atacaaggac	agaacgacaa	540
gtcctggaac	acattagyc	gtcgccattt	ttggtaacat	tacattatgc	ttccagaca	600
gaaaccaaac	ttcatctcat	tttagattat	ataaatgggtg	gtgaactttt	tacctctctc	660
tctcaaagag	agcgtttcac	agagcatgag	gtgcagattt	atgttgagaa	gattgtgctt	720
gccctcgaac	atctccacaa	gttggggatt	atatatcgtg	atattaagct	tgagaatatt	780
ctacttgatt	ctaattggcca	tgtggtgctg	acagattttg	gtctgagtaa	ggagtttgtg	840
gctgatgaaa	ctgaaagagc	atattccttt	tgtggaacta	ttgaatacat	ggcaccagat	900
attgtcagag	ggggagattc	aggacatgac	aaggcagttg	actgggtggag	tttgggtgtt	960
ctaattgtatg	aattactaac	tggagcatct	cctttcactg	ttgatggaga	aaaaaattcc	1020
caagctgaga	tatctaggag	aatattaaaa	agtgagcctc	catatcccca	agaaatgagt	1080
gctttagcga	aagaccta	tcagcgtctt	ttgatgaaag	atcccaagaa	gagattggga	1140
tgtggtccac	gtgatgcaga	tgaatcaaaa	gaacatctct	tctttcagaa	aataaattgg	1200
gatgatttag	ccgcccacaaa	agtgcctgca	ccattttaagc	cagtcattcg	agatgaatta	1260
gatgtgagta	actttgcaga	agagttcaca	gaaatggatc	ccacttatcc	tcccgcagcc	1320
ctgccccaga	gttctgagaa	gctgtttcag	ggctattcct	ttgttgctcc	ttccatccta	1380
ttcaagcgta	atgcagctgt	catagacctt	cttcagtttc	acatgggagt	tgaacgtcct	1440
ggagtgcaca	atgttgccag	gagtgcattg	atgaaggact	ctccattcta	tcaacactat	1500
gacctagatt	tgaaggacaa	acccctggga	gaaggtagtt	tttcaatttg	tcgaaagtgt	1560
gtgcataaaa	aaagtaacca	agcttttgca	gtcaaaaata	tcagcaaaaag	gatggaagcc	1620
aatactcaaa	aggaaataac	agctctggaa	ctctgtgaag	gacaccccaa	tattgtgaag	1680
ttgcatgaag	tttttcatga	tcagcttcac	acgtttctag	tgatggaact	tctgaatgga	1740
ggagaactgt	ttgagcgc	taagaaaaag	aagcacttca	gtgagacgga	agccagctac	1800
atcatgagga	agctgttttc	agctgtaagc	cacatgcattg	atgttgaggt	ggtgcacagg	1860
gatctgaaac	ctgagaattt	attgttcacc	gatgaaaatg	acaattttgga	aattaaaaata	1920
attgattttg	gatttgcacg	gctaaagcca	ccggataatc	agccccctgaa	gactccatgc	1980
ttcacccttc	attatgccgc	cccagagctc	ttgaatcaga	acggctacga	tgagtcctgt	2040
gacctgtgga	gcttgggcgt	cattttgtac	acaatgttgt	caggacaggt	tcccttccaa	2100
tctcatgacc	gaagtgtgac	gtgtaccagc	gcggtggaaa	tcatgaagaa	aattaaaaag	2160
ggagatttct	cctttgaagg	agaagcctgg	agaatgtat	ccaagaggc	taaagatttg	2220
atccaaggac	ttctcacagt	agatccaaac	aaaaggctta	aaatgtctgg	cttgagggtac	2280
aatgaatggc	tacaagatgg	aagtcagctg	tcctccaatc	ctctgatgac	tccggatatt	2340
ctaggatctt	ccggagctgc	cgtgcatacc	tgtgtgaaag	caaccttcca	cgcttttaac	2400
aaatacaaga	gagaggggtt	ttgccttcag	aatgttgata	aggccccctt	ggctaagaga	2460
agaaaaatga	aaaagactag	caccagtacc	gagacacgca	gcagttccag	tgagatttcc	2520
cattcttctt	ctctctattc	tcacggtaaa	actacaccca	ccaagacact	gcagcccagc	2580
aatcctgccg	acagcaataa	ccgggagacc	ctcttccagt	tctcggactc	agtagcttag	2640

PF-0565 USN

```

gcatggtagg agtgtatcag tgatccattg cacctttatt cctcagcat atgcctgagg 2700
cgatctttta tgcttttaaa aatgtttccc gttggtctca ttggaatctg cctcctaata 2760
atTTTTTTca ggaaaacctg tttggttatt ctcatcaca agcactggac agagaatgtt 2820
actgtgaata gagcacatat tactcttttt agcaacctag catgatgcc acaagactat 2880
tcttgaaaga gcaaagggtc ctgtaaatth aattagggct agatttgagc tgcttgtaag 2940
tcacagggtt tccagatgtc tgccaacaag aaatgactca tactgtgatg ataccttttg 3000
ctttgccttg tggacaatgt ggggttttga aatttgacc cttcaaaca tgatttatca 3060
gagaaagggg tctgttttca aaaaagattc tgtaatgaat tttatgtgtg gcatatactt 3120
atTTcttgag agaagatttt aacttattgt tttattttta tggttacata tgatgataac 3180
ctgctattat taaacttttt ctaaaaagtg aaaaaaaaa aaaaa 3225

```

```

<210> 53
<211> 2110
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3013946

```

```

<400> 53
tcgccgagcc cgtecgccgc cgccatggcc accacgggtga cctgcacccg cttcaccgac 60
gagtaccagc tctacgagga tattggcaag ggggctttct ctgtgggtccg acgctgtgtc 120
aagctctgca ccggccatga gtatgcagcc aagatcatca acaccaagaa gctgtcagcc 180
agagatcacc agaagctgga gagagaggct cggatctgcc gccttctgaa gcattccaac 240
atcggtgcgtc tccacgacag catctccgag gagggtctcc actacctggt cttcgatctg 300
gtcactggtg gggagctctt tgaagacatt gtggcagag agtactacag cgaggctgat 360
gccagtcact gtatccagca gatcctggag gccgttctcc attgtcacca aatgggggtc 420
gtccacagay acctcaagcc ggagaacctg cttctggcca gcaagtgcaa aggggctgca 480
gtgaagctgg cagacttcgg cctagctatc gaggtgcagg gggaccagca gcatgggtt 540
ggtttcgctg gcacaccagg ctacctgtcc cctgagggtc ttcgcaaaga ggcgtatggc 600
tagcctgttg acatctgggc atgtgggggtg atcctgtaca tctgtctgt gggctacca 660
gccttctgag acgaggacca gcacaagctg taccaycaga tcaaggctgg tgccatgac 720
tcccgctccc ctgagtggga caccgtcact cctgaagcca aaaacctcat caaccagatg 780
ctgaccatca accctgccaa gcgcatacaca gcccatgagg cctgaagca cccgtgggtc 840
tgccaaagct ccacggtagc atccatgatg cacagacagg agactgtgga gtgtctgaaa 900
aagttcaatg ccaggagaaa gctcaaggga gccatcctca ccaccatgct ggccacacgg 960
aatttctcag ccaagagttt actcaacaag aaagcagatg gagtcaagcc ccagacgaat 1020
agcaccaaaa acagtgcagc cgccaccagc cccaaaggga cgcttctcc tgccgcctg 1080
gagcctcaaa ccaccgtcat ccataaccca gtggacggga ttaaggagtc ttctgacagt 1140
gccaatacca ccatagagga tgaagacgt aaagcccca ggggtcccga catcctgagc 1200
tcagttagga ggggctcggg agccccagaa gccgaggggc cctgccctg cccatctccg 1260
gtccctttg gccccctgcc agctccatcc cccaggatct ctgacatcct gaactctgtg 1320
agaaggggtt caggaacccc agaagccgag gggccctct cagcggggcc cccgccctgc 1380
ctgtctccgg ctctcctagg cccctgtcc tccccgtccc ccaggatctc tgacatcctg 1440
aactctgtga ggaggggtc agggacccca gaagccaagg gccctcggc agtggggccc 1500
ccgccctgcc catctccgac tatccctggc cccctgccca ccccatccc gaagcaggag 1560
atcataaaga ccacggagca gctcatcgag gccgtcaaca acggtgactt tgaggcctac 1620
gcgaaaatct gtgaccagag gctgacctcg tttgagcctg aagcactggg caacctgggt 1680
gaagggatgg acttccacag attctacttc gagaacctgc tggccaagaa cagcaagcca 1740
atccacacga ccatcctgaa cccacacgtg cacgtcattg gagaggatgc cgcctgcate 1800
gtttacatcc ggctcacgca gtacattgac gggcagggcc ggccccgcac cagccagtct 1860
gaggagaccc gcgtgtggca ccgccgcgac ggcaagtggc agaattgtgca cttccactgc 1920
tcgggcgcgc ctgtggcccc gctgcagtga agagctgcgc cctggtttcg ccggacagag 1980
ttgggttttg gagccccact gccctcgggc acacggcctg cctgtcgcac gtttgtgtct 2040
gcctcgttcc ctccccgtgt gccctgtgtct gcagaaaaac aagaccagat gtgatttgtt 2100
aaaaaaaaa 2110

```

```

<210> 54
<211> 2140
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 067967

```

PF-0565 USN

&lt;400&gt; 54

```

gtgcgctgag ctgcagtgtc tggctcgagag taccgctggg agcgtcgcgc cgcgaggagca 60
gccgtccccg cgtagggtggc gtggccgacc ggacccccaa ctggcgccctc tccccgcgcg 120
gggtccccgag ctaggagatg ggaggcacag ctcgctgggccc tgggcggaag gatgcggggc 180
cgcttggggc cgggtccccg ccccgagcagc ggaggttggg ggatggtgtc tatgacacct 240
tcatgatgat agatgaaacc aaatgtcccc cctgttcaaa tgtactctgc aatccttctg 300
aaccaccttc acccagaaga ctaaatatga ccactgagca gtttacagga gatcatactc 360
agcacttttt ggatggagggt gagatgaagg tagaacagct gtttcaagaa tttggcaaca 420
gaaaaatccaa tactattcag tcagatggca tcagtgtactc tgaaaaatgc tctcctactg 480
tttctcaggg taaaagttca gattgcttga atacagtaaa atccaacagt tcatccaagg 540
cacccaaagt ggtgcctctg actccagaac aagccctgaa gcaatataaa caccacctca 600
ctgcctatga gaaactggaa ataattaatt atccagaaat ttactttgtg ggtccaaatg 660
ccaagaaaag acatggagtt attgggtggc ccaataatgg agggatgat gatgcagatg 720
gggcctatat tcatgtacct cgagaccatc tagcttatcg atatgaggtg ctgaaaatta 780
ttggcaaggg gagttttggg caggtggcca gggcttatga tcacaaactt cgacagtacg 840
tggccctaaa aatgggtgcgc aatgagaagc gctttcatcg tcaagcagct gaggagatcc 900
ggatttttga gcatcttaag aaacaggata aaactggtag tatgaacgtt atccacatgc 960
tggaaagttt cacattccgg aacctggttt gcatggcctt tgaattgctg agcatagacc 1020
tttatgagct gattaaaaaa aataagtttc aggggttttag cgtccagttg gtacgcaagt 1080
ttgcccagtc catcttgcaa tctttggatg cctccacaa aaataagatt attcactgcg 1140
atctgaagcc agaaaacatt ctctgaaac accacgggcy cagttcaacc aagggtcattg 1200
actttgggtc cagctgtttc gagtaccaga agctctacac atatatccag tctcggttct 1260
acagagctcc agaaatcatc ttaggaagcc gctacagcac accaattgac atatggagtt 1320
ttggctgcac ccttcagaaa cttttaacag gacagcctct ctccctgga gaggatgag 1380
gagaccagtt ggcctgcagt atggagcttc tagggatgcc accacaaaaa cttctggagc 1440
aatccaaacg tgccaagtac tttattaatt ccaagggcat accccgctac tgctctgtga 1500
ctacccaagg agatgggagg gttgtgcttg tggggggctg ctcacgtagg ggtaaaaagc 1560
gggggtcccc aggcagcaaa gactggggga cagcactgaa aggggtgtgat gactacttgt 1620
ttatagagtt cttgaaaagg tgtcttcaat gggaccctc tgcccycttg accccagctc 1680
aagcattaaag acacccttgg attagcaagt ctgtccccag acctctcacc accatagaca 1740
aggtgtcagg gaaacgggta gttaatcctg caagtgtctt ccaggggattg ggttccaaagc 1800
tgctccagtt tgttggaata gccaaataagc ttaaagctaa cttaatgtca gaaaccaatg 1860
gtagtatacc cctatgcagt gtattgcaa aactgattag ctagtggaca gagatatgcc 1920
cagagatyca tatgtgtata tttttatgat cttacaaaacc tgcacaaatga aaaaatgcaa 1980
gcccattggt ggaatgtttt gtcagagttag acttttttta aacaagacaa aacattttta 2040
tatgattata aaagaattct tcaagggcta attacctaac cagcttgat tggccatctg 2100
gaatatgcat taaatgactt tttataggtc aaaaaaaaaa 2140

```

&lt;210&gt; 55

&lt;211&gt; 1728

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 346275

&lt;400&gt; 55

```

gacagacaaa gcgcgcgccac gcgtccgcac gtcggatggt tgtagcagtc agagagcaga 60
acatgagcat ctgccaggtc tgggtcccccc cctgcaggga gaaatctgtc tccaacagga gatctgggaa 120
ttccccctctg aagagccacc cctgcaggga gaaatctgtc tccaacagga gatctgggaa 180
gaccatagtg agaagtgtc tccaagaggt ccgcacagcg ggccttttcc gaagtgggtt 240
tagcgaagag aaggcaactg gcaagctctt tgcgtgtgaag tgtatcccta agaaggcgct 300
gaagggcaag gaaagcagca tagagaatga gatagccgtc ctgagaaaga ttaagcatga 360
aaatattggt gccctggaag acatttatga aagcccaaat cacctgtact tggcatgca 420
gctggtgtcc ggtggagagc tgtttgaccg gatagtggag aaggggtttt atacagagaa 480
ggatgccagc actctgatcc gccaaagtctt ggacgccgtg tactatctcc acagaatggg 540
catcgtccac agagacctca agccccgaaa tctctgttac tacagtcaag atgaggagtc 600
caaaataatg atcagtgtct ttggattgtc aaaaatggag ggcaaaggag atgtgatgtc 660
cactgcctgt ggaactccag gctatgtcgc tectgaagtc ctgcgccaga aaccttacag 720
caaagccgtt gactgctggt ccacggaggt gattgacctac atcttgcctc gcggtaccc 780
tcctttttat gatgaaaatg actccaagct ctttgagcag atcctcaagg cggaaatatga 840
gtttgactct ccctactggg atgacatctc cgactctgca aaagacttca ttcggaacct 900
gatggagaag gaccgaata aaagatacac gtgtgagcag gcagctcgcc acctatggat 960
cgctggtgac acagccctca acaaaaacat ccacaggtcc gtcagcgccc agatccggaa 1020
aaactttgcc aagagcaaat ggagacaagc atttaatgcc acggccgtcg tgagacatat 1080
gagaaaacta cacctcggca gcagcctgga cagttcaaat gcaagtgttt cgagcagcct 1140

```

PF-0565 USN

```

cagtttggcc agccaaaaag actgtgcgta tgtagcaaaa ccagaatccc tcagctgaca 1200
ctgaagacga gcctgggggtg gagaggaggg agccggcatc tgccgagcac ctccgtgttg 1260
ccaggcgctt tctatactta atcccatgtc atgcgacctt aggacttttt ttaacatgta 1320
atcactgggc cgggtgcagt ggctcacgcc tgtaatccca acactttggg aggctgaggc 1380
aggaggactg tttgagttca ggagttttta gaccagcctg accaaccatgg tgaaccccca 1440
tctctactaa aatataaaaa ttagccgggt gtgggtggcg gcacctgtaa tgtcagctac 1500
ttgggaggct gaggcaggag aatcacttga acccaggaag cggagggttg aatgagctga 1560
gatcacacca ctgcactcca gcctgggtga cagattgaga ctccctctca aaaaaaaaag 1620
ggaaatcatt gaacactcgt ggaaccctag gtattgcata ttccatttac ggtttgggaa 1680
tccagggtc aagtctctgc aggggtaccg agctcgagat cgtaatca 1728

```

&lt;210&gt; 56

&lt;211&gt; 1610

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 283746

&lt;400&gt; 56

```

gtgcctctg aaggagaacc attttccatc tctttcatag tttttcccc cagtcagcgt 60
ggtagcggtt ttctccgcgg cagtgcagct aattgttttt gcctcttttag ccaagacttc 120
cgccctcgat caagatggtg gttggacggc ctccctaacc tttacggggc ctggcggtgc 180
tgacgcctga gctggtaggg gtggagcagg taggaaacag caaatgcaga agctgctgcg 240
cggaagtcgg ccatggactg gaaagaagtt cttcgctggc gcctagcgac gcccacacac 300
tgtccaaaca ctgctgctg aagatgaagt cttactacag aaattaagag aggaatcaag 360
agctgtcttt ctacaaagaa aaagcagaga actgttagat aatgaagaat tacagaactt 420
atgggttttg ctggacaaac accagacacc acctatgatt ggagaggaag cgatgatcaa 480
ttacgaaaac tttttgaagy ttggtgaaaa ggctggagca aagtgcagc aatttttcac 540
agcaaaagtc tttgctaaac tctttcatc agattcatat ggaagaattt ccatcatgca 600
gttctttaat tatgtcatga gaaaagtttg gcttcatcaa acaagaatag gactcagttt 660
atatgatgtc gctgggcagg ggtaccttcg ggaatctgat ttagaaaact acatattgga 720
acttatccct acgttgccac aattagatgg tctggaaaaa tctttctact ccttttatgt 780
ttgtacagca gttaggaagt tcttcttctt tttagatcct ttaagaacag gaaagataaa 840
aattcaagat attttagcat gcagcttctt agatgattta ttggagctaa gggatgagga 900
actgtccaag gagagtcaag aaacaaattg gttttctgct ccttctgccc taagagttta 960
tggccagtac ttgaatcttg ataaagatca caatggcatg ctcagtaaaag aagaactctc 1020
acgctatgga acagctacca tgaccaatgt cttcttagac cgtgttttcc aggagtgtct 1080
cacttatgat ggagaaatgg actataagac ctacttggac tttgtccttg cattagaaaa 1140
cagaaaggaa cctgcagctc tacaatatat tttcaaactg cttgatattg agaacaaagg 1200
atacctgaat gtcttttcac ttaattattt ctttagggcc atacaggaac taatgaaaat 1260
ccatggacaa gatcctgttt catttcaaga tgtcaaggat gaaatctttg acatggtaaa 1320
accaaaggat cctttgaaaa tctctcttca ggatttaatc aacagtaatc aaggagacac 1380
agtaaccacc attctaateg atttgaatgg cttctggact tacgagaaca gagaggctct 1440
tgttgcaaat gacagtgaat actctgcaga ccttgatgat acatgatctc tgaaagacta 1500
gactgtctta tattatgaga tacttgaatg ctgcatgtaa agcctttaa gcaaaatcct 1560
cagaaatggt ctaaataaaa cacttgatat gcctagagaa aaaaaaaaaa 1610

```

&lt;210&gt; 57

&lt;211&gt; 1290

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2696537

&lt;400&gt; 57

```

ccggctcccc cggggaagtt ctaggccgcc gcacagaaag ccctgccttc cagccgggt 60
ctctggagcg ccctgggttg cccggccggt ccctgccgct gacttggtga cactgcgagc 120
actcagtcct tcccgcgcg ctcctcccc cccgccccgc cgctcctcct cctgtaaca 180
tgccatagtg cgctgcgac cacacggccg gggcgctagc gttcgcttc agccaccatg 240
gggaatggga tgaacaagat cctgcccggc ctgtacatcg gcaacttcaa agatgccaga 300
gacgcggaac aattgagcaa gaacaagggt acacatatc tgtctgtcca tgatagtgc 360
aggcctatgt tggaggaggt taaataacct tgcacccag cagcggattc accatctcaa 420
aacctgacaa gacatttcaa agaaagtatt aaattcattc acgagtgcg gctcccggt 480

```

PF-0565 USN

```

gagagctgcc ttgtacactg cctggccggg gtctccagga gcgtgacact ggtgatcgca 540
tacatcatga cctgcactga ctttggctgg gaggatgcc tgcacaccgt gcgtgctggg 600
agatcctgtg ccaaccccaa cgtgggcttc cagagacagc tccaggagtt tgagaagcat 660
gaggtccatc agtatcgga gtggctgaag gaagaatatg gagagagccc tttgcaggat 720
gcagaagaag ccaaaaacat tctggccgct ccgggaattc tgaagttctg ggcctttctc 780
agaagactgt aatgtacctg aagttttctga aatattgcaa acccacagag ttttaggctgg 840
tgctgccaaa aagaaaagca acatagagtt taagtatcca gtagtattt gtaaacctgt 900
ttttcatttg aagctgaata tatacgtagt catgtttatg ttgagaacta aggatattct 960
ttagcaagag aaaatatattt ccccttatcc ccactgctgt ggaggtttct gtacctcgct 1020
tggatgcctg taaggatccc gggagccttg ccgcactgcc ttgtgggtgg cttggcgctc 1080
gtgattgctt cctgtgaacg cctcccaagg acgagcccag tgtagttgtg tggcgtgaac 1140
tctgcccggtg tgttctcaaa ttccccagct tgggaaatag cccttgggtg gggttttatc 1200
tctggtttgt gttctccgtg gtggaattga ccgaaagctc tatgttttcg ttaataaagg 1260
gcaacttagc caagtttaaa aaaaaaaaaa 1290

```

<210> 58  
 <211> 2281  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 551178

```

<400> 58
tgatgatcca gatgttaaag cacaagtgga agtgcgtgcc gctgcactac gtgcttccag 50
cctggatgca catgaagaga ccatcagtat agaaaagaga agtgatttgc aagatgaact 120
ggatataaat gagctaccaa attgtaaaat aaatcaagaa gattctgtgc ctttaactag 180
cgatgctggt gagaatatgg actccactct tcactatatt cacagcgatt cagacttgag 240
caacaatagc agttttagcc ctgatgagga aaggagaact aaagtacaag atgttgtacc 300
tcaggcgctg ttagatcagt atttatctat gactgacctc tctcgtgca agacggttga 360
cactgaaatt gctaagcact gtgcatatag cctccctggg gtggccttga cactcggaag 420
acagaattgg cactgcctga gagagacgta tgagactctg gcctcagaca tgcagtggaa 480
agttegacga actctagcat tctccatcca cgagcttgca gttattcttg gagatcaatt 540
gacagctgca gatctgggtc caatttttta tggattttta aaagacctcg atgaagtcag 600
gataggtgtt cttaaacact tgcattgatt tctgaagctt cttcatattg acaaaagaag 660
agaatatctt tatcaacttc aggagttttt ggtgacagat aatagtagaa attggcggtt 720
tcgagctgaa ctggtgaac agctgacctt acttctagag ttatatagtc ccagagatgt 780
ttatgactat ttacgtccca ttgctctgaa tctgtgtgca gacaaagttt cttctgttcg 840
ttggatttcc tacaagttgg tcagcgagat ggtgaagaag ctgcacgagg caacaccacc 900
aacgttcgga gtggacctca tcaatgagct tgtggagaac tttggcagat gtcccaagt 960
gtctggctcg caagcctttg tctttgtctg ccagactgtc attgaggatg actgccttcc 1020
catggaccag ttfgtgtgac atctcatgcc gcattctgta accttagcaa atgacagggt 1080
tcctaacgtg cgagtgtctg ttgcaaagac attaagacaa actctactag aaaaagacta 1140
tttcttggcc tctgccagct gccaccagga ggtgtggag cagaccatca tggctcttca 1200
gatggaccgt gacagcgatg tcaagtattt tgcaagcacc caccctgcca gtaccaaact 1260
ctccgaagat gccatgagca cagcgtcttc aacctactag aaggcttgaa tctcgggtgtc 1320
tttctgtctt ccatgagagc cgagggttcag tgggcattcg ccacgcatgt gacctgggat 1380
agcttttcgg ggaggagaga ccttcctctc ctgcggactt cattgcagggt gcaagttgcc 1440
tacacccaat accagggatt tcaagagtca agagaaagta cagtaaaccac tattatctta 1500
tcttgacttt aaggggaaat aatttctcag aggtattata ttgtcaccga agccttaaat 1560
ccttctgtct tctgactga atgaaacttg aattggcaga gcatttttct tatggaaggg 1620
atgagattcc cagagacctg cattgctttc tctggtttt atttaacaat cgacaaatga 1680
aattcttaca gcctgaaggc agacgtgtgc ccagatgtga aagagacctt cagtatcagc 1740
cctaactctt ctctcccagg aaggacttgc tgggctctgt ggccagctgt ccagcccagc 1800
cctgtgtgtg aatcgtttgt gacgtgtgca aatgggaaag gaggggtttt tacatctctc 1860
aaaggacctg atgccaacac aagtaggatt gacttaaact cttaagcgca gcatattgtc 1920
gtacacattt acagaatggg tgctgagtgt ctgtgtctga ttttttcatg ctggctcatga 1980
cctgaaggaa atttattaga cgtataatgt atgtctgggt tttttaactt gatcatgatc 2040
agctctgagg tgcaacttct tcacatactg tacatacctg tgaccactct tgggagtgtc 2100
gcagtcttta atcatgctgt ttaaactgtt gtggcacaag ttctctgtgc caaataaact 2160
ttattaataa gatctataga gagagatata tactctttg attgttttct agatgtctac 2220
caataaatgc aatttgtgac ctgtattaat gatttaaagt gggaaactag attaaaatat 2280
a 2281

```

<210> 59  
 <211> 632

PF-0565 USN

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 619292

&lt;400&gt; 59

```

cggacgcgtg ggggtccagcc gcagctccag caccgaggac ttctgctacg tcttcacggg 60
ggagctggaa cgaggccccc cgggctggg gatgggcctg atcgacggga tgcacacgca 120
cctgggcgcc cccgggctct acatccagac cctgctcccc ggcagccccg cagcggccga 180
cgggcgcctg tcgctggggg accgtatcct ggaggtgaat ggcagcagcc tcctgggcct 240
tggctacctg agagctgtgg acctgatccg tcatggcggg aagaagatgc ggttcctggg 300
cgcaagtcac gacgttggga aacagccaag aagatccatt tccgcagccc cctctcttag 360
gggggctgcg aggacacccc cacaggcccc gcacccgggc ccacctgggtg aactgggct 420
tctcccccgc ttcgtccctg ttttgtaact gaccaagttg ggtcccgggt ggggagcctc 480
acctggggga catgcctgtt gataacatgc atctcagttg aggttctatt tatatggcag 540
atgacgtgaa attgtgatgt ttgttacaga gcttttatgt ttaaagactt caatggagaa 600
gtacgggttca ataaactatt tttcccgctc tt 632

```

&lt;210&gt; 60

&lt;211&gt; 2347

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2054049

&lt;400&gt; 60

```

accagtttta tcatggattc atcctgaaag tcaagccaca atcaactcggg ttagccagcc 60
catygttggg gtgagtgga agcgaagcaa agaagatgaa aaataccttc aagctatcat 120
gattccaat gccagctct acaaaatctt tatatttgat gcccggccaa gtgttaatgc 180
gtttgccaa aaggcaaagg gtggagggtta tgaagtgaa gatgcctatc aaaatgctga 240
actagttttc ctggatatcc acaatattca tgttatgaga gaatcattac gaaaacttaa 300
ggagattgtg taccccaaca ttgaggaaac ccaactgggtg tctaacttgg aatctactca 360
ttggctagaa catattaagc ttattcttgc aggggctctt aggattgctg acaaggtaga 420
gtcagggaa acgtctgtgg tagtgcatg cagtgtatgg tgggatcgca cagctcagct 480
cacttccctt gccatgctca tgttggatgg atactatcga accatccgag gatttgaagt 540
ccttgtggag aaagaattgg taagttttgg acatcgattt caactaagag ttggccatgg 600
agataagaac catgcagatg cagacagatc gcctgttttt cttcaattta ttgactgtgt 660
ctggcagatg acaagacagt ttctaccgc atttgaattc aatgagtatt ttctcattac 720
cattttggac cacctatata gctgcttatt cggaacatc ctctgttaata gtgaacaaca 780
gagaggaaaa gagaatcttc ctaaaaggac tgtgtcactg tggctttaca taaacagcca 840
gctggaagac ttcactaatc ctctctatgg gagctattcc aatcatgtcc tttatccagt 900
agccagcatg gcacacatg agctctgggt gggatattac ataagggtgga atccacggat 960
gaaaccacag gaacctattc acaacagata caaagaactt cttgctaacc gagcagagct 1020
tcagaaaaaa gtagaggaa tacagagaga gatttctaac cgatcaacct catcctcaga 1080
gagagccagc tctcctgcac agtgtgtcac tctgtccaa actgttgtat aaaggactgt 1140
aagatcaggg gcatcattgc tatacactct tgattacact ggcagctcta tgagttagaa 1200
gtcttcggaa tttagaacc atctatgaga gaaagtccag tcactttatt tatttttaaa 1260
ctctctagga tgagtttaga actgtagcag tgcaggtggc ttaagtgaag taactccata 1320
tgtaattaca tgattatgat actaatcttt taagtatcca aagaatatta aaatacttca 1380
atcctggatt cacagtggga acaagtttct attaaaaggc aaatgctgtt acaaattttt 1440
ggcatctggt aatattaaaa ccatttttaga aatacactct gtgctcactg tgcagaggaa 1500
catcagtttt caaaccaaca ctgaaattct gtggcatcac atatatggg ccttgatgtc 1560
atgacagatc aaaatcattt gatatccctt tctccattct aggtttttct ttttttcagt 1620
aactgattta ccttgatcac ttttcaactt ccatattctt catatagtaa aaggcaaagt 1680
gttgaagata ctacggtgtg gtagtagttg aaaattattg ccgtcattat ttacatactt 1740
aagacatatt agcaagtgtg tccaaaatgg gaggccttat agatgtgctt gggggaaaaa 1800
gaagggggaga aagtagccat acaggagttc aaagaattcc atgcccttca gattagccca 1860
attaccagaa acatcatgaa agatatttta aaaactaatt atttactaca gtgtatttca 1920
cttgtcttgt gtgtctgaac acacagaagc taattagcaa gtttttaaga agtattttaa 1980
aatcttacta ggattgacat tttttctgaa ttctgtataa atagcttata gtgagaagta 2040
ctgtgctcaa attttacatt tttttccttt gcaaattctg taatttcaact caacgattaa 2100
gtctaccaa gaacacactg catgtaaaag atgtattaca atctcaaagc cagtaaaaga 2160
aatcttgctt cactgttcac ctgctacaag taagagtttg gtgctggtag aaacatttga 2220

```

PF-0565 USN

ctctgatgtc tattttatctc tacataagag ccatatgtaa tgtactgtaa caaaggagct 2280  
 tcttgtcccc ttgggtctttt aattaaaaga aattccaact gactttttaa ctttaaaaaa 2340  
 aaaaaaa 2347

<210> 61  
 <211> 1737  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2843910

<400> 61  
 ccggggctga gcgctcgggt gcagcggcgc ggaggccgtc tccctgggtct gccgcgggtcc 60  
 ccgcccgtcc cgcgcgcggc tgccatggca ggagccggag ggttcgggtg ccccgcgggc 120  
 ggcaacgact tccagtgggtg cttctcgcag gtcaaggggg ccatcgacga ggacgtggcc 180  
 gaagcggaca tcatttccac cgttgagttt aattaactct gagatcttct tgcacacagga 240  
 gacaagggcg gcagagttgt tatttttcag cgtgaacaag agaataaaag ccgcctcat 300  
 tctagggggag aatataatgt ttacagcacc ttccaaagtc atgaaccgga gtttgactat 360  
 ttgaaaagtc tagaaattga ggaaaaaatt aataaaatta ggtgggttacc acaacagaat 420  
 gctgctcatt ttctactgtc tacaaatgat aaaactataa aattatggaa aataagtga 480  
 cgggataaaa gagcagaagg ttataacctg aaagacgaag atggaagact tcgagacca 540  
 tttaggatca cggcgctacg ggtcccaata ttgaagccca tggatcttat ggtagaagcg 600  
 agtccacggc gaatttttgc aaatgctcac acatatcata taaattccat ttcagtaa 660  
 agtgatcatg aaacatatct ttctgcagat gacctgagaa ttaatttatg gcacttagaa 720  
 atcacagata gaagctttaa catcgtggac atcaagcctg ctaacatgga ggagctgacc 780  
 aaagtcatca ctgcagccga gttccaccgc caccagtgcg acgtgttcgt ctacagcagt 840  
 agcaaaggga ccatccgcct gtgtgacatg cgtcctcgg cctgtgcga cagacactcc 900  
 agttttttgc aagagcctga agatcccagc agtaggtcct tcttctcaga aataatttca 960  
 tccatatccg atgtaaaatt cagtcatagt gggcggtaca tgatgaccag agactacctg 1020  
 tcgggtgaagg hgtgggacct caacatggag agcaggccgg tggagacca ccaggtccac 1080  
 pagtaactgc gcagcaagct ctgctctctc catgagaacg actgcattct tgacaagtct 1140  
 gagtgttctt ggaacgggtc ggatagcgcc atcatgaccg ggtcctataa caacttcttc 1200  
 aggatgtttg atagagacac gcggagggat gtgacctgg aggcctcgag agagagcagc 1260  
 aaaccgcygc ccagcctcaa accccggaag gtgtgtacgg ggggtaagcg gagaaagac 1320  
 jagatcagtg tggacagctt ggacttcaac aagaagatcc tgcacacagc tggcaccoc 1380  
 gtggacaatg tcattgccgt ggctgccacc aataacttgt acatattcca ggacaaaatc 1440  
 aactagagac gcgaacgtga ggaccaagtc ttgtcttgca tagttaagcc ggacattttt 1500  
 ctgtcagaga aaaggcatca ttgtccgctc cattaagaac agtgacgcac ctgctacttc 1560  
 ccttcacaga cacaggagaa agccgcctcc gctggaggcc cgggtgtggt ccgcctcggc 1620  
 gaggcgcgag acaggcgctg ctgctcacgt ggagacgctc tcgaagcaga gttgacggac 1680  
 actgctccca aaaggtcatt actcagaata aatgtattta tttcaaaaaa aaaaaaa 1737



WO 00/06728

PCT/US99/17132

## SEQUENCE LISTING

&lt;110&gt; INYCTE PHARMACEUTICALS, INC.

HILLMAN, Jennifer L.

LAL, Preeti

TANG, Y. Tom

CORLEY, Neil C.

GUEGLER, Karl J.

BAUGHN, Mariah R.

PATTERSON, Chandra

BANDMAN, Olga

AU-YOUNG, Janice

GORGONE, Gina A.

YUE, Henry

AZIMZAI, Yalda

REDDY, Roopa

LU, Dyung Aina M.

SHIH, Leo L.

&lt;120&gt; PHOSPHORYLATION EFFECTORS

&lt;130&gt; PF-0565 PCT

&lt;140&gt; To Be Assigned

&lt;141&gt; Herewith

<150> 09/123,494; unassigned; 09/152,814; unassigned; 09/173,482;  
unassigned;60/106,889; 60/109,093; 60/113,796;<151> 1998-07-28; 1998-07-28; 1998-09-14; 1998-09-14; 1998-10-14;  
1998-10-14;1998-11-03; 1998-11-19; 1998-12-22

&lt;160&gt; 61

&lt;170&gt; PERL Program

&lt;210&gt; 1

&lt;211&gt; 300

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 132240

&lt;400&gt; 1

Met	Glu	Ser	Pro	Leu	Glu	Ser	Gln	Pro	Leu	Asp	Ser	Asp	Arg	Ser
1				5					10					15
Ile	Lys	Glu	Ser	Ser	Phe	Glu	Glu	Ser	Asn	Ile	Glu	Asp	Pro	Leu
				20					25					30
Ile	Val	Thr	Pro	Asp	Cys	Gln	Glu	Lys	Thr	Ser	Pro	Lys	Gly	Val
				35					40					45
Glu	Asn	Pro	Ala	Val	Gln	Glu	Ser	Asn	Gln	Lys	Met	Leu	Gly	Pro
				50					55					60
Pro	Leu	Glu	Val	Leu	Lys	Thr	Leu	Ala	Ser	Lys	Arg	Asn	Ala	Val
				65					70					75

```

Ala Phe Arg Ser Phe Asn Ser His Ile Asn Ala Ser Asn Asn Ser
      80      85      90
Glu Pro Ser Arg Met Asn Met Thr Ser Leu Asp Ala Met Asp Ile
      95     100     105
Ser Cys Ala Tyr Ser Gly Ser Tyr Pro Met Ala Ile Thr Pro Thr
     110     115     120
Gln Lys Arg Arg Ser Cys Met Pro His Gln Thr Pro Asn Gln Ile
     125     130     135
Lys Ser Gly Thr Pro Tyr Arg Thr Pro Lys Ser Val Arg Arg Gly
     140     145     150
Val Ala Pro Val Asp Asp Gly Arg Ile Leu Gly Thr Pro Asp Tyr
     155     160     165
Leu Ala Pro Glu Leu Leu Leu Gly Arg Ala His Gly Pro Ala Val
     170     175     180
Asp Trp Trp Ala Leu Gly Val Cys Leu Phe Glu Phe Leu Thr Gly
     185     190     195
Ile Pro Pro Phe Asn Asp Glu Thr Pro Gln Gln Val Phe Gln Asn
     200     205     210
Ile Leu Lys Arg Asp Ile Pro Trp Pro Glu Gly Glu Glu Lys Leu
     215     220     225
Ser Asp Asn Ala Gln Ser Ala Val Glu Ile Leu Leu Thr Ile Asp
     230     235     240
Asp Thr Lys Arg Ala Gly Met Lys Glu Leu Lys Arg His Pro Leu
     245     250     255
Phe Ser Asp Val Asp Trp Glu Asn Leu Gln His Gln Thr Met Pro
     260     265     270
Phe Ile Pro Gln Pro Asp Asp Glu Thr Asp Thr Ser Tyr Phe Glu
     275     280     285
Ala Arg Asn Thr Ala Gln His Leu Thr Val Ser Gly Phe Ser Leu
     290     295     300

```

&lt;210&gt; 2

&lt;211&gt; 147

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2180116

&lt;400&gt; 2

```

Met Ala Ala Gln Arg Leu Gly Lys Arg Val Leu Ser Lys Leu Gln
  1      5      10      15
Ser Pro Ser Arg Ala Arg Gly Pro Gly Gly Ser Pro Gly Gly Met
     20     25     30
Gln Lys Arg His Ala Arg Val Thr Val Lys Tyr Asp Arg Arg Glu
     35     40     45
Leu Gln Arg Arg Leu Asp Val Glu Lys Trp Ile Asp Gly Arg Leu
     50     55     60
Glu Glu Leu Tyr Arg Gly Met Glu Ala Asp Met Pro Asp Glu Ile
     65     70     75
Asn Ile Asp Glu Leu Leu Glu Leu Glu Ser Glu Glu Glu Arg Ser
     80     85     90
Arg Lys Ile Gln Gly Leu Leu Lys Ser Cys Gly Lys Pro Val Glu
     95    100    105

```

WO 00/06728

PCT/US99/17132

Asp	Phe	Ile	Gln	Glu	Leu	Leu	Ala	Lys	Leu	Gln	Gly	Leu	His	Arg
				110					115					120
Gln	Pro	Gly	Leu	Arg	Gln	Pro	Ser	Pro	Ser	His	Asp	Gly	Ser	Leu
				125					130					135
Ser	Pro	Leu	Gln	Asp	Arg	Ala	Arg	Thr	Ala	His	Pro			
				140					145					

<210> 3  
 <211> 431  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 2197671

<400> 3

Met	Ala	His	Ser	Pro	Val	Gln	Ser	Gly	Leu	Pro	Gly	Met	Gln	Asn
1				5					10					15
Leu	Lys	Ala	Asp	Pro	Glu	Glu	Leu	Phe	Thr	Lys	Leu	Glu	Lys	Ile
				20					25					30
Gly	Lys	Gly	Ser	Phe	Gly	Glu	Val	Phe	Lys	Gly	Ile	Asp	Asn	Arg
				35					40					45
Thr	Gln	Lys	Val	Val	Ala	Ile	Lys	Ile	Ile	Asp	Leu	Glu	Glu	Ala
				50					55					60
Glu	Asp	Glu	Ile	Glu	Asp	Ile	Gln	Gln	Glu	Ile	Thr	Val	Leu	Ser
				65					70					75
Gln	Cys	Asp	Ser	Pro	Tyr	Val	Thr	Lys	Tyr	Tyr	Gly	Ser	Tyr	Leu
				80					85					90
Lys	Asp	Thr	Lys	Leu	Trp	Ile	Ile	Met	Glu	Tyr	Leu	Gly	Gly	Gly
				95					100					105
Ser	Ala	Leu	Asp	Leu	Leu	Glu	Pro	Gly	Arg	Leu	Asp	Glu	Thr	Gln
				110					115					120
Ile	Ala	Thr	Ile	Leu	Arg	Glu	Ile	Leu	Lys	Gly	Leu	Asp	Tyr	Leu
				125					130					135
His	Ser	Glu	Lys	Lys	Ile	His	Arg	Asp	Ile	Lys	Ala	Ala	Asn	Val
				140					145					150
Leu	Leu	Ser	Glu	His	Gly	Glu	Val	Lys	Leu	Ala	Asp	Phe	Gly	Val
				155					160					165
Ala	Gly	Gln	Leu	Thr	Asp	Thr	Gln	Ile	Lys	Arg	Asn	Thr	Phe	Val
				170					175					180
Gly	Thr	Pro	Phe	Trp	Met	Ala	Pro	Glu	Val	Ile	Lys	Gln	Ser	Ala
				185					190					195
Tyr	Asp	Ser	Lys	Ala	Asp	Ile	Trp	Ser	Leu	Gly	Ile	Thr	Ala	Ile
				200					205					210
Glu	Leu	Ala	Arg	Gly	Glu	Pro	Pro	His	Ser	Glu	Leu	His	Pro	Met
				215					220					225
Lys	Val	Leu	Phe	Leu	Ile	Pro	Lys	Asn	Asn	Pro	Pro	Thr	Leu	Glu
				230					235					240
Gly	Asn	Tyr	Ser	Lys	Pro	Leu	Lys	Glu	Phe	Val	Glu	Ala	Cys	Leu
				245					250					255
Asn	Lys	Glu	Pro	Ser	Phe	Arg	Pro	Thr	Ala	Lys	Glu	Leu	Leu	Lys
				260					265					270
His	Lys	Phe	Ile	Leu	Arg	Asn	Ala	Lys	Lys	Thr	Ser	Tyr	Leu	Thr
				275					280					285

WO 00/06728

PCT/US99/17132

Glu	Leu	Ile	Asp	Arg	Tyr	Lys	Arg	Trp	Lys	Ala	Glu	Gln	Ser	His
				290					295					300
Asp	Asp	Ser	Ser	Ser	Glu	Asp	Ser	Asp	Ala	Glu	Thr	Asp	Gly	Gln
				305					310					315
Ala	Ser	Gly	Gly	Ser	Asp	Ser	Gly	Asp	Trp	Ile	Phe	Thr	Ile	Arg
				320					325					330
Glu	Lys	Asp	Pro	Lys	Asn	Leu	Glu	Asn	Gly	Ala	Leu	Gln	Pro	Ser
				335					340					345
Asp	Leu	Asp	Arg	Asn	Lys	Met	Lys	Asp	Ile	Pro	Lys	Arg	Pro	Phe
				350					355					360
Ser	Gln	Cys	Leu	Ser	Thr	Ile	Ile	Ser	Pro	Leu	Phe	Ala	Glu	Leu
				365					370					375
Lys	Glu	Lys	Ser	Gln	Ala	Cys	Gly	Gly	Asn	Leu	Gly	Ser	Ile	Glu
				380					385					390
Glu	Leu	Arg	Gly	Ala	Ile	Tyr	Leu	Ala	Glu	Glu	Ala	Cys	Pro	Gly
				395					400					405
Ile	Ser	Asp	Thr	Met	Val	Ala	Gln	Leu	Val	Gln	Arg	Leu	Gln	Arg
				410					415					420
Tyr	Ser	Leu	Ser	Gly	Gly	Gly	Thr	Ser	Ser	His				
				425					430					

&lt;210&gt; 4

&lt;211&gt; 218

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2594943

&lt;400&gt; 4

Met	Asn	Cys	Arg	Ser	Glu	Val	Leu	Glu	Val	Ser	Val	Glu	Gly	Arg
1				5					10					15
Gln	Val	Glu	Glu	Ala	Met	Leu	Ala	Val	Leu	His	Thr	Val	Leu	Leu
				20					25					30
His	Arg	Ser	Thr	Gly	Lys	Phe	His	Tyr	Lys	Lys	Glu	Gly	Thr	Tyr
				35					40					45
Ser	Ile	Gly	Thr	Val	Gly	Thr	Gln	Asp	Val	Asp	Cys	Asp	Phe	Ile
				50					55					60
Asp	Phe	Thr	Tyr	Val	Arg	Val	Ser	Ser	Glu	Glu	Leu	Asp	Arg	Ala
				65					70					75
Leu	Arg	Lys	Val	Val	Gly	Glu	Phe	Lys	Asp	Ala	Leu	Arg	Asn	Ser
				80					85					90
Gly	Gly	Asp	Gly	Leu	Gly	Gln	Met	Ser	Leu	Glu	Phe	Tyr	Gln	Lys
				95					100					105
Lys	Lys	Ser	Arg	Trp	Pro	Phe	Ser	Asp	Glu	Cys	Ile	Pro	Trp	Glu
				110					115					120
Val	Trp	Thr	Val	Lys	Val	His	Val	Val	Ala	Leu	Ala	Thr	Glu	Gln
				125					130					135
Glu	Arg	Gln	Ile	Cys	Arg	Glu	Lys	Val	Gly	Glu	Lys	Leu	Cys	Glu
				140					145					150
Lys	Ile	Ile	Asn	Ile	Val	Glu	Val	Met	Asn	Arg	His	Glu	Tyr	Leu
				155					160					165
Pro	Lys	Met	Pro	Thr	Gln	Ser	Glu	Val	Asp	Asn	Val	Phe	Asp	Thr
				170					175					180

WO 00/06728

PCT/US99/17132

Gly	Leu	Arg	Asp	Val	Gln	Pro	Tyr	Leu	Tyr	Lys	Ile	Ser	Phe	Gln
				185					190					195
Ile	Thr	Asp	Ala	Leu	Gly	Thr	Ser	Val	Thr	Thr	Thr	Met	Arg	Arg
				200					205					210
Leu	Ile	Lys	Asp	Thr	Leu	Ala	Leu							
				215										

&lt;210&gt; 5

&lt;211&gt; 474

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1513871

&lt;400&gt; 5

Met	Ile	Met	Asn	Lys	Met	Lys	Asn	Phe	Lys	Arg	Arg	Phe	Ser	Leu
1				5					10					15
Ser	Val	Pro	Arg	Thr	Glu	Thr	Ile	Glu	Glu	Ser	Leu	Ala	Glu	Phe
				20					25					30
Thr	Glu	Gln	Phe	Asn	Gln	Leu	His	Asn	Arg	Arg	Asn	Glu	Asn	Leu
				35					40					45
Gln	Leu	Gly	Pro	Leu	Gly	Arg	Asp	Pro	Pro	Gln	Glu	Cys	Ser	Thr
				50					55					60
Phe	Ser	Pro	Thr	Asp	Ser	Gly	Glu	Glu	Pro	Gly	Gln	Leu	Ser	Pro
				65					70					75
Gly	Val	Gln	Phe	Gln	Arg	Arg	Gln	Asn	Gln	Arg	Arg	Phe	Ser	Met
				80					85					90
Glu	Asp	Val	Ser	Lys	Arg	Leu	Ser	Leu	Pro	Met	Asp	Ile	Arg	Leu
				95					100					105
Pro	Gln	Glu	Phe	Leu	Gln	Lys	Leu	Gln	Met	Glu	Ser	Pro	Asp	Leu
				110					115					120
Pro	Lys	Pro	Leu	Ser	Arg	Met	Ser	Arg	Arg	Ala	Ser	Leu	Ser	Asp
				125					130					135
Ile	Gly	Phe	Gly	Lys	Leu	Glu	Thr	Tyr	Val	Lys	Leu	Asp	Lys	Leu
				140					145					150
Gly	Glu	Gly	Thr	Tyr	Ala	Thr	Val	Phe	Lys	Gly	Arg	Ser	Lys	Leu
				155					160					165
Thr	Glu	Asn	Leu	Val	Ala	Leu	Lys	Glu	Ile	Arg	Leu	Glu	His	Glu
				170					175					180
Glu	Gly	Ala	Pro	Cys	Thr	Ala	Ile	Arg	Glu	Val	Ser	Leu	Leu	Lys
				185					190					195
Asn	Leu	Lys	His	Ala	Asn	Ile	Val	Thr	Leu	His	Asp	Leu	Ile	His
				200					205					210
Thr	Asp	Arg	Ser	Leu	Thr	Leu	Val	Phe	Glu	Tyr	Leu	Asp	Ser	Asp
				215					220					225
Leu	Lys	Gln	Tyr	Leu	Asp	His	Cys	Gly	Asn	Leu	Met	Ser	Met	His
				230					235					240
Asn	Val	Lys	Ile	Phe	Met	Phe	Gln	Leu	Leu	Arg	Gly	Leu	Ala	Tyr
				245					250					255
Cys	His	His	Arg	Lys	Ile	Leu	His	Arg	Asp	Leu	Lys	Pro	Gln	Asn
				260					265					270
Leu	Leu	Ile	Asn	Glu	Arg	Gly	Glu	Leu	Lys	Leu	Ala	Asp	Phe	Gly
				275					280					285

Leu Ala Arg Ala Lys Ser Val Pro Thr Lys Thr Tyr Ser Asn Glu  
 290 295 300  
 Val Val Thr Leu Trp Tyr Arg Pro Pro Asp Val Leu Leu Gly Ser  
 305 310 315  
 Thr Glu Tyr Ser Thr Pro Ile Asp Met Trp Gly Val Gly Cys Ile  
 320 325 330  
 His Tyr Glu Met Ala Thr Gly Arg Pro Leu Phe Pro Gly Ser Thr  
 335 340 345  
 Val Lys Glu Glu Leu His Leu Ile Phe Arg Leu Leu Gly Thr Pro  
 350 355 360  
 Thr Glu Glu Thr Trp Pro Gly Val Thr Ala Phe Ser Glu Phe Arg  
 365 370 375  
 Thr Tyr Ser Phe Pro Cys Tyr Leu Pro Gln Pro Leu Ile Asn His  
 380 385 390  
 Ala Pro Arg Leu Asp Thr Asp Gly Ile His Leu Leu Ser Ser Leu  
 395 400 405  
 Leu Leu Tyr Glu Ser Lys Ser Arg Met Ser Ala Glu Ala Ala Leu  
 410 415 420  
 Ser His Ser Tyr Phe Arg Ser Leu Gly Glu Arg Val His Gln Leu  
 425 430 435  
 Glu Asp Thr Ala Ser Ile Phe Ser Leu Lys Glu Ile Gln Leu Gln  
 440 445 450  
 Lys Asp Pro Gly Tyr Arg Gly Leu Ala Phe Gln Gln Pro Gly Arg  
 455 460 465  
 Gly Lys Asn Arg Arg Gln Ser Ile Phe  
 470

&lt;210&gt; 6

&lt;211&gt; 540

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 156108

&lt;400&gt; 6

Met Asn Gly Glu Ala Ile Cys Ser Ala Leu Pro Thr Ile Pro Tyr  
 1 5 10 15  
 His Lys Leu Ala Asp Leu Arg Tyr Leu Ser Arg Gly Ala Ser Gly  
 20 25 30  
 Thr Val Ser Ser Ala Arg His Ala Asp Trp Arg Val Gln Val Ala  
 35 40 45  
 Val Lys His Leu His Ile His Thr Pro Leu Leu Asp Ser Glu Arg  
 50 55 60  
 Lys Asp Val Leu Arg Glu Ala Glu Ile Leu His Lys Ala Arg Phe  
 65 70 75  
 Ser Tyr Ile Leu Pro Ile Leu Gly Ile Cys Asn Glu Pro Glu Phe  
 80 85 90  
 Leu Gly Ile Val Thr Glu Tyr Met Pro Asn Gly Ser Leu Asn Glu  
 95 100 105  
 Leu Leu His Arg Lys Thr Glu Tyr Pro Asp Val Ala Trp Pro Leu  
 110 115 120  
 Arg Phe Arg Ile Leu His Glu Ile Ala Leu Gly Val Asn Tyr Leu

WO 00/06728

PCT/US99/17132

				125					130				135	
His	Asn	Met	Thr	Pro	Pro	Leu	Leu	His	His	Asp	Leu	Lys	Thr	Gln
				140					145					150
Asn	Ile	Leu	Leu	Asp	Asn	Glu	Phe	His	Val	Lys	Ile	Ala	Asp	Phe
				155					160					165
Gly	Leu	Ser	Lys	Trp	Arg	Met	Met	Ser	Leu	Ser	Gln	Ser	Arg	Ser
				170					175					180
Ser	Lys	Ser	Ala	Pro	Glu	Gly	Gly	Thr	Ile	Ile	Tyr	Met	Pro	Pro
				185					190					195
Glu	Asn	Tyr	Glu	Pro	Gly	Gln	Lys	Ser	Arg	Ala	Ser	Ile	Lys	His
				200					205					210
Asp	Ile	Tyr	Ser	Tyr	Ala	Val	Ile	Thr	Trp	Glu	Val	Leu	Ser	Arg
				215					220					225
Lys	Gln	Pro	Phe	Glu	Asp	Val	Thr	Asn	Pro	Leu	Gln	Ile	Met	Tyr
				230					235					240
Ser	Val	Ser	Gln	Gly	His	Arg	Pro	Val	Ile	Asn	Glu	Glu	Ser	Leu
				245					250					255
Pro	Tyr	Asp	Ile	Pro	His	Arg	Ala	Arg	Met	Ile	Ser	Leu	Ile	Glu
				260					265					270
Ser	Gly	Trp	Ala	Gln	Asn	Pro	Asp	Glu	Arg	Pro	Ser	Phe	Leu	Lys
				275					280					285
Cys	Leu	Ile	Glu	Leu	Glu	Pro	Val	Leu	Arg	Thr	Phe	Glu	Glu	Ile
				290					295					300
Thr	Phe	Leu	Glu	Ala	Val	Ile	Gln	Leu	Lys	Lys	Thr	Lys	Leu	Gln
				305					310					315
Ser	Val	Ser	Ser	Ala	Ile	His	Leu	Cys	Asp	Lys	Lys	Lys	Met	Glu
				320					325					330
Leu	Ser	Leu	Asn	Ile	Pro	Val	Asn	His	Gly	Pro	Gln	Glu	Glu	Ser
				335					340					345
Cys	Gly	Ser	Ser	Gln	Leu	His	Glu	Asn	Ser	Gly	Ser	Pro	Glu	Thr
				350					355					360
Ser	Arg	Ser	Leu	Pro	Ala	Pro	Gln	Asp	Asn	Asp	Phe	Leu	Ser	Arg
				365					370					375
Lys	Ala	Gln	Asp	Cys	Tyr	Phe	Met	Lys	Leu	His	His	Cys	Pro	Gly
				380					385					390
Asn	His	Ser	Trp	Asp	Ser	Thr	Ile	Ser	Gly	Ser	Gln	Arg	Ala	Ala
				395					400					405
Phe	Cys	Asp	His	Lys	Thr	Thr	Pro	Cys	Ser	Ser	Ala	Ile	Ile	Asn
				410					415					420
Pro	Leu	Ser	Thr	Ala	Gly	Asn	Ser	Glu	Arg	Leu	Gln	Pro	Gly	Ile
				425					430					435
Ala	Gln	Gln	Trp	Ile	Gln	Ser	Lys	Arg	Glu	Asp	Ile	Val	Asn	Gln
				440					445					450
Met	Thr	Glu	Ala	Cys	Leu	Asn	Gln	Ser	Leu	Asp	Ala	Leu	Leu	Ser
				455					460					465
Arg	Asp	Leu	Ile	Met	Lys	Glu	Asp	Tyr	Glu	Leu	Val	Ser	Thr	Lys
				470					475					480
Pro	Thr	Arg	Thr	Ser	Lys	Val	Arg	Gln	Leu	Leu	Asp	Thr	Thr	Asp
				485					490					495
Ile	Gln	Gly	Glu	Glu	Phe	Ala	Lys	Val	Ile	Val	Gln	Lys	Leu	Lys
				500					505					510
Asp	Asn	Lys	Gln	Met	Gly	Leu	Gln	Pro	Tyr	Pro	Glu	Ile	Leu	Val
				515					520					525
Val	Ser	Arg	Ser	Pro	Ser	Leu	Asn	Leu	Leu	Gln	Asn	Lys	Ser	Met
				530					535					540

WO 00/06728

PCT/US99/17132

<210> 7  
 <211> 454  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 2883243

<400> 7  
 Met Tyr Asn Thr Val Trp Asn Met Glu Asp Leu Asp Leu Glu Tyr  
 1 5 10 15  
 Ala Lys Thr Asp Ile Asn Cys Gly Thr Asp Leu Met Phe Tyr Ile  
 20 25 30  
 Glu Met Asp Pro Pro Ala Leu Pro Pro Lys Pro Pro Lys Pro Thr  
 35 40 45  
 Thr Val Ala Asn Asn Gly Met Asn Asn Asn Met Ser Leu Gln Asp  
 50 55 60  
 Ala Glu Trp Tyr Trp Gly Asp Ile Ser Arg Glu Glu Val Asn Glu  
 65 70 75  
 Lys Leu Arg Asp Thr Ala Asp Gly Thr Phe Leu Val Arg Asp Ala  
 80 85 90  
 Ser Thr Lys Met His Gly Asp Tyr Thr Leu Thr Leu Arg Lys Gly  
 95 100 105  
 Gly Asn Asn Lys Leu Ile Lys Ile Phe His Arg Asp Gly Lys Tyr  
 110 115 120  
 Gly Phe Ser Asp Pro Leu Thr Phe Ser Ser Val Val Glu Leu Ile  
 125 130 135  
 Asn His Tyr Arg Asn Glu Ser Leu Ala Gln Tyr Asn Pro Lys Leu  
 140 145 150  
 Asp Val Lys Leu Leu Tyr Pro Val Ser Lys Tyr Gln Gln Asp Gln  
 155 160 165  
 Val Val Lys Glu Asp Asn Ile Glu Ala Val Gly Lys Lys Leu His  
 170 175 180  
 Glu Tyr Asn Thr Gln Phe Gln Glu Lys Ser Arg Glu Tyr Asp Arg  
 185 190 195  
 Leu Tyr Glu Glu Tyr Thr Arg Thr Ser Gln Glu Ile Gln Met Lys  
 200 205 210  
 Arg Thr Ala Ile Glu Ala Phe Asn Glu Thr Ile Lys Ile Phe Glu  
 215 220 225  
 Glu Gln Cys Gln Thr Gln Glu Arg Tyr Ser Lys Glu Tyr Ile Glu  
 230 235 240  
 Lys Phe Lys Arg Glu Gly Asn Glu Lys Glu Ile Gln Arg Ile Met  
 245 250 255  
 His Asn Tyr Asp Lys Leu Lys Ser Arg Ile Ser Glu Ile Ile Asp  
 260 265 270  
 Ser Arg Arg Arg Leu Glu Glu Asp Leu Lys Lys Gln Ala Ala Glu  
 275 280 285  
 Tyr Arg Glu Ile Asp Lys Arg Met Asn Ser Ile Lys Pro Asp Leu  
 290 295 300  
 Ile Gln Leu Arg Lys Thr Arg Asp Gln Tyr Leu Met Trp Leu Thr  
 305 310 315  
 Gln Lys Gly Val Arg Gln Lys Lys Leu Asn Glu Trp Leu Gly Asn  
 320 325 330  
 Glu Asn Thr Glu Asp Gln Tyr Ser Leu Val Glu Asp Asp Glu Asp  
 335 340 345



WO 00/06728

PCT/US99/17132

Leu Pro His His Asp Glu Lys Thr Trp Asn Val Gly Ser Ser Asn  
 350 355 360  
 Arg Asn Lys Ala Glu Asn Leu Leu Arg Gly Lys Arg Asp Gly Thr  
 365 370 375  
 Phe Leu Val Arg Glu Ser Ser Lys Gln Gly Cys Tyr Ala Cys Ser  
 380 385 390  
 Val Val Val Asp Gly Glu Val Lys His Cys Val Ile Asn Lys Thr  
 395 400 405  
 Ala Thr Gly Tyr Gly Phe Ala Glu Pro Tyr Asn Leu Tyr Ser Ser  
 410 415 420  
 Leu Lys Glu Leu Val Leu His Tyr Gln His Thr Ser Leu Val Gln  
 425 430 435  
 His Asn Asp Ser Leu Asn Val Thr Leu Ala Tyr Pro Val Tyr Ala  
 440 445 450  
 Gln Gln Arg Arg

&lt;210&gt; 8

&lt;211&gt; 502

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 3173355

&lt;400&gt; 8

Met Phe Gly Thr Leu Leu Leu Tyr Cys Phe Phe Leu Ala Thr Val  
 1 5 10 15  
 Pro Ala Leu Ala Glu Thr Gly Gly Glu Arg Gln Leu Ser Pro Glu  
 20 25 30  
 Lys Ser Glu Ile Trp Gly Pro Gly Leu Lys Ala Asp Val Val Leu  
 35 40 45  
 Pro Ala Arg Tyr Phe Tyr Ile Gln Ala Val Asp Thr Ser Gly Asn  
 50 55 60  
 Lys Phe Thr Ser Ser Pro Gly Glu Lys Val Phe Gln Val Lys Val  
 65 70 75  
 Ser Ala Pro Glu Glu Gln Phe Thr Arg Val Gly Val Gln Val Leu  
 80 85 90  
 Asp Arg Lys Asp Gly Ser Phe Ile Val Arg Tyr Arg Met Tyr Ala  
 95 100 105  
 Ser Tyr Lys Asn Leu Lys Val Glu Ile Lys Phe Gln Gly Gln His  
 110 115 120  
 Val Ala Lys Ser Pro Tyr Ile Leu Lys Gly Pro Val Tyr His Glu  
 125 130 135  
 Asn Cys Asp Cys Pro Leu Gln Asp Ser Ala Ala Trp Leu Arg Glu  
 140 145 150  
 Met Asn Cys Pro Glu Thr Ile Ala Gln Ile Gln Arg Asp Leu Ala  
 155 160 165  
 His Phe Pro Ala Val Asp Pro Glu Lys Ile Ala Val Glu Ile Pro  
 170 175 180  
 Lys Arg Phe Gly Gln Arg Gln Ser Leu Cys His Tyr Thr Leu Lys  
 185 190 195  
 Asp Asn Lys Val Tyr Ile Lys Thr His Gly Glu His Val Gly Phe  
 200 205 210  
 Arg Ile Phe Met Asp Ala Ile Leu Leu Ser Leu Thr Arg Lys Val

215 220 225  
 Lys Met Pro Asp Val Glu Leu Phe Val Asn Leu Gly Asp Trp Pro  
 230 235 240  
 Leu Glu Lys Lys Lys Ser Asn Ser Asn Ile His Pro Ile Phe Ser  
 245 250 255  
 Trp Cys Gly Ser Thr Asp Ser Lys Asp Ile Val Met Pro Thr Tyr  
 260 265 270  
 Asp Leu Thr Asp Ser Val Leu Glu Thr Met Gly Arg Val Ser Leu  
 275 280 285  
 Asp Met Met Ser Val Gln Ala Asn Thr Gly Pro Pro Trp Glu Ser  
 290 295 300  
 Lys Asn Ser Thr Ala Val Trp Arg Gly Arg Asp Ser Arg Lys Glu  
 305 310 315  
 Arg Leu Glu Leu Val Lys Leu Ser Arg Lys His Pro Glu Leu Ile  
 320 325 330  
 Asp Ala Ala Phe Thr Asn Phe Phe Phe Phe Lys His Asp Glu Asn  
 335 340 345  
 Leu Tyr Gly Pro Ile Val Lys His Ile Ser Phe Phe Asp Phe Phe  
 350 355 360  
 Lys His Lys Tyr Gln Ile Asn Ile Asp Gly Thr Val Ala Ala Tyr  
 365 370 375  
 Arg Leu Pro Tyr Leu Leu Val Gly Asp Ser Val Val Leu Lys Gln  
 380 385 390  
 Asp Ser Ile Tyr Tyr Glu His Phe Tyr Asn Glu Leu Gln Pro Trp  
 395 400 405  
 Lys His Tyr Ile Pro Val Lys Ser Asn Leu Ser Asp Leu Leu Glu  
 410 415 420  
 Lys Leu Lys Trp Ala Lys Asp His Asp Glu Glu Ala Lys Lys Ile  
 425 430 435  
 Ala Lys Ala Gly Gln Glu Phe Ala Arg Asn Asn Leu Met Gly Asp  
 440 445 450  
 Asp Ile Phe Cys Tyr Tyr Phe Lys Leu Phe Gln Glu Tyr Ala Asn  
 455 460 465  
 Leu Gln Val Ser Glu Pro Gln Ile Arg Glu Gly Met Lys Arg Val  
 470 475 480  
 Glu Pro Gln Thr Glu Asp Asp Leu Phe Pro Cys Thr Cys His Arg  
 485 490 495  
 Lys Lys Thr Lys Asp Glu Leu  
 500

&lt;210&gt; 9

&lt;211&gt; 282

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 5116906

&lt;400&gt; 9

Met Trp Ala Cys Gly Val Ile Leu Tyr Ile Leu Leu Val Gly Tyr  
 1 5 10 15  
 Pro Pro Phe Trp Asp Glu Asp Gln His Arg Leu Tyr Gln Gln Ile  
 20 25 30  
 Lys Ala Gly Ala Tyr Asp Phe Pro Ser Pro Glu Trp Asp Thr Val  
 35 40 45

WO 00/06728

PCT/US99/17132

```

Thr Pro Glu Ala Lys Asp Leu Ile Asn Lys Met Leu Thr Ile Asn
      50              55              60
Pro Ala Lys Arg Ile Thr Ala Ser Glu Ala Leu Lys His Pro Trp
      65              70              75
Ile Cys Gln Arg Ser Thr Val Ala Ser Met Met His Arg Gln Glu
      80              85              90
Thr Val Asp Cys Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu Lys
      95              100             105
Gly Ala Ile Leu Thr Thr Met Leu Ala Thr Arg Asn Phe Ser Ala
      110             115             120
Ala Lys Ser Leu Leu Lys Lys Pro Asp Gly Val Lys Glu Ser Thr
      125             130             135
Glu Ser Ser Asn Thr Thr Ile Glu Asp Glu Asp Val Lys Ala Arg
      140             145             150
Lys Gln Glu Ile Ile Lys Val Thr Glu Gln Leu Ile Glu Ala Ile
      155             160             165
Asn Asn Gly Asp Phe Glu Ala Tyr Thr Lys Ile Cys Asp Pro Gly
      170             175             180
Leu Thr Ala Phe Glu Pro Glu Ala Leu Gly Asn Leu Val Glu Gly
      185             190             195
Met Asp Phe His Arg Phe Tyr Phe Glu Asn Ala Leu Ser Lys Ser
      200             205             210
Asn Lys Pro Ile His Thr Ile Ile Leu Asn Pro His Val His Leu
      215             220             225
Val Gly Asp Asp Ala Ala Cys Ile Ala Tyr Ile Arg Leu Thr Gln
      230             235             240
Tyr Met Asp Gly Ser Gly Met Pro Lys Thr Met Gln Ser Glu Glu
      245             250             255
Thr Arg Val Trp His Arg Arg Asp Gly Lys Trp Gln Asn Val His
      260             265             270
Phe His Arg Ser Gly Ser Pro Thr Val Pro Ile Asn
      275             280

```

&lt;210&gt; 10

&lt;211&gt; 510

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 940589

&lt;400&gt; 10

```

Met Lys Ala Asp Ile Lys Ile Trp Ile Leu Thr Gly Asp Lys Gln
  1              5              10             15
Glu Thr Ala Ile Asn Ile Gly His Ser Cys Lys Leu Leu Lys Lys
      20              25             30
Asn Met Gly Met Ile Val Ile Asn Glu Gly Ser Leu Asp Ser Phe
      35              40             45
Ser Asn Thr Gln Asn Ser Arg Lys Glu Ala Val Leu Leu Ala Lys
      50              55             60
Met Lys His Pro Asn Ile Val Ala Phe Lys Glu Ser Phe Glu Ala
      65              70             75
Glu Gly His Leu Tyr Ile Val Met Glu Tyr Cys Asp Gly Gly Asp
      80              85             90

```

WO 00/06728

PCT/US99/17132

Leu Met Gln Lys Ile Lys Gln Gln Lys Gly Lys Leu Phe Pro Glu	95	100	105
Asp Met Ile Leu Asn Trp Phe Thr Gln Met Cys Leu Gly Val Asn	110	115	120
His Ile His Lys Lys Arg Val Leu His Arg Asp Ile Lys Ser Lys	125	130	135
Asn Ile Phe Leu Thr Gln Asn Gly Lys Val Lys Leu Gly Asp Phe	140	145	150
Gly Ser Ala Arg Leu Leu Ser Asn Pro Met Ala Phe Ala Cys Thr	155	160	165
Tyr Val Gly Thr Pro Tyr Tyr Val Pro Pro Glu Ile Trp Glu Asn	170	175	180
Leu Pro Tyr Asn Asn Lys Ser Asp Ile Trp Ser Leu Gly Cys Ile	185	190	195
Leu Tyr Glu Leu Cys Thr Leu Lys His Pro Phe Gln Ala Asn Ser	200	205	210
Trp Lys Asn Leu Ile Leu Lys Val Cys Gln Gly Cys Ile Ser Pro	215	220	225
Leu Pro Ser His Tyr Ser Tyr Glu Leu Gln Phe Leu Val Lys Gln	230	235	240
Met Phe Lys Arg Asn Pro Ser His Arg Pro Ser Ala Thr Thr Leu	245	250	255
Leu Ser Arg Gly Ile Val Ala Arg Leu Val Gln Lys Cys Leu Pro	260	265	270
Pro Glu Ile Ile Met Glu Tyr Gly Glu Glu Val Leu Glu Glu Ile	275	280	285
Lys Asn Ser Lys His Asn Thr Pro Arg Lys Lys Thr Asn Pro Ser	290	295	300
Arg Ile Arg Ile Ala Leu Gly Asn Glu Ala Ser Thr Val Gln Glu	305	310	315
Glu Glu Gln Asp Arg Lys Gly Ser His Thr Asp Leu Glu Ser Ile	320	325	330
Asn Glu Asn Leu Val Glu Ser Ala Leu Arg Arg Val Asn Arg Glu	335	340	345
Glu Lys Gly Asn Lys Ser Val His Leu Arg Lys Ala Ser Ser Pro	350	355	360
Asn Leu His Arg Arg Gln Trp Glu Lys Asn Val Pro Asn Thr Ala	365	370	375
Leu Thr Ala Leu Glu Asn Ala Ser Ile Leu Thr Ser Ser Leu Thr	380	385	390
Ala Glu Asp Asp Arg Gly Gly Ser Val Ile Lys Tyr Ser Lys Asn	395	400	405
Thr Thr Arg Lys Gln Trp Leu Lys Glu Thr Pro Asp Thr Leu Leu	410	415	420
Asn Ile Leu Lys Asn Ala Asp Leu Ser Leu Ala Phe Gln Thr Tyr	425	430	435
Thr Ile Tyr Arg Pro Gly Ser Glu Gly Phe Leu Lys Gly Pro Leu	440	445	450
Ser Glu Glu Thr Glu Ala Ser Asp Ser Val Asp Gly Gly His Asp	455	460	465
Ser Val Ile Leu Asp Pro Glu Arg Leu Glu Pro Gly Leu Asp Glu	470	475	480
Glu Asp Thr Asp Phe Glu Glu Glu Asp Asp Asn Pro Asp Trp Val	485	490	495
Ser Glu Leu Lys Lys Arg Ala Gly Trp Gln Gly Leu Cys Asp Arg	500	505	510

WO 00/06728

PCT/US99/17132

<210> 11  
 <211> 248  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 304421

<400> 11  
 Met Ala Glu Thr Ser Leu Pro Glu Leu Gly Gly Glu Asp Lys Ala  
 1 5 10 15  
 Thr Pro Cys Pro Ser Ile Leu Glu Leu Glu Glu Leu Leu Arg Ala  
 20 25 30  
 Gly Lys Ser Ser Cys Ser Arg Val Asp Glu Val Trp Pro Asn Leu  
 35 40 45  
 Phe Ile Gly Asp Ala Met Asp Ser Leu Gln Lys Gln Asp Leu Arg  
 50 55 60  
 Arg Pro Lys Ile His Gly Ala Val Gln Ala Ser Pro Tyr Gln Pro  
 65 70 75  
 Pro Thr Leu Ala Ser Leu Gln Arg Leu Leu Trp Val Arg Gln Ala  
 80 85 90  
 Ala Thr Leu Asn His Ile Asp Glu Val Trp Pro Ser Leu Phe Leu  
 95 100 105  
 Gly Asp Ala Tyr Ala Ala Arg Asp Lys Ser Lys Leu Ile Gln Leu  
 110 115 120  
 Gly Ile Thr His Val Val Asn Ala Ala Ala Gly Lys Phe Gln Val  
 125 130 135  
 Asp Thr Gly Ala Lys Phe Tyr Arg Gly Met Ser Leu Glu Tyr Tyr  
 140 145 150  
 Gly Ile Glu Ala Asp Asp Asn Pro Phe Phe Asp Leu Ser Val Tyr  
 155 160 165  
 Phe Leu Pro Val Ala Arg Tyr Ile Arg Ala Ala Leu Ser Val Pro  
 170 175 180  
 Gln Gly Arg Val Leu Val His Cys Ala Met Gly Val Ser Arg Ser  
 185 190 195  
 Ala Thr Leu Val Leu Ala Phe Leu Met Ile Tyr Glu Asn Met Thr  
 200 205 210  
 Leu Val Glu Ala Ile Gln Thr Val Gln Ala His Arg Asn Ile Cys  
 215 220 225  
 Pro Asn Ser Gly Phe Leu Arg Gln Leu Gln Val Leu Asp Asn Arg  
 230 235 240  
 Leu Gly Arg Glu Thr Gly Arg Phe  
 245

<210> 12  
 <211> 810  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 1213802

WO 00/06728

PCT/US99/17132

&lt;400&gt; 12

Met	Pro	Asn	Gln	Gly	Glu	Asp	Cys	Tyr	Phe	Phe	Phe	Tyr	Ser	Thr
1				5					10					15
Cys	Thr	Lys	Gly	Asp	Ser	Cys	Pro	Phe	Arg	His	Cys	Glu	Ala	Ala
			20						25					30
Ile	Gly	Asn	Glu	Thr	Val	Cys	Thr	Leu	Trp	Gln	Glu	Gly	Arg	Cys
			35						40					45
Phe	Arg	Gln	Val	Cys	Arg	Phe	Arg	His	Met	Glu	Ile	Asp	Lys	Lys
			50						55					60
Arg	Ser	Glu	Ile	Pro	Cys	Tyr	Trp	Glu	Asn	Gln	Pro	Thr	Gly	Cys
			65						70					75
Gln	Lys	Leu	Asn	Cys	Ala	Phe	His	His	Asn	Arg	Gly	Arg	Tyr	Val
			80						85					90
Asp	Gly	Leu	Phe	Leu	Pro	Pro	Ser	Lys	Thr	Val	Leu	Pro	Thr	Val
			95						100					105
Pro	Glu	Ser	Pro	Glu	Glu	Val	Lys	Ala	Ser	Gln	Leu	Ser	Val	
			110						115					120
Gln	Gln	Asn	Lys	Leu	Ser	Val	Gln	Ser	Asn	Pro	Ser	Pro	Gln	Leu
			125						130					135
Arg	Ser	Val	Met	Lys	Val	Glu	Ser	Ser	Glu	Asn	Val	Pro	Ser	Pro
			140						145					150
Thr	His	Pro	Pro	Val	Val	Ile	Asn	Ala	Ala	Asp	Asp	Asp	Glu	Asp
			155						160					165
Asp	Asp	Asp	Gln	Phe	Ser	Glu	Glu	Gly	Asp	Glu	Thr	Lys	Thr	Pro
			170						175					180
Thr	Leu	Gln	Pro	Thr	Pro	Glu	Val	His	Asn	Gly	Leu	Arg	Val	Thr
			185						190					195
Ser	Val	Arg	Lys	Pro	Ala	Val	Asn	Ile	Lys	Gln	Gly	Glu	Cys	Leu
			200						205					210
Asn	Phe	Gly	Ile	Lys	Thr	Leu	Glu	Glu	Ile	Lys	Ser	Lys	Lys	Met
			215						220					225
Lys	Glu	Lys	Ser	Lys	Lys	Gln	Gly	Glu	Gly	Ser	Ser	Gly	Val	Ser
			230						235					240
Ser	Leu	Leu	Leu	His	Pro	Glu	Pro	Val	Pro	Gly	Pro	Glu	Lys	Glu
			245						250					255
Asn	Val	Arg	Thr	Val	Val	Arg	Thr	Val	Thr	Leu	Ser	Thr	Lys	Gln
			260						265					270
Gly	Glu	Glu	Pro	Leu	Val	Arg	Leu	Ser	Leu	Thr	Glu	Arg	Leu	Gly
			275						280					285
Lys	Arg	Lys	Phe	Ser	Ala	Gly	Gly	Asp	Ser	Asp	Pro	Pro	Leu	Lys
			290						295					300
Arg	Ser	Leu	Ala	Gln	Arg	Leu	Gly	Lys	Lys	Val	Glu	Ala	Pro	Glu
			305						310					315
Thr	Asn	Ile	Asp	Lys	Thr	Pro	Lys	Lys	Ala	Gln	Val	Ser	Lys	Ser
			320						325					330
Leu	Lys	Glu	Arg	Leu	Gly	Met	Ser	Ala	Asp	Pro	Asp	Asn	Glu	Asp
			335						340					345
Ala	Thr	Asp	Lys	Val	Asn	Lys	Val	Gly	Glu	Ile	His	Val	Lys	Thr
			350						355					360
Leu	Glu	Glu	Ile	Leu	Leu	Glu	Arg	Ala	Ser	Gln	Lys	Arg	Gly	Glu
			365						370					375
Leu	Gln	Thr	Lys	Leu	Lys	Thr	Glu	Gly	Pro	Ser	Lys	Thr	Asp	Asp
			380						385					390
Ser	Thr	Ser	Gly	Ala	Arg	Ser	Ser	Ser	Thr	Ile	Arg	Ile	Lys	Thr
			395						400					405
Phe	Ser	Glu	Val	Leu	Ala	Glu	Lys	Lys	His	Arg	Gln	Gln	Glu	Ala

WO 00/06728

PCT/US99/17132

	410		415		420
Glu Arg Gln Lys	Ser Lys Lys Asp Thr	Thr Cys Ile Lys Leu	Lys		
	425		430		435
Ile Asp Ser Glu	Ile Lys Lys Thr Val	Val Leu Pro Pro Ile	Val		
	440		445		450
Ala Ser Arg Gly	Gln Ser Glu Glu Pro	Ala Gly Lys Thr Lys	Ser		
	455		460		465
Met Gln Glu Val	His Ile Lys Thr Leu	Glu Glu Ile Lys Leu	Glu		
	470		475		480
Lys Ala Leu Arg	Val Gln Gln Ser Ser	Glu Ser Ser Thr Ser	Ser		
	485		490		495
Pro Ser Gln His	Glu Ala Thr Pro Gly	Ala Arg Arg Leu Leu	Arg		
	500		505		510
Ile Thr Lys Arg	Thr Gly Met Lys Glu	Glu Lys Asn Leu Gln	Glu		
	515		520		525
Gly Asn Glu Val	Asp Ser Gln Ser Ser	Ile Arg Thr Glu Ala	Lys		
	530		535		540
Glu Ala Ser Gly	Glu Thr Thr Gly Val	Asp Ile Thr Lys Ile	Gln		
	545		550		555
Val Lys Arg Cys	Glu Thr Met Arg Glu	Lys His Met Gln Lys	Gln		
	560		565		570
Gln Glu Arg Glu	Lys Ser Val Leu Thr	Pro Leu Arg Gly Asp	Val		
	575		580		585
Ala Ser Cys Asn	Thr Gln Val Ala Glu	Lys Pro Val Leu Thr	Ala		
	590		595		600
Val Pro Gly Ile	Thr Arg His Leu Thr	Lys Arg Leu Pro Thr	Lys		
	605		610		615
Ser Ser Gln Lys	Val Glu Val Glu Thr	Ser Gly Ile Gly Asp	Ser		
	620		625		630
Leu Leu Asn Val	Lys Cys Ala Ala Gln	Thr Leu Glu Lys Arg	Gly		
	635		640		645
Lys Ala Lys Pro	Lys Val Asn Val Lys	Pro Ser Val Val Lys	Val		
	650		655		660
Val Ser Ser Pro	Lys Leu Ala Pro Lys	Arg Lys Ala Val Glu	Met		
	665		670		675
His Ala Ala Val	Ile Ala Ala Val Lys	Pro Leu Ser Ser Ser	Ser		
	680		685		690
Val Leu Gln Glu	Pro Pro Ala Lys Lys	Ala Ala Val Ala Val	Val		
	695		700		705
Pro Leu Val Ser	Glu Asp Lys Ser Val	Thr Val Pro Glu Ala	Glu		
	710		715		720
Asn Pro Arg Asp	Ser Leu Val Leu Pro	Pro Thr Gln Ser Ser	Ser		
	725		730		735
Asp Ser Ser Pro	Pro Glu Val Ser Gly	Pro Ser Ser Ser Gln	Met		
	740		745		750
Ser Met Lys Thr	Arg Arg Leu Ser Ser	Ala Ser Thr Gly Lys	Pro		
	755		760		765
Pro Leu Ser Val	Glu Asp Asp Phe Glu	Lys Leu Ile Trp Glu	Ile		
	770		775		780
Ser Gly Gly Lys	Leu Glu Ala Glu Ile	Asp Leu Asp Pro Gly	Lys		
	785		790		795
Asp Glu Asp Asp	Leu Leu Leu Glu Leu	Ser Glu Met Ile Asp	Ser		
	800		805		810

&lt;210&gt; 13

WO 00/06728

PCT/US99/17132

&lt;211&gt; 549

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1378134

&lt;400&gt; 13

```

Met Arg Arg Arg Ala Ser Asn Ala Ala Ala Ala Ala His Thr Ile
  1          5          10          15
Gly Gly Ser Lys His Thr Met Asn Asp His Leu His Val Gly Ser
          20          25          30
His Ala His Gly Gln Ile Gln Val Arg Gln Leu Phe Glu Asp Asn
          35          40          45
Ser Asn Lys Arg Thr Val Leu Thr Thr Gln Pro Asn Gly Leu Thr
          50          55          60
Thr Val Gly Lys Thr Gly Leu Pro Val Val Pro Glu Arg Gln Leu
          65          70          75
Asp Ser Ile His Arg Arg Gln Gly Ser Ser Thr Ser Leu Lys Ser
          80          85          90
Met Glu Gly Met Gly Lys Val Lys Ala Thr Pro Met Thr Pro Glu
          95          100          105
Gln Ala Met Lys Gln Tyr Met Gln Lys Leu Thr Ala Phe Glu His
          110          115          120
His Glu Ile Phe Ser Tyr Pro Glu Ile Tyr Phe Leu Gly Leu Asn
          125          130          135
Ala Lys Lys Arg Gln Gly Met Thr Gly Gly Pro Asn Asn Gly Gly
          140          145          150
Tyr Asp Asp Asp Gln Gly Ser Tyr Val Gln Val Pro His Asp His
          155          160          165
Val Ala Tyr Arg Tyr Glu Val Leu Lys Val Ile Gly Lys Gly Ser
          170          175          180
Phe Gly Gln Val Val Lys Ala Tyr Asp His Lys Val His Gln His
          185          190          195
Val Ala Leu Lys Met Val Arg Asn Glu Lys Arg Phe His Arg Gln
          200          205          210
Ala Ala Glu Glu Ile Arg Ile Leu Glu His Leu Arg Lys Gln Asp
          215          220          225
Lys Asp Asn Thr Met Asn Val Ile His Met Leu Glu Asn Phe Thr
          230          235          240
Phe Arg Asn His Ile Cys Met Thr Phe Glu Leu Leu Ser Met Asn
          245          250          255
Leu Tyr Glu Leu Ile Lys Lys Asn Lys Phe Gln Gly Phe Ser Leu
          260          265          270
Pro Leu Val Arg Lys Phe Ala His Ser Ile Leu Gln Cys Leu Asp
          275          280          285
Ala Leu His Lys Asn Arg Ile Ile His Cys Asp Leu Lys Pro Glu
          290          295          300
Asn Ile Leu Leu Lys Gln Gln Gly Arg Ser Gly Ile Lys Val Ile
          305          310          315
Asp Phe Gly Ser Ser Cys Tyr Glu His Gln Arg Val Tyr Thr Tyr
          320          325          330
Ile Gln Ser Arg Phe Tyr Arg Ala Pro Glu Val Ile Leu Gly Ala
          335          340          345
Arg Tyr Gly Met Pro Ile Asp Met Trp Ser Leu Gly Cys Ile Leu

```



WO 00/06728

PCT/US99/17132

350	355	360
Ala Glu Leu Leu Thr Gly Tyr Pro Leu	Leu Pro Gly Glu Asp Glu	
365	370	375
Gly Asp Gln Leu Ala Cys Met Ile Glu	Leu Leu Gly Met Pro Ser	
380	385	390
Gln Lys Leu Leu Asp Ala Ser Lys Arg	Ala Lys Asn Phe Val Ser	
395	400	405
Ser Lys Gly Tyr Pro Arg Tyr Cys Thr	Val Thr Thr Leu Ser Asp	
410	415	420
Gly Ser Val Val Leu Asn Gly Gly Arg	Ser Arg Arg Gly Lys Leu	
425	430	435
Arg Gly Pro Pro Glu Ser Arg Glu Trp	Gly Asn Ala Leu Lys Gly	
440	445	450
Cys Asp Asp Pro Leu Phe Leu Asp Phe	Leu Lys Gln Cys Leu Glu	
455	460	465
Trp Asp Pro Ala Val Arg Met Thr Pro	Gly Gln Ala Leu Arg His	
470	475	480
Pro Trp Leu Arg Arg Arg Leu Pro Lys	Pro Pro Thr Gly Glu Lys	
485	490	495
Thr Ser Val Lys Arg Ile Thr Glu Ser	Thr Gly Ala Ile Thr Ser	
500	505	510
Ile Ser Lys Leu Pro Pro Pro Ser Ser	Ser Ala Ser Lys Leu Arg	
515	520	525
Thr Asn Leu Ala Gln Met Thr Asp Ala	Asn Gly Asn Ile Gln Gln	
530	535	540
Arg Thr Val Leu Pro Lys Leu Val Ser		
545		

&lt;210&gt; 14

&lt;211&gt; 416

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1490070

&lt;400&gt; 14

Met Met Pro Gln Leu Gln Phe Lys Asp	Ala Phe Trp Cys Arg Asp
1	5 10 15
Phe Thr Ala His Thr Gly Tyr Glu Val	Leu Leu Gln Arg Leu Leu
20	25 30
Asp Gly Arg Lys Met Cys Lys Asp Met	Val Glu Leu Leu Trp Gln
35	40 45
Arg Ala Gln Ala Glu Glu Arg Tyr Gly	Lys Glu Leu Val Gln Ile
50	55 60
Ala Arg Lys Ala Gly Gly Gln Thr Glu	Ile Asn Ser Leu Arg Ala
65	70 75
Ser Phe Asp Ser Leu Lys Gln Gln Met	Glu Asn Val Gly Ser Ser
80	85 90
His Ile Gln Leu Ala Leu Thr Leu Arg	Glu Glu Leu Arg Ser Leu
95	100 105
Glu Glu Phe Arg Glu Arg Gln Lys Glu	Gln Arg Lys Lys Tyr Glu
110	115 120
Ala Val Met Asp Arg Val Gln Lys Ser	Lys Leu Ser Leu Tyr Lys

WO 00/06728

PCT/US99/17132

	125		130		135
Lys Ala Met Glu Ser Lys Lys Thr Tyr		Glu Gln Lys Cys Arg Asp			
	140		145		150
Ala Asp Asp Ala Glu Gln Ala Phe Glu		Arg Ile Ser Ala Asn Gly			
	155		160		165
His Gln Lys Gln Val Glu Lys Ser Gln		Asn Lys Ala Arg Gln Cys			
	170		175		180
Lys Asp Ser Ala Thr Glu Ala Glu Arg		Val Tyr Arg Gln Ser Ile			
	185		190		195
Ala Gln Leu Glu Lys Val Arg Ala Glu		Trp Glu Gln Glu His Arg			
	200		205		210
Thr Thr Cys Glu Ala Phe Gln Leu Gln		Glu Phe Asp Arg Leu Thr			
	215		220		225
Ile Leu Arg Asn Ala Leu Trp Val His		Ser Asn Gln Leu Ser Met			
	230		235		240
Gln Cys Val Lys Asp Asp Glu Leu Tyr		Glu Glu Val Arg Leu Thr			
	245		250		255
Leu Glu Gly Cys Ser Ile Asp Ala Asp		Ile Asp Ser Phe Ile Gln			
	260		265		270
Ala Lys Ser Thr Gly Thr Glu Pro Pro		Ala Pro Val Pro Tyr Gln			
	275		280		285
Asn Tyr Tyr Asp Arg Glu Val Thr Pro		Leu Thr Ser Ser Pro Gly			
	290		295		300
Ile Gln Pro Ser Cys Gly Met Ile Lys		Arg Phe Ser Gly Leu Leu			
	305		310		315
His Gly Ser Pro Lys Thr Thr Ser Leu		Ala Ala Ser Ala Ala Ser			
	320		325		330
Thr Glu Thr Leu Thr Pro Thr Pro Glu		Arg Asn Glu Gly Val Tyr			
	335		340		345
Thr Ala Ile Ala Val Gln Glu Ile Gln		Gly Asn Pro Ala Ser Pro			
	350		355		360
Ala Gln Glu Tyr Arg Ala Leu Tyr Asp		Tyr Thr Ala Gln Asn Pro			
	365		370		375
Asp Glu Leu Asp Leu Ser Ala Gly Asp		Ile Leu Glu Val Ile Leu			
	380		385		390
Glu Gly Glu Asp Gly Trp Trp Thr Val		Glu Arg Asn Gly Gln Arg			
	395		400		405
Gly Phe Val Pro Gly Ser Tyr Leu Glu		Lys Leu			
	410		415		

&lt;210&gt; 15

&lt;211&gt; 425

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1997814

&lt;400&gt; 15

Met Glu Gln Gly Leu Glu Glu Glu Glu Glu Val Asp Pro Arg Ile			
1	5	10	15
Gln Gly Glu Leu Glu Lys Leu Asn Gln Ser Thr Asp Asp Ile Asn			
	20	25	30
Arg Arg Glu Thr Glu Leu Glu Asp Ala Arg Gln Lys Phe Arg Ser			
	35	40	45

WO 00/06728

PCT/US99/17132

Val	Leu	Val	Glu	Ala	Thr	Val	Lys	Leu	Asp	Glu	Leu	Val	Lys	Lys	
				50					55					60	
Ile	Gly	Lys	Ala	Val	Glu	Asp	Ser	Lys	Pro	Tyr	Trp	Glu	Ala	Arg	
				65					70					75	
Arg	Val	Ala	Arg	Gln	Ala	Gln	Leu	Glu	Ala	Gln	Lys	Ala	Thr	Gln	
				80					85					90	
Asp	Phe	Gln	Arg	Ala	Thr	Glu	Val	Leu	Arg	Ala	Ala	Lys	Glu	Thr	
				95					100					105	
Ile	Ser	Leu	Ala	Glu	Gln	Arg	Leu	Leu	Glu	Asp	Asp	Lys	Arg	Gln	
				110					115					120	
Phe	Asp	Ser	Ala	Trp	Gln	Glu	Met	Leu	Asn	His	Ala	Thr	Gln	Arg	
				125					130					135	
Val	Met	Glu	Ala	Glu	Gln	Thr	Lys	Thr	Arg	Ser	Glu	Leu	Val	His	
				140					145					150	
Lys	Glu	Thr	Ala	Ala	Arg	Tyr	Asn	Ala	Ala	Met	Gly	Arg	Met	Arg	
				155					160					165	
Gln	Leu	Glu	Lys	Lys	Leu	Lys	Arg	Ala	Ile	Asn	Lys	Ser	Lys	Pro	
				170					175					180	
Tyr	Phe	Glu	Leu	Lys	Ala	Lys	Tyr	Tyr	Val	Gln	Leu	Glu	Gln	Leu	
				185					190					195	
Lys	Lys	Thr	Val	Asp	Asp	Leu	Gln	Ala	Lys	Leu	Thr	Leu	Ala	Lys	
				200					205					210	
Gly	Glu	Tyr	Lys	Met	Ala	Leu	Lys	Asn	Leu	Glu	Met	Ile	Ser	Asp	
				215					220					225	
Glu	Ile	His	Glu	Arg	Arg	Arg	Ser	Ser	Ala	Met	Gly	Pro	Arg	Gly	
				230					235					240	
Cys	Gly	Val	Gly	Ala	Glu	Gly	Ser	Ser	Thr	Ser	Val	Glu	Asp	Leu	
				245					250					255	
Pro	Gly	Ser	Lys	Pro	Glu	Pro	Asp	Ala	Ile	Ser	Val	Ala	Ser	Glu	
				260					265					270	
Ala	Phe	Glu	Asp	Asp	Ser	Cys	Ser	Asn	Phe	Val	Ser	Glu	Asp	Asp	
				275					280					285	
Ser	Glu	Thr	Gln	Ser	Val	Ser	Ser	Phe	Ser	Ser	Gly	Pro	Thr	Ser	
				290					295					300	
Pro	Ser	Glu	Met	Pro	Asp	Gln	Phe	Pro	Ala	Val	Val	Arg	Pro	Gly	
				305					310					315	
Ser	Leu	Asp	Leu	Pro	Ser	Pro	Val	Ser	Leu	Ser	Glu	Phe	Gly	Met	
				320					325					330	
Met	Phe	Pro	Val	Leu	Gly	Pro	Arg	Ser	Glu	Cys	Ser	Gly	Ala	Ser	
				335					340					345	
Ser	Pro	Glu	Cys	Glu	Val	Glu	Arg	Gly	Asp	Arg	Ala	Glu	Gly	Ala	
				350					355					360	
Glu	Asn	Lys	Thr	Ser	Asp	Lys	Ala	Asn	Asn	Asn	Arg	Gly	Leu	Ser	
				365					370					375	
Ser	Ser	Ser	Gly	Ser	Gly	Gly	Ser	Ser	Lys	Ser	Gln	Ser	Ser	Thr	
				380					385					390	
Ser	Pro	Glu	Gly	Gln	Ala	Leu	Glu	Asn	Arg	Met	Lys	Gln	Leu	Ser	
				395					400					405	
Leu	Gln	Cys	Ser	Lys	Gly	Arg	Asp	Gly	Ile	Ile	Ala	Asp	Ile	Lys	
				410					415					420	
Met	Val	Gln	Ile	Gly											
				425											

&lt;210&gt; 16

&lt;211&gt; 1135

WO 00/06728

PCT/US99/17132

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2299715

&lt;400&gt; 16

Met	Ala	Asn	Asp	Ser	Pro	Ala	Lys	Ser	Leu	Val	Asp	Ile	Asp	Leu	
1				5					10					15	
Ser	Ser	Leu	Arg	Asp	Pro	Ala	Gly	Ile	Phe	Glu	Leu	Val	Glu	Val	
			20						25					30	
Val	Gly	Asn	Gly	Thr	Tyr	Gly	Gln	Val	Tyr	Lys	Gly	Arg	His	Val	
			35						40					45	
Lys	Thr	Gly	Gln	Leu	Ala	Ala	Ile	Lys	Val	Met	Asp	Val	Thr	Glu	
			50						55					60	
Asp	Glu	Glu	Glu	Glu	Ile	Lys	Leu	Glu	Ile	Asn	Met	Leu	Lys	Lys	
			65						70					75	
Tyr	Ser	His	His	Arg	Asn	Ile	Ala	Thr	Tyr	Tyr	Gly	Ala	Phe	Ile	
			80						85					90	
Lys	Lys	Ser	Pro	Pro	Gly	His	Asp	Asp	Gln	Leu	Trp	Leu	Val	Met	
			95						100					105	
Glu	Phe	Cys	Gly	Ala	Gly	Ser	Ile	Thr	Asp	Leu	Val	Lys	Asn	Thr	
			110						115					120	
Lys	Gly	Asn	Thr	Leu	Lys	Glu	Asp	Trp	Ile	Ala	Tyr	Ile	Ser	Arg	
			125						130					135	
Glu	Ile	Leu	Arg	Gly	Leu	Ala	His	Leu	His	Ile	His	His	Val	Ile	
			140						145					150	
His	Arg	Asp	Ile	Lys	Gly	Gln	Asn	Val	Leu	Leu	Thr	Glu	Asn	Ala	
			155						160					165	
Gly	Val	Lys	Leu	Val	Asp	Phe	Gly	Val	Ser	Ala	Gln	Leu	Asp	Arg	
			170						175					180	
Thr	Val	Gly	Arg	Arg	Asn	Thr	Phe	Ile	Gly	Thr	Pro	Tyr	Trp	Met	
			185						190					195	
Ala	Pro	Glu	Val	Ile	Ala	Cys	Asp	Glu	Asn	Pro	Asp	Ala	Thr	Tyr	
			200						205					210	
Asp	Tyr	Arg	Ser	Asp	Leu	Trp	Ser	Cys	Gly	Ile	Thr	Ala	Ile	Glu	
			215						220					225	
Met	Ala	Glu	Gly	Ala	Pro	Pro	Leu	Cys	Asp	Met	His	Pro	Met	Arg	
			230						235					240	
Ala	Leu	Phe	Leu	Ile	Pro	Arg	Asn	Pro	Pro	Pro	Arg	Leu	Lys	Ser	
			245						250					255	
Lys	Lys	Trp	Ser	Lys	Lys	Phe	Phe	Ser	Phe	Ile	Glu	Gly	Cys	Leu	
			260						265					270	
Val	Lys	Asn	Tyr	Met	Gln	Arg	Pro	Ser	Thr	Glu	Gln	Leu	Leu	Lys	
			275						280					285	
His	Pro	Phe	Ile	Arg	Asp	Gln	Pro	Asn	Glu	Arg	Gln	Val	Arg	Ile	
			290						295					300	
Gln	Leu	Lys	Asp	His	Ile	Asp	Arg	Thr	Arg	Lys	Lys	Arg	Gly	Glu	
			305						310					315	
Lys	Asp	Glu	Thr	Glu	Tyr	Glu	Tyr	Ser	Gly	Ser	Glu	Glu	Glu	Glu	
			320						325					330	
Glu	Glu	Val	Pro	Glu	Gln	Glu	Gly	Glu	Pro	Ser	Ser	Ile	Val	Asn	
			335						340					345	
Val	Pro	Gly	Glu	Ser	Thr	Leu	Arg	Arg	Asp	Phe	Leu	Arg	Leu	Gln	

WO 00/06728

PCT/US99/17132

	350		355		360
Gln Glu Asn Lys Glu Arg Ser Glu Ala		Leu Arg Arg Gln Gln Leu			
	365		370		375
Leu Gln Glu Gln Gln Leu Arg Glu Gln		Glu Glu Tyr Lys Arg Gln			
	380		385		390
Leu Leu Ala Glu Arg Gln Lys Arg Ile		Glu Gln Gln Lys Glu Gln			
	395		400		405
Arg Arg Arg Leu Glu Glu Gln Gln Arg		Arg Glu Arg Glu Ala Arg			
	410		415		420
Arg Gln Gln Glu Arg Glu Gln Arg Arg		Arg Glu Gln Glu Glu Lys			
	425		430		435
Arg Arg Leu Glu Glu Leu Glu Arg Arg		Arg Lys Glu Glu Glu Glu			
	440		445		450
Arg Arg Arg Ala Glu Glu Glu Lys Arg		Arg Val Glu Arg Glu Gln			
	455		460		465
Glu Tyr Ile Arg Arg Gln Leu Glu Glu		Glu Gln Arg His Leu Glu			
	470		475		480
Val Leu Gln Gln Gln Leu Leu Gln Glu		Gln Ala Met Leu Leu His			
	485		490		495
Asp His Arg Arg Pro His Pro Gln His		Ser Gln Gln Pro Pro Pro			
	500		505		510
Pro Gln Gln Glu Arg Ser Lys Pro Ser		Phe His Ala Pro Glu Pro			
	515		520		525
Lys Ala His Tyr Glu Pro Ala Asp Arg		Ala Arg Glu Val Pro Val			
	530		535		540
Arg Thr Thr Ser Arg Ser Pro Val Leu		Ser Arg Arg Asp Ser Pro			
	545		550		555
Leu Gln Gly Ser Gly Gln Gln Asn Ser		Gln Ala Gly Gln Arg Asn			
	560		565		570
Ser Thr Ser Ile Glu Pro Arg Leu Leu		Trp Glu Arg Val Glu Lys			
	575		580		585
Leu Val Pro Arg Pro Gly Ser Gly Ser		Ser Ser Gly Ser Ser Asn			
	590		595		600
Ser Gly Ser Gln Pro Gly Ser His Pro		Gly Ser Gln Ser Gly Ser			
	605		610		615
Gly Glu Arg Phe Arg Val Arg Ser Ser		Ser Lys Ser Glu Gly Ser			
	620		625		630
Pro Ser Gln Arg Leu Glu Asn Ala Val		Lys Lys Pro Glu Asp Lys			
	635		640		645
Lys Glu Val Phe Arg Pro Leu Lys Pro		Ala Asp Leu Thr Ala Leu			
	650		655		660
Ala Lys Glu Leu Arg Ala Val Glu Asp		Val Arg Pro Pro His Lys			
	665		670		675
Val Thr Asp Tyr Ser Ser Ser Ser Glu		Glu Ser Gly Thr Thr Asp			
	680		685		690
Glu Glu Asp Asp Asp Val Glu Gln Glu		Gly Ala Asp Glu Ser Thr			
	695		700		705
Ser Gly Pro Glu Asp Thr Arg Ala Ala		Ser Ser Leu Asn Leu Ser			
	710		715		720
Asn Gly Glu Thr Glu Ser Val Lys Thr		Met Ile Val His Asp Asp			
	725		730		735
Val Glu Ser Glu Pro Ala Met Thr Pro		Ser Lys Glu Gly Thr Leu			
	740		745		750
Ile Val Arg Gln Thr Gln Ser Ala Ser		Ser Thr Leu Gln Lys His			
	755		760		765
Lys Ser Ser Ser Ser Phe Thr Pro Phe		Ile Asp Pro Arg Leu Leu			

WO 00/06728

PCT/US99/17132

Gln Ile Ser Pro	770	775	780
Ser Ser Gly Thr Thr	785	790	795
Phe Ser Cys Asp	800	805	810
Gly Met Arg Pro Glu	815	820	825
Thr Arg Lys Gly	830	835	840
Ser Val Val Asn Val	845	850	855
Pro Gln Ser Asp	860	865	870
Thr Pro Glu Ile Arg	875	880	885
Asn Ser Glu Ile	890	895	900
Leu Cys Ala Ala Leu	905	910	915
Val Gly Thr Glu	920	925	930
Ser Gly Leu Met Leu	935	940	945
Gly Lys Val Tyr	950	955	960
Pro Leu Ile Asn Arg	965	970	975
Arg Arg Phe Gln Gln	980	985	990
Met Asp Val Leu Glu	995	1000	1005
Gly Leu Asn Val Leu	1010	1015	1020
Val Thr Ile Ser Gly	1025	1030	1035
Lys Asp Lys Leu Arg	1040	1045	1050
Val Tyr Tyr Leu Ser	1055	1060	1065
Trp Leu Arg Asn Lys	1070	1075	1080
Ile Leu His Asn Asp	1085	1090	1095
Pro Glu Val Glu Lys	1100	1105	1110
Lys Lys Gln Gly Trp	1115	1120	1125
Thr Val Gly Asp	1130		
Leu Glu Gly Cys Val			
His Tyr Lys Val Val			
Lys Tyr Val Val Lys			
Tyr Glu Arg Ile			
Lys Phe Leu Val Ile			
Ala Leu Lys Ser Ser			
Val Glu Val Tyr Ala			
Trp Ala Pro Lys Pro			
Tyr His Lys Phe Met			
Ala Phe Lys Ser Phe			
Gly Glu Leu Val His			
Gly Ser Cys Ala Gly			
Phe His Ala Val Asp			
Val Asp Ser Gly Ser			
Val Tyr Asp Ile Tyr			
Leu Pro Thr His Ile			
Gln Cys Ser Ile Lys			
Pro His Ala Ile Ile			
Ile Leu Pro Asn Thr			
Asp Gly Met Glu Leu			
Leu Val Cys Tyr Glu			
Asp Glu Gly Val Tyr			
Val Asn Thr Tyr Gly			
Arg Ile Thr Lys Asp			
Val Leu Gln Trp Gly			
Glu Met Pro Thr Ser			
Val Ala Tyr Ile Arg			
Ser Asn Gln Thr Met			
Gly Trp Gly Glu Lys			
Ala Ile Glu Ile Arg			
Ser Val Glu Thr Gly			
His Leu Asp Gly Val			
Phe Met His Lys Arg			
Ala Gln Arg Leu Lys			
Phe Leu Cys Glu Arg			
Asn Asp Lys Val Phe			
Phe Ala Ser Val Arg			
Ser Gly Gly Ser Ser			
Gln Val Tyr Phe Met			
Thr Leu Gly Arg Thr			
Ser Leu Leu Ser Trp			

&lt;210&gt; 17

&lt;211&gt; 228

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

WO 00/06728

PCT/US99/17132

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 209854

&lt;400&gt; 17

```

Met Pro Thr Asn Cys Ala Ala Ala Gly Cys Ala Thr Thr Tyr Asn
 1              5              10              15
Lys His Ile Asn Ile Ser Phe His Arg Phe Pro Leu Asp Pro Lys
              20              25              30
Arg Arg Lys Glu Trp Val Arg Leu Val Arg Arg Lys Asn Phe Val
              35              40              45
Pro Gly Lys His Thr Phe Leu Cys Ser Lys His Phe Glu Ala Ser
              50              55              60
Cys Phe Asp Leu Thr Gly Gln Thr Arg Arg Leu Lys Met Asp Ala
              65              70              75
Val Pro Thr Ile Phe Asp Phe Cys Thr His Ile Lys Ser Met Lys
              80              85              90
Leu Lys Ser Arg Asn Leu Leu Lys Lys Asn Asn Ser Cys Ser Pro
              95              100             105
Ala Gly Pro Ser Asn Leu Lys Ser Asn Ile Ser Ser Gln Gln Val
              110             115             120
Leu Leu Glu His Ser Tyr Ala Phe Arg Asn Pro Met Glu Ala Lys
              125             130             135
Lys Arg Ile Ile Lys Leu Glu Lys Glu Ile Ala Ser Leu Arg Arg
              140             145             150
Lys Met Lys Thr Cys Leu Gln Lys Glu Arg Arg Ala Thr Arg Arg
              155             160             165
Trp Ile Lys Ala Thr Cys Leu Val Lys Asn Leu Glu Ala Asn Ser
              170             175             180
Val Leu Pro Lys Gly Thr Ser Glu His Met Leu Pro Thr Ala Leu
              185             190             195
Ser Ser Leu Pro Leu Glu Asp Phe Lys Ile Leu Glu Gln Asp Gln
              200             205             210
Gln Asp Lys Thr Leu Leu Ser Leu Asn Leu Lys Gln Thr Lys Ser
              215             220             225
Thr Phe Ile

```

&lt;210&gt; 18

&lt;211&gt; 503

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1384286

&lt;400&gt; 18

```

Met Ala Thr Thr Val Thr Cys Thr Arg Phe Thr Asp Glu Tyr Gln
 1              5              10              15
Leu Tyr Glu Asp Ile Gly Lys Gly Ala Phe Ser Val Val Arg Arg
              20              25              30
Cys Val Lys Leu Cys Thr Gly His Glu Tyr Ala Ala Lys Ile Ile
              35              40              45
Asn Thr Lys Lys Leu Ser Ala Arg Asp His Gln Lys Leu Glu Arg

```

WO 00/06728

PCT/US99/17132

50	55	60
Glu Ala Arg Ile Cys Arg Leu Leu Lys His Ser Asn Ile Val Arg		
65	70	75
Leu His Asp Ser Ile Ser Glu Glu Gly Phe His Tyr Leu Val Phe		
80	85	90
Asp Leu Val Thr Gly Gly Glu Leu Phe Glu Asp Ile Val Ala Arg		
95	100	105
Glu Tyr Tyr Ser Glu Ala Asp Ala Ser His Cys Ile Gln Gln Ile		
110	115	120
Leu Glu Ala Val Leu His Cys His Gln Met Gly Val Val His Arg		
125	130	135
Asp Leu Lys Pro Glu Asn Leu Leu Leu Ala Ser Lys Cys Lys Gly		
140	145	150
Ala Ala Val Lys Leu Ala Asp Phe Gly Leu Ala Ile Glu Val Gln		
155	160	165
Gly Asp Gln Gln Ala Trp Phe Gly Phe Ala Gly Thr Pro Gly Tyr		
170	175	180
Leu Ser Pro Glu Val Leu Arg Lys Glu Ala Tyr Gly Lys Pro Val		
185	190	195
Asp Ile Trp Ala Cys Gly Val Ile Leu Tyr Ile Leu Leu Val Gly		
200	205	210
Tyr Pro Pro Phe Trp Asp Glu Asp Gln His Lys Leu Tyr Gln Gln		
215	220	225
Ile Lys Ala Gly Ala Tyr Asp Phe Pro Ser Pro Glu Trp Asp Thr		
230	235	240
Val Thr Pro Glu Ala Lys Asn Leu Ile Asn Gln Met Leu Thr Ile		
245	250	255
Asn Pro Ala Lys Arg Ile Thr Ala His Glu Ala Leu Lys His Pro		
260	265	270
Trp Val Cys Gln Arg Ser Thr Val Ala Ser Met Met His Arg Gln		
275	280	285
Glu Thr Val Glu Cys Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu		
290	295	300
Lys Gly Ala Ile Leu Thr Thr Met Leu Ala Thr Arg Asn Phe Ser		
305	310	315
Ala Ala Lys Ser Leu Leu Asn Lys Lys Ala Asp Gly Val Lys Pro		
320	325	330
His Thr Asn Ser Thr Lys Asn Ser Ala Ala Ala Thr Ser Pro Lys		
335	340	345
Gly Thr Leu Pro Pro Ala Ala Leu Glu Ser Ser Asp Ser Ala Asn		
350	355	360
Thr Thr Ile Glu Asp Glu Asp Ala Lys Ala Arg Lys Gln Glu Ile		
365	370	375
Ile Lys Thr Thr Glu Gln Leu Ile Glu Ala Val Asn Asn Gly Asp		
380	385	390
Phe Glu Ala Tyr Ala Lys Ile Cys Asp Pro Gly Leu Thr Ser Phe		
395	400	405
Glu Pro Glu Ala Leu Gly Asn Leu Val Glu Gly Met Asp Phe His		
410	415	420
Arg Phe Tyr Phe Glu Asn Leu Leu Ala Lys Asn Ser Lys Pro Ile		
425	430	435
His Thr Thr Ile Leu Asn Pro His Val His Val Ile Gly Glu Asp		
440	445	450
Ala Ala Cys Ile Ala Tyr Ile Arg Leu Thr Gln Tyr Ile Asp Gly		
455	460	465
Gln Gly Arg Pro Arg Thr Ser Gln Ser Glu Glu Thr Arg Val Trp		



WO 00/06728

PCT/US99/17132

	470	475	480
His Arg Arg Asp Gly Lys Trp Gln Asn Val His Phe His Cys Ser			
	485	490	495
Gly Ala Pro Val Ala Pro Leu Gln			
	500		

<210> 19  
 <211> 433  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 1512656

<400> 19  
 Met Thr Gly Glu Ala Gln Ala Gly Arg Lys Arg Ser Arg Ala Arg  
 1 5 10 15  
 Pro Glu Gly Thr Glu Pro Val Arg Arg Glu Arg Thr Gln Pro Gly  
 20 25 30  
 Leu Gly Pro Gly Arg Ala Arg Ala Met Ala Ala Glu Ala Thr Ala  
 35 40 45  
 Val Ala Gly Ser Gly Ala Val Gly Gly Cys Leu Ala Lys Asp Gly  
 50 55 60  
 Leu Gln Gln Ser Lys Cys Pro Asp Thr Thr Pro Lys Arg Arg Arg  
 65 70 75  
 Ala Ser Ser Leu Ser Arg Asp Ala Glu Arg Arg Ala Tyr Gln Trp  
 80 85 90  
 Cys Arg Glu Tyr Leu Gly Gly Ala Trp Arg Arg Val Gln Pro Glu  
 95 100 105  
 Glu Leu Arg Val Tyr Pro Val Ser Gly Gly Leu Ser Asn Leu Leu  
 110 115 120  
 Phe Arg Cys Ser Leu Pro Asp His Leu Pro Ser Val Gly Glu Glu  
 125 130 135  
 Pro Arg Glu Val Leu Leu Arg Leu Tyr Gly Ala Ile Leu Gln Gly  
 140 145 150  
 Val Asp Ser Leu Val Leu Glu Ser Val Met Phe Ala Ile Leu Ala  
 155 160 165  
 Glu Arg Ser Leu Gly Pro Gln Leu Tyr Gly Val Phe Pro Glu Gly  
 170 175 180  
 Arg Leu Glu Gln Tyr Ile Pro Ser Arg Pro Leu Lys Thr Gln Glu  
 185 190 195  
 Leu Arg Glu Pro Val Leu Ser Ala Ala Ile Ala Thr Lys Met Ala  
 200 205 210  
 Gln Phe His Gly Met Glu Met Pro Phe Thr Lys Glu Pro His Trp  
 215 220 225  
 Leu Phe Gly Thr Met Glu Arg Tyr Leu Lys Gln Ile Gln Asp Leu  
 230 235 240  
 Pro Pro Thr Gly Leu Pro Glu Met Asn Leu Leu Glu Met Tyr Ser  
 245 250 255  
 Leu Lys Asp Glu Met Gly Asn Leu Arg Lys Leu Leu Glu Ser Thr  
 260 265 270  
 Pro Ser Pro Val Val Phe Cys His Asn Asp Ile Gln Glu Gly Asn

WO 00/06728

PCT/US99/17132

	275	280	285
Ile Leu Leu Leu Ser Glu Pro Glu Asn Ala Asp Ser Leu Met Leu			
	290	295	300
Val Asp Phe Glu Tyr Ser Ser Tyr Asn Tyr Arg Gly Phe Asp Ile			
	305	310	315
Gly Asn His Phe Cys Glu Trp Val Tyr Asp Tyr Thr His Glu Glu			
	320	325	330
Trp Pro Phe Tyr Lys Ala Arg Pro Thr Asp Tyr Pro Thr Gln Glu			
	335	340	345
Gln Gln Leu His Phe Ile Arg His Tyr Leu Ala Glu Ala Lys Lys			
	350	355	360
Gly Glu Thr Leu Ser Gln Glu Glu Gln Arg Lys Leu Glu Glu Asp			
	365	370	375
Leu Leu Val Glu Val Ser Arg Tyr Ala Leu Ala Ser His Phe Phe			
	380	385	390
Trp Gly Leu Trp Ser Ile Leu Gln Ala Ser Met Ser Thr Ile Glu			
	395	400	405
Phe Gly Tyr Leu Asp Tyr Ala Gln Ser Arg Phe Gln Phe Tyr Phe			
	410	415	420
Gln Gln Lys Gly Gln Leu Thr Ser Val His Ser Ser Ser			
	425	430	

&lt;210&gt; 20

&lt;211&gt; 527

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2098635

&lt;400&gt; 20

Met Ser Leu Cys Gly Ala Arg Ala Asn Ala Lys Met Met Ala Ala		
1	5	10
Tyr Asn Gly Gly Thr Ser Ala Ala Ala Ala Gly His His His His		
	20	25
His His His His Leu Pro His Leu Pro Pro Pro His Leu Leu His		
	35	40
His His His Pro Gln His His Leu His Pro Gly Ser Ala Ala Ala		
	50	55
Val His Pro Val Gln Gln His Thr Ser Ser Ala Ala Ala Ala Ala		
	65	70
Ala Ala Ala Ala Ala Ala Ala Ala Met Leu Asn Pro Gly Gln Gln		
	80	85
Gln Pro Tyr Phe Pro Ser Pro Ala Pro Gly Gln Ala Pro Gly Pro		
	95	100
Ala Ala Ala Ala Pro Ala Gln Val Gln Ala Ala Ala Ala Ala Thr		
	110	115
Val Lys Ala His His His Gln His Ser His His Pro Gln Gln Gln		
	125	130
Leu Asp Ile Glu Pro Asp Arg Pro Ile Gly Tyr Gly Ala Phe Gly		
	140	145
Val Val Trp Ser Val Thr Asp Pro Arg Asp Gly Lys Arg Val Ala		
	155	160
Leu Lys Lys Met Pro Asn Val Phe Gln Asn Leu Val Ser Cys Lys		

WO 00/06728

PCT/US99/17132

	170		175		180
Arg Val Phe Arg	Glu Leu Lys Met Leu Cys Phe Phe Lys His Asp				
	185		190		195
Asn Val Leu Ser	Ala Leu Asp Ile Leu Gln Pro Pro His Ile Asp				
	200		205		210
Tyr Phe Glu Glu	Ile Tyr Val Val Thr Glu Leu Met Gln Ser Asp				
	215		220		225
Leu His Lys Ile	Ile Val Ser Pro Gln Pro Leu Ser Ser Asp His				
	230		235		240
Val Lys Val Phe	Leu Tyr Gln Ile Leu Arg Gly Leu Lys Tyr Leu				
	245		250		255
His Ser Ala Gly	Ile Leu His Arg Asp Ile Lys Pro Gly Asn Leu				
	260		265		270
Leu Val Asn Ser	Asn Cys Val Leu Lys Ile Cys Asp Phe Gly Leu				
	275		280		285
Ala Arg Val Glu	Glu Leu Asp Glu Ser Arg His Met Thr Gln Glu				
	290		295		300
Val Val Thr Gln	Tyr Tyr Arg Ala Pro Glu Ile Leu Met Gly Ser				
	305		310		315
Arg His Tyr Ser	Asn Ala Ile Asp Ile Trp Ser Val Gly Cys Ile				
	320		325		330
Phe Ala Glu Leu	Leu Gly Arg Arg Ile Leu Phe Gln Ala Gln Ser				
	335		340		345
Pro Ile Gln Gln	Leu Asp Leu Ile Thr Asp Leu Leu Gly Thr Pro				
	350		355		360
Ser Leu Glu Ala	Met Arg Thr Ala Cys Glu Gly Ala Lys Ala His				
	365		370		375
Ile Leu Arg Gly	Pro His Lys Gln Pro Ser Leu Pro Val Leu Tyr				
	380		385		390
Thr Leu Ser Ser	Gln Ala Thr His Glu Ala Val His Leu Leu Cys				
	395		400		405
Arg Met Leu Val	Phe Asp Pro Ser Lys Arg Ile Ser Ala Lys Asp				
	410		415		420
Ala Leu Ala His	Pro Tyr Leu Asp Glu Gly Arg Leu Arg Tyr His				
	425		430		435
Thr Cys Met Cys	Lys Cys Cys Phe Ser Thr Ser Thr Gly Arg Val				
	440		445		450
Tyr Thr Ser Asp	Phe Glu Pro Val Thr Asn Pro Lys Phe Asp Asp				
	455		460		465
Thr Phe Glu Lys	Asn Leu Ser Ser Val Arg Gln Val Lys Glu Ile				
	470		475		480
Ile His Gln Phe	Ile Leu Glu Gln Gln Lys Gly Asn Arg Val Pro				
	485		490		495
Leu Cys Ile Asn	Pro Gln Ser Ala Ala Phe Lys Ser Phe Ile Ser				
	500		505		510
Ser Thr Val Ala	Gln Pro Ser Glu Met Pro Pro Ser Pro Leu Val				
	515		520		525

Trp Glu

&lt;210&gt; 21

&lt;211&gt; 322

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

WO 00/06728

PCT/US99/17132

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2446646

&lt;400&gt; 21

```

Met Glu Gly Ile Ser Asn Phe Lys Thr Pro Ser Lys Leu Ser Glu
 1          5          10          15
Lys Lys Lys Ser Val Leu Cys Ser Thr Pro Thr Ile Asn Ile Pro
          20          25          30
Ala Ser Pro Phe Met Gln Lys Leu Gly Phe Gly Thr Gly Val Asn
          35          40          45
Val Tyr Leu Met Lys Arg Ser Pro Arg Gly Leu Ser His Ser Pro
          50          55          60
Trp Ala Val Lys Lys Ile Asn Pro Ile Cys Asn Asp His Tyr Arg
          65          70          75
Ser Val Tyr Gln Lys Arg Leu Met Asp Glu Ala Lys Ile Leu Lys
          80          85          90
Ser Leu His His Pro Asn Ile Val Gly Tyr Arg Ala Phe Thr Glu
          95          100          105
Ala Asn Asp Gly Ser Leu Cys Leu Ala Met Glu Tyr Gly Gly Glu
          110          115          120
Lys Ser Leu Asn Asp Leu Ile Glu Glu Arg Tyr Lys Ala Ser Gln
          125          130          135
Asp Pro Phe Pro Ala Ala Ile Ile Leu Lys Val Ala Leu Asn Met
          140          145          150
Ala Arg Gly Leu Lys Tyr Leu His Gln Glu Lys Lys Leu Leu His
          155          160          165
Gly Asp Ile Lys Ser Ser Asn Val Val Ile Lys Gly Asp Phe Glu
          170          175          180
Thr Ile Lys Ile Cys Asp Val Gly Val Ser Leu Pro Leu Asp Glu
          185          190          195
Asn Met Thr Val Thr Asp Pro Glu Ala Cys Tyr Ile Gly Thr Glu
          200          205          210
Pro Trp Lys Pro Lys Glu Ala Val Glu Glu Asn Gly Val Ile Thr
          215          220          225
Asp Lys Ala Asp Ile Phe Ala Phe Gly Leu Thr Leu Trp Glu Met
          230          235          240
Met Thr Leu Ser Ile Pro His Ile Asn Leu Ser Asn Asp Asp Asp
          245          250          255
Asp Glu Asp Lys Thr Phe Asp Glu Ser Asp Phe Asp Asp Glu Ala
          260          265          270
Tyr Tyr Ala Ala Leu Gly Thr Arg Pro Pro Ile Asn Met Glu Glu
          275          280          285
Leu Asp Glu Ser Tyr Gln Lys Val Ile Glu Leu Phe Ser Val Cys
          290          295          300
Thr Asn Glu Asp Pro Lys Asp Arg Pro Ser Ala Ala His Ile Val
          305          310          315
Glu Ala Leu Glu Thr Asp Val
          320

```

&lt;210&gt; 22

&lt;211&gt; 802

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

WO 00/06728

PCT/US99/17132

&lt;223&gt; Incyte Clone Number: 2764911

&lt;400&gt; 22

Met	Glu	Glu	Glu	Gly	Gly	Ser	Ser	Gly	Gly	Ala	Ala	Gly	Thr	Ser
1				5					10					15
Ala	Asp	Gly	Gly	Asp	Gly	Gly	Glu	Gln	Leu	Leu	Thr	Val	Lys	His
				20					25					30
Glu	Leu	Arg	Thr	Ala	Asn	Leu	Thr	Gly	His	Ala	Glu	Lys	Val	Gly
				35					40					45
Ile	Glu	Asn	Phe	Glu	Leu	Leu	Lys	Val	Leu	Gly	Thr	Gly	Ala	Tyr
				50					55					60
Gly	Lys	Val	Phe	Leu	Val	Arg	Lys	Ile	Ser	Gly	His	Asp	Thr	Gly
				65					70					75
Lys	Leu	Tyr	Ala	Met	Lys	Val	Leu	Lys	Lys	Ala	Thr	Ile	Val	Gln
				80					85					90
Lys	Ala	Lys	Thr	Thr	Glu	His	Thr	Arg	Thr	Glu	Arg	Gln	Val	Leu
				95					100					105
Glu	His	Ile	Arg	Gln	Ser	Pro	Phe	Leu	Val	Thr	Leu	His	Tyr	Ala
				110					115					120
Phe	Gln	Thr	Glu	Thr	Lys	Leu	His	Leu	Ile	Leu	Asp	Tyr	Ile	Asn
				125					130					135
Gly	Gly	Glu	Leu	Phe	Thr	His	Leu	Ser	Gln	Arg	Glu	Arg	Phe	Thr
				140					145					150
Glu	His	Glu	Val	Gln	Ile	Tyr	Val	Gly	Glu	Ile	Val	Leu	Ala	Leu
				155					160					165
Glu	His	Leu	His	Lys	Leu	Gly	Ile	Ile	Tyr	Arg	Asp	Ile	Lys	Leu
				170					175					180
Glu	Asn	Ile	Leu	Leu	Asp	Ser	Asn	Gly	His	Val	Val	Leu	Thr	Asp
				185					190					195
Phe	Gly	Leu	Ser	Lys	Glu	Phe	Val	Ala	Asp	Glu	Thr	Glu	Arg	Ala
				200					205					210
Tyr	Ser	Phe	Cys	Gly	Thr	Ile	Glu	Tyr	Met	Ala	Pro	Asp	Ile	Val
				215					220					225
Arg	Gly	Gly	Asp	Ser	Gly	His	Asp	Lys	Ala	Val	Asp	Trp	Trp	Ser
				230					235					240
Leu	Gly	Val	Leu	Met	Tyr	Glu	Leu	Leu	Thr	Gly	Ala	Ser	Pro	Phe
				245					250					255
Thr	Val	Asp	Gly	Glu	Lys	Asn	Ser	Gln	Ala	Glu	Ile	Ser	Arg	Arg
				260					265					270
Ile	Leu	Lys	Ser	Glu	Pro	Pro	Tyr	Pro	Gln	Glu	Met	Ser	Ala	Leu
				275					280					285
Ala	Lys	Asp	Leu	Ile	Gln	Arg	Leu	Leu	Met	Lys	Asp	Pro	Lys	Lys
				290					295					300
Arg	Leu	Gly	Cys	Gly	Pro	Arg	Asp	Ala	Asp	Glu	Ile	Lys	Glu	His
				305					310					315
Leu	Phe	Phe	Gln	Lys	Ile	Asn	Trp	Asp	Asp	Leu	Ala	Ala	Lys	Lys
				320					325					330
Val	Pro	Ala	Pro	Phe	Lys	Pro	Val	Ile	Arg	Asp	Glu	Leu	Asp	Val
				335					340					345
Ser	Asn	Phe	Ala	Glu	Glu	Phe	Thr	Glu	Met	Asp	Pro	Thr	Tyr	Ser
				350					355					360
Pro	Ala	Ala	Leu	Pro	Gln	Ser	Ser	Glu	Lys	Leu	Phe	Gln	Gly	Tyr
				365					370					375
Ser	Phe	Val	Ala	Pro	Ser	Ile	Leu	Phe	Lys	Arg	Asn	Ala	Ala	Val
				380					385					390
Ile	Asp	Pro	Leu	Gln	Phe	His	Met	Gly	Val	Glu	Arg	Pro	Gly	Val

WO 00/06728

PCT/US99/17132

	395		400		405
Thr Asn Val Ala Arg Ser Ala Met Met Lys Asp Ser Pro Phe Tyr					
	410		415		420
Gln His Tyr Asp Leu Asp Leu Lys Asp Lys Pro Leu Gly Glu Gly					
	425		430		435
Ser Phe Ser Ile Cys Arg Lys Cys Val His Lys Lys Ser Asn Gln					
	440		445		450
Ala Phe Ala Val Lys Ile Ile Ser Lys Arg Met Glu Ala Asn Thr					
	455		460		465
Gln Lys Glu Ile Thr Ala Leu Glu Leu Cys Glu Gly His Pro Asn					
	470		475		480
Ile Val Lys Leu His Glu Val Phe His Asp Gln Leu His Thr Phe					
	485		490		495
Leu Val Met Glu Leu Leu Asn Gly Gly Glu Leu Phe Glu Arg Ile					
	500		505		510
Lys Lys Lys Lys His Phe Ser Glu Thr Glu Ala Ser Tyr Ile Met					
	515		520		525
Arg Lys Leu Val Ser Ala Val Ser His Met His Asp Val Gly Val					
	530		535		540
Val His Arg Asp Leu Lys Pro Glu Asn Leu Leu Phe Thr Asp Glu					
	545		550		555
Asn Asp Asn Leu Glu Ile Lys Ile Ile Asp Phe Gly Phe Ala Arg					
	560		565		570
Leu Lys Pro Pro Asp Asn Gln Pro Leu Lys Thr Pro Cys Phe Thr					
	575		580		585
Leu His Tyr Ala Ala Pro Glu Leu Leu Asn Gln Asn Gly Tyr Asp					
	590		595		600
Glu Ser Cys Asp Leu Trp Ser Leu Gly Val Ile Leu Tyr Thr Met					
	605		610		615
Leu Ser Gly Gln Val Pro Phe Gln Ser His Asp Arg Ser Leu Thr					
	620		625		630
Cys Thr Ser Ala Val Glu Ile Met Lys Lys Ile Lys Lys Gly Asp					
	635		640		645
Phe Ser Phe Glu Gly Glu Ala Trp Lys Asn Val Ser Gln Glu Ala					
	650		655		660
Lys Asp Leu Ile Gln Gly Leu Leu Thr Val Asp Pro Asn Lys Arg					
	665		670		675
Leu Lys Met Ser Gly Leu Arg Tyr Asn Glu Trp Leu Gln Asp Gly					
	680		685		690
Ser Gln Leu Ser Ser Asn Pro Leu Met Thr Pro Asp Ile Leu Gly					
	695		700		705
Ser Ser Gly Ala Val His Thr Cys Val Lys Ala Thr Phe His					
	710		715		720
Ala Phe Asn Lys Tyr Lys Arg Glu Gly Phe Cys Leu Gln Asn Val					
	725		730		735
Asp Lys Ala Pro Leu Ala Lys Arg Arg Lys Met Lys Lys Thr Ser					
	740		745		750
Thr Ser Thr Glu Thr Arg Ser Ser Ser Ser Glu Ser Ser His Ser					
	755		760		765
Ser Ser Ser His Ser His Gly Lys Thr Thr Pro Thr Lys Thr Leu					
	770		775		780
Gln Pro Ser Asn Pro Ala Asp Ser Asn Asn Pro Glu Thr Leu Phe					
	785		790		795
Gln Phe Ser Asp Ser Val Ala					
	800				

WO 00/06728

PCT/US99/17132

<210> 23  
 <211> 641  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 3013946

<400> 23  
 Met Ala Thr Thr Val Thr Cys Thr Arg Phe Thr Asp Glu Tyr Gln  
 1 5 10 15  
 Leu Tyr Glu Asp Ile Gly Lys Gly Ala Phe Ser Val Val Arg Arg  
 20 25 30  
 Cys Val Lys Leu Cys Thr Gly His Glu Tyr Ala Ala Lys Ile Ile  
 35 40 45  
 Asn Thr Lys Lys Leu Ser Ala Arg Asp His Gln Lys Leu Glu Arg  
 50 55 60  
 Glu Ala Arg Ile Cys Arg Leu Leu Lys His Ser Asn Ile Val Arg  
 65 70 75  
 Leu His Asp Ser Ile Ser Glu Glu Gly Phe His Tyr Leu Val Phe  
 80 85 90  
 Asp Leu Val Thr Gly Gly Glu Leu Phe Glu Asp Ile Val Ala Arg  
 95 100 105  
 Glu Tyr Tyr Ser Glu Ala Asp Ala Ser His Cys Ile Gln Gln Ile  
 110 115 120  
 Leu Glu Ala Val Leu His Cys His Gln Met Gly Val Val His Arg  
 125 130 135  
 Asp Leu Lys Pro Glu Asn Leu Leu Leu Ala Ser Lys Cys Lys Gly  
 140 145 150  
 Ala Ala Val Lys Leu Ala Asp Phe Gly Leu Ala Ile Glu Val Gln  
 155 160 165  
 Gly Asp Gln Gln Ala Trp Phe Gly Phe Ala Gly Thr Pro Gly Tyr  
 170 175 180  
 Leu Ser Pro Glu Val Leu Arg Lys Glu Ala Tyr Gly Lys Pro Val  
 185 190 195  
 Asp Ile Trp Ala Cys Gly Val Ile Leu Tyr Ile Leu Leu Val Gly  
 200 205 210  
 Tyr Pro Pro Phe Trp Asp Glu Asp Gln His Lys Leu Tyr Gln Gln  
 215 220 225  
 Ile Lys Ala Gly Ala Tyr Asp Phe Pro Ser Pro Glu Trp Asp Thr  
 230 235 240  
 Val Thr Pro Glu Ala Lys Asn Leu Ile Asn Gln Met Leu Thr Ile  
 245 250 255  
 Asn Pro Ala Lys Arg Ile Thr Ala His Glu Ala Leu Lys His Pro  
 260 265 270  
 Trp Val Cys Gln Arg Ser Thr Val Ala Ser Met Met His Arg Gln  
 275 280 285  
 Glu Thr Val Glu Cys Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu  
 290 295 300  
 Lys Gly Ala Ile Leu Thr Thr Met Leu Ala Thr Arg Asn Phe Ser  
 305 310 315  
 Ala Lys Ser Leu Leu Asn Lys Lys Ala Asp Gly Val Lys Pro Gln  
 320 325 330  
 Thr Asn Ser Thr Lys Asn Ser Ala Ala Ala Thr Ser Pro Lys Gly  
 335 340 345

WO 00/06728

PCT/US99/17132

```

Thr Leu Pro Pro Ala Ala Leu Glu Pro Gln Thr Thr Val Ile His
350 355 360
Asn Pro Val Asp Gly Ile Lys Glu Ser Ser Asp Ser Ala Asn Thr
365 370 375
Thr Ile Glu Asp Glu Asp Ala Lys Ala Pro Arg Val Pro Asp Ile
380 385 390
Leu Ser Ser Val Arg Arg Gly Ser Gly Ala Pro Glu Ala Glu Gly
395 400 405
Pro Leu Pro Cys Pro Ser Pro Ala Pro Phe Gly Pro Leu Pro Ala
410 415 420
Pro Ser Pro Arg Ile Ser Asp Ile Leu Asn Ser Val Arg Arg Gly
425 430 435
Ser Gly Thr Pro Glu Ala Glu Gly Pro Leu Ser Ala Gly Pro Pro
440 445 450
Pro Cys Leu Ser Pro Ala Leu Leu Gly Pro Leu Ser Ser Pro Ser
455 460 465
Pro Arg Ile Ser Asp Ile Leu Asn Ser Val Arg Arg Gly Ser Gly
470 475 480
Thr Pro Glu Ala Lys Gly Pro Ser Pro Val Gly Pro Pro Pro Cys
485 490 495
Pro Ser Pro Thr Ile Pro Gly Pro Leu Pro Thr Pro Ser Arg Lys
500 505 510
Gln Glu Ile Ile Lys Thr Thr Glu Gln Leu Ile Glu Ala Val Asn
515 520 525
Asn Gly Asp Phe Glu Ala Tyr Ala Lys Ile Cys Asp Pro Gly Leu
530 535 540
Thr Ser Phe Glu Pro Glu Ala Leu Gly Asn Leu Val Glu Gly Met
545 550 555
Asp Phe His Arg Phe Tyr Phe Glu Asn Leu Leu Ala Lys Asn Ser
560 565 570
Lys Pro Ile His Thr Thr Ile Leu Asn Pro His Val His Val Ile
575 580 585
Gly Glu Asp Ala Ala Cys Ile Ala Tyr Ile Arg Leu Thr Gln Tyr
590 595 600
Ile Asp Gly Gln Gly Arg Pro Arg Thr Ser Gln Ser Glu Glu Thr
605 610 615
Arg Val Trp His Arg Arg Asp Gly Lys Trp Gln Asn Val His Phe
620 625 630
His Cys Ser Gly Ala Pro Val Ala Pro Leu Gln
635 640

```

&lt;210&gt; 24

&lt;211&gt; 588

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 067967

&lt;400&gt; 24

```

Met Gly Gly Thr Ala Arg Gly Pro Gly Arg Lys Asp Ala Gly Pro
1 5 10 15
Pro Gly Ala Gly Leu Pro Pro Gln Gln Arg Arg Leu Gly Asp Gly
20 25 30
Val Tyr Asp Thr Phe Met Met Ile Asp Glu Thr Lys Cys Pro Pro

```



WO 00/06728

PCT/US99/17132

	35		40		45
Cys Ser Asn Val	Leu Cys Asn Pro Ser Glu	Pro Pro Ser Pro Arg			
	50		55		60
Arg Leu Asn Met	Thr Thr Glu Gln Phe Thr Gly Asp His Thr Gln				
	65		70		75
His Phe Leu Asp	Gly Gly Glu Met Lys Val Glu Gln Leu Phe Gln				
	80		85		90
Glu Phe Gly Asn Arg	Lys Ser Asn Thr Ile Gln Ser Asp Gly Ile				
	95		100		105
Ser Asp Ser Glu Lys	Cys Ser Pro Thr Val Ser Gln Gly Lys Ser				
	110		115		120
Ser Asp Cys Leu Asn	Thr Val Lys Ser Asn Ser Ser Ser Lys Ala				
	125		130		135
Pro Lys Val Val	Pro Leu Thr Pro Glu Gln Ala Leu Lys Gln Tyr				
	140		145		150
Lys His His Leu Thr	Ala Tyr Glu Lys Leu Glu Ile Ile Asn Tyr				
	155		160		165
Pro Glu Ile Tyr Phe	Val Gly Pro Asn Ala Lys Lys Arg His Gly				
	170		175		180
Val Ile Gly Gly	Pro Asn Asn Gly Gly Tyr Asp Asp Ala Asp Gly				
	185		190		195
Ala Tyr Ile His Val	Pro Arg Asp His Leu Ala Tyr Arg Tyr Glu				
	200		205		210
Val Leu Lys Ile Ile	Gly Lys Gly Ser Phe Gly Gln Val Ala Arg				
	215		220		225
Val Tyr Asp His Lys	Leu Arg Gln Tyr Val Ala Leu Lys Met Val				
	230		235		240
Arg Asn Glu Lys Arg	Phe His Arg Gln Ala Ala Glu Glu Ile Arg				
	245		250		255
Ile Leu Glu His Leu	Lys Lys Gln Asp Lys Thr Gly Ser Met Asn				
	260		265		270
Val Ile His Met Leu	Glu Ser Phe Thr Phe Arg Asn His Val Cys				
	275		280		285
Met Ala Phe Glu Leu	Leu Ser Ile Asp Leu Tyr Glu Leu Ile Lys				
	290		295		300
Lys Asn Lys Phe Gln	Gly Phe Ser Val Gln Leu Val Arg Lys Phe				
	305		310		315
Ala Gln Ser Ile Leu	Gln Ser Leu Asp Ala Leu His Lys Asn Lys				
	320		325		330
Ile Ile His Cys Asp	Leu Lys Pro Glu Asn Ile Leu Leu Lys His				
	335		340		345
His Gly Arg Ser Ser	Thr Lys Val Ile Asp Phe Gly Ser Ser Cys				
	350		355		360
Phe Glu Tyr Gln Lys	Leu Tyr Thr Tyr Ile Gln Ser Arg Phe Tyr				
	365		370		375
Arg Ala Pro Glu Ile	Ile Leu Gly Ser Arg Tyr Ser Thr Pro Ile				
	380		385		390
Asp Ile Trp Ser Phe	Gly Cys Ile Leu Ala Glu Leu Leu Thr Gly				
	395		400		405
Gln Pro Leu Phe Pro	Gly Glu Asp Glu Gly Asp Gln Leu Ala Cys				
	410		415		420
Met Met Glu Leu Leu	Gly Met Pro Pro Pro Lys Leu Leu Glu Gln				
	425		430		435
Ser Lys Arg Ala Lys	Tyr Phe Ile Asn Ser Lys Gly Ile Pro Arg				
	440		445		450
Tyr Cys Ser Val Thr	Thr Gln Ala Asp Gly Arg Val Val Leu Val				

WO 00/06728

PCT/US99/17132

	455		460		465
Gly Gly Arg Ser	Arg Arg Gly Lys Lys	Arg Gly Pro Pro Gly Ser			
	470		475		480
Lys Asp Trp Gly	Thr Ala Leu Lys Gly	Cys Asp Asp Tyr Leu Phe			
	485		490		495
Ile Glu Phe Leu	Lys Arg Cys Leu His	Trp Asp Pro Ser Ala Arg			
	500		505		510
Leu Thr Pro Ala	Gln Ala Leu Arg His	Pro Trp Ile Ser Lys Ser			
	515		520		525
Val Pro Arg Pro	Leu Thr Thr Ile Asp	Lys Val Ser Gly Lys Arg			
	530		535		540
Val Val Asn Pro	Ala Ser Ala Phe Gln	Gly Leu Gly Ser Lys Leu			
	545		550		555
Pro Pro Val Val	Gly Ile Ala Asn Lys	Leu Lys Ala Asn Leu Met			
	560		565		570
Ser Glu Thr Asn	Gly Ser Ile Pro Leu	Cys Ser Val Leu Pro Lys			
	575		580		585
Leu Ile Ser					

&lt;210&gt; 25

&lt;211&gt; 389

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 346275

&lt;400&gt; 25

Met Ser Asp Val	Cys Ser Ser Gln Arg	Ala Glu His Glu His Leu
1	5	10 15
Pro Gly Leu Val	Pro Pro Pro Ser Gly	Met Gly Val Arg Lys Gly
	20	25 30
Ser Ser Pro Leu	Lys Ser His Pro Cys Arg	Glu Lys Ser Val Ser
	35	40 45
Asn Arg Arg Ser	Gly Lys Thr Ile Val	Arg Ser Ala Val Glu Glu
	50	55 60
Val Arg Thr Ala	Gly Leu Phe Arg Ser	Gly Phe Ser Glu Glu Lys
	65	70 75
Ala Thr Gly Lys	Leu Phe Ala Val Lys	Cys Ile Pro Lys Lys Ala
	80	85 90
Leu Lys Gly Lys	Glu Ser Ser Ile Glu	Asn Glu Ile Ala Val Leu
	95	100 105
Arg Lys Ile Lys	His Glu Asn Ile Val	Ala Leu Glu Asp Ile Tyr
	110	115 120
Glu Ser Pro Asn	His Leu Tyr Leu Val	Met Gln Leu Val Ser Gly
	125	130 135
Gly Glu Leu Phe	Asp Arg Ile Val Glu	Lys Gly Phe Tyr Thr Glu
	140	145 150
Lys Asp Ala Ser	Thr Leu Ile Arg Gln	Val Leu Asp Ala Val Tyr
	155	160 165
Tyr Leu His Arg	Met Gly Ile Val His	Arg Asp Leu Lys Pro Glu
	170	175 180
Asn Leu Leu Tyr	Tyr Ser Gln Asp Glu	Glu Ser Lys Ile Met Ile
	185	190 195

WO 00/06728

PCT/US99/17132

Ser	Asp	Phe	Gly	Leu	Ser	Lys	Met	Glu	Gly	Lys	Gly	Asp	Val	Met
				200										210
Ser	Thr	Ala	Cys	Gly	Thr	Pro	Gly	Tyr	Val	Ala	Pro	Glu	Val	Leu
				215										225
Ala	Gln	Lys	Pro	Tyr	Ser	Lys	Ala	Val	Asp	Cys	Trp	Ser	Ile	Gly
				230										240
Val	Ile	Ala	Tyr	Ile	Leu	Leu	Cys	Gly	Tyr	Pro	Pro	Phe	Tyr	Asp
				245										255
Glu	Asn	Asp	Ser	Lys	Leu	Phe	Glu	Gln	Ile	Leu	Lys	Ala	Glu	Tyr
				260										270
Glu	Phe	Asp	Ser	Pro	Tyr	Trp	Asp	Asp	Ile	Ser	Asp	Ser	Ala	Lys
				275										285
Asp	Phe	Ile	Arg	Asn	Leu	Met	Glu	Lys	Asp	Pro	Asn	Lys	Arg	Tyr
				290										300
Thr	Cys	Glu	Gln	Ala	Ala	Arg	His	Pro	Trp	Ile	Ala	Gly	Asp	Thr
				305										315
Ala	Leu	Asn	Lys	Asn	Ile	His	Glu	Ser	Val	Ser	Ala	Gln	Ile	Arg
				320										330
Lys	Asn	Phe	Ala	Lys	Ser	Lys	Trp	Arg	Gln	Ala	Phe	Asn	Ala	Thr
				335										345
Ala	Val	Val	Arg	His	Met	Arg	Lys	Leu	His	Leu	Gly	Ser	Ser	Leu
				350										360
Asp	Ser	Ser	Asn	Ala	Ser	Val	Ser	Ser	Ser	Leu	Ser	Leu	Ala	Ser
				365										375
Gln	Lys	Asp	Cys	Ala	Tyr	Val	Ala	Lys	Pro	Glu	Ser	Leu	Ser	
				380										385

&lt;210&gt; 26

&lt;211&gt; 343

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 283746

&lt;400&gt; 26

Met	Ile	Gly	Glu	Glu	Ala	Met	Ile	Asn	Tyr	Glu	Asn	Phe	Leu	Lys
1				5					10					15
Val	Gly	Glu	Lys	Ala	Gly	Ala	Lys	Cys	Lys	Gln	Phe	Phe	Thr	Ala
				20					25					30
Lys	Val	Phe	Ala	Lys	Leu	Leu	His	Thr	Asp	Ser	Tyr	Gly	Arg	Ile
				35					40					45
Ser	Ile	Met	Gln	Phe	Phe	Asn	Tyr	Val	Met	Arg	Lys	Val	Trp	Leu
				50					55					60
His	Gln	Thr	Arg	Ile	Gly	Leu	Ser	Leu	Tyr	Asp	Val	Ala	Gly	Gln
				65					70					75
Gly	Tyr	Leu	Arg	Glu	Ser	Asp	Leu	Glu	Asn	Tyr	Ile	Leu	Glu	Leu
				80					85					90
Ile	Pro	Thr	Leu	Pro	Gln	Leu	Asp	Gly	Leu	Glu	Lys	Ser	Phe	Tyr
				95					100					105
Ser	Phe	Tyr	Val	Cys	Thr	Ala	Val	Arg	Lys	Phe	Phe	Phe	Phe	Leu
				110					115					120
Asp	Pro	Leu	Arg	Thr	Gly	Lys	Ile	Lys	Ile	Gln	Asp	Ile	Leu	Ala
				125					130					135

WO 00/06728

PCT/US99/17132

Cys Ser Phe Leu Asp Asp Leu Leu Glu Leu Arg Asp Glu Glu Leu  
 140 145 150  
 Ser Lys Glu Ser Gln Glu Thr Asn Trp Phe Ser Ala Pro Ser Ala  
 155 160 165  
 Leu Arg Val Tyr Gly Gln Tyr Leu Asn Leu Asp Lys Asp His Asn  
 170 175 180  
 Gly Met Leu Ser Lys Glu Glu Leu Ser Arg Tyr Gly Thr Ala Thr  
 185 190 195  
 Met Thr Asn Val Phe Leu Asp Arg Val Phe Gln Glu Cys Leu Thr  
 200 205 210  
 Tyr Asp Gly Glu Met Asp Tyr Lys Thr Tyr Leu Asp Phe Val Leu  
 215 220 225  
 Ala Leu Glu Asn Arg Lys Glu Pro Ala Ala Leu Gln Tyr Ile Phe  
 230 235 240  
 Lys Leu Leu Asp Ile Glu Asn Lys Gly Tyr Leu Asn Val Phe Ser  
 245 250 255  
 Leu Asn Tyr Phe Phe Arg Ala Ile Gln Glu Leu Met Lys Ile His  
 260 265 270  
 Gly Gln Asp Pro Val Ser Phe Gln Asp Val Lys Asp Glu Ile Phe  
 275 280 285  
 Asp Met Val Lys Pro Lys Asp Pro Leu Lys Ile Ser Leu Gln Asp  
 290 295 300  
 Leu Ile Asn Ser Asn Gln Gly Asp Thr Val Thr Thr Ile Leu Ile  
 305 310 315  
 Asp Leu Asn Gly Phe Trp Thr Tyr Glu Asn Arg Glu Ala Leu Val  
 320 325 330  
 Ala Asn Asp Ser Glu Asn Ser Ala Asp Leu Asp Asp Thr  
 335 340

<210> 27  
 <211> 184  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 2696537

<400> 27  
 Met Gly Asn Gly Met Asn Lys Ile Leu Pro Gly Leu Tyr Ile Gly  
 1 5 10 15  
 Asn Phe Lys Asp Ala Arg Asp Ala Glu Gln Leu Ser Lys Asn Lys  
 20 25 30  
 Val Thr His Ile Leu Ser Val His Asp Ser Ala Arg Pro Met Leu  
 35 40 45  
 Glu Gly Val Lys Tyr Leu Cys Ile Pro Ala Ala Asp Ser Pro Ser  
 50 55 60  
 Gln Asn Leu Thr Arg His Phe Lys Glu Ser Ile Lys Phe Ile His  
 65 70 75  
 Glu Cys Arg Leu Arg Gly Glu Ser Cys Leu Val His Cys Leu Ala  
 80 85 90  
 Gly Val Ser Arg Ser Val Thr Leu Val Ile Ala Tyr Ile Met Thr  
 95 100 105  
 Val Thr Asp Phe Gly Trp Glu Asp Ala Leu His Thr Val Arg Ala  
 110 115 120

WO 00/06728

PCT/US99/17132

Gly Arg Ser Cys Ala Asn Pro Asn Val Gly Phe Gln Arg Gln Leu  
 125 130 135  
 Gln Glu Phe Glu Lys His Glu Val His Gln Tyr Arg Gln Trp Leu  
 140 145 150  
 Lys Glu Glu Tyr Gly Glu Ser Pro Leu Gln Asp Ala Glu Glu Ala  
 155 160 165  
 Lys Asn Ile Leu Ala Ala Pro Gly Ile Leu Lys Phe Trp Ala Phe  
 170 175 180  
 Leu Arg Arg Leu

<210> 29  
 <211> 118  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 619292

<400> 29  
 Met Gly Leu Ile Asp Gly Met His Thr His Leu Gly Ala Pro Gly  
 1 5 10 15  
 Leu Tyr Ile Gln Thr Leu Leu Pro Gly Ser Pro Ala Ala Ala Asp  
 20 25 30  
 Gly Arg Leu Ser Leu Gly Asp Arg Ile Leu Glu Val Asn Gly Ser  
 35 40 45  
 Ser Leu Leu Gly Leu Gly Tyr Leu Arg Ala Val Asp Leu Ile Arg  
 50 55 60  
 His Gly Gly Lys Lys Met Arg Phe Leu Val Ala Lys Ser Asp Val  
 65 70 75  
 Gly Lys Gln Pro Arg Arg Ser Ile Ser Ala Arg Pro Leu Ser Arg  
 80 85 90  
 Gly Ala Ala Arg Thr Pro Pro Gln Ala Arg His Pro Val Pro Pro  
 95 100 105  
 Gly Asp Thr Gly Leu Pro Pro Ala Phe Val Pro Val Leu  
 110 115

<210> 30  
 <211> 356  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 2054049

<400> 30  
 Met Val Gly Val Ser Gly Lys Arg Ser Lys Glu Asp Glu Lys Tyr  
 1 5 10 15  
 Leu Gln Ala Ile Met Asp Ser Asn Ala Gln Ser His Lys Ile Phe  
 20 25 30  
 Ile Phe Asp Ala Arg Pro Ser Val Asn Ala Val Ala Asn Lys Ala  
 35 40 45  
 Lys Gly Gly Gly Tyr Glu Ser Glu Asp Ala Tyr Gln Asn Ala Glu

WO 00/06728

PCT/US99/17132

	50		55		60
Leu Val Phe Leu Asp Ile His Asn Ile His Val Met Arg Glu Ser					
	65		70		75
Leu Arg Lys Leu Lys Glu Ile Val Tyr Pro Asn Ile Glu Glu Thr					
	80		85		90
His Trp Leu Ser Asn Leu Glu Ser Thr His Trp Leu Glu His Ile					
	95		100		105
Lys Leu Ile Leu Ala Gly Ala Leu Arg Ile Ala Asp Lys Val Glu					
	110		115		120
Ser Gly Lys Thr Ser Val Val Val His Cys Ser Asp Gly Trp Asp					
	125		130		135
Arg Thr Ala Gln Leu Thr Ser Leu Ala Met Leu Met Leu Asp Gly					
	140		145		150
Tyr Tyr Arg Thr Ile Arg Gly Phe Glu Val Leu Val Glu Lys Glu					
	155		160		165
Trp Leu Ser Phe Gly His Arg Phe Gln Leu Arg Val Gly His Gly					
	170		175		180
Asp Lys Asn His Ala Asp Ala Asp Arg Ser Pro Val Phe Leu Gln					
	185		190		195
Phe Ile Asp Cys Val Trp Gln Met Thr Arg Gln Phe Pro Thr Ala					
	200		205		210
Phe Glu Phe Asn Glu Tyr Phe Leu Ile Thr Ile Leu Asp His Leu					
	215		220		225
Tyr Ser Cys Leu Phe Gly Thr Phe Leu Cys Asn Ser Glu Gln Gln					
	230		235		240
Arg Gly Lys Glu Asn Leu Pro Lys Arg Thr Val Ser Leu Trp Ser					
	245		250		255
Tyr Ile Asn Ser Gln Leu Glu Asp Phe Thr Asn Pro Leu Tyr Gly					
	260		265		270
Ser Tyr Ser Asn His Val Leu Tyr Pro Val Ala Ser Met Arg His					
	275		280		285
Leu Glu Leu Trp Val Gly Tyr Tyr Ile Arg Trp Asn Pro Arg Met					
	290		295		300
Lys Pro Gln Glu Pro Ile His Asn Arg Tyr Lys Glu Leu Leu Ala					
	305		310		315
Lys Arg Ala Glu Leu Gln Lys Lys Val Glu Glu Leu Gln Arg Glu					
	320		325		330
Ile Ser Asn Arg Ser Thr Ser Ser Ser Glu Arg Ala Ser Ser Pro					
	335		340		345
Ala Gln Cys Val Thr Pro Val Gln Thr Val Val					
	350		355		

&lt;210&gt; 31

&lt;211&gt; 453

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2843910

&lt;400&gt; 31

Met	Ala	Gly	Ala	Gly	Gly	Phe	Gly	Cys	Pro	Ala	Gly	Gly	Asn	Asp
1					5				10				15	
Phe	Gln	Trp	Cys	Phe	Ser	Gln	Val	Lys	Gly	Ala	Ile	Asp	Glu	Asp

WO 00/06728

PCT/US99/17132

20	25	30
Val Ala Glu Ala Asp Ile Ile Ser Thr	Val Glu Phe Asn Tyr Ser	
35	40	45
Gly Asp Leu Leu Ala Thr Gly Asp Lys	Gly Gly Arg Val Val Ile	
50	55	60
Phe Gln Arg Glu Gln Glu Asn Lys Ser	Arg Pro His Ser Arg Gly	
65	70	75
Glu Tyr Asn Val Tyr Ser Thr Phe Gln	Ser His Glu Pro Glu Phe	
80	85	90
Asp Tyr Leu Lys Ser Leu Glu Ile Glu	Glu Lys Ile Asn Lys Ile	
95	100	105
Arg Trp Leu Pro Gln Gln Asn Ala Ala	His Phe Leu Leu Ser Thr	
110	115	120
Asn Asp Lys Thr Ile Lys Leu Trp Lys	Ile Ser Glu Arg Asp Lys	
125	130	135
Arg Ala Glu Gly Tyr Asn Leu Lys Asp	Glu Asp Gly Arg Leu Arg	
140	145	150
Asp Pro Phe Arg Ile Thr Ala Leu Arg	Val Pro Ile Leu Lys Pro	
155	160	165
Met Asp Leu Met Val Glu Ala Ser Pro	Arg Arg Ile Phe Ala Asn	
170	175	180
Ala His Thr Tyr His Ile Asn Ser Ile	Ser Val Asn Ser Asp His	
185	190	195
Glu Thr Tyr Leu Ser Ala Asp Asp Leu	Arg Ile Asn Leu Trp His	
200	205	210
Leu Glu Ile Thr Asp Arg Ser Phe Asn	Ile Val Asp Ile Lys Pro	
215	220	225
Ala Asn Met Glu Glu Leu Thr Glu Val	Ile Thr Ala Ala Glu Phe	
230	235	240
His Pro His Gln Cys Asn Val Phe Val	Tyr Ser Ser Ser Lys Gly	
245	250	255
Thr Ile Arg Leu Cys Asp Met Arg Ser	Ser Ala Leu Cys Asp Arg	
260	265	270
His Ser Lys Phe Phe Glu Glu Pro Glu	Asp Pro Ser Ser Arg Ser	
275	280	285
Phe Phe Ser Glu Ile Ile Ser Ser Ile	Ser Asp Val Lys Phe Ser	
290	295	300
His Ser Gly Arg Tyr Met Met Thr Arg	Asp Tyr Leu Ser Val Lys	
305	310	315
Val Trp Asp Leu Asn Met Glu Ser Arg	Pro Val Glu Thr His Gln	
320	325	330
Val His Glu Tyr Leu Arg Ser Lys Leu	Cys Ser Leu Tyr Glu Asn	
335	340	345
Asp Cys Ile Phe Asp Lys Phe Glu Cys	Cys Trp Asn Gly Ser Asp	
350	355	360
Ser Ala Ile Met Thr Gly Ser Tyr Asn	Asn Phe Phe Arg Met Phe	
365	370	375
Asp Arg Asp Thr Arg Arg Asp Val Thr	Leu Glu Ala Ser Arg Glu	
380	385	390
Ser Ser Lys Pro Arg Ala Ser Leu Lys	Pro Arg Lys Val Cys Thr	
395	400	405
Gly Gly Lys Arg Arg Lys Asp Glu Ile	Ser Val Asp Ser Leu Asp	
410	415	420
Phe Asn Lys Lys Ile Leu His Thr Ala	Trp His Pro Val Asp Asn	
425	430	435
Val Ile Ala Val Ala Ala Thr Asn Asn	Leu Tyr Ile Phe Gln Asp	

WO 00/06728

PCT/US99/17132

440

445

450

Lys Ile Asn

&lt;210&gt; 32

&lt;211&gt; 1221

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 132240

&lt;400&gt; 32

```

cttttcctgg aatttctata atggaaagtc cattagaaag tcagccctta gattcagata 60
gaagcatcaa agaatcctct tttgaagaat caaatattga agatccactt attgtaacac 120
cagattgcc aaaaaagacc tcacaaaag gtgtcgagaa ccctgctgta caagagagta 180
accaaaaaat gttaggctct cctttggagg tgctgaaaac gttagcctct aaaagaaatg 240
ctgttgcttt tcgaagtgtt aacagtcata ttaatgcata caataactca gaaccatcca 300
gaatgaacat gacttcttta gatgcaatgg atatttcgtg tgctacagt ggttcatatc 360
ccatggctat aaccctact caaaaaagaa gatcctgtat gccacatcag accccaaatc 420
agatcaagtc gggaactcca taccgaactc cgaagagtgt gagaagaggg gtggcccccg 480
ttgatgatgg gcgaattcta ggaaccccag actaccttgc acctgagctg ttactaggca 540
gggcccagtg tctgcggtta gactgggtgg cacttggagt ttgcttggtt gaatttctaa 600
caggaattcc ccctttcaat gatgaaacac cacaacaagt attccagaat attctgaaaa 660
gagatatccc ttggccagaa ggtgaagaaa agttatctga taatgctcaa agtgcagtag 720
aaatactttt aaccattgat gatacaaaag gagctggaat gaaagagcta aaacgtcatc 780
ctctcttcag tgatgtggac tgggaaaatc tgcagcatca gactatgcct ttcaccccc 840
agccagatga tgaacagat acctcctatt ttgaagccag gaatactgct cagcacctga 900
ctgtatctgg atttagtctg tagcacaaaa attttccttt tagtctagcc ttgtgttata 960
gaatgaactt gcataattat atactcctta atactagatt gatctaaggg ggaaagatca 1020
ttatttaacc tagttcaatg tgcttttaat gtacgttaca gctttcacag agttaaagg 1080
ctgaaaggaa tatagtcagt aatttatctt aacctcaaaa ctgtatataa atcttcaaag 1140
cttttttcat ttattttatt tgtttattgc actttatgaa aactgaagca tcaataaaat 1200
tagaggacac taaaaaaaaa a 1221

```

&lt;210&gt; 33

&lt;211&gt; 542

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2180116

&lt;400&gt; 33

```

tggccaggct gggccagca gcgcgatggc agctcagcgg ctgggcaagc gcgtgctgag 60
caagctgcag tctccatcgc gggcccgagg gccagggggc agtcccgggg ggatgcagaa 120
gcggcacgcg cgcgtcaccg tcaagtatga ccggcgggag ctgcagcggc ggctggacgt 180
ggagaagtgg atcgacgggc gcctggagga gctgtaccgc ggcagggagg cagacatgcc 240
cgatgagatc aacattgatg aattgttggg gttagagagt gaagaggaga gaagccggaa 300
aatccaggga ctctgaaagt catgtgggaa acctgtcgag gacttcatcc aggagctgct 360
ggcaaagctt caaggcctcc acaggcagcc cggcctccgc cagccaagcc cctcccacga 420
cggcagcctc agccccctcc aggaccgggc ccggactgct caccctgac cctcttgac 480
tctccctgcc ccccgagcgc cggccagctt gcttgtgtat aagttgtatt taatggattc 540

```



WO 00/06728

PCT/US99/17132

tt

542

<210> 34  
 <211> 2778  
 <212> DNA  
 <213> Homo sapiens  
  
 <220>  
 <221> misc\_feature  
 <222> 2548, 2557, 2645, 2722, 2557, 2762, 2765  
 <223> Incyte Clone Number: 2197671

<400> 34  
 cgcgagatcgt cgcgggcccg cgcgtcccg cccaggaagtg gccgtcctga gcgccatggc 60  
 tcaactcccc gtgcagtcgg gcctgcccgg catgcagaac cttaaaggcag acccagaaga 120  
 gcttttttaca aaactagaga aaattgggaa gggctccttt ggagaggtgt tcaaaggcat 180  
 tgacaatcgg actcagaaag tgggtgccat aaagatcatt gatctggaag aagctgaaga 240  
 tgagatagag gacattcaac aagaaatcac agtgctgagt cagtgtgaca gtccatattgt 300  
 aaccaaatat tatggatcct atctgaagga tacaaaatta tggataataa tggaatatct 360  
 tgggtggaggc tccgcactag atctattaga acctggccga ttagatgaaa cccagatcgc 420  
 tactatatta agagaaatac tgaaaggact cgattatctc cattcggaga agaaaatcca 480  
 cagagacatt aaagcggcca acgtcctgct gtctgagcat ggcgaggtga agctggcgga 540  
 ctttggcgtg gctggccagc tgacagacac ccagatcaaa aggaacacct tcgtgggcac 600  
 ccattcttg atggcaccgg aggtcatcaa acagtcggcc tatgactcga aggcagacat 660  
 ctggtccctg ggcataacag ctattgaact tgcaagagg gaaccacctc attccgagct 720  
 gcaccccatg aaagttttat tctcattcc aaagaacaac ccaccgacgt tgggaaggaaa 780  
 ctacagtaaa cccctcaagg agtttgtgga ggctgtttg aataaggagc cgagctttag 840  
 acccactgct aaggagttat tgaagcaca gtttatacta cgcaatgcaa agaaaacttc 900  
 ctacttgacc gagctcatcg acaggtacaa gagatggaag gccgagcaga gccatgacga 960  
 ctcgagctcc gaggattccg acgcggaaac agatggccaa gcctcggggg gcagtgattc 1020  
 tggggactgg atcttcacaa tccgagaaaa agatcccaag aatctcgaga atggagctct 1080  
 tcagccatcg gacttggaca gaaataagat gaaagacatc ccaaaggagg ctttctctca 1140  
 gtgtttatct acaattattt ctctctgtt tgcaaggtt aaggagaaga gccaggcgtg 1200  
 cggagggaaac ttgggtcca ttgaagagct ccgagggggc atctacctag cggaggaggc 1260  
 gtgccctggc atctccgaca ccatggtggc ccagctcgtg cagcggctcc agagatactc 1320  
 tctaagtggg ggaggaactt catccactg aaattccttt ggcatttggg gttttgtttt 1380  
 tctttttttt cttcttcac ctcctccttt tttaaaagtc aacgagagcc ttcgctgact 1440  
 ccaccgaaga ggtgcgccac tgggagccac cccagtgcc aagcggccgc cagggacaca 1500  
 cacagtcttc actgtgctgc agccagatga agtctctcag atgggtgggg agggtcagct 1560  
 ccttccagcg atcattttat tttattttat tacttttgtt tttaatttta accatagtgc 1620  
 acatattcca ggaaagtgtc tttaaaaaca aaaacaaacc ctgaaatgta tatttgggat 1680  
 tatgataagg caactaaaga catgaaacct caggtatcct gctttaagtt gataactccc 1740  
 tctgggagct ggagaatcgc tctggtggat ggggtgtacag atttgtatat aatgtcattt 1800  
 ttaccgaaac cctttcggcg tgcataagga atcactgtgt acaaactggc caagtgcctc 1860  
 tgtagataac gtcagtggag taaatattcg acaggccata acttgagtct attgccttgc 1920  
 ctttattaca tgtacatttt gaattctgtg accagtgatt tgggttttat tttgtatttg 1980  
 cagggtttgt cattaataat taatgccct ctcttacaga aactcctat ttgtacctca 2040  
 acaaatgcaa attttcccc tttgccctac gccctttttg gtacacctag aggttgattt 2100  
 cctttttcat cgatgggtact atttcttagt gttttaaatt ggaacatatc ttgcctcatg 2160  
 aagcttttaa ttataatttt cagtttctcc ccatgaagcg ctctcgtctg acatttgttt 2220  
 ggaatcgtgc cactgctggt ctgcgccaga tgtaccgtcc tttccaatac gattttctgt 2280  
 tgcaccttgt agtggattct gcataatc tttccacct aaaaatgtct gaatgcttac 2340  
 acaaataaat tttataacac gcttattttg catactcctt gaaatgtgac tcttcagagg 2400  
 acagggtagc tgctgtgtat gtgtggccgt gcgtgtgtac tcgtggctgt gtgtgtgtga 2460

WO 00/06728

PCT/US99/17132

```

tgagacactt tggagactc cagggagaag ttcccagggc tggagctgcc gagggtcccag 2520
gtcagcgccc tgggctgctt gcgcaatngc tcaccngat gatgcattgg aggttgctga 2580
cctgtgcgat tgctgtagcg gttgccaggg accttaaggg gttattttgc ttccctggga 2640
ggggncctat gtttctagge aagcagccat gtgtctaatt ttctgggttt gctgtgggga 2700
cctgattggg ggagggggaa anctttgggg ttcttgaggt gggaggggtc gtgccancaa 2760
tnttncctgg taaaaaag

```

&lt;210&gt; 35

&lt;211&gt; 1424

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2594943

&lt;400&gt; 35

```

ggctcagcct ccgacccagg tgggtctggag cctgccggga gagggtgggc atctgagagg 60
ctgggtcggtt actgtggttg ggggaggttg gagctgtttt aaccgtgtgc cccctctcct 120
gtgccggcgt gggcatcccc cggggcagtg gaacgcgggc gctcctccag cttccgagtc 180
cagccagcct gggcgcgggg cgccgcccc gagacacccg aggagtccgt tccctccctgg 240
ttacgtggac tgtggagctg gtctcttggt gctcagcgcc gtgcggaggt tgaagcgtag 300
ctgcggaggt cgcaccaggg cgtgaggagg aggaggaagg gcatgagccg agcttgaggga 360
atccgtgtct caaactctac actcaagggg ggcccttggg tagggtgaag atccccctgtc 420
tttatccctag ttccacacct tgggtgtgggt tactgggtgc aggatgaact gtcgctcgga 480
ggtgctggag gtgtcggttg aggggcggca ggtggaggag gccatgctgg ctgtgctgca 540
cacggtgctt ctgcaccgca gcacaggcaa gttccactac aagaaggagg gcacctactc 600
cattggcacc tggggcacc aggatgttga ctgtgacttc atcgacttca cttatgtgctg 660
tgtctcttct gaggaactgg atcgtgccct gcgcaagggt gttggggagt tcaaggatgc 720
actgcgcaac tctggtggcg atgggctggg gcagatgtcc ttggagttct accagaagaa 780
gaagtctcgc tggccattct cagacgagtg catcccatgg gaagtgtgga cggccaagggt 840
gcatgtggta gccctggcca cggagcagga gcggcagatc tgccgggaga aggtgggtga 900
gaaactctgc gagaagatca tcaacatcgt ggaggtgatg aatcggcatg agtacttgcc 960
caagatgccc acacagtcgg aggtggataa cgtgtttgac acaggcttgc gggacgtgca 1020
gccctacctg tacaagatct ccttccagat cactgatgcc ctgggcacct cagtcaccac 1080
caccatgcgc aggtcatca aagacaccct tgccctctga gcgtcgctgg atctctggga 1140
gctccttgat ggctccaga ccttggtttt tgggaattgc acttttgggc ctttgggtctc 1200
tggaaacctgc tctgggtcat tgggtgagact tggaaagggc agcccccgct ggcttcttgg 1260
ttttgtggtt gccagcctca ggtcatcctt ttaatctttg ctgatggttc agtccctgcc 1320
ctactgtctc tccatagccc tgggtgggtc ccccttcttt ctccactgta cagaagagcc 1380
accactggga tggggaataa agttgagaac atgaaaaaaa aaaa 1424

```

&lt;210&gt; 36

&lt;211&gt; 1839

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1513871

&lt;400&gt; 36

```

ctcctcctc ggccagctca ggttgagct tctctgggga actgctcacc tttccggagc 60
aggggaagct gccccgtgcc cgggagggag cgggcgcacc gcggccccca ggacacgcgc 120
tgacccggtt gccagtcctc tcatgatcat gaacaagatg aagaacttta agcgccgttt 180
ctccctgtca gtgccccgca ctgagaccat tgaagaatcc ttggctgaat tcacggagca 240

```

WO 00/06728

PCT/US99/17132

```

attcaaccag ctccacaacc ggcggaatga gaacttgcag ctcggtcctc ttggcagaga 300
ccccccgcag gaggtcagca ccttctcccc aacagacagc ggggaggagc cggggcagct 360
ctcccctggc gtgcagttcc agcggcgcca gaaccagcgc cgcttctcca tggaggacgt 420
cagcaagagg ctctctctgc ccatggatat ccgcctgccc caggaattcc tacagaagct 480
acagatggag agcccagatc tgcccaagcc gctcagccgc atgtcccgcc gggcctccct 540
gtcagacatt ggctttggga aactggaaac atacgtgaaa ctggacaaac tgggagaggg 600
cacctatgcc acagtcttca aagggcgagc caaactgacg gagaacctg tggccctgaa 660
agagatccgg ctggagcacg aggagggagc gccctgcact gccatccgag aggtgtctct 720
gctgaagaac ctgaagcacg ccaatattgt gaccctgcat gacctcatcc acacagatcg 780
gtccctcacc ctggtgtttg agtacctgga cagtgcactg aagcagtatc tggaccactg 840
tgggaacctc atgagcatgc acaacgtcaa gattttcatg ttccagctgc tccggggcct 900
cgcctactgt caccaccgca agatcctgca ccgggacctg aagccccaga acctgctcat 960
caacgagagg ggggagctga agctggccga ctttggactg gccaggggcca agtcagtgcc 1020
cacaagact tactccaatg aggtggtgac cctgtggtac agggcccccg atgtgctgct 1080
gggatccaca gagtactcca cccccattga tatgtggggc gtgggctgca tccactacga 1140
gatggccaca gggaggcccc tcttcccggg ctccacagtc aaggaggagc tgcacctcat 1200
ctttcgctc ctccgggaccc ccacagaaga gacgtggccc ggcgtgaccg ccttctctga 1260
gttccgcacc tacagcttcc cctgctacct ccgcagccg ctcatcaacc acgcgccag 1320
gttggtacg gatggcatcc acctcctgag cagcctgtct ctgtatgaat ccaagagtct 1380
catgtcagca gaggctgccc tgagtcactc ctacttccgg tctctgggag agcgtgtgca 1440
ccagcttgaa gacactgcct ccactctctc cctgaaggag atccagctcc agaaggaccc 1500
aggctaccga ggcttggcct tccagcagcc aggacgaggg aagaacaggc ggcagagcat 1560
cttctgagcc acgcccacct tgctgtggcc aagggaacaag agatcacatg gagcacaaat 1620
tcgggtagga tggagcctgt gtggccctcg gaggactgaa gaacgagggc tgacagcagc 1680
ctggaagacc gcttggcagg cttttggcca agtgtttttc tttgtggttt cgtctgctg 1740
ccagtagttt cagtggatac aacgtgcttt aggagttggg tgggaaagtc ttgctagagg 1800
gtttaggggg aggtttctac cgttgactcg gtttagggc 1839

```

&lt;210&gt; 37

&lt;211&gt; 2024

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 156108

&lt;400&gt; 37

```

gtcagctctg gttcggagaa gcagcggctg gcgtggggcca tccgggggaat gggcgccctc 60
gtgacctagt gttgcggggc aaaaagggtc ttgccggcct cgctcgtgca ggggcgtatc 120
tgggcgcctg agcgcggcgt gggagccttg ggagccgcgc cagcaggggg cacaccgga 180
accggcctga gcgccgggga ccatgaacgg ggaggccatc tgcagcgccc tgcccacct 240
tccctaccac aaactcgccg acctgcgcta cctgagccgc ggcgcctctg gcactgtgtc 300
gtccgcccgc cacgcagact ggcgcgtcca ggtggccgtg aagcacctgc acatccacac 360
tccgctgctc gacagtgaag gaaaggatgt cttaagagaa gctgaaattt tacacaaagc 420
tagatttagt tacattcttc caattttggg aatttgcaat gagcctgaat ttttgggaat 480
agttactgaa tacatgccaa atggatcatt aaatgaactc ctacatagga aaactgaata 540
tcttgatgtt gcttggccat tgagatttct catcctgcat gaaattgccc ttggtgtaaa 600
ttacctgcac aatatgactc ctctttact tcatcatgac ttgaagactc agaatatctt 660
attggacaat gaatttcatg ttaagattgc agattttggt ttatcaaagt ggcgcctgat 720
gtccctctca cagtcacgaa gtagcaaatc tgcaccagaa ggaggggaaa ttatctatat 780
gccacctgaa aactatgaac ctggacaaaa atcaaggggc agtatcaagc acgatataata 840
tagctatgca gttatcacat gggaagtgtt atccagaaaa cagccttttg aagatgtcac 900
caatcctttg cagataatgt atagtgtgc acaaggacat cgacctgtta ttaatgaaga 960
aagtttgcca tatgatatac ctccaccgag acgtatgatc tctctaataa aaagtggatg 1020

```

WO 00/06728

PCT/US99/17132

```

ggcacaaaat ccagatgaaa gaccatcttt cttaaaatgt ttaatagaac ttgaaccagt 1080
tttgagaaca tttgaagaga taacttttct tgaagctggt attcagctaa agaaaacaaa 1140
gttacagagt gtttcaagtg ccattcacct atgtgacaag aagaaaatgg aattatctct 1200
gaacatacct gtaaatcatg gtccacaaga ggaatcatgt ggatcctctc agctccatga 1260
aaatagtggg tctcctgaaa cttcaagggt cctgccagct cctcaagaca atgatttttt 1320
atctagaaaa gctcaagact gttattttat gaagctgcat cactgtcctg gaaatcacag 1380
ttgggatagc accatttctg gatctcaaag ggctgcattc tgtgatcaca agaccactcc 1440
atgctcttca gcaataataa atccactctc aactgcagga aactcagaac gtctgcagcc 1500
tggatatagc cagcagtggg tccagagcaa aagggaagac attgtgaacc aaatgacaga 1560
agcctgcctt aaccagtcgc tagatgccct tctgtccagg gacttgatca tgaaagagga 1620
ctatgaactt gttagtacca agcctacaag gacctcaaaa gtcagacaat tactagacac 1680
tactgacatc caaggagaag aatttgccaa agttatagta caaaaattga aagataacaa 1740
acaaatgggt cttcagcctt acccggaat acttggtgtt tctagatcac catcttttaa 1800
tttacttcaa aataaaagca tgtaagtgtg tgtttttcaa gaagaaatgt gtttcataaa 1860
aggatattta tatctctgtt gctttgactt tttttatata aaatccgtga gtattaaagc 1920
tttattgaag gttctttggg taaatattag tctccctcca tgacactgca gtattttttt 1980
taattaatac aagtaaaaag tttgaatttt gctacataaa aaaa 2024

```

&lt;210&gt; 38

&lt;211&gt; 1861

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2883243

&lt;400&gt; 38

```

gcttcttagt gaggttggca ttatgttaag gctggtatgg aagacaactg atgaagcagg 60
agtggctctg tgacattttt ctgacttgat tggctggggc gtgtgatgta ataggtttca 120
gtgcagcccc ttataggttt taaaatgaat tccaagacac cattacaaag aaagccggac 180
tcttttctta taactgagct cagccaagga aactcttgca caaatgtaca atactgtttg 240
gaatatggaa gacctggatt tagaatatgc caagacagat ataaattgtg gcacagactt 300
gatgttttat atagaaatgg acccaccagc actgcctcct aaaccaccaa aacctactac 360
tgtagccaac aacgggtatga ataacaatat gtccttacia gatgctgaat ggtactgggg 420
agatatctcg agggagaag tgaatgaaaa acttcgagat acagcagacg ggaccttttt 480
ggtacgagat gcgtctacta aaatgcatgg tgattatact cttacactaa ggaaaggggg 540
aaataacaaa ttaatcaaaa tatttcacg agatgggaaa tatggcttct ctgaccatt 600
aaccttcagt tctgtggttg aattaataaa ccactaccgg aatgaatctc tagctcagta 660
taatcccaa ttggatgtga aattacttta tccagtatcc aaataccaac aggatcaagt 720
tgtcaagaa gataatattg aagctgtagg gaaaaatta catgaatata acactcagtt 780
tcaagaaaa agtcgagaat atgatagatt atatgaagaa tatacccgca catcccagga 840
aatccaaatg aaaaggacag ctattgaagc atttaatgaa accataaaaa tatttgaaga 900
acagtgccag acccaagagc ggtacagcaa agaatacata gaaaagttaa aacgtgaagg 960
caatgagaaa gaaatacaaa ggattatgca taattatgat aagttgaagt ctgcaatcag 1020
tgaaattatt gacagtagaa gaagattgga agaagacttg aagaagcagg cagctgagta 1080
tcgagaaatt gacaaacgta tgaacagcat taaaccagac cttatccagc tgagaaagac 1140
gagagaccaa tacttgatgt ggttgactca aaaaggtgtt cggcaaaaga agttgaacga 1200
gtgggtgggc aatgaaaaca ctgaagacca atattcactg gtggaagatg atgaagattt 1260
gccccatcat gatgagaaga catggaatgt tgggaagcagc aaccgaaaca aagctgaaaa 1320
cctgttgcca gggaagcgag atggcacttt tcttgtccgg gagagcagta aacagggtctg 1380
ctatgcctgc tctgtagtgg tggacggcga agtaaagcat tgtgtcataa acaaaacagc 1440
aactggctat ggctttgccg agccctataa cttgtacagc tctctgaaag aactggtgct 1500
acattaccaa cacacctccc ttgtgcagca caagactcc ctcaatgtca cactagccta 1560
cccagtatat gcacagcaga ggcgatgaag cgcttactct ttgatccttc tctgaagtt 1620

```

WO 00/06728

PCT/US99/17132

cagccaccct gaggcctctg gaaagcaaag ggctcctctc cagtctgata tgtgaattga 1680  
 gctgcagaaa cgaagccaac tttttttgga tgggactagt gctttctttc acaaaaaaga 1740  
 agtaggggaa gacatgcagc ctaaggctgt atgatgacca cacgttecta agctggagtg 1800  
 cttatccctt ctttttcttt ttttctttgg tttaatttaa agccacaacc acatacaaca 1860  
 c 1861

<210> 39  
 <211> 2045  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 3173355

<400> 39  
 cttggctgga acctgagacg gattcgctcc caaatgatgc tccagtggca ggagcaactc 60  
 aagttcatca ttgtcctgag agagaggagc agcgcggttc tcggccggga cagcagaacg 120  
 ccaggggacc ctcacctggg cgcgcggggg cacgggcttt gattgtcctg gggtcgaggga 180  
 gacccgcgcg cctgccctgc acgcccggcg gcaacctttg cagtcgctgt ggctgctgcg 240  
 atcgcccggc gggtcctgc cgaaggctcg gctgcttctg tccacctctt acacttcttc 300  
 atttatcggt ggatcatttc gagagtcctg cttgtaaagt tttggcactt tgctacttta 360  
 ttgcttcttt ctggcgacag ttccagcact cgccgagacc ggccggagaaa ggcagctgag 420  
 cccggagaag agcgaaatat ggggacccgg gctaaaagca gacgtcgtcc ttcccgcgcg 480  
 ctatttctat attcaggcag tggatacatc aggggaataaa ttcacatctt ctccaggcga 540  
 aaaggtcttc caggtgaaag tctcagcacc agaggagcaa ttcactagag ttggagtcca 600  
 ggttttagac cgaaaagatg ggtccttcat agtaagatac agaagtgtat caagctacaa 660  
 aaatctgaag gtggaaatta aattccaagg gcaacatgtg gccaaatccc catatatatt 720  
 aaaagggccg gtttaccatg agaactgtga ctgtcctctg caagatagtg cagcctggct 780  
 acgggagatg aactgccctg aaaccattgc tcagattcag agagatctgg cacatttccc 840  
 tgctgtggat ccagaaaaga ttgcagtaga aatcccaaaa agatttggac agaggcagag 900  
 cctatgtcac tacaccttaa aggataacaa ggtttatata aagactcatg gtgaacatgt 960  
 aggttttaga attttcatgg atgccatact actttctttg actagaaagg tgaagatgcc 1020  
 agatgtggag ctctttgtta atttgggaga ctggcctttg gaaaaaaga aatccaattc 1080  
 aaacatccat ccgatctttt cctggtgtgg ctccacagat tccaaggata tcgtgatgcc 1140  
 tacgtacgat ttgactgatt ctgttctgga aaccatgggc cgggtaagtc tggatatgat 1200  
 gtccgtgcaa gctaacacgg gtcctcctg ggaaagcaaa aattccactg ccgtctggag 1260  
 agggcgagac agccgcaaag agagactcga gctgggttaa ctcagtagaa aacaccacga 1320  
 actcatagac gctgctttca ccaacttttt cttctttaaa cacgatgaaa acctgtatgg 1380  
 tcccattgtg aaacatatatt cattttttga tttcttcaag cataagtatc aaataaatat 1440  
 cgatggcact gtagcagctt atcgctgcc atatttgcta gttggtgaca gtgttgtgct 1500  
 gaagcaggat tccatctact atgaacattt ttacaatgag ctgcagccct ggaaacacta 1560  
 cattccagtt aagagcaacc tgagcgatct gctagaaaaa cttaaatggg cgaaagatca 1620  
 cgatgaagag gccaaaaaga tagcaaaagc aggacaagaa ttgcaagaa ataactctcat 1680  
 gggcgatgac atattctgtt attatttcaa acttttccag gaatatgcca atttacaagt 1740  
 gagtgcagccc caaatccgag agggcatgaa aagggtagaa ccacagactg aggacgacct 1800  
 cttcccttgt acttgccata ggaaaaagac caaagatgaa ctctgatatg caaaataact 1860  
 tctattagaa taatggtgct ctgaagactc ttcttaacta aaaagaagaa tttttttaag 1920  
 tattaattcc atggacaata taaaatctgt gtgattgttt gcagtatgaa gacacatttc 1980  
 tacttatgca gtattctcat gactgtactt taaagtacat ttttagaatt ttataataaa 2040  
 accac 2045

&lt;210&gt; 40

WO 00/06728

PCT/US99/17132

&lt;211&gt; 1260

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 5116906

&lt;400&gt; 40

```

cgatattttt ctttcttagt ttcccatttc atattgtttt gtcaaataca ctgtgactca 60
ttaacatctc ttttccctag gttttgctgg cacacctgga tatctttctc cagaagtgtt 120
acgtaaagat ccttatggaa agccagtggg tatgtgggca tgtgggtgtca ttctctatat 180
tctacttggt ggggtatccac ctttctggga tgaagaccaa cacagactct atcagcagat 240
caaggctgga gcttatgatt ttccatcacc agaatgggac acggtgactc ctgaagccaa 300
agacctcatc aataaaatgc ttactatcaa cctgcccaca cgcatcacag cctcagaggc 360
actgaagcac ccatggatct gtcaacgttc tactgttgct tccatgatgc acagacagga 420
gactgtagac tgcttgaaga aatttaaatgc tagaagaaaa cttaaagggtg ccatcttgac 480
aactatgctg gctacaagga atttctcagc agccaagagt ttgttgaaga aaccagatgg 540
agtaaaggag tcaactgaga gttcaaatac aacaattgag gatgaagatg tgaaagcacg 600
aaagcaagag attatcaaag tcaactgaaca actgatcgaa gctatcaaca atggggactt 660
tgaagcctac acaaaaatct gtgacccagg ccttactgct tttgaacctg aagctttggg 720
taatttagtg gaagggatgg attttcaccc atttactttt gaaaatgctt tgtccaaaag 780
caataaacca atccacacta ttattctaaa cctcatgta catctggtag gggatgatgc 840
cgcctgcata gcatatatta ggctcacaca gtacatggat ggcagtggaa tgccaaagac 900
aatgcagtca gaagagactc gtgtgtggca ccgccgggat ggaaagtggc agaattgtca 960
ttttcatcgc tcgggggtcac caacagtacc catcaactaa atttcaacag tgccacttct 1020
gcattctctg ttctcaaggc acctggatgg tgacctggg ccgtcctctc ctcctcttca 1080
tgcattgttc tgagtgcatt aagttgtgaa ggctctacat gtaatgcata tgtgatgcac 1140
catcttatca tatattcctt cctatacatt gtttacactt caactacggg gatgttccac 1200
acaaacttaa attactgttg gcaaaacaat agggggagat tagacaaaaa aaaaaaaaaa 1260

```

&lt;210&gt; 41

&lt;211&gt; 2059

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 940589

&lt;400&gt; 41

```

aaacataga aacgctaatt aaagcagaca tcaaaatctg gatccttaca ggggacaagc 60
aagaaactgc cattaacatc ggacactcct gcaaactgtt gaagaagaac atgggaatga 120
ttgttataaa tgaaggctct cttgattctt tctctaatac acagaattct aggaaggagg 180
ctgttctttt agccaaaatg aaacacccta atattgttgc cttcaaagaa tcatttgaag 240
ctgaaggaca cttgtatatt gtgatggaat actgtgatgg aggggatcta atgcaaaaaga 300
ttaaacagca gaaaggaaag ttatttcctg aagacatgat acttaattgg tttacccaaa 360
tgtgccttgg agtaaatcac attcacaaga aacgtgtgct acacagagat atcaagtcca 420
agaatatctt cctcactcag aatggaaaag tgaaattggg agactttgga tctgcccgtc 480
ttctctccaa tccgatggca tttgcttgta cctatgtggg aactccttat tatgtgcttc 540
cagaaatttg ggaaaacctg ccttataaca ataaaagtga catctggtcc ttgggttgca 600
tcctgtatga actctgtacc cttaagcatc catttcaggc aaatagtgtg aaaaatctta 660
tcctcaaagt atgtcaaggg tgcatacgtc cactgccgtc tcattactcc tatgaactcc 720
agttcctagt caagcagatg tttaaaagga atccctcaca tcgcccctcg gctacaacgc 780
ttctctctcg aggcacgtga gctcggcttg tccagaagtg cttacccccc gagatcatca 840

```

WO 00/06728

PCT/US99/17132

```

tggaatatgg tgaggaagta ttagaagaaa taaaaaatc gaagcataac acaccaagaa 900
aaaaaacaaa cccagcaga atcaggatag ctttgggaaa tgaagcaagc acagtgcagg 960
aggaagaaca agatagaaag ggtagccata ctgatttggg aagcattaat gaaaatttag 1020
ttgaaagtgc attgagaaga gtaaacagag aagaaaaagg taataagtca gtccatctga 1080
ggaaagccag ttcaccaa attcacatagac gacagtggga gaaaaatgta cccaatacag 1140
ctcttacagc tttggaaaat gcatccatac tcacctccag ttaacagca gaggacgata 1200
gaggtgggtc tgtaataaag tacagcaaaa atactactcg taagcagtgg ctcaaagaga 1260
ccccggacac tttgttgaac atccttaaga atgctgatct cagcttggct tttcaaacat 1320
acacaatata tagaccaggt tcagaagggt tcttgaaagg cccctgtct gaagaaacag 1380
aagcatcgga cagtgttgat ggaggtcacg attctgtcat tttggatcca gagcgacttg 1440
agcctgggct agatgaggag gacacggact ttgaggagga agatgacaac cccgactggg 1500
tgtcagagct gaagaagcga gctggatggc aaggcctgtg cgacagataa tgcctgagga 1560
aatgttctcg agtcacgctg aggagagcct tcactcagga gttcatgctg agatgatcat 1620
gagttcatgc gacgtatatt ttccttttga aacagaatga agcagaggaa actcttaata 1680
cttaaaatcg ttcttgatta gtatcgtgag tttgaaaagt ctagaactcc tgtaagtttt 1740
tgaactcaag ggagaaggta tagtggaatg agtgtgagca tcgggctttg cagtcccata 1800
gaacagaaat gggatgctag cgtgccacta cctactttgt tgattgtggg aaattactta 1860
acctcttcaa gccccaat cctcaaccat aaaatgaaga taataatgcc tacctcagag 1920
ggatgctgac cacagacctt tatagcagcc cgtatgatat tattcacatt atgatatgtg 1980
tttattatta tgtgactctt tttacatttc ctaaagggtt gagaattaaa tatatttaat 2040
tatgaaaaaa aaaaaaaaaa 2059

```

&lt;210&gt; 42

&lt;211&gt; 1023

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 304421

&lt;400&gt; 42

```

gaggcagagg ggtgggcggg ctggcccatg gctgagacct ctctcccaga gctgggggga 60
gaggacaaag ccacgccttg cccagcatc ctggagctgg aggagctcct gcgggcaggg 120
aagtcttctt gcagcctgtt ggacgaagtt tggcccaacc ttttcatagg agatgcgatg 180
gactcactgc agaagcagga cctccggagg cccaagatcc atggggcagt ccaggcatct 240
ccctaccagc cgccacatt ggcttcgctg cagecgttgc tgtgggtccg tcaggctgcc 300
acactgaacc atatcgatga ggtctggccc agcctcttcc tgggagatgc gtacgcagcc 360
cgggacaaga gcaagctgat ccagctggga atcaccacg ttgtgaatgc cgctgcaggg 420
aagttccagg tggacacagg tgccaaatc taccgtggaa tgtccctgga gtactatggc 480
atcgaggcgg atgacaaccc cttcttcgac ctacgtgtct actttctgcc tgttgctcga 540
tacatccgag ctgccctcag tgttccccaa ggccgcgtgc tggtagactg tgccatgggg 600
gtaagccgct ctgccacact tgtcctggcc ttcctcatga tctatgagaa catgacgctg 660
gtagaggcca tccagacggg gcaggccac cgcaatatct gccctaactc aggcttcctc 720
cggcagctcc aggttctgga caaccgactg gggcgggaga cggggcggtt ctgatctggc 780
aggcagccag gatccctgac ccttggecca accccaccag cctggccctg ggaacagcag 840
gctctgctgt ttctagtga cctgagatgt aaacagcaag tgggggctga ggcagaggca 900
gggatagctg ggtggtgacc tcttagcggg tggatttccc tgaccaatt cagagattct 960
ttatgcaaaa gtgagttcag tccatctcta taataaata ttcacgtca taaaaaaaaa 1020
aaa 1023

```

&lt;210&gt; 43

&lt;211&gt; 4416

&lt;212&gt; DNA

WO 00/06728

PCT/US99/17132

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1213802

&lt;400&gt; 43

```

gaaatttttt tctgcctcat tattattaat tcatggattg agtggttggt cgacctacag 60
gcgtaataga ttggaactca gtgaagacac agatgttcct gttcagagca accagctaatt 120
gattacagtt taaagacaat ttctgtgatc aagttgtcat ttggaagatt aaacccattt 180
cacgaggact tggagcctgg tccttgcttt gaggaagcag tggcttggtt caagaagcca 240
cttctgatct aagaatctac ccagcatgcc taatcaagga gaagactgct attttttttt 300
ctattccaca tgtaccaaag gcgacagctg cccattccgt cactgtgaag ctgcaatagg 360
aaatgaaact gtttgacat tatggcaaga agggcgctgt tttcgacagg tgtgcagggt 420
tcggcacatg gagattgata aaaaacgcag tgaaattcct tgttattggg aaaatcagcc 480
aacaggatgt caaaaattaa actgcgcttt ccatacaaat agaggacgat atgttgatgg 540
ccttttecta cctccgagca aaactgtgtt gccactgtg cctgagtcac cagaagagga 600
agtgaaggct agccaacttt cagttcagca gaacaaattg tctgtccagt ccaatccttc 660
ccctcagctg cggagcgtaa tgaaagtaga aagttccgaa aatgttecta gccccacgca 720
tccaccagtt gtaattaatg ctgcagatga tgatgaagat gatgatgatc agttttctga 780
ggaaggtgat gaaacaaaa cacctaccct gcaaccaact cctgaagttc acaatggatt 840
acgagtgact tctgtccgga aacctgcagt caatataaag caaggtgaat gtttgaattt 900
tggaataaaa actcttgagg aaattaagtc aaagaaaatg aaggaaaaat ctaagaagca 960
aggtgagggt tcttcaggag tttccagtct tttactccac cctgagcccg ttccagggtcc 1020
tgaaaaagaa aatgtcagga ctgtggtgag gacagtaact ctctccacca aacaaggaga 1080
agaacccttg gttagattga gtcttactga gagactggg aaacgaaaat tttcagcagg 1140
cggtgacagt gatcctccat taaagcgtag cctggcacag aggctaggga agaaagttga 1200
agctccagaa actaacattg acaaaacacc aaagaaagct caagtttcca agtctcttaa 1260
ggagcgatta ggcattgtcag ctgatccaga taatgaggat gcaacagata aagttaataa 1320
agttggtgag atccatgtga agacattaga agaaattctt cttgaaagag ccagtcagaa 1380
acgtggagaa ttgcaaaact aactcaagac agaaggacct tcaaaaactg atgattctac 1440
ttcaggagca agaagctcct ccactatccg tatcaaaacc ttctctgagg tcttggtgta 1500
aaaaaaacat cggcagcagg aagcagagag acaaaaaagc aaaaaggata caacttgcat 1560
caagctaaag attgatagtg aaattaaaaa aacagtagtt ttgccacca ttggtgccag 1620
cagaggacaa tcagaggagc ctgcaggtaa acaaaagtct atgcaggagg tgcacatcaa 1680
gacgtggaa gaaattaaac tggagaaggc actgagggtg cagcagagct ctgagagcag 1740
caccagctcc ccgtctcaac acgaggccac tccaggggca aggcggctgc tgcgaatcac 1800
caaaagaaca gggatgaaag aagagaagaa ccttcaggaa ggaaatgaag ttgattctca 1860
gagcagttat agaacagaag ctaaagaggc ttcaggtgag accacaggag ttgacatcac 1920
taaaattcaa gtcaagagat gtgagaccat gagagagaag cacatgcaga aacagcagga 1980
gagggaaaaa tcagtcttga cactcttcg gggagatgta gcctcttgca ataccaagt 2040
ggcagagaaa ccagtgtcct ctgctgtgcc aggaatcaca cggcacctga ccaagcggct 2100
tcccacaaag tcatcccaga aggtggagggt agaaacctca gggattggag actcattatt 2160
gaatgtgaaa tgtgcagcac agaccttgga aaaaaggggt aaagctaaac ccaaagtga 2220
cgtgaagcca tctgtggtta aagttgtgtc atcccccaa ttggcccaa aacgtaaggc 2280
agtggagatg cacgtgctg tcatcgccgc tgtgaagcca ctcatgcca gcagtgtcct 2340
acaggaaccc ccagccaaaa aggcagctgt ggctgtgtgc ccgttgtct ctgaggacaa 2400
atcagtcact gtgcctgaag cagaaaatcc tagagacagt cttgtgtgtc ctccaacca 2460
gtcctcttca gattcctcac ccccgagggt gtctggccct tcctcatccc aaatgagcat 2520
gaaaactcgc cgactcagct ctgcctcaac aggaaagccc ccactctctg tggaggatga 2580
ttttgagaaa ctaatatggg agatttcagg aggc aaattg gaagctgaga ttgacctgga 2640
tcctgggaaa gatgaagatg accttctgct tgagctatca gaaatgattg atagctgaag 2700
gtggtagtga ggacacttta aaaaaaaat cgccaaaaaa ctggacttag ttcatctat 2760
tgtaacattt acctgagatg atcatttctt tagtctagaa ttgccccaa atcagaagta 2820
tacctctgaa ttatctgtat gtgtcctgga ttccttgggg tcagattttt aaagttactt 2880

```



WO 00/06728

PCT/US99/17132

```

tataaccatt ttgtccattt gatgccattg tttatcatct tttgagaaaa aagttctgtc 2940
atacccttct ctccacaaaa aagagactga gaggagatc aagtgaaggg gtgcaagcga 3000
acttagtgac tccttgaggt gtttgtcagt tttggttttt ttcttctttg ttgtattctt 3060
tatgtattgt cttgatgtac ttaatattac ctgagtttga aatggatgaa gacagctgct 3120
accattaagg accaaatttt atgctaccac taaacaaaaa taccactca gtctgtgta 3180
aattgtatgt ctttttaaag gtatttaaag attcaactaa gctttaaaga gggctgagca 3240
gctcaggaag cctgtaatgt gggcataact ctttggacct gatcttgatg cttctgctgc 3300
tctgttagcc tctgaagagc aatatctaatt ttattattac tgtaattttt taaaaggcct 3360
taaagtgcct caggggtccc ctgaaactaa ttttctattt ctgggattcc ctggattcat 3420
tatatgagat ggtgacatga ttagaggaat tcttttttag tatgaaaatt gtcccttttc 3480
ttcttcagta cttgcctcct tgctggcatt gaattaacac agggacaaaa tttggttaat 3540
tttttatttc taactctccc aacaaacccc tgttgcccag tatttgtttg gtggccttta 3600
accacctgag ggaaaaaatg agcttattca agctgccaat atttatctat gggctgtagc 3660
agtacactga attgtactgt gccagggata ttgagatgct ctgggggtgt attgtatacc 3720
tgccagtttt cttcatttct gaattgagtt ttcttttctt gatgttggtt tccttcatat 3780
cacctcaagg ttttagatttg tgaaggaata agcatgatgg aaataatagt cttgaaagga 3840
gatatgttgt atataatcag gaggaagagg aaggaaggac ttaccatttt tgatattttg 3900
ctgtaggttg ccagttttgt ttctcatagg gaaatctgac ccacctgtca tgttggtccc 3960
taaggaaactg ctggtgtaag cggctcatca agagttgaac ttcacgtagc cttgttgagg 4020
atatggaaaa ggaagaaagc cacaggactg cccattcagt cttgggaaga ttgggatgat 4080
tctgcacaag caaaaatgac tgaagtttat gtatagacac acctctacca atccatcttc 4140
agctgactga atgttgtatg atagcccttc tccaaagcag aggtagaatg ttcaggtttc 4200
accatggatt ttctacttat ttctgttttg gaatcagctt acagattcca ggtccctttt 4260
gtatatattc tttattcttt tgctttttta aaaaataatt ttgtttcata tttaaagcac 4320
ttgtattagt caatgtttcg tgttcgcgat tatttgaacc atttgccctt acagaaagag 4380
aaatacttgt ttgtgtttta aataaaaactg atgtag 4416

```

&lt;210&gt; 44

&lt;211&gt; 2068

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1378134

&lt;400&gt; 44

```

gcagtcctac agtccgctga tgcgtcgccg ggccagcaac gctgcgcgccc cagcccacac 60
gattggcggc agtaagcaca caatgaatga tcacctgcat gtcggcagcc acgctcacgg 120
acagatccag gttcgacagt tgtttgagga taacagtaac aagcggacag tgctcacgac 180
acaaccaaatt gggcttaca cagtgggcaa aacgggcttg ccagtgggtc cagagcggca 240
gctggacagc attcatagac ggcaggggag ctccacctct ctaaagtcca tggaaaggcat 300
ggggaagggt aaagccaccc ccattgacacc tgaacaagca atgaagcaat acatgcaaaa 360
actcacagcc ttcgaaacacc atgagatttt cagctaccct gaaatatatt tcttgggtct 420
aaatgctaag aagcgccagg gcatgacagg tgggcccac aatgggtggc atgatgatga 480
ccagggatca tatgtgcagg tgcacctcga tcacgtggct tacaggtatg aggtcctcaa 540
ggtcattggg aaggggagct ttgggcaggt ggtcaaggcc tacgatcaca aagtccacca 600
gcacgtggcc ctaaaagatg tgcggaatga gaagcgcttc caccggcaag cagcggagga 660
gatccgaatc ctggaacacc tgcggaagca ggacaaggat aacacaatga atgtcatcca 720
tatgctggag aattttcacct tccgcaacca catctgcatg acgtttgagc tgctgagcat 780
gaacctctat gagctcatca agaagaataa attccagggc ttcagtctgc ctttgggtcg 840
caagtttgcc cactcgattc tgcagtgcct ggatgctttg cacaaaaaca gaataattca 900
ctgtgacctt aagcccagga acattttggt aaagcagcag ggtagaagcg gtattaaagt 960
aattgatttt ggctccagtt gttacgagca tcagcgtgtc tacacgtaca tccagtcgcg 1020
tttttaccgg gctccagaag tgatccttgg ggccaggat ggcatgccc ttgatatgtg 1080

```

WO 00/06728

PCT/US99/17132

```

gagcctgggc tgcatttttag cagagctcct gacgggttac cccctcttgc ctggggaaga 1140
tgaaggggac cagctggcct gtatgattga actgttgggc atgccctcac agaaactgct 1200
ggatgcatcc aaacgagcca aaaattttgt gagctccaag gggtatcccc gttactgcac 1260
tgtcacgact ctctcagatg gctctgtggt cctaaacgga ggccgttccc ggagggggaa 1320
actgaggggc ccaccggaga gcagagagtg ggggaacgcg ctgaaggggt gtgatgatcc 1380
ccttttcctt gacttcttaa aacagtgttt agagtgggat cctgcagtgc gcctgacccc 1440
aggccaggct ttgcggcacc cctggctgag gaggcggttg ccaaagcctc ccaccgggga 1500
gaaaacgtca gtgaaaagga taactgagag caccggtgct atcacatcta tatccaagtt 1560
acctccacct tctagctcag ctcccaaact gaggactaat ttggcgaga tgacagatgc 1620
caatgggaat attcagcaga ggacagtgtt gccaaaactt gttagctgag ctacgtccc 1680
ctgatgctgg taacctgaaa gatacgacat tgctgagcct tactgggttg aaaaggagta 1740
gctcagacct gtttttattt gctcaataac tctactcatt tgtatctttt cagcacttaa 1800
ttttaatgta agaaagtgtt tcattttgtt ttataaaaat acatgaggac aatgctttta 1860
gtttttatac ttccagaaac tttttgtgtt ctaaaagtac aatgagcctt actgtattta 1920
gtgtggcaga ataataacat cagtggcagg ccactgatta cttcatgact gccacgcatt 1980
tacagattgg tgtcaaagac attcactatg tttttatggt tcatgttata tcttccccag 2040
ggtgacagcc ccttaaggcc ctcccttt 2068

```

&lt;210&gt; 45

&lt;211&gt; 1850

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1490070

&lt;400&gt; 45

```

gggctgcctg cctgcctgcc tgctgcctg gccgggccc agctccagcc tgcctcttcc 60
actggccact gcctcccacc cagggtctgg atccctgctc cctgccctgg gtcccagact 120
gtgtcctcca tcaccgcagg tcgggtgaggg gctgggctgg acaccagggc ccgccctccc 180
atcactgagc tccactcctt cctcattttg ctgctgattc tagcccaaaa caaaacaggt 240
tgagcttttt cctcccctca gaagctcctc tctggctcgt ggctgccttc tgagtgttgc 300
agacggcgcc ggccgggaag gggggcctgg gccagccctg ccaggactgg gacgtgtctg 360
ctggcgcttg gccctccatc aggcagcctt gtggcaggag agtgagcttt gccggcgag 420
acgcctgagg atgatgcccc agctgcagtt caaagatgcc ttttgggtgca gggacttcac 480
agccacacag ggctacgagg tgctgctgca gcggttctg gatggcagga agatgtgcaa 540
agacatggtg gagctactgt ggcagagggc ccaggcggag gagcggtacg ggaaggagct 600
ggtgcagatc gcacggaagg caggtggcca gacggagatc aactccctga gggcctcctt 660
tgactccttg aagcagcaaa tggagaatgt gggcagctca cacatccagc tggccctgac 720
cctgcgtgag gagctgcgga gtctcgagga gtttcgtgag aggcagaagg agcagaggaa 780
gaagtatgag gccgtcatgg accgggtcca gaagagcaag ctgtcgctct acaagaaggc 840
catggagtcc aagaagacat acgagcagaa gtgccgggac gcggacgacg cggagcaggc 900
cttcgagcgc attagcgcca acggccacca gaagcaggtg gagaagagtc agaacaaggc 960
caggcagtgc aaggactcgg ccaccgaggc agagcgggta tacaggcaga gcattgcgca 1020
gctggagaag gtccgggctg agtgggagca ggagcaccgg accacctgtg aggcctttca 1080
gctgcaagag tttgaccggc tgaccattct ccgcaacgcc ctgtgggtgc acagcaacca 1140
gctctccatg cagtgtgtca aggatgatga gctctacgag gaagtgcggc tgacgttgga 1200
aggctgcagc atagacggcg acatcgacag tttcatccag gccaaagaca cgggcacaga 1260
gccccccgct ccggtgccct accagaacta ttacgatcgg gaggtcaccg cgctgaccag 1320
cagccctggc atacagccgt cctgcggcat gataaagagg ttctctggac tgctgcacgg 1380
aagtcccaag accacttcgt tggcagcttc tgctgcgtcc acagagaccg tgacccccc 1440
ccccgagcgg aatgaggggtg tctacacagc ctacgcagtg caggagatac agggaaaccc 1500
ggcctcacca gccaggagt accgggcgct ctacgattat acagcgaga acccagatga 1560
gctggacctg tccgcgggag acatccctgga ggtgatcctg gaaggggagg atggctggtg 1620

```

WO 00/06728

PCT/US99/17132

gactgtggag aggaacgggc agcgtggctt cgtccctggt tcctacctgg agaagctttg 1680  
 aggaagggcc aggagcccct tcggacctgc cctgccagtg gagccagcag tgccccagc 1740  
 actgtcccca ccttgctagg gcccagaacc aagcgtcccc cagccccgag agggagcctg 1800  
 tcgtctccca gggaataaag gagtgcgttc tgttctcaaa aaaaaaaaaa 1850

&lt;210&gt; 46

&lt;211&gt; 2534

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1997814

&lt;400&gt; 46

gaagagggga tggagcaggg gctggaggag gaagaagagg tggatccccg gatccagggga 60  
 gaactggaga agttaaatca gtccacggat gatataca gacgggagac tgaacttgag 120  
 gatgctcgtc agaagttccg ctctgttctg gttgaagcaa cggtgaaact ggatgaactg 180  
 gtgaagaaaa ttggcaaagc tgtggaagac tccaagccct actgggaggc acggagggtg 240  
 gcgaggcagg ctgagctgga agctcagaaa gccacgcagg acttccagag ggccacagag 300  
 gtgctccgtg ccgccaagga gaccatctcc ctggccgagc agcggctgct ggaggatgac 360  
 aagcggcagt tcgactccgc ctggcaggag atgctgaatc acgccactca gagggtcatg 420  
 gaggcggagc agaccaagac caggagcgag ctggtgcata aggagacggc agccagggtac 480  
 aatgccgccca tggggccgcat gcgacagctg gagaagaaac tcaagagagc catcaacaag 540  
 tccaagcctt attttgaact caaggcaaag tactatgtgc agctcgagca actgaaaaag 600  
 actgtggatg acctgcaggc caaactgacc ctggcaaaag gcgagtacaa gatggccctg 660  
 aagaacctgg agatgatctc agatgagatc cagcagcggc ggcgctccag tgccatgggg 720  
 cctcggggat gcgggtgttg tctgagggc agcagcacat ctgtggagga tctgccaggg 780  
 agcaaacctg agcctgatgc catttctgtg gcctcggagg cctttgaaga tgacagctgt 840  
 agcaactttg tgtctgaaga tgactcggaa acccagtcgg tgtccagctt tagttcagga 900  
 ccaacaagcc cgtctgagat gcctgaccag ttccctgcgg ttgtgaggcc tggcagcctg 960  
 gatctgcccc gccctgtgtc cctgtcagag tttgggatga tgttcccagt gttgggcccct 1020  
 cgaagtgaat gcagcggggc ctccctccct gaatgtgaag tagaacgagg agacagggga 1080  
 gaaggggcag agaataaaac aagtgacaaa gccacaaca accggggcct cagcagtagc 1140  
 agtggcagtg ttggcagcag taagagccaa agcagcacct cccctgaggg ccaggccttg 1200  
 gagaaccgga tgaagcagct ctccctacag tgctcaaagg gaagagatgg aattattgct 1260  
 gacataaaaa tgggtgcagat tggctgattc atcctgggccc ctggccgatg tgcatatcaa 1320  
 cattttatata tggaaactgga gaacattgtg ccaataatca tttaatatat gccaaatctt 1380  
 acacgtctac tctaaactgc tctaataaag ttctcagtgac cttgagggct aaagattgtt 1440  
 cttctgggta agagctcttg ggctgggttt tcaagagcaga gttcttgttg tgggtagact 1500  
 gtgactaggt tcacagcctt tgtggaacat tccgtataac ggcattgttg aagcaataac 1560  
 tagttcctat gaaagaacca gagctgggaa gatggctggg aagccaggcc aaagtggggg 1620  
 caacagcttg cttctctttc tcttctcacc ctcagtttgt atgggaaaat ggagatgtcc 1680  
 tctccacttt atcccacgat atctaaatga aaaagaaaga aaaccacac acaaagcaaa 1740  
 aactcaagta ttaagagcac atatttttga ccagtgagg gcttaaaaaa aaaaaaatcc 1800  
 aagaacacaa ttcattttca ccacctctgg tgttcagagg gggcttttaa aaaagcgtgt 1860  
 atgctgggat acccattaaa accattttct agaaggctac catgagctgc actttttggg 1920  
 gtgggaaagg tgaatgccag tggggatgcg gggggatgag ggtaggaggg acttatagaa 1980  
 ggggatttgt ggctgtgggg gagaagggtc tacagcataa gccttatcct gccagccaag 2040  
 gggatttatt ctaagagaag tgcattgtga gaattgttgc cactgttatt agattgacaa 2100  
 gatgttaatt tctctgtagg ttgtaacttt aaaaataaat gaaattattt aagggttatg 2160  
 ctgcactagt attccttaga ggaaacagtt ctttaaggtt aggaaagggg gtaggcaggc 2220  
 atgtgttggc aaaggctgtt aatagtagtt aagtgttaag actgcttttc ttaacgttt 2280  
 tcatggtaat gcataattag agcactgtat ttttgtcttg ttaagaaaat ttagcatttc 2340  
 taaaagaaaa aagcaaccct ctttcaaact gttaattctg tcacagcctg tatatttttag 2400

WO 00/06728

PCT/US99/17132

```

tcatttgtaa atctcttcat acaatagtga cttctttttt gactgataca gtatcttaat 2460
tacaagggtta ttttgtactt gtcttaatac actaagtgtg ataaaaacgg cttgagaaaa 2520
gttaaaaaaa aaaa                                     2534

```

&lt;210&gt; 47

&lt;211&gt; 3786

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2299715

&lt;400&gt; 47

```

ccgtcctcga ggcgaggaga gtaccggggc ggccccgctg ccgcgcgagg agcgcggctc 60
gcggcctggg ctgcggctga gatacacaga gcgacagaga catttattgt tatttgttt 120
ttgggtggcaa aaagggaaaa tggcgaacga cccccctgca aaaagtctgg tggacatcga 180
cctctcctcc ctgcgggatc ctgctgggat ttttgagctg gtggaagtgg ttggaaatgg 240
cacctatgga caagtctata agggtcgaca tgtaaaacg ggtcagttgg cagccatcaa 300
agttatggat gtcactgagg atgaagagga agaaatcaaa ctggagataa atatgctaaa 360
gaaatactct catcacagaa acattgcaac atattatggg gctttcatca aaaagagccc 420
tccaggacat gatgaccaac tctggcttgt tatggagttc tgtggggctg ggtccattac 480
agaccttgtg aagaacacca aagggaaacac actcaaagaa gactggatcg cttacatctc 540
cagagaaatc ctgaggggac tggcacatct tcacattcat catgtgattc accgggatat 600
caagggccag aatgtgttgc tgactgagaa tgacgggggtg aaacttggtg actttgggtg 660
gagtgctcag ctggacagga ctgtggggcg gagaaatacg ttcataaggca ctccctactg 720
gatggctcct gaggtcatcg cctgtgatga gaaccacagat gccacctatg attacagaag 780
tgatcttttg tcttgaggca ttacagccat tgagatggca gaagggtgctc cccctctctg 840
tgacatgcat ccaatgagag cactgtttct cattcccaga aaccctcctc cccggctgaa 900
gtcaaaaaaa tggtcgaaga agtttttttag ttttatagaa ggggtgcctgg tgaagaatta 960
catgcagcgg ccctctacag agcagctttt gaaacatcct tttataaggg atcagccaaa 1020
tgaaaggcaa gttagaatcc agcttaagga tcatatagat cgtaccagga agaagagagg 1080
cgagaaagat gaaactgagt atgagtacag tgggagtga gaaagagagg aggaagtgcc 1140
tgaacaggaa ggagagccaa gttccattgt ggaactgcct ggtgagtcta ctcttcgccc 1200
agatttcctg agactgcagc aggagaacaa ggaacgttcc gaggtctctc ggagacaaca 1260
gttactacag gagcaacagc tccgggagca ggaagaatat aaaaggcaac tgctggcaga 1320
gagacagaag cggattgagc agcagaaaga acagaggcga cggctagaag agcaacaaag 1380
gagagagcgg gaagctagaa ggcagcagga acgtgaacag cgaaggagag aacaagaaga 1440
aaagaggcgt ctagaggagt tggagagaag gcgcaaagaa gaagaggaga ggagacgggc 1500
agaagaagaa aagaggagag ttgaaagaga acaggagtat atcaggcgac agctagaaga 1560
ggagcagcgg cacttggaag tccttcagca gcagctgctc caggagcagg ccatgttact 1620
gcatgaccat aggaggccgc acccgagca ctgcagcag ccgccaccac cgcagcagga 1680
aaggagcaag ccaagcttcc atgctcccga gcccaaagcc cactacgagc ctgctgaccg 1740
agcgcgagag gttcctgtga gaacaacatc tcgctcccct gttctgtccc gtcgagattc 1800
cccactgcag ggcagtgggc agcagaatag ccaggcagga cagagaaact ccaccagtat 1860
tgagcccagg cttctgtggg agagagtggg gaagctgggt cccagacctg gcagtggcag 1920
ctcctcaggg tccagcaact caggatccca gcccggtct caccctgggt ctgagagtgg 1980
ctccggggaa cgcttcagag tgagatcatc atccaagtct gaaggctctc catctcagcg 2040
cctggaaaat gcagtgaaa aacctgaaga taaaaaggaa gttttcagac ccctcaagcc 2100
tgctgatctg accgcactgg ccaaagagct tcgagcagtg gaagatgtac ggccacctca 2160
caaagtaacg gactactcct catccagtga ggagtcgggg acgacggatg aggaggacga 2220
cgatgtggag caggaagggg ctgacgagtc cacctcagga ccagaggaca ccagcagc 2280
gtcatctctg aatttgagca atggtgaaac ggaatctgtg aaaaccatga ttgtccatga 2340
tgatgtagaa agtgagccgg ccatgacccc atccaaggag ggcactctaa tcgtccgcca 2400
gactcagtcg gctagtagca cactccagaa acacaaatct tcctcctcct ttacaccttt 2460

```

WO 00/06728

PCT/US99/17132

```

tatagacccc agattactac agattttctcc atctagcgga acaacagtga catctgtggt 2520
gggattttcc tgtgatggga tgagaccaga agccataagg caagatccta cccggaaaagg 2580
ctcagtgggtc aatgtgaatc ctaccaacac taggccacag agtgacaccc cggagattcg 2640
taaatacaag aagaggttta actctgagat tctgtgtgct gccttatggg gagtgaattt 2700
gctagtgggt acagagagtg gcctgatgct gctggacaga agtggccaag ggaaggtcta 2760
tcctcttatc aaccgaagac gatttcaaca aatggacgta cttgagggct tgaatgtctt 2820
ggtgacaata tctggcaaaa aggataagtt acgtgtctac tatttgcctt ggtaaagaaa 2880
taaaatactt cacaatgatc cagaagttga gaagaagcag ggatggacaa ccgtagggga 2940
tttggaagga tgtgtacatt ataaagttgt aaaaatgaa agaatacaat ttctggtgat 3000
tgctttgaag agttctgtgg aagtctatgc gtgggcacca aagccatata acaaatttat 3060
ggcctttaag tcatttggag aattggtaca tggatcctgt gctggattcc atgctgttga 3120
tgtggattca ggatcagttc atgacattta tctaccaaca catatccagt gtagcatcaa 3180
accccatgca atcatcatcc tccccaatc agatggaatg gagcttctgg tgtgctatga 3240
agatgagggg gtttatgtaa acacatatgg aaggatcacc aaggatgtag ttctacagt 3300
gggagagatg cctacatcag tagcatatat tccatccaat cagacaatgg gctggggaga 3360
gaaggccata gagatccgat ctgtggaaac tggtcacttg gatgggtgtg tcatgcacaa 3420
aagggtcaa agactaaaat tcttgtgtga acgcaatgac aaggtgttct ttgcctctgt 3480
tcggtctggt ggcagcagtc aggtttattt taggcctta ggcaggactt ctcttctgag 3540
ctggtagaag cagtgtgac cagggattac tggcctccag agtcttcaag atcctgagaa 3600
cttggaattc cttgtaactg gagctcggag ctgcaccgag ggcaaccagg acagctgtgt 3660
gtgcagacct catgtgttgg gttctctccc ctccctctctg ttctctttat ataccagttt 3720
atccccattc tttttttttt tcttactcca aaataaatca aggtgcaat gcagctggtg 3780
ctgtta 3786

```

&lt;210&gt; 48

&lt;211&gt; 1182

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 209854

&lt;400&gt; 48

```

gttgggtgaag tcaagcgaag ggcactagag ctccaggagg gccagttctg tgggctctag 60
tcggccatat taataaagag aaagggaagg ctgaccgtcc ttgcctccg cccccacata 120
cacaccctt cttccactc cgctctcacg actaagctct cacgattaag gcacgcctgc 180
ctcgattgtc cagcctctgc cagaagaaag cttagcagcc agcgcctcag tagagacct 240
agggcgctga atgagtggga aagggaatg ccgaccaat gcgctgcggc gggctgtgcc 300
actacctaca acaagcacat taacatcagc ttccacaggt ttctttgga tcctaaaaga 360
agaaaagaat gggttcgctt ggttaggcgc aaaaattttg tgccaggaaa acacactttt 420
ctttgttcaa agcactttga agcctcctgt tttgacctaa caggacaaac tcgacgactt 480
aaaatggatg ctgttccaac cattttttgat ttttgtacct atataaagtc tatgaaactc 540
aagtcaagga atcttttgaa gaaaaacaac agttgttctc cagctggacc atctaattta 600
aatcaaaaca ttagtagtca gcaagtacta cttgaacaca gctatgcctt taggaatcct 660
atggaggcaa aaaagaggat cattaaactg gaaaaagaaa tagcaagctt aagaagaaaa 720
atgaaaactt gcctacaaaa ggaacgcaga gcaactcgaa gatggatcaa agccacgtgt 780
ttggtaaaga atttagaagc aaatagtgtt ttacctaaag gtacatcaga acacatgtta 840
ccaactgcct taagcagttc tcctttggaa gattttaaga tccttgaaca agatcaacaa 900
gataaaacac tgctaagttc aaatctaaaa cagaccaaga gtaccttcat ttaaatttag 960
cttgacacaga gcttgatgcc tatccttcat tcttttcaga agtaaagata attatggcac 1020
ttatgccaaa attcattatt taataaagtt ttaactgaag taacattact gaatttgtga 1080
agacttgatt acaaaaagaat aaaaaacttc atatggaaat tttatttgaa aatgagtgga 1140
agtgccttac attagaatta cggactttca aaactatgat aa 1182

```

WO 00/06728

PCT/US99/17132

<210> 49  
 <211> 1676  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 1384286

<400> 49  
 tcgccgagcc cgtccgccgc cgccatggcc accacgggtga cctgcacccg cttcacccgac 60  
 gagtaccagc tctacgagga tattggcaag ggggctttct ctgtgggtccg acgctgtgtc 120  
 aagctctgca ccggccatga gtatgcagcc aagatcatca acaccaagaa gctgtcagcc 180  
 agagatcacc agaagctgga gagagaggct cggatctgcc gccttctgaa gcattccaac 240  
 atcgtgcgtc tccacgacag catctccgag gagggcttcc actacctggt cttcgatctg 300  
 gtcactgggtg gggagctctt tgaagacatt gtggcgagag agtactacag cgaggctgat 360  
 gccagtcact gtatccagca gatectggag gccgttctcc attgtcacca aatgggggtc 420  
 gtccacagag acctcaagcc ggagaacctg cttctggcca gcaagtgcaa aggggctgca 480  
 gtgaagctgg cgacttcgg cctagctatc gaggtgcagg gggaccagca ggcatgggtt 540  
 ggtttcgctg gcacaccagg ctacctgtcc cctgaggtcc ttcgcaaaga ggcgtacggc 600  
 aagcccgtgg acatctgggc atgtgggggtg atcctgtaca tcctgctcgt gggctaccca 660  
 cccttctggg acgaggacca gcacaagctg taccagcaga tcaaggctgg tgccatgac 720  
 ttcccgctcc ctgagtggga caccgtcact cctgaagcca aaaacctcat caaccagatg 780  
 ctgaccatca accctgccaa gcgcatcaca gcccatgagg ccctgaagca cccgtgggtc 840  
 tgccaacgct ccacggtagc atccatgatg cacagacagg agactgtgga gtgtctgaaa 900  
 aagttcaatg ccaggagaaa gctcaaggga gccatcctca ccaccatgct ggccacacgg 960  
 aatttctcag cagccaagag tttactcaac aagaaagcag atggagtcaa gccccatacg 1020  
 aatagcacca aaaacagtgc agccgccacc agcccaaaag ggacgcttcc tcctgccgcc 1080  
 ctggagtctt ctgacagtgc caataccacc atagaggatg aagacgctaa agcccgggaag 1140  
 caggagatca ttaagaccac ggagcagctc atcgaggccg tcaacaacgg tgactttgag 1200  
 gcctacgca aaatctgtga cccagggctg acctcgtttg agcctgaagc actgggcaac 1260  
 ctgggtgaag ggatggactt ccacagattc tacttcgaga acctgctggc caagaacagc 1320  
 aagccgatcc acacgacat cctgaacca cactgtcacg tcattggaga ggatgccgcc 1380  
 tgcacgctt acatccggct cacgcagtac attgacgggc agggccggcc ccgcaccagc 1440  
 cagtctgagg agaccgcgt gtggcacgc cgcgacggca agtggcagaa cgtgcacttc 1500  
 cactgctcgg gcgcgcctgt ggccccgctg cagtgaagag ctgcgccctg gtttcgcccg 1560  
 acagagttgg tgtttggagc ccgactgccc tcgggcacac ggctgcctg tcgcatgttt 1620  
 gtgtctgcct cgttccctcc cctggtgcct gtgtctgcag aaaaacaagc ccgact 1676

<210> 50  
 <211> 1597  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 1512656

<400> 50  
 tcggccttcg gaaagacccc cgggcccggg caccgagaga gccgagcgcc gcagccgtga 60  
 gccgaataga gccggagaga cccgagtatg accggagaag cccaggccgg ccggaagagg 120  
 agccgagcgc ggccggaagg aaccgagccc gtccgaaggg agcggacgca gcctggcctg 180  
 gggccccggtc gagccccgc catggcgggc gagggcacag ctgtggccgg aagcggggct 240  
 gttggcggtc gcctggccaa agacggcttg cagcagtcta agtggccgga cactacccca 300  
 aaacggcggc gcgcctcgtc gctgtcgcgt gacgcagagc gccgagccta ccaatgggtg 360

WO 00/06728

PCT/US99/17132

```

cgggagtact tgggcggggc ctggcgccga gtgcagcccg aggagctgag ggtttaccce 420
gtgagcggag gcctcagcaa cctgctcttc cgctgctcgc tcccgacca cctgcccagc 480
gttgccgagg agccccggga ggtgcttctg cggctgtacg gagccatctt gcagggcgctg 540
gactccctgg tgctagaaag cgtgatgttc gccatacttg cggagcggtc gctggggccc 600
cagctgtacg gagtcttccc agagggccgg ctggaacagt acatcccaag tcggccattg 660
aaaactcaag agcttcgaga gccagtgttg tcagcagcca ttgccacgaa gatggcgcaa 720
tttcatggca tggagatgcc ttccaccaag gagccccact ggctgtttgg gaccatggag 780
cggtagcctaa aacagatcca ggacctgccc ccaactggcc tccctgagat gaacctgctg 840
gagatgtaca gcctgaagga tgagatgggc aacctcagga agttactaga gtctaccca 900
tcgccagtcg tcttctgcca caatgacatc caggaaggga acatcttgct gctctcagag 960
ccagaaaatg ctgacagcct catgctgggt gacttcgagt acagcagtta taactatagg 1020
ggcttttgaca ttgggaacca tttttgtgag tgggtttatg attatactca cgaggaatgg 1080
cctttctaca aagcaaggcc cacagactac cccactcaag aacagcagtt gcattttatt 1140
cgtcattacc tggcagaggc aaagaaaggt gagacctct cccaagagga gcagagaaaa 1200
ctggaagaag atttgctggg agaagtcagt cggtagctc tggcatccca tttcttctgg 1260
ggctctgtgg ccactctcca ggcattccatg tccaccatag aatttggtta cttggactat 1320
gccagtcctc gggtccagtt ctacttccag cagaaggggc agctgaccag tgtccactcc 1380
tcatcctgac tccaccctcc cactccttgg atttctcctg gagcctccag ggcaggacct 1440
tggagggagg aacaacgagc agaaggccct ggcgactggg ctgagcccc aagtgaacct 1500
gaggttcagg agaccggcct gtctctgagt ttgagtagg ccccatggct ggcaggccag 1560
agccccgtgc tgtgtatgta acacaataaa caagctg 1597

```

&lt;210&gt; 51

&lt;211&gt; 2145

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2098635

&lt;400&gt; 51

```

cccacgcgtc cggacagctt gacctagttt gctttccaat caaagggcat ttattttgaa 60
tgtctctttg tggcgcaaga gccaacgcaa aaatgatggc ggcttacaat ggcgggtacat 120
ctgcagcagc agcaggtcac caccaccacc atcaccacca ccttccacac ctccctcctc 180
ctcacctgct tcaccaccac caccctcaac accatcttca tccggggctg gctgcccgtg 240
tacacctgt acagcagcac acctcttcgg cagctgcggc agccgcagca gcggctgcag 300
ctgcagccat gttaaaccct gggcaacaac agccatattt cccatcaccg gcaccggggc 360
aggctcctgg accagctgca gcagccccag ctccaggtaca ggctgccgca gctgctacag 420
ttaaggcgca ccatcatcag cactcgcac atccacagca gcagctggat attgagccgg 480
atagacctat tggatatgga gcctttgggtg ttgtctgggt agtaacagat ccaagagatg 540
gaaagagagt agcgctcaaa aagatgccc acgtcttcca gaatctgggt tcttgcaaaa 600
gggtcttccg ggaattgaag atgttgtgtt tttttaagca tgataatgta ctctctgccc 660
ttgacatact ccaacctcca cacattgact attttgaaga aatatatgtt gtcacagaat 720
tgatgcagag tgacctacat aaaattatcg tctctcctca accactcagc tcagatcatg 780
tcaaagtttt tctttatcag attttgcgag gtttgaaata tctccattca gctggcattt 840
tacatcgaga cattaagcca gggaaatctc ttgtgaacag caactgtgtt ctaaagattt 900
gtgattttgg attggccaga gtggaagagt tagatgaatc ccgtcatatg actcaggaag 960
ttgttactca gtattatcgg gtccagaaa tctgatggg cagccgtcat tacagcaatg 1020
ctattgacat ctgggtctgtg ggatgtatct ttgcagaact actaggacga agaatttgt 1080
ttcaggcaca gattcccat cagcagttgg atttgatcac ggatctgttg ggcacaccat 1140
cactggaagc aatgaggaca gcttgtgaag gcgctaaggc acatatactc aggggtcctc 1200
ataaacagcc atctcttct gtactctata ccctgtctag ccaggctaca catgaagctg 1260
ttcatctcct ttgcaggatg ttggtctttg atccatccaa aagaatatcc gctaaggatg 1320
ccttagccca cccctaccta gatgaagggc gactacgata tcacacatgt atgtgtaaat 1380

```

WO 00/06728

PCT/US99/17132

```

gttgcttttc cacctccact ggaagagttt ataccagtga ctttgagcct gtcaccaatc 1440
ccaaatttga tgacactttc gagaagaacc tcagttctgt ccgacagggt aaagaaatta 1500
ttcatcagtt cattttggaa cagcagaaag gaaacagagt gcctctctgc atcaaccctc 1560
agtctgctgc ttttaagagc tttattagtt ccactgttgc tcagccatct gagatgcccc 1620
catctcctct ggtgtgggag tgatggtgga agataatgta ctactgaaga tgtaatgtag 1680
ctttccactg gagtctggga tttgcaattc tggagggttaa tcatgcttgt actgtaattt 1740
tactaatgaa gttttaaatt aacaaccact acttgatatga tatgaataat atttagaaat 1800
gttactagac ttttaactct gtaaagtggg tgtgctttta gaagaaaaat attttacca 1860
gagttgcaca tgttttatga atttagtgca gctgttatgg ctcacctcag aacaaaagag 1920
aattgaacca aatttgggag tttgggggtt tatgttttgt ttttcttttc taaaatgaag 1980
tgagattgtt cacacacaca cacacacaca cacacacaca cacaaacaca aaggacagtc 2040
atacattttg atatttgagc cattcctaaa gatttggggg tttctaaaac taaagaatct 2100
aggaaccttg cctgcgacca atcatggagc cacgtgagct gatcg 2145

```

&lt;210&gt; 52

&lt;211&gt; 1454

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2446646

&lt;400&gt; 52

```

gggttcgaat tgcaacggca gctgccgggc gtatgtgttg gtgctagagg cagctgcagg 60
gtctcgctgg gggccgctcg ggaccaattt tgaagaggta cttggccacg acttattttc 120
acctccgacc tttccttcca ggcggtgaga ctctggactg agagtggcct tcacaatgga 180
agggatcagt aatttcaaga caccaagcaa attatcagaa aaaaagaaat ctgtattatg 240
ttcaactcca actataaata tcccggcctc tccgtttatg cagaagcttg gctttggtac 300
tggggtaaat gtgtacctaa tgaaaagatc tccaagaggt ttgtctcatt ctcttgggc 360
tgtaaaaaag attaactcta tatgtaatga tcattatcga agtgtgtatc aaaagagact 420
aatggatgaa gctaagattt tgaaaagcct tcatcatcca aacattgttg gttatcgtgc 480
ttttactgaa gccaatgatg gcagtctgtg tcttgctatg gaatatggag gtgaaaagtc 540
tctaatgac ttaatagaag aacgatataa agccagccaa gatccttttc cagcagccat 600
aattttaaaa gttgctttga atatggcaag aggggttaaag tatctgcacc aagaaaaagaa 660
actgcttcac ggagacataa agtcttcaaa tgttgtaatt aaaggcgatt ttgaaacaat 720
taaaatctgt gatgtaggag tctctctacc actggatgaa aatatgactg tgactgaccc 780
tgaggcttgt tacattggca cagagccatg gaaacccaaa gaagctgtgg aggagaatgg 840
tgttattact gacaaggcag acatatttgc ctttggcctt actttgtggg aaatgatgac 900
tttatcgatt ccacacatta atctttcaaa tgatgatgat gatgaagata aaacttttga 960
tgaaagtgat tttgatgatg aagcatacta tgcagcgttg ggaactaggc cacctattaa 1020
tatggaagaa ctggatgaat cataccagaa agtaattgaa ctcttctctg tatgcactaa 1080
tgaagaccct aaagatcgtc cttctgctgc acacattgtt gaagctctgg aaacagatgt 1140
ctagtgatca tctcagctga agtgtggcct gcgtaataaa ctgtttattc caaaatattt 1200
acatagttac tatcagtagt tattagactc taaaattggc atatttgagg accatagttt 1260
cttgtaaca tatggataac tatttctaata atgaaatatg cttatattgg ctataagcac 1320
ttggaattgt actgggtttt ctgtaaagtt ttagaaacta gctacataag tactttgata 1380
ctgctcatgc tgacttaaaa cactagcagt aaaacgctgt aaactgtaac attaaattga 1440
atgaccatta cttt 1454

```

&lt;210&gt; 53

&lt;211&gt; 3225

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens



WO 00/06728

PCT/US99/17132

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2764911

&lt;400&gt; 53

```

tggagcaggg ggcgggtttgg ttgcgcggta ctacgcggtgc ccgccgaatg gggaggaggc 60
gaggagcgag ccgtgcggcc agagcgggaa agagactcgt ctttgcgtcc gaggttctgga 120
gccgccgcac cccgactcct ggggccgcgg cagcggctgc gaggggacgg gcgtccgctg 180
tctcctgggt tcccctcgta gcgacccgcg ggatcgga aaaggagaa gatggaggag 240
gaggggtggca gcagcggcgg cgcgcggggg accagcgcgg acggcggcga cggaggagag 300
cagctcctca ctgtcaagca cgagctgcgg actgctaatt tgacaggaca tgctgagaag 360
gtgggaatag aaaattttga gtcctgaag gtccaggaa ctggagctta tggaaaagta 420
tttctagttc gtaaaataag tggccatgat actggaaaagc tgtatgccat gaaagttttg 480
aaaaaggcaa caatcggtca aaaggccaaa accacagagc atacaaggac agaacgacaa 540
gtcctggaac acattaggca gtcgccattt ttggtaacat tacattatgc ttccagaca 600
gaaaccaaac ttcattctcat tttagattat ataaatgggtg gtgaactttt taccatctt 660
tctcaaagag agcgtttcac agagcatgag gtgcagattt atgttggaga gattgtgctt 720
gccctcgaac atctccacaa gttggggatt atatatcgtg atattaagct tgagaatatt 780
ctacttgatt ctaatggcca tgtgttgctg acagattttg gtctgagtaa ggagtttgtg 840
gctgatgaaa ctgaaagagc atattccttt tgtggaacta ttgaatacat ggcaccagat 900
attgtcagag ggggagattc aggacatgac aaggcagttg actggtggag tttgggtgtt 960
ctaattgatg aattactaac tggagcatct cctttcactg ttgatggaga aaaaaattcc 1020
caagctgaga tatctaggag aatattaaaa agtgagcctc catatcccca agaaatgagt 1080
gcttttagcga aagacctaat tcagcgtctt ttgatgaaag atcccaagaa gagattggga 1140
tgtggtccac gtgatgcaga tgaaatcaaa gaacatctct tctttcagaa aataaattgg 1200
gatgatttag ccgccaaaaa agtgcctgca ccatttaagc cagtcattcg agatgaatta 1260
gatgtgagta actttgcaga agagttcaca gaaatggatc ccacttattc tccgcagcc 1320
ctgccccaga gttctgagaa gctgtttcag ggctattcct ttgttgetcc tccatccta 1380
ttcaagcgta atgcagctgt catagaccct cttcagtttc acatgggagt tgaacgtcct 1440
ggagtgacaa atgttgccag gagtgcgaatg atgaaggact ctccattcta tcaacactat 1500
gacctagatt tgaaggacaa acccctggga gaaggtagtt tttcaatttg tgcgaaagtgt 1560
gtgcataaaa aaagtaacca agcttttgca gtcaaaataa tcagcaaaag gatggaagcc 1620
aatactcaaa aggaaataac agctctggaa ctctgtgaag gacaccccaa tattgtgaag 1680
ttgcatgaag tttttcatga tcagcttcac acgtttctag tgatggaact tctgaatgga 1740
ggagaactgt ttgagcgcat taagaaaaag aagcacttca gtgagacgga agccagctac 1800
atcatgagga agcttgtttc agctgtaagc cacatgcatg atgttggagt ggtgcacagg 1860
gatctgaaac ctgagaattt attgttcacc gatgaaaatg acaatttgga aattaaaata 1920
attgattttg gatttgcacg gctaaagcca ccggataatc agcccctgaa gactccatgc 1980
ttcacccttc attatgccgc ccagagctc ttgaatcaga acggctacga tgagtctgt 2040
gacctgtgga gcttgggcgt cattttgtac acaatgttgt caggacagggt tcccttccaa 2100
tctcatgacc gaagtttgac gtgtaccagc gcggtggaaa tcatgaagaa aattaaaaag 2160
ggagatttct cctttgaagg agaagcctgg aagaatgtat cccaagaggc taaagatttg 2220
atccaaggac ttctcacagt agatccaaac aaaaggctta aaatgtctgg cttgaggtag 2280
aatgaatggc tacaagatgg aagtgcgctg tccccaatc ctctgatgac tccggatatt 2340
ctaggatctt ccggagctgc cgtgcatacc tgtgtgaaag caaccttcca cgcctttaac 2400
aaatacaaga gagaggggtt ttgccttcag aatgttgata aggccctttt ggctaagaga 2460
agaaaaatga aaaagactag caccagtacc gagacacgca gcagttccag tgagagttcc 2520
cattcttctt cctctcattc tcacggtaaa actacacca ccaagacact gcagcccagc 2580
aatcctgccc acagcaataa cccggagacc ctctccagt tctcggactc agtagcttag 2640
gcatggtagg agtgtatcag tgatccattg cacctttatt ccctcagcat atgcctgagg 2700
cgatctttta tgcttttaaa aatgtttccc gttggtctca ttggaatctg cctcctaattg 2760
atttttttca ggaaaacctg tttggttacc ctcatcctaa agcactggac agagaatgtt 2820
actgtgaata gacacatat tactcttttt agcaacctag catgatgcca acaagctat 2880
tcttgaaaga gcaaaggttc ctgtaaaatt aattagggct agatttgagc tgcctgtaag 2940
tcacaggttt tccagatgtc tgccaacaag aaatgactca tactgtgatg ataccttttg 3000
ctttgccttg tggacaatgt gggtttttga aatttgcacc cttcaacaa tgatttatca 3060

```

WO 00/06728

PCT/US99/17132

gagaaagggg tctgttttca aaaaagattc tgtaatgaat tttatgtgtg gcatatactt 3120  
 atttcttgag agaagatttt aacttattgt ttttatttta tggttacata tgatgataac 3180  
 ctgctattat taaacttttt ctaaaaagtg aaaaaaaaaa aaaaa 3225

&lt;210&gt; 54

&lt;211&gt; 2110

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 3013946

&lt;400&gt; 54

tgcgcgagcg cgtccgcgcg cgccatggcc accacgggtga cctgcacccg cttcacccgac 60  
 gagtaccagc tctacgagga tattggcaag ggggttttct ctgtgggtccg acgctgtgtc 120  
 aagctctgca ccggccatga gtatgcagcc aagatcatca acaccaagaa gctgtcagcc 180  
 agagatcacc agaagctgga gagagaggct cggatctgcc gccttctgaa gcattccaac 240  
 atcgtgcgtc tccacgacag catctccgag gagggtctcc actacctggt cttcgatctg 300  
 gtcactgggtg gggagctctt tgaagacatt gtggcgagag agtactacag cgaggctgat 360  
 gccagtcaact gtatccagca gatcctggag gccgttctcc attgtcacca aatgggggtc 420  
 gtccacagag acctcaagcc ggagaacctg cttctggcca gcaagtgcaa aggggctgca 480  
 gtgaagctgg cagacttcgg cctagctatc gaggtgcagg gggaccagca ggcgtggtt 540  
 ggtttcgctg gcacaccagg ctacctgtcc cctgagggtc ttcgcaaaga ggcgtatggc 600  
 aagcctgtgg acatctgggc atgtggggtg atcctgtaca tcctgctcgt gggctaccca 660  
 cccttctggg acgaggacca gcacaagctg taccagcaga tcaaggctgg tgcctatgac 720  
 ttcccgctcc ctgagtggga caccgtcaact cctgaagcca aaaacctcat caaccagatg 780  
 ctgaccatca accctgccaa gcgcatacaca gcccatgagg ccctgaagca cccgtgggtc 840  
 tgccaacgct ccacggtagc atccatgatg cacagacagg agactgtgga gtgtctgaaa 900  
 aagttcaatg ccaggagaaa gctcaaggga gccatcctca ccaccatgct ggccacacgg 960  
 aatttctcag ccaagagttt actcaacaag aaagcagatg gagtcaagcc ccagacgaat 1020  
 agcaccaaaa acagtgcagc cgccaccagc cccaaaggga cgcttctctc tgccgcctg 1080  
 gagcctcaaa ccaccgtcat ccataaccca gtggacggga ttaaggagt cttctgacagt 1140  
 gccaatacca ccatagagga tgaagacgct aaagcccccga ggggtcccga catcctgagc 1200  
 tcagtgagga ggggtctcggg agccccagaa gccgaggggc ccctgccctg cccatctccg 1260  
 gctccctttg gccccctgcc agctccatcc cccaggatct ctgacatcct gaactctgtg 1320  
 agaaggggtt caggaacccc agaagccgag gggccctctc cagcggggcc cccgccctgc 1380  
 ctgtctccgg ctctcctagg cccctgttcc tccccgtccc ccaggatctc tgacatcctg 1440  
 aactctgtga ggagggggtc agggacccca gaagccaagg gccctctccc agtggggccc 1500  
 ccgccctgcc catctccgac tatccctggc cccctgcccc ccccatcccg gaagcaggag 1560  
 atcattaaga ccacggagca gctcatcgag gccgtcaaca acggtgactt tgaggcctac 1620  
 gcgaaaatct gtgaccaggt gctgacctcg tttgagcctg aagcactggg caacctgggt 1680  
 gaagggatgg acttccacag attctacttc gagaacctgc tggccaagaa cagcaagcca 1740  
 atccacacga ccatacctgaa cccacacgtg cacgtcattg gagaggatgc cgctgcatc 1800  
 gcttacatcc ggctcacgca gtacattgac gggcagggcc ggccccgcac cagccagtct 1860  
 gaggagaccc gcgtgtggca ccgccgcgac ggcaagtggc agaattgtgca cttccactgc 1920  
 tcgggcgcgc ctgtggcccc gctgcagtga agagctgcgc cctgggttctg ccggacagag 1980  
 ttgggtgttg gagcccgaact gccctcgggc acacggcctg cctgtcgcat gtttgtgtct 2040  
 gcctcgttcc ctccccgtgt gcctgtgtct gcagaaaaaac aagaccagat gtgatttgtt 2100  
 aaaaaaaaaa 2110

&lt;210&gt; 55

&lt;211&gt; 2140

&lt;212&gt; DNA

WO 00/06728

PCT/US99/17132

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 067967

&lt;400&gt; 55

```

gtgcgctgag ctgcagtgtc tggctcgagag taccctgtggg agcgtcgcgc cgcgagggca 60
gccgtcccgg cgtaggtggc gtggccgacc ggaccccca ctggcgccctc tcccgcgcgc 120
gggtcccagag ctaggagatg ggaggcacag ctctgtgggcc tgggcggaag gatgcggggc 180
cgctggggc cgggctccc cccagcagc ggaggttggg ggatggtgtc tatgacacct 240
tcatgatgat agatgaaacc aaatgtcccc cctgttcaaa tgtactctgc aatccttctg 300
aaccaccttc acccagaaga ctaaatatga cactgagca gtttacagga gatcatactc 360
agcacttttt ggatggagggt gagatgaagg tagaacagct gtttcaagaa tttggcaaca 420
gaaaatccaa tactattcag tcagatggca tcagtgaact tgaaaaatgc tctcctactg 480
tttctcaggg taaaagttca gattgcttga atacagtaaa atccaacagt tcatccaagg 540
cacccaaagt ggtgcctctg actccagaac aagcctgaa gcaatataaa caccacctca 600
ctgcctatga gaaactggaa ataattaatt atccagaaat ttactttgtg ggtccaaatg 660
ccaagaaaag acatggagtt attggtggtc ccaataatgg agggatgat gatgcagatg 720
gggcctatat tcatgtacct cgagaccatc tagcttatcg atatgaggtg ctgaaaatta 780
ttggcaaggg gagttttggg caggtggcca gggctatga tcacaaactt cgacagtacg 840
tgccctaaa aatggtgcgc aatgagaagc gctttcatcg tcaagcagct gaggagatcc 900
ggattttgga gcatcttaag aaacaggata aaactggtag tatgaacgtt atccacatgc 960
tggaaagttt cacattccgg aaccatgttt gcatggcctt tgaattgctg agcatagacc 1020
tttatgagct gattaaaaaa aataagtttc agggtttttag cgtccagttg gtacgcaagt 1080
ttgccagtc catcttgcaa tctttggatg cctccacaa aaataagatt attcactgcy 1140
atctgaagcc agaaaacatt ctctgaaac accacgggcy cagttcaacc aaggtcattg 1200
actttgggtc cagctgtttc gagtaccaga agctctacac atatatccag tctcggttct 1260
acagaccatcc agaaatcatc ttaggaagcc gctacagcac accaattgac atatggagtt 1320
ttggctgcat ccttgcaaaa cttttaacag gacagcctct cttccctgga gaggatgaag 1380
gagaccagtt ggctgcatg atggagcttc tagggatgcc accacaaaaa cttctggagc 1440
aatccaaacg tgccaagtac tttattaatt ccaagggcat acccgctac tgctctgtga 1500
ctaccagggc agatgggagg gttgtgcttg tggggggtcg ctcacgtagg ggtaaaaagc 1560
gggggtcccc aggcagcaaa gactggggga cagcactgaa aggggtgtgat gactacttgt 1620
ttatagagtt cttgaaaagg tgtcttcaact gggaccctc tgcccgcttg acccagctc 1680
aagcattaag acacccttg attagcaagt ctgtccccag acctctcacc accatagaca 1740
aggtgtcagg gaaacgggta gttaatcctg caagtgttt ccagggattg ggttccaagc 1800
tgctccagtg tggtggaata gccaaataag ttaaagctaa cttaatgtca gaaaccaatg 1860
gtagtatacc cctatgcagt gtattgcaaa aactgattag ctagtggaca gagatatgcc 1920
cagagatgca tatgtgtata tttttatgat cttacaaacc tgcaaatgga aaaaatgcaa 1980
gccatttgtt ggatgttttt gttagagtag acttttttta aacaagacaa aacattttta 2040
tatgattata aaagaattct tcaagggcta attacctaac cagcttgtat tggccatctg 2100
gaatatgcat taaatgactt tttataggtc aaaaaaaaaa 2140

```

&lt;210&gt; 56

&lt;211&gt; 1728

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 346275

&lt;400&gt; 56

```

gacagacaaa ggcgcgccac gcgtccgcat gtcggatgtt tgtagcagtc agagagcaga 60

```

WO 00/06728

PCT/US99/17132

```

acatgagcat ctgccaggtc tggttccccc accatcaggg atgggagtga gaaaggggag 120
tccccctctg aagagccacc cctgcaggga gaaatctgtc tccaacagga gatctgggaa 180
gaccatagtg agaagtgtg tgaagaggt ccgcacagcg ggccttttcc gaagtgggtt 240
tagcgaagag aaggcaactg gcaagctctt tgctgtgaag tgtatcccta agaaggcgct 300
gaagggcaag gaaagcagca tagagaatga gatagccgtc ctgagaaaga ttaagcatga 360
aaatattgtt gccctgggag acatttatga aagcccaaat cacctgtact tggatcatgca 420
gctggtgtcc ggtggagagc tgtttgaccg gatagtggag aaggggtttt atacagagaa 480
ggatgccagc actctgatcc gccaggtctt ggacgcctg tactatctcc acagaatggg 540
catcgccac agagacctca agcccgaata tctctgtac tacagtcaag atgaggagtc 600
caaaataatg atcagtgaat ttggattgtc aaaaatggag ggcaaaggag atgtgatgtc 660
cactgcctgt ggaactccag gctatgtcgc tcctgaagtc ctgcgccaga aaccttacag 720
caaagccgtt gactgctggt ccacgcgagt gattgcctac atcttctct cgggctaccc 780
tcctttttat gatgaaaatg actccaagct ctttgagcag atcctcaagg cggaatatga 840
gtttgactct ccctactggg atgacatctc cgactctgca aaagacttca ttcggaacct 900
gatggagaag gaccgcaata aaagatacac gtgtgagcag gcagctcggc acctatggat 960
cgctggtgac acagccctca acaaaaacat ccacgagtc gtcagcgccc agatccggaa 1020
aaactttgcc aagagcaaat ggagacaagc atttaatgcc acggccgtcg tgagacatat 1080
gagaaaacta cacctcggca gcagcctgga cagttcaaat gcaagtgtt cgagcagcct 1140
cagtttgccc agccaaaaag actgtgcgta ttagcaaaa ccagaatccc tcagctgaca 1200
ctgaagacga gctgggggtg gagaggagg agccggcacc tgccgagcac ctctgtttg 1260
ccaggcgctt tctatactta atcccatgtc atgcgacct aggactttt ttaacatgta 1320
atcactgggc cgggtgcagt ggctcacgcc tgtaatccca acactttggg aggtgaggc 1380
aggaggactg tttgagttca ggagttttaa gaccagcctg accaacaatg tgaaacccca 1440
tctctactaa aatataaaaa ttagccgggt gtggtggcga gcacctgtaa tgtcagctac 1500
ttgggaggct gaggcaggag aatcacttga acccaggaag cggaggttgc aatgagctga 1560
gatcacacca ctgactcca gcctgggtga cagattgaga ctccctctca aaaaaaaaag 1620
ggaaatcatt gaacactcgt ggaaccctag gtattgcata ttccatttac ggtttgggaa 1680
tccagggtc aagtctctgc aggggtaccg agctcgagat cgtaatca 1728

```

&lt;210&gt; 57

&lt;211&gt; 1610

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 283746

&lt;400&gt; 57

```

gtcgctctg aaggagaacc attttccatc tctttcatag ttttttccc cagtcagcgt 60
ggtagcggta ttctccgcgg cagtgcagat aattgtttt gctcttttag ccaagacttc 120
cgccctcgat caagatggtg gttggacggc ctctctaacc ttacggggc ctggcgggtc 180
tgacgcctga gctggtaggg gtggagcagg taggaaacag caaatgcaga agctgctgcg 240
cggaagtcgg ccatggactg gaaagaagtt ctctcgtcgg gcctagcgac gcccaacacc 300
tgtccaaaca ctgcctgctg aagatgaagt cttactacag aaattaagag aggaatcaag 360
agctgtcttt ctacaaaaga aaagcagaga actgttagat aatgaagaat tacagaactt 420
atggtttttg ctggacaaac accagacacc acctatgatt ggagaggaag cgatgatcaa 480
ttacgaaaac tttttgaagg ttggtgaaaa ggctggagca aagtgcagc aatttttcac 540
agcaaaagtc tttgctaaac tccttcatac agattcatat ggaagaattt ccatcatgca 600
gttctttaat tatgtcatga gaaaagtgtt gttcatcaa acaagaatag gactcagttt 660
atatgatgtc gctgggcagg ggtaccttcg ggaatctgat ttagaaaact acatattgga 720
acttatccct acgttgccac aattagatgg tctggaaaaa tctttctact ccttttatgt 780
ttgtacagca gttaggaagt tcttctctt tttagatcct ttaagaacag gaaagataaa 840
aattcaagat atttttagcat gcagcttcct agatgattta ttggagctaa gggatgagga 900

```

WO 00/06728

PCT/US99/17132

```

actgtccaag gagagtcaag aaacaaattg gttttctgct ctttctgccc taagagttta 960
tggeccagtac ttgaatcttg ataaagatca caatggcatg ctacagtaaag aagaactctc 1020
acgctatgga acagctacca tgaccaatgt cttcttagac cgtgttttcc aggagtgtct 1080
cacttatgat ggagaaatgg actataagac ctacttggac tttgtccttg cattagaaaa 1140
cagaaaggaa cctgcagctc tacaatatat tttcaaactg cttgatattg agaacaaagg 1200
atacctgaat gtcttttcac ttaattatct ctttagggcc atacaggaac taatgaaaat 1260
ccatggacaa gatcctgttt catttcaaga tgtcaaggat gaaatctttg acatggtaaa 1320
accaaaggat cttttgaaaa tctctcttca ggatttaatc aacagtaatc aaggagacac 1380
agtaaccacc attctaatacg atttgaatgg cttctggact tacgagaaca gagaggctct 1440
tggtgcaaat gacagtgaat actctgcaga ccttgatgat acatgatctc tgaaagacta 1500
gactgtctta tattatgaga tacttgaatg ctgcatgtaa agcctttaaa gcaaaatcct 1560
cagaaatggt ctaaataaaa cacttgatat gcctagagaa aaaaaaaaaa 1610

```

&lt;210&gt; 58

&lt;211&gt; 1290

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2696537

&lt;400&gt; 58

```

ccggtccccg ccgggaagtt ctaggcgcgc gcacagaaaag ccctgcccctc cacgcggggt 60
ctctggagcg ccctggggttg cccggccgggt ccctgcccgt gacttggtga cactgcgagc 120
actcagtcce tcccgcgcgc ctctccccg cccgccccgc cgtctectct cctgttaaca 180
tgccatagtg cgcctgcgac cacacggcgc gggcgctagc gttcgccttc agccaccatg 240
gggaatggga tgaacaagat cctgcceggc ctgtacatcg gcaacttcaa agatgccaga 300
gacgcgggaa aattgagcaa gaacaagggt acacatattc tgtctgtcca tgatagtgcc 360
aggcctatgt tggagggagt taaataacct tgcaccccag cagcggattc accatctcaa 420
aacctgacaa gacatttcaa agaaagtatt aaattcattc acgagtgcgc gctccgcggg 480
gagagctgcc ttgtacactg cctggccggg gtctccagga gcgtgacact ggtgatcgca 540
tacatcatga ccgtcactga ctttggctgg gaggatgccc tgcacaccgt gcgtgctggg 600
agatcctgtg ccaaccccaa cgtgggcttc cagagacagc tccaggagtt tgagaagcat 660
gaggtccatc agtatcggca gtggctgaag gaagaatatg gagagagccc tttgcaggat 720
gcagaagaag ccaaaaacat tctggccgct ccgggaattc tgaagtcttg ggcctttctc 780
agaagactgt aatgtacctg aagtttctga aatattgcaa acccacagag tttaggctgg 840
tgctgccaaa aagaaaagca acatagagtt taagtatcca gtagtgattt gtaaacttgt 900
ttttcatttg aagctgaata tatacgtagt catgtttatg ttgagaacta aggatattct 960
ttagcaagag aaaatatatt ccccttatcc ccactgctgt ggaggtttct gtacctcgct 1020
tggatgcctg taaggatccc gggagccttg ccgcactgcc ttgtgggtgg cttggcgctc 1080
gtgattgctt cctgtgaacg cctcccaagg acgagcccag tgtagtgttg tggcgtgaac 1140
tctgcccggt tggtctcaaa tccccagct tgggaaatag cccttgggtg gggttttatc 1200
tctggtttgt gttctccgtg gtggaattga ccgaaagctc tatgttttcg ttaataaagg 1260
gcaacttagc caagtttaaa aaaaaaaaaa 1290

```

&lt;210&gt; 59

&lt;211&gt; 2281

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 551178

WO 00/06728

PCT/US99/17132

&lt;400&gt; 59

```

tgatgatcca gatgttaaag cacaagtgga agtgetgtcc gctgcactac gtgcttccag 60
cctggatgca catgaagaga ccatcagtat agaaaagaga agtgatttgc aagatgaact 120
ggatataaat gagctaccaa attgtaaaat aaatcaagaa gattctgtgc ctttaatcag 180
cgatgctgtt gagaatatgg actccactct tcaactatatt cacagcgatt cagacttgag 240
caacaatagc agtttttagcc ctgatgagga aaggagaact aaagtacaag atgttgtacc 300
tcaggcggtt ttagatcagt atttatctat gactgaccct tctcgtgcac agacgggtga 360
cactgaaatt gctaagcact gtgcatatag cctccctggg gtggccttga cactcggaag 420
acagaattgg cactgcctga gagagacgta tgagactctg gcctcagaca tgcagtggaa 480
agttcgacga actctagcat tctccatcca cgagcttgca gttattcttg gagatcaatt 540
gacagctgca gatctgggtc caatttttaa tggattttta aaagacctcg atgaagtcag 600
gatagggttt cttaaacact tgcattgattt tctgaagctt cttcatattg acaaaagaag 660
agaatatctt tatcaacttc aggagttttt ggtgacagat aatagtagaa attggcgggt 720
tcgagctgaa ctggctgaac agctgatttt acttctagag ttatatagtc ccagagatgt 780
ttatgactat ttacgtccca ttgctctgaa tctgtgtgca gacaaaagtt cttctgttcg 840
ttggatttcc tacaagttgg tcagcgagat ggtgaagaag ctgcacgcgg caacaccacc 900
aacgttcgga gtggacctca tcaatgagct tgtggagaac tttggcagat gtcccaagt 960
gtctggtcgg caagcctttg tctttgtctg ccagactgtc attgaggatg actgccttcc 1020
catggaccag tttgctgtgc atctcatgcc gcattctgta acctagcaa atgacagggt 1080
tctaactggt cgagtgtgc ttgcaaagac attaaagaca actctactag aaaaagacta 1140
tttcttggcc tctccagct gccaccagga ggctgtggag cagaccatca tggctcttca 1200
gatggaccgt gacagcgatg tcaagtattt tgcaagcatc caccctgcca gtaccaaatt 1260
ctccgaagat gccatgagca cagegtcttc aacctactag aaggcttgaa tctcgggtgtc 1320
tttctgtctt ccatgagagc cgaggttcag tgggcattcg ccacgcagtgt gacctgggat 1380
agctttcggt ggaggagaga ccttcctctc ctgctggactt cattgcaggt gcaagttgcc 1440
tacaccaat accagggatt tcaagagtca agagaaagta cagtaaacac tattatctta 1500
tcttgacttt aaggggaaat aatttctcag aggtattataa ttgtcaccga agccttaaat 1560
ccttctgtct tctgactga atgaaacttg aattggcaga gcattttcct tatggaaggg 1620
atgagattcc cagagacctg cattgctttc tcttggtttt atttaacaat cgacaaatga 1680
aattcttaca gcctgaaggc agacgtgtgc ccagatgtga aagagacctt cagtatcagc 1740
cctaactctt ctctcccagg aaggacttgc tgggctctgt ggccagctgt ccagcccagc 1800
cctgtgtgtg aatcgtttgt gacgtgtgca aatgggaaag gaggggtttt tacatctcct 1860
aaaggacctg atgccaacac aagtaggatt gacttaaaact cttaaagcgca gcattattgct 1920
gtacacattt acagaatggt tgctgagtgt ctgtgtctga ttttttcatg ctggctcatga 1980
cctgaaggaa atttattaga cgtataatgt atgtctggtg tttttaactt gatcatgatc 2040
agctctgagg tgcaacttct tcacatactg tacataacctg tgaccactct tgggagtgtc 2100
gcagtcttta atcatgtgt ttaaactgtt gtggcacaag ttctcttctc caataaaaat 2160
ttattaataa gatctataga gagagatata tacacttttg attgttttct agatgtctac 2220
caataaatgc aatttgtgac ctgtattaat gattttaaagt gggaaactag attaaaaat 2280
a 2281

```

&lt;210&gt; 60

&lt;211&gt; 632

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 619292

&lt;400&gt; 60

```

cggacgcgtg gggccagacc gcagctccag caccgaggac ttctgtacg tcttcacgg 60
ggagctggaa cgaggccctt cgggctggg gatgggcctg atcgacggga tgcacacgca 120
cctgggcgct cccgggctct acatccagac cctgctcccg ggcagccccg cagcggccga 180
cgggcgcctg tcgctggggg accgtatcct ggaggtgaat ggcagcagcc tcttgggct 240

```

WO 00/06728

PCT/US99/17132

```

tggctacctg agagctgtgg acctgatccg tcatggcggg aagaagatgc ggttcctggg 300
cgcgaaagtc gacgttgga aacagccaag aagatccatt tccgcacgcc cctctctag 360
gggggctgag aggacacccc cacaggcccg gcacccgggc ccacctggg acactgggct 420
tctcccgcc ttcgtccctg ttttgtaact gaccaagtgg ggtcccggt ggggagcctc 480
acctgggga catgcctgtt gataacatgc atctcagtgt aggttctatt tatatggcag 540
atgacgtgaa attgtgatgt ttgttacaga gcttttatgt ttaaagactt caatggagaa 600
gtacggttca ataaactatt tttcccgctt tt 632

```

&lt;210&gt; 61

&lt;211&gt; 2347

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2054049

&lt;400&gt; 61

```

cccagtttta tcatggattc atcctgaaag tcaagccaca atcactcggg gtagccagcc 60
catggttgga gtgagtgga agcgaaagcaa agaagatgaa aaataccttc aagctatcat 120
ggattccaat gcccagttct acaaaatctt tatatttgat gcccgccaa gtgttaatgc 180
tgttgccaac aaggcaaagg gtggagggtta tgaaagtga gatgcctatc aaaatgctga 240
actagttttc ctggatatcc acaatattca tggtatgaga gaatcattac gaaaacttaa 300
ggagattgtg taccacaaca ttgaggaaac ccactgggtg tctaacttgg aatctactca 360
ttggctagaa catattaagc ttattcttgc aggggctctt aggattgctg acaaggtaga 420
gtcaggggaag acgtctgtgg tagtgcatgg cagtgtgggt tgggatcgca cagctcagct 480
cacttccctt gccatgctca tggttggatgg atactatcga accatccgag gatttgaagt 540
ccttgtggag aaagaatggc taagttttgg acatcgattt caactaagag ttggccatgg 600
agataagaac catgcagatg cagacagatc gcctgttttt cttcaattta ttgactgtgt 660
ctggcagatg acaagacagt ttctaccgc atttgaattc aatgagtatt ttctcattac 720
cattttggac cacctataca gctgcttatt cggaacattc ctctgtaata gtgaacaaca 780
gagaggaaaa gagaatcttc ctaaaaggac tgtgtcactg tggctttaca taaacagcca 840
gctggaagac ttcactaatc ctctctatgg gagctattcc aatcatgtcc tttatccagt 900
agccagcatg cgccacctag agctctgggt gggatattac ataagggtga atccacggat 960
gaaaccacag gaacctattc acaacagata caaagaactt cttgctaaac gagcagagct 1020
tcagaaaaaa gtagaggaac tacagagaga gatttctaac cgatcaacct catcctcaga 1080
gagagccagc tctcctgcac agtgtgtcac tcctgtccaa actgttgtat aaaggactgt 1140
aagatcaggg gcatcattgc tatacactct tgattacact ggcagctcta tgagtagaaa 1200
gtcttcggaa tttagaacct atctatgaga gaaagttcag tcaactttatt tattttaaat 1260
ctctctagga tgagtttaga actgtagcag tgcagggtggc ttaagtgaag taactccata 1320
tgtaattaca tgattatgat actaatcttt taagtatcca aagaatatta aaatacttca 1380
atcctggatt cacagtggga acaagtttct attaaaaggc aaatgctgtt acaaattttt 1440
ggcatctggg aatattaaaa ccatttttaga aatacactct gtgctcactg tgcagaggaa 1500
catcagtttt caaaccaaca ctgaaattct gtggcatcac atattattggg ccttgatgtc 1560
atgacagatc aaaatcattt gatatccctt tctccattct aggtttttct ttttttcagt 1620
aactgattta ccttgatcac ttttcaactt ccatattctt catatagtaa aaggcaaagt 1680
gttgaagata ctacgggtgtg gtagtagttg aaaattattg ccgtcattat ttacatactt 1740
aagacatatt agcaaagttga tccaaaatgg gaggccttat agatgtgctt gggggaaaat 1800
gaaggggaga aagtagccat acaggagtgc aaagaattcc atgcccttca gattagccca 1860
attaccagaa acatcatgaa agatatttta aaaactaatt atttactaca gtgtatttca 1920
cttgtcttgt gtgtctgaac acacagaagc taattagcaa gtttttaaga agtattttaa 1980
aatcttacta ggattgacat tttttctgaa ttctgtataa atagcttata gtgagaagta 2040
ctgtgctcaa attttacatt tttttccttt gcaaattctg taatttcact caacgattaa 2100
gtctacaaaa gaacacactg catgtaaaag atgtattaca atctcaaagc cagtaaaaga 2160
aatcttgctt cactgttcac ctgctacaag taagagtttg gtgctggtag aaacatttga 2220

```

WO 00/06728

PCT/US99/17132

```

ctctgatgtc tattttattc tacataagag ccatatgtaa tgtactgtaa caaaggagct 2280
tcttgteccc ttggtctttt aattaaaaga aattccaact gactttttaa ctttaaaaaa 2340
aaaaaaa                                     2347

```

&lt;210&gt; 62

&lt;211&gt; 1737

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2843910

&lt;400&gt; 62

```

ccgggggtga gcgctcggct gcagcggcgc ggaggccgtc tccctgggtct gccgcgggtcc 60
ccgcccgtcc cgccgcgggc tgccatggca ggagccggag ggttcggctg ccccgccgggc 120
ggcaacgact tccagtgggtg cttctcgcag gtcaaggggg ccacgcacga ggacgtggcc 180
gaagcggaca tcatttcac cgttgagttt aattactctg gagatcttct tgcaacagga 240
gacaagggcg gcagagttgt tatttttcag cgtgaacaag agaataaaag ccgccctcat 300
tctaggggag aatataatgt ttacagcacc ttcaaagtc atgaaccgga gtttgactat 360
ttgaaaagtc tagaaattga ggaaaaaatt aataaaatta ggtgggttacc acaacagaat 420
gctgctcatt ttctactgtc tacaaatgat aaaactataa aattatggaa aataagtga 480
cgggataaaa gagcagaagg ttataacctg aaagacgaag atggaagact tcgagacca 540
tttaggatca cggcgctacg ggtcccaata ttgaagccca tggatcttat ggtagaagcg 600
agtccacggc gaatttttgc aaatgctcac acatatcata taaattccat ttcagtaaat 660
agtgatcatg aaacatatct ttctgcagat gacctgagaa ttaatttatg gcacttagaa 720
atcacagata gaagctttaa catcgtggac atcaagcctg ctaacatgga ggagctgacc 780
gaagtcacga ctgcagccga gttccacccg caccagtgc aactgttcgt ctacagcagt 840
agcaaaagga ccatccgcct gtgtgacatg cgctcctcgg cctgtgcga cagacactcc 900
aagttttttg aagagcctga agatcccagc agtaggtcct tcttctcaga aataatttca 960
tccatatccg atgtaaaatt cagtcatagt gggcgggtaca tgatgaccag agactacctg 1020
tcggtgaagg tgtgggacct caacatggag agcaggcccg tggagacca ccaggtccac 1080
gagtacctgc gcagcaagct ctgctctctc tatgagaacg actgcatctt tgacaagttt 1140
gagtgttgct ggaacggttc ggatagcgcc atcatgaccg ggtcctataa caacttcttc 1200
aggatgtttg atagagacac gcggagggat gtgaccctgg aggcctcgag agagagcagc 1260
aaaccgcgcg ccagcctcaa accccggaag gtgtgtacgg ggggtaagcg gaggaagac 1320
gagatcagtg tggacagtct ggacttcaac aagaagatcc tgcacacagc ctggcacccc 1380
gtggacaatg tcattgccgt ggctgccacc aataacttgt acatattcca ggacaaaatc 1440
aactagagac gcgaacgtga ggaccaagtc ttgtcttgca tagttaagcc ggacattttt 1500
ctgtcagaga aaaggcatca ttgtccgctc cattaagaac agtgacgcac ctgctacttc 1560
ccttcacaga cacaggagaa agccgcctcc gctggaggcc cgggtgtggt ccgcctcggc 1620
gaggcgcgag acaggcgctg ctgctcacgt ggagacgctc tcgaagcaga gttgacggac 1680
actgctccca aaaggtcatt actcagaata aatgtattta tttcaaaaaa aaaaaaa 1737

```